学术周报 · IF≥10

肿瘤领域文献阅读汇编

2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
245
临床研究
62
基础研究
183
IF≥20
82
IF 10-20
163
子领域
11
期刊种类
79
数据日期
2026-10-31

★本周 Top 10 高影响力文献

#论文期刊IF
1Cancer-associated fibroblasts: origins, functional heterogeneity and therapeutic potential.Signal transduction and targeted therapyIF 81.2
2The AMPK signaling pathway in cell metabolism and human diseases.Signal transduction and targeted therapyIF 81.2
3KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cance...Cancer cellIF 56.1
4A sex-specific platelet switch controls anti-tumor immunity in glioblastoma.Cancer cellIF 56.1
5Intrinsic resistance to KRAS inhibition: Interfering with interferon.Cancer cellIF 56.1
6Tumour assembloids recapitulate tumour-CAF-T cell crosstalk in renal cancer.NatureIF 56.1
7Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers.NatureIF 56.1
8SWI/SNF complexes shape 3D chromatin architecture through CTCF and cohesin.NatureIF 56.1
9CPS + EG and Neo-Bioscore predict individual outcomes but not trial results after neoadjuvant therap...Cancer cellIF 56.1
10Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications...Cancer cellIF 56.1

Ŧ期刊分布统计

期刊篇数IF
Cancer letters30IF 11.8
Science advances12IF 13.9
ACS sensors11IF 10.9
Cancer discovery9IF 29.5
Advanced healthcare materials8IF 11.0
Cancer research7IF 22.6
Nucleic acids research7IF 15.0
Cancer cell7IF 56.1
Blood7IF 23.9
ACS nano7IF 17.3

1血液肿瘤 (88篇)

临床研究 (17篇)

Blood cancer journal IF 13.8 2026-10-30 PMID: 42963359
Socioeconomic status (SES) is well recognized as an important determinant of cancer incidence and survival. However, its impact on outcomes in patients with mantle cell lymphoma (MCL) remains poorly characterized. We conducted a nationwide, population-based retrospective longitudinal study using German cancer registry data, including all patients diagnosed with MCL between 2013 and 2023. Regional SES was assessed annually at the district level using quintiles of the German Index of Socioeconomic Deprivation. The primary outcomes were 5-year absolute survival (AS) and relative survival (RS) as a proxy for disease-specific survival. A total of 8871 patients were included. Five-year AS and RS were 62.6% (95% CI, 61.5-63.7) and 72.1% (95% CI, 70.8-73.4), respectively. However, no meaningful differences in AS were observed between patients residing in districts of the lowest and highest SES quintiles (62.0% vs 63.1%). This nationwide population-based study indicates that regional socioeconomic deprivation was not associated with clinically relevant differences in survival outcomes among MCL patients in Germany between 2013 and 2023. These findings differ from previously described patterns in other lymphomas, suggesting that biological disease characteristics may exert a stronger influence on MCL survival than social determinants.
中文摘要:社会经济状况(SES)已被公认为癌症发病和生存的重要决定因素,但其对套细胞淋巴瘤(MCL)患者结局的影响仍缺乏充分描述。我们利用德国癌症登记数据开展了一项全国性、基于人群的回顾性纵向研究,纳入2013年至2023年间确诊的所有MCL患者。区域SES按地区层面每年使用德国社会经济剥夺指数的五分位进行评估。主要结局为5年绝对生存(AS)和相对生存(RS),后者作为疾病特异性生存的替代指标。共纳入8871例患者。5年AS和RS分别为62.6%(95% CI,61.5-63.7)和72.1%(95% CI,70.8-73.4)。然而,居住在SES最低和最高五分位地区的患者之间,AS未见有意义的差异(62.0% vs 63.1%)。这项全国性、基于人群的研究表明,2013年至2023年间,德国MCL患者的区域社会经济剥夺与生存结局的临床相关差异无关。这些发现不同于其他淋巴瘤中已描述的模式,提示生物学疾病特征对MCL生存的影响可能强于社会决定因素。
Trends in cancer IF 21.6 2026-10-30 PMID: 42963249
Advancements in in vivo stable isotope tracing have revolutionized our understanding of cancer metabolism, transitioning the field from static metabolomic snapshots to dynamic metabolic pathway activities. However, interpreting raw fractional enrichment data presents significant biological and analytical challenges. This review systematically examines the methodological landscape of in vivo tracing, addressing the interpretive gap created by clinical constraints, such as single-timepoint surgical sampling. We dissect how secondary circulating tracers and the inherent heterogeneity of the tumor microenvironment can confound metabolic signals. We highlight the critical transition to metabolic flux analysis as the requisite computational step to overcome these challenges and to identify targetable metabolic vulnerabilities in precision oncology.
中文摘要:体内稳定同位素示踪的进展改变了我们对癌症代谢的理解,使该领域从静态代谢组快照转向动态代谢通路活性。然而,解读原始同位素分数富集数据在生物学和分析上存在显著挑战。本综述系统考察体内示踪的方法学格局,处理由临床限制(如单时间点手术取样)造成的解读缺口。我们剖析循环中的次级示踪剂和肿瘤微环境固有异质性如何干扰代谢信号。我们强调向代谢通量分析的关键转变,这是克服这些挑战并在精准肿瘤学中识别可靶向代谢脆弱性的必要计算步骤。
Journal of the American Academy of Dermatology IF 12.3 2026-10-30 PMID: 42962928
Non-surgical treatment of patients with early-stage (1-2 cm diameter) cutaneous squamous cell carcinoma (CSCC) remains an unmet need. This study investigates low-dose intralesional cemiplimab for these patients. The primary objective was safety of low-dose intralesional cemiplimab. Efficacy was a secondary objective. This was an open-label, phase 1 pilot study with dose escalation and expansion cohorts (NCT03889912). One lesion was injected per patient. Cemiplimab was initially administered at 5, 15, and 44 mg weekly, for 12 weeks. Subsequently, Expansion Cohorts A and B received 5 mg intralesional cemiplimab weekly or every 2 weeks, respectively, for 6 weeks. Visual response assessments were performed at Weeks 7 and 13, and surgery at Week 13. Across 41 patients, cemiplimab showed an acceptable safety profile. In Expansion Cohorts A and B, treatment-emergent adverse events were all grade ≤2. Week 13 visual and pathologic complete response rates were both 58.3% in Cohort A and 41.7% and 66.7%, respectively, in Cohort B. The small number of participants limits generalizability. Intralesional cemiplimab administration may have been variable. Low-dose intralesional cemiplimab demonstrated efficacy against early-stage CSCC, with an acceptable safety profile. These data support further study of 5 mg intralesional cemiplimab weekly.
中文摘要:早期(直径1–2厘米)皮肤鳞状细胞癌(CSCC)患者的非手术治疗仍存在未满足需求。该研究评估低剂量病灶内注射西米普利单抗用于这类患者的情况,主要目标为低剂量病灶内西米普利单抗的安全性,疗效为次要目标。这是一项开放标签1期探索性研究,包含剂量递增和扩展队列(NCT03889912)。每例患者注射一个病灶。西米普利单抗初始按5、15和44 mg每周给药,持续12周。随后扩展队列A和B分别接受5 mg病灶内西米普利单抗每周1次或每2周1次,持续6周。第7周和第13周进行视觉反应评估,第13周手术。41例患者中,西米普利单抗显示出可接受的安全性。扩展队列A和B中,治疗中出现的不良事件均为≤2级。第13周时,队列A的视觉和病理完全缓解率均为58.3%;队列B分别为41.7%和66.7%。参与人数较少限制了结果的普遍性。病灶内西米普利单抗给药可能存在差异。低剂量病灶内西米普利单抗对早期CSCC显示出疗效,安全性可接受。这些数据支持进一步研究5 mg病灶内西米普利单抗每周给药。
Journal of obesity & metabolic syndrome IF 12.7 2026-10-30 PMID: 42843855
Obesity has traditionally been defined by body mass index (BMI), a pragmatic but biologically limited measure that fails to capture adiposity distribution, tissue dysfunction, and heterogeneity in disease risk. To address these limitations, a recent Lancet Diabetes & Endocrinology Commission proposed a disease-oriented redefinition of obesity, distinguishing clinical obesity-excess adiposity causing organ dysfunction or functional impairment-from preclinical obesity, characterized by excess adiposity without established dysfunction. This shift has important implications for diagnosis, epidemiology, and health policy. In this review, we critically appraise the conceptual framework, emerging evidence, and implementation challenges of the new Lancet Commission definition of clinical obesity. Population-based studies from diverse regions consistently demonstrate marked discordance between BMI-defined and clinical obesity, with clinical obesity showing stronger associations with cardiometabolic disease, mortality, functional limitation, and cancer risk. These findings highlight the limitations of universal BMI thresholds, particularly in Asian populations with a predisposition to visceral adiposity at lower BMI levels. We compare the Lancet Commission framework with existing staging systems, including the Edmonton Obesity Staging System and the European Association for the Study of Obesity framework, and identify key challenges related to causal attribution, binary classification, scalability, and ethnic adaptation. Finally, we propose a refined, population-sensitive and pragmatic approach that conceptualizes preclinical and clinical obesity as stages along a trajectory, incorporates ethnicity-adapted adiposity thresholds, and emphasizes readily available clinical criteria for determining dysfunction and disease. The resulting definition of clinical obesity should support more precise and equitable obesity care.
中文摘要:肥胖传统上以体重指数(BMI)定义,这是一种实用但生物学上受限的指标,无法反映脂肪分布、组织功能障碍和疾病风险异质性。为应对这些局限,近期《柳叶刀-糖尿病与内分泌学》委员会提出以疾病为导向的肥胖再定义,区分临床肥胖——过剩脂肪导致器官功能障碍或功能受损——与临床前肥胖,后者指存在过剩脂肪但尚无明确功能障碍。这一转变对诊断、流行病学和卫生政策有重要影响。这篇综述批判性评估新委员会临床肥胖定义的概念框架、新证据和实施挑战。来自不同地区的人群研究一致显示,BMI定义的肥胖与临床肥胖存在明显不一致,临床肥胖与心血管代谢疾病、死亡、功能受限和癌症风险的关联更强。这些发现凸显通用BMI阈值的局限,尤其在较低BMI即易发生内脏脂肪蓄积的亚洲人群中。我们将委员会框架与现有分期系统比较,包括埃德蒙顿肥胖分期系统和欧洲肥胖研究协会框架,并识别因果归因、二分分类、可扩展性和种族适配方面的关键挑战。我们提出一种更精细、对人群敏感且务实的路径,将临床前肥胖和临床肥胖视为同一轨迹上的阶段,纳入适配种族的脂肪阈值,并强调采用易获得的临床标准判定功能障碍和疾病。由此形成的临床肥胖定义应支持更精准和公平的肥胖诊疗。
Journal of obesity & metabolic syndrome IF 12.7 2026-10-30 PMID: 42843854
Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.
中文摘要:肥胖仍是不断加剧的全球健康危机,影响近十亿成年人,并显著增加心血管代谢疾病、恶性肿瘤和过早死亡风险。代谢与减重手术(MBS)已发展为治疗重度肥胖的有效且持久手段,可带来持续减重并显著缓解肥胖相关合并症(如2型糖尿病和心血管疾病)。尽管安全性、疗效和长期结局不断改善,MBS仍明显未被充分利用,仅覆盖不足1%的符合条件患者。持续存在的障碍包括患者和医生认知有限、对手术风险的误解以及获得诊疗方面的显著差异。与此同时,胰高血糖素样肽-1受体激动剂(GLP-1 RAs)的快速应用改变了肥胖的药物治疗格局,可有效实现药物减重,但也引发对其对MBS使用、持久性和成本效果影响的疑问。新证据显示,MBS带来的减重幅度和持久性优于单用GLP-1 RAs,但两类治疗并非必须竞争。GLP-1 RAs可作为「新辅助」治疗以优化手术候选资格,或作为减重不足或术后体重反弹的辅助治疗。本综述整合MBS术式、结局、获取差异以及GLP-1 RA时代肥胖治疗观念演变的最新数据。我们提出一种慢性体重管理模型,将药物治疗、手术和多学科照护整合为连续的治疗谱系。将MBS与GLP-1 RAs定位为个体化诊疗路径中的互补手段,可能改善长期结局、扩大可及性,并更好应对肥胖复杂而慢性的本质。
JAMA oncology IF 23.9 2026-10-29 PMID: 42955008
Alterations in the fibroblast growth factor receptor (FGFR) pathway, particularly FGFR3, are among the most common genomic events in urothelial carcinoma (UC) and represent a cornerstone of precision oncology. Although FGFR3 alterations predominate, selected FGFR2 fusions also identify patients who may benefit from targeted therapy. This review summarizes the biology, molecular diagnostics, and evolving clinical applications of FGFR alterations in UC. FGFR2/3 alterations are clinically actionable biomarkers across non-muscle-invasive, muscle-invasive, metastatic, and upper-tract UC. Comprehensive genomic profiling, tissue sequencing, plasma circulating tumor DNA, urine-based molecular assays, and molecular residual disease assessment are expanding their roles in diagnosis, treatment selection, surveillance, and disease monitoring. Recent clinical studies support combination strategies, next-generation FGFR inhibitors, and earlier use of FGFR-directed therapy, while emerging technologies, including artificial intelligence-assisted pathology and integrated multi-omic biomarkers, may further improve patient selection. FGFR alterations have become integral to the molecular classification and precision management of UC. Continued advances in molecular diagnostics, liquid biopsy, biomarker-guided therapy, and next-generation FGFR inhibitors are expected to further personalize care. This review provides a practical framework for integrating FGFR biomarkers into contemporary management and highlights emerging developments likely to influence future clinical practice.
中文摘要:成纤维细胞生长因子受体(FGFR)通路改变,尤其是FGFR3改变,是尿路上皮癌(UC)中最常见的基因组事件之一,也是精准肿瘤学的重要基础。尽管以FGFR3改变为主,部分FGFR2融合也可识别可能从靶向治疗中获益的患者。该综述总结UC中FGFR改变的生物学、分子诊断及不断演变的临床应用。FGFR2/3改变是非肌层浸润性、肌层浸润性、转移性及上尿路UC中具有临床可操作性的生物标志物。全面基因组分析、组织测序、血浆循环肿瘤DNA、尿液分子检测及分子残留病灶评估,正在拓展其在诊断、治疗选择、监测和疾病管理中的作用。近期临床研究支持联合策略、下一代FGFR抑制剂及更早使用FGFR靶向治疗;人工智能辅助病理和多组学整合生物标志物等新兴技术可能进一步改善患者选择。FGFR改变已成为UC分子分型和精准管理的重要组成部分。分子诊断、液体活检、生物标志物指导治疗及下一代FGFR抑制剂的持续进展,有望进一步推动个体化诊疗。该综述提供将FGFR生物标志物整合到当代管理中的实用框架,并强调可能影响未来临床实践的新进展。
Blood IF 23.9 2026-10-29 PMID: 42683850
Engineered T cells have transformed hemato-oncology, but chimeric antigen receptor (CAR) transgene-bearing T-cell malignancies have emerged as a rare and serious genomic safety signal after CAR T-cell therapy. Available data support a multistep model in which pre-existing clonal fitness, CAR T-cell manufacture, vector integration, construct biology, and postinfusion selection may contribute to different degrees. We review reported cases of CAR transgenic T-cell lymphoproliferative neoplasms and propose practical diagnostic criteria with a proportionate approach to genomic surveillance.
中文摘要:工程化T细胞已改变血液肿瘤学格局,但携带嵌合抗原受体(CAR)转基因的T细胞恶性肿瘤已成为CAR T细胞治疗后一种罕见而严重的基因组安全性信号。现有数据支持多步骤模型:既有的克隆适应性、CAR T细胞制备、载体整合、构建体生物学以及输注后选择可能在不同程度上共同参与。我们综述已报道的CAR转基因T细胞淋巴增殖性肿瘤病例,并提出实用的诊断标准,以及对基因组监测采取相称的方法。
Experimental hematology & oncology IF 17.5 2026-10-28 PMID: 42958448
Timdarpacept (IMM01) is a recombinant signal regulatory protein α-IgG1 fusion protein that exerts antitumor activity by blocking the "don't eat me" signal while simultaneously activating the "eat me" signal, inducing robust antibody-dependent cellular phagocytosis. We report the final phase II results of treatment-naïve higher risk chronic myelomonocytic leukemia (CMML) patients treated with IMM01 in combination with azacitidine. We assessed the safety and efficacy of IMM01 in combination with azacitidine (AZA) as first-line therapy for newly diagnosed CMML patients. IMM01 was administered intravenously at 2.0 mg/kg weekly, and AZA was administered subcutaneously at 75 mg/m² on days 1-7 of each 28-day cycle. As of the data cut-off on May 13, 2025, 24 patients were enrolled. Of 22 efficacy-evaluable patients, the overall response rate (ORR) was 72.7% (16/22; 95% CI 49.8-89.3), including 27.3% complete response (CR), 13.6% marrow CR (mCR) with hematologic improvement (HI), 4.5% HI alone, and 27.3% mCR alone. The median time to response was 1.8 months (range, 0.9-3.6), and the median duration of response was 16.9 months (95% CI 5.1-NE). Median overall survival and progression-free survival were 22.2 months (95% CI 9.0-NE) and 17.8 months (95% CI 5.3-NE), respectively. The most common grade ≥ 3 treatment-related adverse events (≥ 10%) were lymphopenia (66.7%), leukopenia (62.5%), neutropenia (62.5%), thrombocytopenia (58.3%), anemia (33.3%), and pneumonia (16.7%). IMM01 in combination with AZA was generally well tolerated and effective in treatment-naïve higher risk CMML patients. Trial registration ClinicalTrials.gov identifier: NCT05140811.
中文摘要:Timdarpacept(IMM01)是一种重组信号调节蛋白α-IgG1融合蛋白,通过阻断「别吃我」信号并同时激活「吃我」信号发挥抗肿瘤作用,诱导强效的抗体依赖细胞吞噬。本文报告IMM01联合阿扎胞苷治疗初治高危慢性粒单核细胞白血病(CMML)患者的II期最终结果。研究评估IMM01联合阿扎胞苷作为新诊断CMML患者一线治疗的安全性与疗效。IMM01按2.0 mg/kg每周静脉给药,阿扎胞苷按75 mg/m²在每个28天周期的第1–7天皮下给药。截至2025年5月13日数据截止,共入组24例患者。22例可评估疗效患者中,总缓解率为72.7%(16/22;95% CI 49.8–89.3),其中完全缓解27.3%,骨髓完全缓解伴血液学改善13.6%,单纯血液学改善4.5%,单纯骨髓完全缓解27.3%。中位起效时间1.8个月(范围0.9–3.6),中位缓解持续时间16.9个月(95% CI 5.1–NE)。中位总生存期与无进展生存期分别为22.2个月(95% CI 9.0–NE)和17.8个月(95% CI 5.3–NE)。最常见的≥3级治疗相关不良事件(≥10%)为淋巴细胞减少(66.7%)、白细胞减少(62.5%)、中性粒细胞减少(62.5%)、血小板减少(58.3%)、贫血(33.3%)和肺炎(16.7%)。IMM01联合阿扎胞苷在初治高危CMML患者中总体耐受良好且有效。试验注册ClinicalTrials.gov标识符:NCT05140811。
ESMO open IF 10.6 2026-10-28 PMID: 42950584
The growing administrative burden associated with clinical research has become a major challenge for investigators and research teams, contributing to increased costs, delays in trial implementation, and reduced research efficiency. In response, the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) have led multiple initiatives aimed at streamlining clinical research, identifying unnecessary bureaucracy and promoting more pragmatic, patient-focused approaches. In line with these initiatives from ESMO, ASCO and other stakeholders, the recent ICH Good Clinical Practice (GCP) guideline E6(R3) has incorporated numerous changes to rationalise the administrative procedures in clinical research. The revised guideline places substantially greater emphasis on applying proportionality between processes and risks, the relevance of the data, and the reliability of results; avoiding unnecessary complexity and burden in clinical research; and incorporating input from investigators and patients into trial design and conduct. The guideline also clarifies several aspects of clinical trial operations, including informed consent procedures, re-consenting requirements, source documentation, and delegation practices, providing opportunities to reduce administrative burden without compromising participant safety or data integrity. Together, the initiatives led by ESMO, ASCO, and other stakeholders, alongside the principles embedded within GCP E6(R3), reflect the shared recognition that clinical research processes should focus on activities that protect data integrity and the rights and well-being of patients. Effective implementation of these principles will be critical to improving the efficiency, sustainability, and accessibility of clinical research.
中文摘要:临床研究日益增加的行政负担已成为研究者和研究团队的主要挑战,导致成本上升、试验实施延迟和研究效率下降。对此,欧洲肿瘤内科学会(ESMO)和美国临床肿瘤学会(ASCO)牵头了多项旨在简化临床研究的倡议,识别不必要的官僚程序,推动更务实、以患者为中心的方法。与ESMO、ASCO及其他利益相关方的这些倡议一致,近期ICH药物临床试验质量管理规范(GCP)E6(R3)纳入了大量修改,以合理化临床研究中的行政程序。修订后的指南更强调在流程与风险之间应用相称性原则、数据的相关性以及结果的可靠性;避免临床研究中不必要的复杂性和负担;并将研究者和患者的意见纳入试验设计与实施。该指南还澄清了临床试验运营的若干方面,包括知情同意程序、再次知情同意要求、源文件记录和授权实践,为在不损害参与者安全或数据完整性的情况下减少行政负担提供了机会。ESMO、ASCO及其他利益相关方牵头的倡议,连同GCP E6(R3)所体现的原则,共同反映出一种共识:临床研究流程应聚焦于保护数据完整性以及患者权利和福祉的活动。有效实施这些原则对于提高临床研究的效率、可持续性和可及性至关重要。
Cancer letters IF 11.8 2026-10-28 PMID: 42612900
This guideline was developed under the auspices of the Pediatric Neurosurgery Group of the Neurosurgery Branch of the Chinese Medical Association, the Neuro-oncology Expert Committee of the Chinese Society of Clinical Oncology, and the Neuro-oncology Professional Committee of the China Anti-Cancer Association. Craniopharyngioma is the most common tumor in the sellar turcica region among children, with the majority being adamantinomatous craniopharyngioma (ACP) and a smaller proportion being papillary craniopharyngioma (PCP). Management of craniopharyngioma involves not only tumor control but also the treatment of tumor-related hypothalamic dysfunction and pituitary endocrine disorders. To standardize the diagnosis and management of pediatric craniopharyngioma, this guideline incorporates evidence from 398 literature references. It provides recommendations on diagnostic evaluation, surgical strategies, radiotherapy principles, prognostic assessment, follow-up and long-term management, and targeted therapy. This guideline is intended to serve as a reference for healthcare professionals engaged in pediatric neuro-oncology. Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, taking into account the quality of evidence, clinical applicability, and expert consensus. Key recommendations are supported by explanatory rationale. The guideline were reviewed and approved by 35 multidisciplinary experts and 6 external reviewers, followed by formal voting on each recommendation. For areas lacking high-quality evidences, future well-designed clinical trials are recommended to validate and update these recommendations.
中文摘要:本指南由中华医学会神经外科学分会小儿神经外科学组、中国临床肿瘤学会神经肿瘤专家委员会和中国抗癌协会神经肿瘤专业委员会组织制定。颅咽管瘤是儿童鞍区最常见的肿瘤,其中大多数为造釉细胞型颅咽管瘤(ACP),少数为乳头型颅咽管瘤(PCP)。颅咽管瘤的管理不仅包括肿瘤控制,还包括肿瘤相关下丘脑功能障碍和垂体内分泌疾病的治疗。为规范儿童颅咽管瘤的诊断与管理,本指南纳入398篇文献证据,对诊断评估、手术策略、放疗原则、预后评估、随访与长期管理及靶向治疗提出推荐。本指南供从事儿童神经肿瘤工作的医疗专业人员参考。推荐采用推荐分级的评估、制定与评价(GRADE)方法制定,综合考虑证据质量、临床适用性和专家共识,关键推荐附有解释性理由。指南经35名多学科专家和6名外部评审专家审阅并批准,随后对每条推荐进行正式投票。对于缺乏高质量证据的领域,建议未来开展设计良好的临床试验以验证和更新这些推荐。
Cancer letters IF 11.8 2026-10-28 PMID: 42431390
TP53 mutations confer poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Inconsistent definitions of TP53 allelic status and limited access to routine testing impede accurate prognostic risk stratification for this high-risk myeloid population. This multicenter retrospective cohort study analyzed 303 patients with TP53-mutated AML/MDS undergoing allo-HSCT to evaluate the prognostic impact of co-occurring somatic genetic alterations. After a median follow-up of 25 months, the 3-year overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) rates were 55%, 46.9%, 35.9%, and 17.1%, respectively. Multivariate analysis confirmed complex karyotype (CK) as an independent adverse prognostic factor for both OS and PFS. Among 137 patients with available TP53 allelic data (45.2%), no statistically significant survival differences were observed between monoallelic (single-hit) and multiallelic (multi-hit) cases (OS: HR = 0.727, 95% CI 0.405-1.307, P = 0.287; PFS: HR = 0.787, 95% CI 0.466-1.328, P = 0.370), though statistical power was limited. In AML, pre-transplant complete remission (CR) improved OS, and specific concurrent genetic alterations (SCGAs: CBF fusions, NPM1, FLT3-ITD, CEBPA mutations) conferred favorable outcomes. Combined CK and SCGA status stratified AML into a three-tier prognostic model. In MDS, co-occurring myeloid mutations improved PFS; absence of co-mutations or presence of CK was associated with poor prognosis, supporting a two-tier risk framework. This Chinese Blood and Marrow Transplantation Registry Group (CBMTG) study presents an exploratory prognostic model integrating co-occurring genetic alterations, enabling feasible risk stratification for TP53-mutated AML/MDS transplant patients without comprehensive TP53 molecular profiling.
中文摘要:TP53突变使急性髓系白血病(AML)和骨髓增生异常综合征(MDS)患者接受异基因造血干细胞移植(allo-HSCT)后预后不佳。TP53等位基因状态的定义不一致,以及常规检测可及性有限,使这一高危髓系人群难以获得准确的预后风险分层。这项多中心回顾性队列研究分析了303例接受allo-HSCT的TP53突变AML/MDS患者,评估合并存在的体细胞遗传学改变对预后的影响。中位随访25个月,3年总生存(OS)率、无进展生存(PFS)率、累积复发率(CIR)和非复发死亡率(NRM)分别为55%、46.9%、35.9%和17.1%。多因素分析证实复杂核型(CK)是OS和PFS的独立不良预后因素。在137例可获得TP53等位基因资料的患者(45.2%)中,单等位基因(single-hit)与多等位基因(multi-hit)病例之间未见统计学显著的生存差异(OS:HR=0.727,95%CI 0.405-1.307,P=0.287;PFS:HR=0.787,95%CI 0.466-1.328,P=0.370),但统计效能有限。在AML中,移植前达到完全缓解(CR)可改善OS,特定的共存遗传学改变(SCGAs:CBF融合、NPM1、FLT3-ITD、CEBPA突变)与较好结局相关。结合CK与SCGA状态可将AML划分为三层预后模型。在MDS中,共存髓系突变可改善PFS;无共存突变或存在CK与不良预后相关,支持采用两层风险框架。这项中国血液与骨髓移植登记组(CBMTG)研究提出一个整合共存遗传学改变的探索性预后模型,能在缺乏全面TP53分子分型的情况下,对TP53突变AML/MDS移植患者进行可行的风险分层。
Cancer discovery IF 29.5 2026-10-27 PMID: 42945191
Interim results from the phase 3 HARMONi-GI1 trial demonstrate the first-in-class PD-1×VEGF bispecific antibody ivonescimab, combined with gemcitabine and cisplatin, significantly improved overall survival compared with durvalumab plus the same chemotherapy backbone in advanced biliary tract cancer. The regimen may represent a new standard of care for first-line advanced biliary tract cancer, though questions regarding patient selection and applicability beyond Chinese populations remain.
中文摘要:3期HARMONi-GI1试验的中期结果显示,首创的PD-1×VEGF双特异性抗体ivonescimab联合吉西他滨和顺铂,与度伐利尤单抗联合同一化疗骨架相比,在晚期胆道癌中显著改善总生存期。该方案可能成为晚期胆道癌一线治疗的新标准,但患者选择以及在中国人群之外的适用性仍存疑问。
Molecular psychiatry IF 10.4 2026-10-27 PMID: 42934261
To systematically synthesize evidence on the association between antipsychotic medication use and diverse outcomes in individuals with schizophrenia, we searched PubMed, Embase, PsycINFO, and Web of Science from inception to May 1, 2026. Eligible studies were observational studies reporting associations between antipsychotic use and clinical outcomes in individuals with schizophrenia. Two reviewers independently extracted data and assessed study quality. Data was synthesized using multilevel random-effects models. Outcomes were categorized into mortality (including all-cause and cause-specific), somatic disorders, and other clinical outcomes. Sixty-eight studies comprising 1,424,455 individuals were included. Among individuals with schizophrenia, antipsychotic use was associated with lower all-cause mortality (pooled estimate, 0.64; 95% CI, 0.54-0.77) and lower relapse risk (pooled estimate, 0.34; 95% CI, 0.12-0.99) compared with nonuse. In contrast, compared with nonuse, antipsychotic use was associated with higher risks of cancer (1.41; 95% CI, 1.17-1.69), fractures (1.35; 95% CI, 1.17-1.56), and lung infections (1.25; 95% CI, 1.04-1.51), whereas evidence for other outcomes was non-significant. Overall, the evidence base was limited, with several pooled estimates derived from a small number of studies. Subgroup analyses suggested variation by region and study design. Antipsychotic use was associated with lower all-cause mortality and relapse risk, alongside increased risks for some adverse outcomes such as fractures and lung infections. These findings should be interpreted cautiously, as residual confounding and bias may influence the observed associations and preclude causal interpretation. Further studies using rigorous designs are needed to clarify outcome-specific associations.
中文摘要:系统整合精神分裂症患者中抗精神病药使用与多种结局相关性的证据,检索PubMed、Embase、PsycINFO和Web of Science自建库至2026年5月1日。纳入报告抗精神病药使用与精神分裂症患者临床结局相关性的观察性研究。两名评价者独立提取数据并评估研究质量。采用多水平随机效应模型合并数据。结局分为死亡(全因和特定原因)、躯体疾病及其他临床结局。共纳入68项研究、1,424,455名个体。在精神分裂症患者中,与未使用相比,抗精神病药使用与较低的全因死亡率(合并估计值0.64;95% CI 0.54-0.77)和较低的复发风险(0.34;95% CI 0.12-0.99)相关。与未使用相比,抗精神病药使用与较高的癌症(1.41;95% CI 1.17-1.69)、骨折(1.35;95% CI 1.17-1.56)和肺部感染(1.25;95% CI 1.04-1.51)风险相关,其他结局的证据不显著。总体证据基础有限,若干合并估计来自少量研究。亚组分析提示地区和研究设计间存在差异。抗精神病药使用与较低的全因死亡率和复发风险相关,同时与骨折和肺部感染等部分不良结局风险升高相关。这些发现应谨慎解读,残余混杂和偏倚可能影响观察到的关联,不能作因果解释。需要采用严谨设计进一步研究以明确特定结局的关联。
HemaSphere IF 11.3 2026-10 PMID: 42936704
The aims of this study were to assess the prognostic value for progression-free survival (PFS) and the diagnostic value (detection rate of multiple myeloma [MM]-related medullary and extra-medullary disease) of whole-body simultaneous [18F]fluorodeoxyglucose-positron emission tomography coupled with magnetic resonance imaging (WB[18F]FDG-PET/MRI) performed before and after idecabtagene-vicleucel (ide-cel) therapy in patients with triple-class (or more) relapsed/refractory multiple myeloma (RRMM). A total of 73 patients were prospectively enrolled in this monocentric cohort, and 72 of them underwent WB[18F]FDG-PET/MRI imaging before ide-cel (after personalized bridging therapy). Overall, active disease was detected in 64/72 patients (89%). Multivariate analyses showed that the presence of diffuse bone marrow involvement (BMI) pattern on PET (hazard ratio [HR]: 2.65; 95% CI: 1.16-6.1, P = 0.02) or MRI (HR: 2.69; 95% CI: 1.28-5.66, P = 0.009) was associated with shorter PFS. A total of 66 patients underwent [18F]FDG-PET/MRI for response to ide-cel therapy assessment. Diffusion-weighted MRI (DW-MRI) detected residual disease (response assessment category [RAC]2 or higher according to MY-RADS) in 9/66 patients (14%) and PET (no complete metabolic response according to Deauville score) in 7/66 patients (11%). Overall, [18F]FDG-PET/MRI increased residual disease detection to 13 of 66 patients (20%). Patients with residual disease on DW-MRI (RAC2 or higher) had shorter PFS (HR: 4.11; 95% CI: 1.8-9.4; P < 10-3) than those without (RAC1). Achieving at least a partial metabolic response on PET significantly improved the PFS (P = 0.0046) as well. The combination of [18F]FDG-PET and DW-MRI enabled the identification of three distinct risk groups, including a very high-risk group defined by both MRI and PET positivity.
中文摘要:该研究旨在评估三线及以上复发或难治性多发性骨髓瘤(RRMM)患者在接受idecabtagene-vicleucel(ide-cel)治疗前后行全身同步[18F]氟脱氧葡萄糖-正电子发射断层显像/磁共振成像(WB[18F]FDG-PET/MRI)对无进展生存期(PFS)的预后价值,以及对多发性骨髓瘤(MM)相关髓内和髓外病变检出率的诊断价值。单中心队列前瞻性纳入73例患者,其中72例在ide-cel输注前(个体化桥接治疗后)接受WB[18F]FDG-PET/MRI检查。72例中64例(89%)检出活动性疾病。多因素分析显示,PET上弥漫性骨髓受累(BMI)模式(风险比[HR]:2.65;95% CI:1.16-6.1,P=0.02)或MRI上弥漫性BMI模式(HR:2.69;95% CI:1.28-5.66,P=0.009)与更短PFS相关。66例患者接受[18F]FDG-PET/MRI以评估对ide-cel治疗的应答。弥散加权MRI(DW-MRI)在9/66例(14%)中检出残留病(按MY-RADS标准为应答评估类别[RAC]2或更高),PET在7/66例(11%)中未达到完全代谢缓解(按Deauville评分)。总体而言,[18F]FDG-PET/MRI使残留病检出增至66例中的13例(20%)。DW-MRI显示残留病(RAC2或更高)的患者PFS短于无残留病(RAC1)者(HR:4.11;95% CI:1.8-9.4;P<10⁻³)。PET达到至少部分代谢缓解也显著改善PFS(P=0.0046)。[18F]FDG-PET与DW-MRI联合可识别三个不同风险组,其中包括由MRI和PET均阳性定义的极高危组。
European urology IF 29.1 2026-10-26 PMID: 42934071
Innovations have improved outcomes in high-risk localised, locally advanced, and biochemically recurrent prostate cancer (PC), yet high-level evidence remains limited for many management decisions. The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed an international panel on key clinical questions to complement evidence-based guidelines. Here we present the voting results for the questions on high-risk localised, locally advanced, and biochemically recurrent PC from APCCC 2026. Before the conference, a multidisciplinary panel of 144 international PC experts used a modified Delphi process to develop 313 multiple-choice consensus questions, of which 134 covered high-risk localised and locally advanced PC, including prostate-specific antigen (PSA) persistence and PSA recurrence, and side effects of treatment. These questions were administered to the 133 voting panel members "panellists" via a web-based survey prior to the conference. Consensus was defined a priori as ≥75% agreement, with strong consensus defined as ≥90% agreement. Overall, consensus was reached for 44 of the 134 questions (32.8%), with seven questions reaching a strong consensus. Results and limitations The voting results show varying degrees of consensus, as discussed in this article and as detailed in the Supplementary Material. An interactive heat map for the questions can be found at https://apccc.org/APCCC2026-votings-localised-and-locally-advanced-prostate-cancer/. These findings do not include a formal literature review or meta-analysis. The voting results can help physicians and patients navigate controversial areas of clinical management for which evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Importantly, APCCC 2026 once again identified important gaps (areas of no consensus) that merit evaluation in specifically designed trials.
中文摘要:创新已改善高危局限性、局部晚期和生化复发前列腺癌(PC)的结局,但许多管理决策仍缺乏高级别证据。2026年晚期前列腺癌共识会议(APCCC)就关键临床问题对国际专家组进行调查,以补充循证指南。这里呈现APCCC 2026中关于高危局限性、局部晚期和生化复发PC问题的投票结果。会议前,由144名国际PC专家组成的多学科专家组采用改良Delphi流程制定了313个多项选择共识问题,其中134个涉及高危局限性和局部晚期PC,包括前列腺特异性抗原(PSA)持续存在和PSA复发以及治疗副作用。这些问题在会议前通过基于网络的调查发给133名投票专家组成员。共识预先定义为一致率≥75%,强共识定义为一致率≥90%。总体上,134个问题中有44个(32.8%)达成共识,7个问题达成强共识。结果与局限性:投票结果显示不同程度共识,本文讨论并详见补充材料。问题交互式热图见https://apccc.org/APCCC2026-votings-localised-and-locally-advanced-prostate-cancer/。这些发现不包括正式文献综述或荟萃分析。投票结果可帮助医生和患者应对证据稀少或矛盾的临床管理争议领域,也可帮助资助者和政策制定者确定未来研究的优先领域。APCCC 2026再次识别出重要空白(未达成共识的领域),值得在专门设计的试验中评估。
Blood IF 23.9 2026-10-26 PMID: 42932250
Donor cell-derived hematologic neoplasm (DDHN) is defined as a de novo hematologic malignancy originated from transplanted donor stem cells, distinct from the original recipient's disease (ORD). Its prevalence and biological mechanisms remain poorly defined. We conducted a nationwide study to estimate the prevalence of DDHN and characterize its clinical and molecular features. Twenty-four transplantation centers systematically reviewed their allogeneic hematopoietic stem cell transplantation (allo-HSCT) cohorts. DDHN diagnosis required cytogenetic or molecular donor-origin confirmation. Molecular studies included germline-augmented targeted NGS, whole-exome sequencing, and donor-recipient comparative analyses. We identified 39 DDHN cases diagnosed between 2007 and 2025. Among 8,465 allo-HSCT performed between 2013-2022, DDHN prevalence was 0.28%, with a marked predominance after related-donor compared with unrelated transplantation (0.41% vs. 0.06%, p=0.0026). Median latency from transplantation to DDHN diagnosis was 56 months. Most DDHN were myeloid neoplasms, predominantly myelodysplastic neoplasms (51%) and acute myeloid leukemia (36%). Molecular characterization, available in 33 cases, revealed germline predisposition as the predominant underlying mechanism. Pathogenic/likely pathogenic germline variants were identified in 10 cases, involving DDX41 (n=7), CEBPA (n=2), and CHEK2 (n=1), all after a related-donor transplantation. DDX41-associated DDHN showed recurrent somatic hits and low genomic complexity. Donor-derived clonal hematopoiesis was confirmed in only one myeloid case involving U2AF1. These findings support inherited germline predisposition as the potential main molecular driver of DDHN after related allo-HSCT, reinforcing the recommendation for comprehensive germline evaluation of patients at ORD diagnosis prior to transplantation, followed by targeted cascade screening of candidate related donors.
中文摘要:供者细胞来源血液肿瘤(DDHN)是指起源于移植供者干细胞的新发血液系统恶性肿瘤,与原受者疾病(ORD)不同。其患病率和生物学机制仍不明确。我们开展了一项全国性研究,以估计DDHN的患病率并描述其临床和分子特征。24家移植中心系统回顾了各自异基因造血干细胞移植(allo-HSCT)队列。DDHN诊断需要细胞遗传学或分子学证据确认供者来源。分子研究包括增强胚系检测的靶向二代测序、全外显子测序以及供受者比较分析。我们识别出2007年至2025年间诊断的39例DDHN。在2013年至2022年间实施的8465例allo-HSCT中,DDHN患病率为0.28%,亲属供者移植后明显高于无关供者移植(0.41% vs. 0.06%,p=0.0026)。从移植到DDHN诊断的中位潜伏期为56个月。大多数DDHN为髓系肿瘤,主要为骨髓增生异常性肿瘤(51%)和急性髓系白血病(36%)。33例可获得分子特征,分析显示胚系易感性是主要潜在机制。10例检出致病/可能致病胚系变异,涉及DDX41(n=7)、CEBPA(n=2)和CHEK2(n=1),均发生于亲属供者移植后。DDX41相关DDHN表现为复发性体细胞打击和低基因组复杂性。仅1例髓系病例确认供者来源克隆性造血,涉及U2AF1。这些发现支持遗传性胚系易感性是亲属供者allo-HSCT后DDHN的潜在主要分子驱动因素,强化了在移植前于ORD诊断时对患者进行全面胚系评估、随后对候选亲属供者进行靶向级联筛查的建议。
Nature medicine IF 52.5 2026-10-24 PMID: 42926233
Growth differentiation factor-15 (GDF-15) is overexpressed in muscle-invasive bladder cancer (MIBC) and was recently identified as a potential therapeutic target to overcome resistance to programmed cell death protein 1/programmed death ligand 1 (PDL1) blockade. We investigated the safety and efficacy of GDF-15 blockade in an exploratory, stratified, placebo-controlled, single-blinded, nonrandomized phase 2a trial (GDFATHER-NEO). Thirty-one cisplatin-ineligible or cisplatin-refusing patients with newly diagnosed MIBC (clinical T2-T4aN0M0) were stratified by tumor stage and PDL1 combined positive score (CPS) and allocated sequentially to receive three cycles of neoadjuvant nivolumab (N, 480 mg 4-weekly) plus the GDF-15-neutralizing antibody visugromab (V, 20 mg kg-1 4-weekly; n = 16) or placebo (P, n = 15), followed by radical cystectomy or repeat transurethral resection of the bladder tumor. Locally assessed pathologic complete response (pCR, ypT0N0/x) and Response Evaluation Criteria in Solid Tumors v1.1-based radiographic response served as dual primary endpoints. pCR was 33% (5 of 15, 95% confidence interval (CI) 12-62%) in patients receiving N + V versus 8% (1 of 13, 95% CI 0-36%) for N + P; major pathologic response was 60% (95% CI 32-84%) versus 23% (95% CI 5-54%), and radiographic overall response rate was 60% (95% CI 32-84%) versus 15% (95% CI 2-45%), respectively. Responses to N + V were associated with higher baseline densities of total and proliferating (Ki-67+) CD8+ T cells, but independent of CPS and baseline GDF-15 levels in serum and tumor. There were no treatment-related discontinuations or treatment-related delays to surgery; grade 3-4 treatment-related adverse events occurred in two (13%) and three (20%) patients treated with N + V or N + P, respectively. These findings support further evaluation of visugromab in MIBC. ClinicalTrials.gov identifier: NCT06059547 .
中文摘要:生长分化因子15(GDF-15)在肌层浸润性膀胱癌(MIBC)中过表达,近期被确定为克服程序性细胞死亡蛋白1/程序性死亡配体1(PD-L1)阻断耐药的潜在治疗靶点。GDFATHER-NEO是一项探索性、分层、安慰剂对照、单盲、非随机2a期试验,评估GDF-15阻断的安全性和疗效。31例新诊断MIBC(临床T2-T4aN0M0)、不适合或拒绝顺铂的患者按肿瘤分期和PD-L1联合阳性评分(CPS)分层,序贯分配接受三个周期新辅助纳武利尤单抗(N,480 mg,每4周一次)联合GDF-15中和抗体visugromab(V,20 mg/kg,每4周一次;n=16)或安慰剂(P,n=15),随后行根治性膀胱切除术或重复经尿道膀胱肿瘤电切术。局部评估的病理完全缓解(pCR,ypT0N0/x)和基于RECIST v1.1的影像学缓解为双主要终点。N+V组pCR为33%(5/15,95%CI 12-62%),N+P组为8%(1/13,95%CI 0-36%);主要病理缓解分别为60%(95%CI 32-84%)和23%(95%CI 5-54%);影像学总缓解率分别为60%(95%CI 32-84%)和15%(95%CI 2-45%)。N+V的缓解与基线总CD8+ T细胞及增殖性(Ki-67+)CD8+ T细胞密度较高相关,但与CPS及血清和肿瘤基线GDF-15水平无关。无治疗相关停药或治疗相关手术延迟;3-4级治疗相关不良事件在N+V组和N+P组分别发生于2例(13%)和3例(20%)患者。这些结果支持在MIBC中进一步评估visugromab。ClinicalTrials.gov注册号:NCT06059547。

基础研究 (71篇)

Clinical reviews in allergy & immunology IF 11.5 2026-10-31 PMID: 42963446
Complement activation-related pseudoallergy (CARPA) describes a proposed non-IgE-mediated hypersensitivity mechanism in which complement activation contributes causally, often through generation of the anaphylatoxins C3a and C5a. These mediators may activate responsive effector cells and contribute to systemic inflammatory responses that clinically resemble anaphylaxis. Complement activation and complement-associated immediate reactions have been reported with several therapeutic agents and drug-delivery systems, including micelle-solubilized formulations, liposomal drugs, nanoparticle-based therapeutics, PEGylated agents, and biologic therapies; however, the strength of causal evidence varies among products. Importantly, reactions may be driven not only by the active pharmaceutical ingredient but also by formulation components, such as surfactants, solubilizing agents, lipid carriers, and other drug vehicles. As compounded injectable therapies, including intralesional dutasteride, become increasingly used in dermatology, clinicians should recognize that formulation vehicles vary among manufacturers and compounding pharmacies. Certain formulations may contain complement-activating excipients, such as Cremophor EL (polyoxyethylated castor oil), which has been implicated in immediate pseudoallergic reactions. Although CARPA has been widely discussed in oncology, immunology, and nanomedicine, its relevance to a broader range of infusion and injectable therapies remains underrecognized. This narrative review summarizes the mechanisms, clinical features, drug classes, and formulation-related risk factors associated with complement activation and complement-associated reactions, with particular attention to injectables and compounded therapies. Greater awareness of complement-activating formulations may help recognize pseudoallergic reactions, evaluate excipients more carefully, and improve the safe administration of infusion and injectable therapies.
中文摘要:补体激活相关假性过敏(CARPA)描述一种提出的非IgE介导的超敏反应机制,其中补体激活具有因果作用,常通过生成过敏毒素C3a和C5a实现。这些介质可激活有反应性的效应细胞,并促成临床上类似过敏性休克的全身炎症反应。已有多种治疗药物和给药系统报告补体激活及补体相关即刻反应,包括胶束增溶制剂、脂质体药物、纳米颗粒治疗剂、聚乙二醇化药物和生物制剂;不过各产品的因果证据强度不一。反应不仅可由活性药物成分驱动,也可由制剂组分驱动,如表面活性剂、增溶剂、脂质载体和其他药物载体。随着包括病灶内度他雄胺在内的配制注射疗法在皮肤科应用增多,临床医生应认识到不同生产商和配制药房所用的制剂载体存在差异。某些制剂可能含有补体激活辅料,如Cremophor EL(聚氧乙烯化蓖麻油),其与即刻假性过敏反应有关。CARPA在肿瘤学、免疫学和纳米医学中已有广泛讨论,但其与更广泛输注和注射疗法的相关性仍未被充分认识。该叙述性综述总结补体激活及补体相关反应相关机制、临床特征、药物类别和制剂相关危险因素,特别关注注射剂和配制疗法。提高对补体激活制剂的认知,有助于识别假性过敏反应、更仔细评估辅料,并改善输注和注射疗法的安全给药。
Trends in cancer IF 21.6 2026-10-30 PMID: 42963251
Multiplexed spatial profiling has shown that tumor architecture influences therapy response, yet few spatial phenotypes are in clinical use. We opine that the immediate priority is simplification and validation of complex spatial features. We draw a parallel to cartography: maps are useful because they carry a limited set of named features whose meaning is agreed. Tumor maps could be built the same way: from the presence of a defined cell type, its proximity to another, its location within a tissue compartment, its state of activation, or combinations of these. Such features may have more clinical applicability than variable, unsupervised two-dimensional 'neighborhoods'. We propose cancer cartography as the process of assembling such validated features into tumor maps that guide treatment selection.
中文摘要:多重空间分析显示,肿瘤结构会影响治疗反应,但真正进入临床使用的空间表型仍很少。我们认为当务之急是简化并验证复杂的空间特征。可以类比制图学:地图之所以有用,是因为它只承载有限的一组具名要素,且这些要素的含义已获公认。肿瘤图谱亦可照此构建:依据某一明确细胞类型的存在、它与另一细胞类型的邻近关系、它在组织分区中的位置、它的活化状态,或上述要素的组合。相比多变的无监督二维「邻域」,这类特征可能更具临床适用性。我们提出「肿瘤制图」这一过程,即把此类经检验的特征组装成肿瘤图谱,用以指导治疗选择。
Journal of advanced research IF 17.1 2026-10-30 PMID: 42962913
CMTM6 is known to stabilize PD-L1 on cancer cells, facilitating immune evasion, but its role in normal hematopoiesis remains unexplored. Hematopoietic stem cell (HSC) homeostasis is tightly regulated by interferon (IFN) signaling, yet the mechanisms controlling IFN receptor stability are unclear. In this study we investigated whether CMTM6 regulates HSC maintenance and elucidated the underlying molecular pathways. Using a conditional Cmtm6 knockout mouse model (Vav-Cre), we performed flow cytometry, competitive transplantation, single-cell RNA sequencing, co-immunoprecipitation, and functional assays on bone marrow HSCs. Cmtm6 deficiency led to increased HSC proliferation but impaired reconstitution capacity, accompanied by elevated DNA damage and disrupted cell polarity. Single-cell analysis revealed a marked reduction in IFN response pathways. Mechanistically, CMTM6 directly interacted with IFNAR1 and IFNGR1, stabilizing their protein expression. Downstream, Cmtm6 deletion impaired STAT1 phosphorylation and reduced KLF4 expression; single-cell analysis revealed a significant positive correlation between Stat1 activity and Klf4 expression, and STAT1 inhibition in HSCs confirmed that STAT1 activity is required for maintaining KLF4 expression. Notably, KLF4 overexpression partially rescued colony-forming defects and reduced γH2AX foci in Cmtm6-deficient HSCs, identifying KLF4 as a key downstream effector. Additionally, we observed accompanying molecular changes including reduced SIAH2, elevated DYRK2, decreased c-MYC, and increased P53, which may contribute to the observed phenotypes. These findings demonstrate that CMTM6 maintains HSC homeostasis by stabilizing IFN receptors and regulating the IFNR-STAT1-KLF4 signaling axis, revealing a novel physiological function for CMTM6 in hematopoiesis.
中文摘要:CMTM6已知可通过稳定肿瘤细胞PD-L1促进免疫逃逸,但其在正常造血中的作用尚未被探索。造血干细胞(HSC)稳态受干扰素(IFN)信号严密调控,而控制IFN受体稳定性的机制仍不清楚。为探讨CMTM6是否调控HSC维持并阐明其分子通路,利用条件性Cmtm6敲除小鼠模型(Vav-Cre),对骨髓HSC进行流式细胞术、竞争性移植、单细胞RNA测序、免疫共沉淀和功能实验。Cmtm6缺失导致HSC增殖增加但重建能力受损,并伴随DNA损伤升高和细胞极性紊乱。单细胞分析显示IFN反应通路显著降低。机制上,CMTM6直接与IFNAR1和IFNGR1相互作用,稳定其蛋白表达。下游方面,Cmtm6缺失削弱STAT1磷酸化并降低KLF4表达;单细胞分析显示Stat1活性与Klf4表达显著正相关,HSC中抑制STAT1证实STAT1活性是维持KLF4表达所必需。KLF4过表达部分挽救Cmtm6缺陷HSC的集落形成缺陷并减少γH2AX焦点,表明KLF4是关键下游效应分子。还观察到SIAH2降低、DYRK2升高、c-MYC降低和P53升高等伴随分子变化,这些变化可能促成上述表型。这些发现表明CMTM6通过稳定IFN受体并调控IFNR-STAT1-KLF4信号轴维持HSC稳态,揭示了CMTM6在造血中的新生理功能。
Acta biomaterialia IF 10.4 2026-10-30 PMID: 42962839
The standard treatment of ovarian cancer involves surgical resection followed by chemotherapy to target residual microscopic tumors. Current chemotherapy is most commonly delivered intravenously (i.v.) because of the toxicity and difficulty in administering intraperitoneal (i.p.) chemotherapy. However, clinical trials have demonstrated that i.p. chemotherapy is superior to i.v. chemotherapy because it can achieve a higher therapeutic concentration and prolonged retention in the peritoneal cavity. To improve the efficacy and safety of i.p. chemotherapy, we developed an injectable hyaluronic acid (HA)-based hydrogel platform for combinatorial and localized delivery of bevacizumab (BVZ), albumin-bound paclitaxel (nab-paclitaxel, nab-PTX) and carboplatin (CPT) in a manner that responds to the high level of matrix metalloproteinases (MMPs) in the i.p. space. HA and dextran sulfate (DS) are chemically modified to allow hydrogels to form with MMP-degradable crosslinkers in less than 1 min upon injection. The in vitro release of BVZ, nab-PTX and CPT is sensitive to MMP concentration and is sustained for up to 28 days. The combined release of BVZ, nab-PTX and CPT from the hydrogels effectively inhibits angiogenesis and tumor cell proliferation in vitro. Moreover, the i.p. administration of the hydrogel system results in tumor burden reduction comparable to the multiple injections of the free drug combination, with reduced systemic side effects. Our work suggests that the injectable MMP responsive hydrogel is a promising i.p. delivery system of BVZ, nab-PTX and CPT to improve i.p. retention and clinical therapeutic effects for ovarian cancer treatment with minimum side effects. STATEMENT OF SIGNIFICANCE: This study presents the first use of hydrogels for intraperitoneal delivery of bevacizumab (BVZ), carboplatin (CPT), and albumin-bound paclitaxel (nab-PTX) to locally treat ovarian cancer. An injectable hyaluronic acid (HA)-based hydrogels platform can be engineered for combinatorial and localized delivery of BVZ, nab-PTX, and CPT in a manner that responds to the high level of matrix metalloproteinases (MMPs) in the intraperitoneal (i.p.) space. HA and dextran sulfate (DS) are chemically modified to allow hydrogels to form with MMP-degradable crosslinkers in less than 1 min upon injection. The combined release of BVZ, nab-PTX and CPT from the hydrogels results in tumor burden reduction comparable to the multiple injections of the free drug combination, with reduced systemic side effects. This work significantly impacts the field of stimuli-responsive biomaterials and cancer therapeutics by offering a robust, modular, and translationally promising drug delivery platform.
中文摘要:卵巢癌的标准治疗包括手术切除后化疗,以针对残留的微小肿瘤。当前化疗最常采用静脉给药,原因是腹腔化疗具有毒性且给药困难。临床试验已证明腹腔化疗优于静脉化疗,因为它能在腹腔内达到更高的治疗浓度并延长滞留时间。为提高腹腔化疗的疗效和安全性,我们开发了一种可注射的透明质酸基水凝胶平台,用于贝伐珠单抗、白蛋白结合型紫杉醇和卡铂的组合与局部递送,并以腹腔内高水平基质金属蛋白酶为响应条件。透明质酸和硫酸葡聚糖经化学修饰,使水凝胶在注射后不到1分钟内与可被基质金属蛋白酶降解的交联剂形成。贝伐珠单抗、白蛋白结合型紫杉醇和卡铂的体外释放对基质金属蛋白酶浓度敏感,并可持续长达28天。水凝胶释放的三种药物联合可有效抑制体外血管生成和肿瘤细胞增殖。腹腔给予该水凝胶系统可使肿瘤负荷降低程度与多次注射游离药物组合相当,同时减少全身副作用。我们的工作表明,可注射的基质金属蛋白酶响应水凝胶是有前景的腹腔递送系统,可递送贝伐珠单抗、白蛋白结合型紫杉醇和卡铂,改善腹腔滞留和临床治疗效果,并以最少副作用治疗卵巢癌。意义声明:本研究首次使用水凝胶腹腔递送贝伐珠单抗、卡铂和白蛋白结合型紫杉醇以局部治疗卵巢癌。可注射的透明质酸基水凝胶平台可被设计用于贝伐珠单抗、白蛋白结合型紫杉醇和卡铂的组合与局部递送,并以腹腔内高水平基质金属蛋白酶为响应条件。透明质酸和硫酸葡聚糖经化学修饰,使水凝胶在注射后不到1分钟内与可被基质金属蛋白酶降解的交联剂形成。水凝胶释放的三种药物联合可使肿瘤负荷降低程度与多次注射游离药物组合相当,同时减少全身副作用。这项工作通过提供稳健、模块化且具有转化前景的药物递送平台,对刺激响应生物材料和癌症治疗领域产生重要影响。
Immunity IF 30.6 2026-10-30 PMID: 42962666
Cells experiencing mitochondrial stress can undergo apoptosis or cell death that triggers innate immune activation. We examined the mechanisms determining these distinct outcomes in cancer. Abundant mitochondrial DNA (mtDNA) and high expression of the cGAS-STING pathway were features of KRAS-mutant cancers. In a pharmacological screen, MEK inhibitor (MEKi) effectively induced mtDNA release into the cytosol in KRAS-mutant cancer cells. However, MEKi also induced PRKN-mediated mitophagy, which limited mtDNA release by eliminating damaged mitochondria. Inhibition of mitophagy sustained mtDNA efflux and amplified cGAS-STING signaling. Mechanistically, PRKN-mediated mitophagy restrained mitochondrial outer membrane permeabilization (MOMP) to limit mtDNA efflux. The balance between mtDNA and cytochrome c (cyt.c) release defined two immunologically distinct outcomes: immunogenic cell death (ICD) and apoptosis. In preclinical models, combined inhibition of MEK and mitophagy induced robust dendritic cell (DC) activation and promoted CD8+ T cell-mediated antitumor immunity. Consistently, PRKN expression negatively correlated with immune infiltration in human cancers. Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity.
中文摘要:经历线粒体应激的细胞可发生凋亡,或发生触发固有免疫激活的细胞死亡。我们考察了决定癌症中这些不同结局的机制。线粒体DNA(mtDNA)丰度高和cGAS-STING通路高表达是KRAS突变癌症的特征。在药物筛选中,MEK抑制剂(MEKi)有效诱导KRAS突变癌细胞中mtDNA释放至胞质。但MEKi也诱导PRKN介导的线粒体自噬,通过清除受损线粒体限制mtDNA释放。抑制线粒体自噬可维持mtDNA外流并放大cGAS-STING信号。机制上,PRKN介导的线粒体自噬抑制线粒体外膜通透化(MOMP),从而限制mtDNA外流。mtDNA与细胞色素c(cyt.c)释放之间的平衡决定两种免疫学上不同的结局:免疫原性细胞死亡(ICD)与凋亡。在临床前模型中,联合抑制MEK和线粒体自噬可诱导强烈的树突状细胞(DC)活化,并促进CD8+ T细胞介导的抗肿瘤免疫。与此一致,PRKN表达与人类癌症中的免疫浸润呈负相关。这些发现为靶向线粒体动态以增强抗肿瘤免疫的联合策略提供了依据。
Science advances IF 13.9 2026-10-30 PMID: 42962036
The assembly of cellular spheroids into spatially organized assembloids represents a transformative paradigm for modeling complex biological systems. However, the lack of standardized fabrication strategies fundamentally limits the precision and reproducibility of these models, hindering their widespread application. Here, we present a robotic micromanipulation platform-Fluid-Driven Tweezer with Visual Servo Control (FDT-VSC). By integrating multidimensional visual perception with microfluidic control, our system enables the gentle and programmable assembly of diverse cellular spheroids. Leveraging this platform, we achieve the bottom-up construction of structurally defined, heterogeneous multicellular tissues, and the programmed orchestration of multilineage models that recapitulate the complex microenvironments of early organogenesis. Crucially, the system improves consistency during the scalable fabrication of tumor-stroma assembloids, supporting reliable drug screening. These results demonstrate that FDT-VSC advances assembloid-based applications across modular tissue engineering, developmental biology, and drug discovery.
中文摘要:将细胞球体组装成具有空间组织的组装体,为模拟复杂生物系统提供了变革性范式。标准化制造策略的缺乏从根本上限制了这类模型的精度与可重复性,阻碍其广泛应用。研究提出机器人微操作平台——带视觉伺服控制的流体驱动镊子(FDT-VSC)。该平台整合多维视觉感知与微流控,能够温和且可编程地组装多种细胞球体。利用该平台,实现了结构明确的异质多细胞组织的自下而上构建,并按程序编排多谱系模型,以重现早期器官发生的复杂微环境。该系统在肿瘤-基质组装体的可扩展制造中提高了一致性,支持可靠的药物筛选。这些结果表明,FDT-VSC推动了基于组装体的应用,覆盖模块化组织工程、发育生物学和药物发现。
Science advances IF 13.9 2026-10-30 PMID: 42962019
Sprouting angiogenesis is critical for embryogenesis, wound healing, and tumor growth. Here, we show that the liquid crystal framework, which has recently been leveraged to study various morphogenetic events, provides unique insight into angiogenic sprouting. In response to vascular endothelial growth factor, a potent proangiogenic factor, endothelial cells cultured on the surfaces of soft collagen hydrogels form elongated cell streams that coexist with more polygonal cell regions. Angiogenic sprouting initiates preferentially at cell stream tips, where nematic order gradients are most pronounced. We demonstrate that cell streams are associated with large traction forces that lead to three-dimensional deformations of the underlying hydrogel and that stream formation results from a delicate balance between microtubule polymerization and actomyosin contractility. Last, we show that active control of nematic order allows modulation of sprout formation, highlighting the key role of endothelial cell orientation gradients in angiogenic sprouting and paving the way for new therapeutic avenues.
中文摘要:出芽性血管生成对胚胎发育、伤口愈合和肿瘤生长至关重要。本工作表明,近来被用于研究多种形态发生事件的液晶框架,为血管生成出芽提供了独特见解。在强效促血管生成因子血管内皮细胞生长因子作用下,培养于软胶原水凝胶表面的内皮细胞形成伸长的细胞流,并与较多边形细胞区域共存。血管生成出芽优先起始于细胞流末端,该处向列序梯度最为显著。细胞流与较大的牵引力相关,牵引力引起下方水凝胶的三维形变;细胞流的形成源于微管聚合与肌动球蛋白收缩性之间的精细平衡。主动调控向列序可调节出芽形成,凸显内皮细胞取向梯度在血管生成出芽中的关键作用,并为新的治疗途径奠定基础。
Science advances IF 13.9 2026-10-30 PMID: 42962015
PDS5A, a cohesin regulatory subunit, and topoisomerase IIB (TOP2B), an enzyme resolving DNA topological problems, interact with CTCF and regulate transcription and genome organization. We ascertained that PDS5A and TOP2B are recruited to CTCF-bound chromatin cooperatively and that catalytically active TOP2B increases PDS5A occupancy genome wide. Notably, the amino-terminal 95 to 116 amino acids of CTCF interacts with PDS5A, giving rise to CTCF-PDS5A-TOP2B interaction in vitro and to PDS5A chromatin enrichment via active TOP2B in vivo. PDS5A-TOP2B function together in moderating the resultant gene expression and genome organization. Loss of CTCF (95 to 116 amino acids) led to dysregulated gene expression and mildly reduced chromatin loops. In gliomas, PDS5A and TOP2B expression levels vary, but correlate, contributing to distinctive gene expression patterns. Inducible PDS5A knockdown led to reduced TOP2B occupancy and altered gene expression. Furthermore, PDS5A mediated sensitivity to TOP2 cancer drugs in glioma cells. This functional interaction between PDS5A and TOP2B at CTCF boundaries expands upon the mechanisms affecting gene regulation through genome organization, with implications for glioma therapeutics.
中文摘要:黏连蛋白调节亚基PDS5A与解决DNA拓扑问题的拓扑异构酶IIB(TOP2B)均与CTCF相互作用,并调控转录和基因组组织。PDS5A与TOP2B协同募集至CTCF结合的染色质,具有催化活性的TOP2B可在全基因组范围提高PDS5A的占据。CTCF氨基端第95至116位氨基酸与PDS5A相互作用,在体外形成CTCF-PDS5A-TOP2B相互作用,并在体内通过活性TOP2B促进PDS5A的染色质富集。PDS5A与TOP2B共同调节由此产生的基因表达和基因组组织。缺失CTCF第95至116位氨基酸导致基因表达失调并轻度减少染色质环。在胶质瘤中,PDS5A与TOP2B的表达水平存在差异但彼此相关,并促成不同的基因表达模式。诱导型PDS5A敲低导致TOP2B占据减少和基因表达改变。PDS5A还介导胶质瘤细胞对靶向TOP2的肿瘤药物的敏感性。PDS5A与TOP2B在CTCF边界处的功能互作拓展了通过基因组组织影响基因调控的机制,并对胶质瘤治疗具有意义。
Science advances IF 13.9 2026-10-30 PMID: 42962008
Epithelial surfaces are the primary sites of lytic herpes simplex virus 1 (HSV-1) infection following initial exposure or reactivation from latency. To model this complex environment, we used human hair-bearing skin organoids and combined single-cell spatial transcriptomics with imaging to map viral spread and host responses across skin architecture. Our data suggest delayed progression of the HSV-1 life cycle in epidermal keratinocytes and hair follicle cells compared to the dermis. Infection triggered spatially organized host responses, including induction of IER3 in papillary fibroblasts. In basal keratinocytes, IRF3 was up-regulated in both infected and neighboring uninfected cells, consistent with paracrine activation of antiviral signaling. Inflammatory responses were compartmentalized in a cell type-specific manner, with TNFSF9 (4-1BBL) induced in papillary fibroblasts and tumor necrosis factor-α (TNF-α) induced in keratinocytes. Enzyme-linked immunosorbent assays confirmed secretion of these cytokines and the TNF-α-responsive chemokines CXCL2 and CXCL10. CXCL2 expression was enriched in cells adjacent to TNF-α-expressing cells, highlighting spatial coordination of inflammatory signaling. While interferon-β reduced viral replication, TNF-α and 4-1BBL did not, suggesting that their primary role is to orchestrate immune cell recruitment and activation. These findings establish human hair-bearing skin organoids as a physiologically relevant model for investigating spatial host-HSV-1 interactions.
中文摘要:上皮表面是单纯疱疹病毒1型(HSV-1)初次暴露后或潜伏再激活后裂解性感染的主要部位。为模拟这一复杂环境,研究使用人源含毛皮肤类器官,并将单细胞空间转录组学与成像结合,以绘制病毒在皮肤结构中的传播和宿主反应。数据提示,与真皮相比,HSV-1生命周期在表皮角质形成细胞和毛囊细胞中进展延迟。感染触发了空间有序的宿主反应,包括在乳头层成纤维细胞中诱导IER3。在基底角质形成细胞中,感染细胞和邻近未感染细胞的IRF3均上调,符合抗病毒信号旁分泌激活。炎症反应以细胞类型特异方式区室化,TNFSF9(4-1BBL)在乳头层成纤维细胞中诱导,肿瘤坏死因子α(TNF-α)在角质形成细胞中诱导。酶联免疫吸附试验证实这些细胞因子以及TNF-α反应性趋化因子CXCL2和CXCL10的分泌。CXCL2表达富集于邻近表达TNF-α的细胞,显示炎症信号的空间协调。干扰素β降低病毒复制,TNF-α和4-1BBL未降低病毒复制,提示它们的主要作用是协调免疫细胞募集和激活。这些发现确立人源含毛皮肤类器官作为研究宿主与HSV-1空间相互作用的生理相关模型。
Nucleic acids research IF 15.0 2026-10-30 PMID: 42958970
Sex is a critical determinant of cancer susceptibility, clinical prognosis, and therapeutic response. Sex chromosome aberrations, particularly somatic loss of the Y chromosome (LOY) in male malignancies, exert profound impacts on transcriptional regulation, tumor immune microenvironment remodeling, and malignant progression, highlighting an urgent demand for comprehensive integration of single-cell and spatial omics profiles dissecting sex-biased and LOY landscapes across human cancers. Here, we developed XYcellAtlas (http://www.xycellatlas.top/), an integrative database for integration and multidimensional visualization of sex disparities and LOY features across human tissues at single-cell transcriptomic, epigenomic, and spatial-transcriptomic resolutions. This resource aggregates data from 6764 patient samples covering 18 cancer types, eight precancerous lesions, and 21 tissue origins, encompassing over 25.8 million single cells and one million spatial-transcriptomic spots. Leveraging random forest classifiers trained on normal tissue datasets, XYcellAtlas quantifies cell-type-specific LOY frequencies across cell types. Furthermore, it systematically catalogs sex-biased and LOY-associated molecular alterations, including differentially expressed genes, chromatin peaks, core transcription factors, as well as their functional annotations and dysregulatory signatures within malignant cells and the tumor microenvironment. In summary, XYcellAtlas provides a unified, all-in-one analytical platform enabling researchers to query, inspect, quantify, and visualize sex-associated and LOY-derived multi-omics features underlying tumor evolutionary processes.
中文摘要:性别是肿瘤易感性、临床预后和治疗反应的关键决定因素。性染色体异常,尤其是男性恶性肿瘤中Y染色体的体细胞丢失(LOY),会深刻影响转录调控、肿瘤免疫微环境重塑和恶性进展,因此亟需整合单细胞与空间组学图谱,解析人类多种癌症中的性别偏倚和LOY格局。XYcellAtlas(http://www.xycellatlas.top/)由此建立,这是一个整合数据库,可在单细胞转录组、表观基因组和空间转录组分辨率下,对人类组织中的性别差异与LOY特征进行整合和多维可视化。该资源汇集了6764例患者样本,覆盖18种癌症、8种癌前病变和21种组织来源,包含超过2580万个单细胞和100万个空间转录组spot。XYcellAtlas利用在正常组织数据集上训练的随机森林分类器,量化不同细胞类型中的LOY频率。该数据库系统收录了性别偏倚和LOY相关分子改变,包括差异表达基因、染色质峰、核心转录因子,以及这些改变在恶性细胞和肿瘤微环境中的功能注释与失调特征。XYcellAtlas提供统一的一站式分析平台,使研究者能够查询、检查、量化和可视化肿瘤演化过程中的性别相关与LOY来源的多组学特征。
Acta pharmacologica Sinica IF 10.4 2026-10-30 PMID: 42957748
Epilepsy is increasingly viewed as a systemic disorder in which recurrent seizures intersect with vascular, autonomic, respiratory, and cardiac processes to influence cardiovascular vulnerability. Seizure-related neuroinflammation involves multiple interacting mediator pathways, including HMGB1/TLR4-RAGE signaling, inflammasome/IL-1β activation, IL-6/IL-6R-gp130 signaling, albumin/TGF-β signaling following blood-brain barrier (BBB) disruption, and tumor necrosis factor-alpha (TNF-α)/TNF receptor (TNFR) signaling. Within this inflammatory network, TNF/TNFR signaling represents a mechanistically distinct and translationally relevant framework for examining how immune activation intersects with endothelial-barrier dysfunction, neurovascular unit injury, autonomic disturbance, inflammatory communication across neural and cardiovascular compartments, and cardiac vulnerability. This review integrates direct evidence from epilepsy studies with mechanistic insights from related experimental studies of BBB injury, myocardial ischemia-reperfusion injury, cardioprotection, and brain-heart communication. TNF biology is determined by ligand form, receptor subtype, cellular compartment, and disease context. Soluble TNF preferentially engages TNFR1-associated inflammatory and injury-amplifying pathways, whereas transmembrane TNF/TNFR2 signaling may support regulatory or reparative responses in selected settings. In epilepsy, seizure-associated inflammation, BBB dysfunction, glial activation, and autonomic imbalance may interact to increase susceptibility to arrhythmogenic stress, myocardial injury, adverse cardiac remodeling, and cardiorespiratory instability relevant to sudden unexpected death in epilepsy (SUDEP). However, epilepsy-specific evidence directly linking TNF/TNFR signaling to cardiovascular outcomes remains limited, and many mechanistic connections currently rely on converging evidence from neurovascular and cardiovascular research. Future studies should integrate compartment-resolved inflammatory profiling with autonomic, respiratory, electrocardiographic, and cardiac phenotyping to distinguish inflammatory signatures of disease severity from modifiable contributors to cardiovascular risk. Such approaches may enable phenotype-specific strategies to better understand and ultimately mitigate the brain-heart consequences of epilepsy.
中文摘要:癫痫日益被视为一种系统性疾病,反复发作与血管、自主神经、呼吸及心脏过程相互交织,影响心血管易感性。癫痫发作相关神经炎症涉及多条相互作用的介质通路,包括HMGB1/TLR4-RAGE信号、炎症小体/IL-1β激活、IL-6/IL-6R-gp130信号、血脑屏障破坏后的白蛋白/TGF-β信号以及肿瘤坏死因子α(TNF-α)/TNF受体(TNFR)信号。在这一炎症网络中,TNF/TNFR信号提供了一个机制上独特且具有转化相关性的框架,用于考察免疫激活如何与内皮屏障功能障碍、神经血管单元损伤、自主神经紊乱、神经与心血管隔室之间的炎症通讯以及心脏易感性相交织。本综述整合癫痫研究的直接证据与血脑屏障损伤、心肌缺血再灌注损伤、心脏保护及脑-心通讯等相关实验研究的机制见解。TNF生物学由配体形式、受体亚型、细胞隔室和疾病背景决定。可溶性TNF优先激活TNFR1相关的炎症和损伤放大通路,而跨膜TNF/TNFR2信号在特定情形下可能支持调节性或修复性反应。在癫痫中,发作相关炎症、血脑屏障功能障碍、胶质激活和自主神经失衡可能相互作用,增加对致心律失常应激、心肌损伤、不良心脏重构以及与癫痫猝死(SUDEP)相关的心肺不稳定的易感性。然而,直接将TNF/TNFR信号与心血管结局联系起来的癫痫特异性证据仍然有限,许多机制联系目前依赖神经血管和心血管研究的汇聚证据。未来研究应整合隔室分辨的炎症谱分析与自主神经、呼吸、心电图和心脏表型分析,以区分疾病严重程度的炎症特征与心血管风险的可改变贡献因素。此类方法可能促成表型特异性策略,以更好地理解并最终减轻癫痫的脑-心后果。
Science advances IF 13.9 2026-10-30 PMID: 42950051
The GDF15-GFRAL-RET neuroendocrine axis is a key regulator of body-weight homeostasis and metabolic control. GFRAL, a hindbrain-restricted receptor for the stress-responsive cytokine GDF15, signals by assembling a ternary complex with GDF15 and the tyrosine kinase RET. Pathological hyperactivation of this axis drives disease-associated weight loss, including cancer-associated cachexia. Here, we report a GFRAL-binding and GDF15-GFRAL pathway-blocking antibody (GB2Ab) and its humanized lead with potent preclinical efficacy. The GB2Ab Fab-GFRAL D3 crystal structure reveals an induced-fit mechanism in which GB2Ab sterically occludes the GFRAL-RET interface and remodels the primary RET CLD1-CLD2 binding site, providing a structural basis for high-affinity binding, slow dissociation, and potent antagonism. Structure-guided humanization preserves high-affinity and cross-reactivity. The humanized antibody reaches the area postrema, attenuates GDF15-evoked neural activation, ameliorates cachectic phenotypes, and suppresses sympathetic preganglionic activity in an orthotopic cancer cachexia model, establishing receptor-centric GDF15-GFRAL-RET antagonism as a promising strategy for cancer-associated cachexia and other GDF15-driven diseases.
中文摘要:GDF15-GFRAL-RET神经内分泌轴是体重稳态和代谢控制的关键调节通路。GFRAL是应激响应性细胞因子GDF15在后脑受限表达的受体,通过与GDF15及酪氨酸激酶RET组装三元复合物进行信号传导。该轴的病理性过度激活驱动疾病相关体重下降,包括癌症相关恶病质。研究报告一种结合GFRAL并阻断GDF15-GFRAL通路的抗体GB2Ab及其人源化先导分子,具有较强临床前 efficacy。GB2Ab Fab-GFRAL D3晶体结构揭示诱导契合机制,GB2Ab在空间上遮挡GFRAL-RET界面并重塑RET主要CLD1-CLD2结合位点,为高亲和力结合、慢解离和强效拮抗提供结构基础。结构指导的人源化保留了高亲和力和交叉反应性。人源化抗体可到达最后区,减弱GDF15诱发的神经激活,改善恶病质表型,并在原位癌症恶病质模型中抑制交感节前活动,确立以受体为中心的GDF15-GFRAL-RET拮抗作为癌症相关恶病质及其他GDF15驱动疾病的有前景策略。
Science advances IF 13.9 2026-10-30 PMID: 42950024
Intratumoral microbial antigens, which mimic tumor antigens, can be presented by human leukocyte antigen (HLA) molecules, thereby eliciting antitumor immune responses. However, a comprehensive pan-cancer characterization of such molecularly mimicking microbial epitopes is still lacking. Here, we construct a pan-cancer microbial epitope landscape from 1190 samples across 24 cancer types. Pan-cancer analyses reveal that microbial epitopes exhibit higher hydrophobicity, aliphatic indices, and stability than human epitopes. Nine HLA-I alleles tend to bind microbial epitopes, and HLA-C alleles show a stronger tendency to present microbial epitopes than HLA-A and HLA-B alleles. Moreover, we reveal that microbial species capable of generating HLA-I epitopes are more prevalent in tumors, that broadly detected epitopes span more cancer types, and that multiple microbial genera generate numerous immunogenic epitopes. Notably, homologous microbial epitopes and tumor antigens elicit cross-reactive T cell responses, and experimental evidence demonstrates that microbial epitopes exhibit enhanced immunogenicity and antitumor efficacy. Overall, our findings provide a foundation for microbial epitope vaccine development, offering insights for cancer prevention and therapy.
中文摘要:瘤内微生物抗原可模拟肿瘤抗原,并由人类白细胞抗原(HLA)分子呈递,从而引发抗肿瘤免疫应答。然而,此类分子模拟微生物表位的泛癌特征仍缺乏系统描述。该研究基于24种癌症类型的1190份样本构建泛癌微生物表位图谱。泛癌分析显示,微生物表位较人类表位具有更高的疏水性、脂肪族指数和稳定性。九种HLA-I等位基因倾向于结合微生物表位,HLA-C等位基因呈递微生物表位的倾向强于HLA-A和HLA-B等位基因。研究还发现,能够产生HLA-I表位的微生物物种在肿瘤中更常见,广泛检出的表位覆盖更多癌症类型,多个微生物属可产生大量免疫原性表位。同源微生物表位与肿瘤抗原可引发交叉反应性T细胞应答,实验证据表明微生物表位具有增强的免疫原性和抗肿瘤效力。这些发现为微生物表位疫苗开发提供基础,为癌症预防和治疗提供线索。
Journal of hazardous materials IF 10.6 2026-10-29 PMID: 42962649
Algal raceway ponds (ARPs) are considered one of the most promising technologies for the advanced treatment of wastewater treatment plant (WWTP) effluents. In this study, three parallel pilot-scale open ARPs, each assigned to one hydraulic retention time (HRT, 2, 3, or 4 d), were continuously operated for 52 d to assess nutrient and PAH removal, PAH partitioning, and microbial community succession. The 3-d system provided the most favorable observed balance between pond biomass accumulation and pollutant removal, with the highest mean pond biomass concentration (704 mg L-1 (dw)) and mean removal efficiencies of 86.52%, 95.18%, 67.74%, 91.81%, and 73.68% for TN, TP, NH4+-N, NO3--N, and Σ16PAH, respectively. Daily biomass harvesting was highest at 2 d (14.9 g m-2 d-1 (dw)). At the 3-d HRT, the mean removal efficiencies of low-molecular-weight (LMW) and high-molecular-weight (HMW) PAHs were 74.39% and 69.61%, respectively. Distinct microbial assemblages developed in the ARPs, with Golenkinia predominating among microalgal genera, Pseudomonadota among bacterial phyla, and Cercozoa among protozoan phyla. Exploratory association analyses revealed that LMW-PAH removal showed positive directional relationships with OD680 and microalgal diversity, whereas HMW-PAH removal showed predominantly negative relationships with physiological, nutrient-removal, and community indicators. Phase-distribution analysis further showed that HMW-PAHs were enriched in harvested biomass and that logKd increased with logKow. Aqueous BaP-equivalent concentrations were lower in the effluents than in the influent, and incremental lifetime cancer risk estimates for harvested biomass were below 10-6 under the specified adult incidental-ingestion scenario. These findings support the engineering application of open ARP systems for advanced treatment of WWTP effluent.
中文摘要:藻类跑道池(ARP)被认为是污水处理厂(WWTP)出水深度处理最有前景的技术之一。本研究设置三组平行的中试规模开放式ARP,分别对应2 d、3 d和4 d的水力停留时间(HRT),连续运行52 d,评估营养盐与PAH去除、PAH相分配及微生物群落演替。3 d系统在池体生物量积累与污染物去除之间表现出最有利的实测平衡,池体平均生物量浓度最高,为704 mg/L(干重),TN、TP、NH4+-N、NO3--N和Σ16PAH的平均去除率分别为86.52%、95.18%、67.74%、91.81%和73.68%。每日生物量收获量在2 d时最高,为14.9 g m-2 d-1(干重)。在3 d HRT下,低分子量(LMW)和高分子量(HMW)PAH的平均去除率分别为74.39%和69.61%。ARP中形成了不同的微生物 assemblage,微藻属以Golenkinia为主,细菌门以Pseudomonadota为主,原生动物门以Cercozoa为主。探索性关联分析显示,LMW-PAH去除与OD680及微藻多样性呈正向方向关系,而HMW-PAH去除与生理、营养盐去除和群落指标主要呈负向关系。相分配分析进一步表明,HMW-PAH在收获生物量中富集,且logKd随logKow升高而增大。出水中的水相BaP当量浓度低于进水,在设定的成人偶然摄入情景下,收获生物量的增量终生癌症风险估计值低于10^-6。这些结果支持开放式ARP系统用于WWTP出水深度处理的工程应用。
Nature cancer IF 28.0 2026-10-29 PMID: 42957894
Despite decades of investigation, the fundamental molecular and cellular principles that enable bacteria to thrive within the tumor microenvironment have yet to be defined. Here, through a genome‑wide functional screen, we identify the bacterial genes and pathways that govern intratumoral fitness. Targeted deletion of nonglucose phosphotransferase systems to align bacterial metabolic preference with tumor metabolite availability promotes bacterial intratumoral fitness. Integrating multiple metabolic adaptations into a single tumor‑avid Escherichia coli strain (Ec‑TA) results in increased tumor colonization, not only after intratumoral delivery but also after intravenous delivery, leading to increased anti‑tumor efficacy when using Ec‑TA engineered to deliver an encoded immunostimulatory payload. Furthermore, Ec‑TA displaces wild‑type bacteria from pre‑colonized tumors when administered systemically, underscoring its potential for locally delivering therapeutics in the presence of resident tumor microbes. These data demonstrate that adapting bacteria to the unique characteristics of the tumor metabolic microenvironment can drive the development of safer and more effective chassis for next‑generation bacterial cancer therapies.
中文摘要:尽管经过数十年研究,使细菌能够在肿瘤微环境中生存和繁殖的基本分子与细胞原则仍未明确。通过全基因组功能筛选,我们鉴定出决定细菌瘤内适应性的细菌基因和通路。靶向删除非葡萄糖磷酸转移酶系统,使细菌的代谢偏好与肿瘤代谢物可利用性相匹配,可提升细菌的瘤内适应性。将多种代谢适应整合到单一嗜肿瘤大肠杆菌菌株(Ec‑TA)中,可增加肿瘤定植,不仅瘤内递送后如此,静脉递送后也如此;当使用经工程化改造、可递送编码免疫刺激有效载荷的Ec‑TA时,抗肿瘤疗效随之提高。Ec‑TA在全身给药后还能将野生型细菌从已定植的肿瘤中排挤出去,显示其在肿瘤内存在常驻微生物时局部递送治疗物的潜力。这些数据表明,使细菌适应肿瘤代谢微环境的独特特征,可推动开发更安全、更有效的下一代细菌癌症治疗底盘。
Cell death and differentiation IF 13.6 2026-10-29 PMID: 42957859
Anti-inflammatory monocyte-derived macrophages are essential to maintain tissue homeostasis but can also contribute to disease progression, notably in cancer and fibrosis. Deciphering the signaling pathways that govern their generation could therefore unlock new therapeutic opportunities. Here we uncover a previously unrecognized, non-apoptotic function of caspase-8 in driving both monocyte-to-macrophage differentiation and anti-inflammatory macrophages polarization. We identified cathepsin B as a novel upstream activator of caspase-8 through a non-canonical cleavage mechanism, conferring to caspase-8 an original activity profile distinct from its apoptotic role. Disruption of this cathepsin B-caspase-8 axis, either genetically or pharmacologically, not only impairs the generation of anti-inflammatory macrophages but also reprograms them towards a pro-inflammatory phenotype. Our findings position the cathepsin B-caspase-8 axis as an original critical regulatory node in macrophage fate decisions and a promising target for therapeutic reprogramming of human macrophages in cancer, inflammation and fibrotic diseases.
中文摘要:抗炎性单核细胞来源巨噬细胞对维持组织稳态至关重要,但也可能促进疾病进展,尤其是在癌症和纤维化中。阐明调控其生成的信号通路有望带来新的治疗机会。本研究报告胱天蛋白酶-8(caspase-8)一种此前未被认识的非凋亡功能,既可驱动单核细胞向巨噬细胞分化,也可驱动抗炎性巨噬细胞极化。研究确定组织蛋白酶B(cathepsin B)通过一种非经典切割机制作为caspase-8的新型上游激活因子,使caspase-8呈现出不同于其凋亡作用的独特活性谱。通过遗传学或药理学手段破坏组织蛋白酶B-caspase-8轴,不仅损害抗炎性巨噬细胞的生成,还将其重编程为促炎表型。这些发现将组织蛋白酶B-caspase-8轴定位为巨噬细胞命运决定中的关键调控节点,并成为在癌症、炎症和纤维化疾病中对人类巨噬细胞进行治疗性重编程的有前景靶点。
Nature chemical biology IF 15.8 2026-10-29 PMID: 42957846
Proximity labeling (PL) technologies such as APEX2 have transformed spatial multi-omics in live cells, but their long-standing dependence on hydrogen peroxide (H2O2) disrupts redox signaling and prevents use in live animals. Here we introduce H2O2-independent APEX2 (Hi-APEX), which uses a clickable tetrazine-phenol (TP) probe, requiring no enzyme engineering. We show that APEX2 directly catalyzes TP labeling without H2O2 via a mechanism requiring the probe's tetrazine group and oxygen. We benchmark Hi-APEX-based spatial multi-omics by mapping the mitochondrial matrix and dynamic secretomes. Hi-APEX outperforms traditional APEX in capturing redox-sensitive processes such as stress response and ferroptosis, enabling the discovery of authentic stress granule components and protein interaction networks for mitochondria-localized GPX4 (mGPX4). One mGPX4 interactor, TRMT61B, which is known to regulate mitochondrial m1A modifications, promotes ferroptosis. Crucially, Hi-APEX demonstrates in vivo compatibility, enabling direct protein and RNA PL in tumor xenografts and hippocampal neurons, thereby expanding PL-based spatial multi-omics from cellular systems to living organisms.
中文摘要:APEX2等邻近标记(PL)技术改变了活细胞空间多组学,但其长期依赖过氧化氢(H2O2),会干扰氧化还原信号,并使其难以用于活体动物。我们提出不依赖H2O2的APEX2(Hi-APEX),使用可点击的四嗪-苯酚(TP)探针,无需酶工程改造。结果显示,APEX2可通过依赖探针四嗪基团和氧气的机制直接催化TP标记,无需H2O2。我们以线粒体基质和动态分泌组作图对基于Hi-APEX的空间多组学进行基准评估。Hi-APEX在捕获应激反应和铁死亡等氧化还原敏感过程方面优于传统APEX,可发现真实的应激颗粒组分以及线粒体定位GPX4(mGPX4)的蛋白相互作用网络。mGPX4的一个相互作用蛋白TRMT61B已知调控线粒体m1A修饰,可促进铁死亡。关键的是,Hi-APEX具备活体兼容性,可在肿瘤异种移植瘤和海马神经元中直接进行蛋白和RNA邻近标记,从而将基于PL的空间多组学从细胞体系拓展到活体生物。
Nature methods IF 28.3 2026-10-29 PMID: 42957789
Analysis of cell-free DNA (cfDNA) methylation can enable noninvasive disease detection by leveraging tissue-specific epigenetic differences between malignant and nonmalignant cells. However, such analyses can be confounded by the repair of jagged DNA fragment ends during double-stranded sequencing library preparation, which introduces spurious methylation signals into cfDNA molecules. Here we present JEEPERS, a framework to detect and correct jagged-end-induced methylation errors while preserving duplex integrity and native methylation patterns. We showed high fidelity for measuring tumor burden and demonstrated allele-specific methylation differences at recurrent somatic mutations, revealing a link between adjacent CpG methylation and EGFR/TP53 driver and resistance mutations. We further demonstrated enhanced diagnostic performance across liquid biopsy applications, including tumor-type-specific methylation profiles, hemimethylation profiling, epigenetic-clock-based age estimation and cell type deconvolution. By faithfully correcting end-repair errors, JEEPERS provides a versatile framework for integrating mutations and methylation features in cfDNA at high resolution, enabling more precise molecular profiling and disease monitoring.
中文摘要:细胞游离DNA(cfDNA)甲基化分析可利用恶性与非恶性细胞之间的组织特异性表观遗传差异,实现无创疾病检测。然而,在双链测序文库构建过程中,锯齿状DNA片段末端的修复会干扰此类分析,向cfDNA分子引入虚假甲基化信号。为此,我们提出JEEPERS框架,在保持双链完整性和天然甲基化模式的同时,检测并校正锯齿末端诱导的甲基化错误。我们展示了测量肿瘤负荷的高保真度,并证明复发性体细胞突变处存在等位基因特异性甲基化差异,揭示相邻CpG甲基化与EGFR/TP53驱动突变及耐药突变之间的联系。我们进一步在多种液体活检应用中展示了提升的诊断性能,包括肿瘤类型特异性甲基化谱、半甲基化谱、基于表观遗传时钟的年龄估计和细胞类型解卷积。通过忠实校正末端修复错误,JEEPERS提供了一个通用框架,可在高分辨率下整合cfDNA中的突变与甲基化特征,从而实现更精确的分子谱分析和疾病监测。
Nature cell biology IF 22.7 2026-10-29 PMID: 42957783
Although mRNA decoding efficiency influences protein synthesis, it remains unknown whether the translation elongation machinery harbours intrinsic mechanisms that selectively modulate codon decoding to shape proteomes. Here we show that METTL13-catalysed dimethylation of the elongation factor eEF1A at lysine 55 (eEF1AK55me2) enhances decoding of select codons, preferentially increasing pro-oncogenic protein synthesis to promote tumorigenesis and targeted therapy resistance. Proteomic profiling and single-molecule imaging reveal that eEF1AK55me2 increases decoding efficiency, particularly for under-represented codons with weak wobble-position base pairing. In cancer cells, METTL13 knockdown reduced translation of oncogenic mRNA enriched in eEF1AK55me2-dependent codons, including KRAS; synonymous recoding with eEF1AK55me2-independent codons reversed this effect. METTL13 loss inhibited the growth of KRASG12C inhibitor (sotorasib)-resistant lung adenocarcinoma syngeneic tumours and patient-derived xenografts. In relapsed autochthonous KRASG12C-driven lung adenocarcinoma, METTL13 ablation mitigated sotorasib resistance and significantly extended survival in vivo. Among patients receiving a KRASG12C inhibitor, inferred METTL13 activity was associated with inferior clinical response. These findings identify an eEF1AK55me2-mediated mRNA decoding mechanism promoting selective oncogenic protein synthesis and suggest METTL13 targeting may counteract KRAS-inhibitor resistance.
中文摘要:尽管mRNA解码效率影响蛋白质合成,但翻译延伸机器是否具有选择性调节密码子解码以塑造蛋白质组的内在机制仍不清楚。研究显示,METTL13催化延伸因子eEF1A第55位赖氨酸二甲基化(eEF1AK55me2),增强特定密码子的解码,优先增加促癌蛋白合成,从而促进肿瘤发生和靶向治疗耐药。蛋白质组分析和单分子成像显示,eEF1AK55me2提高解码效率,尤其是对摆动位碱基配对较弱且使用频率偏低的密码子。在癌细胞中,敲低METTL13降低了富含eEF1AK55me2依赖密码子的致癌mRNA翻译,包括KRAS;用不依赖eEF1AK55me2的密码子进行同义重编码可逆转这一效应。METTL13缺失抑制KRASG12C抑制剂sotorasib耐药肺腺癌同系移植瘤和患者来源异种移植瘤的生长。在复发的KRASG12C驱动肺腺癌自发模型中,敲除METTL13减轻sotorasib耐药并显著延长体内生存。在接受KRASG12C抑制剂的患者中,推断的METTL13活性与较差的临床反应相关。这些发现确定了一种由eEF1AK55me2介导的mRNA解码机制,促进选择性致癌蛋白合成,并提示靶向METTL13可能对抗KRAS抑制剂耐药。
Cancer letters IF 11.8 2026-10-29 PMID: 42956987
To elucidate the mechanisms underlying therapy-induced resistance, we investigated the temporal dynamics of the polyploid giant cancer cell (PGCC) life cycle following treatment with the microtubule-destabilizing agent vincristine (VCR). Longitudinal live-cell fluorescence imaging revealed that VCR-induced mitotic suppression activated a distinct PGCC life cycle characterized by nuclear amplification and progressive cellular reprogramming. At the cellular level, PGCCs entered a senescence-like state accompanied by an enhanced senescence-associated secretory phenotype (SASP), increased epithelial-mesenchymal transition (EMT), acquisition of early embryonic-like features, and multilineage differentiation potential into ectoderm, mesoderm, and endoderm. PGCC-derived progeny exhibited dose- and time-dependent changes in proliferative behavior, aggressive phenotypes in vitro, along with time-dependent tumorigenic potential in vivo. Remarkably, at the tissue level, PGCCs also underwent spatial nuclear reorganization and self-organization into morphologically defined glandular epithelial structures exhibiting varying degrees of tissue maturation, reminiscent of early embryonic development. Silencing IL1β, IL6, or IL8, or pharmacologically inhibiting their receptors, suppressed PGCC formation, budding, EMT, and embryonic-like reprogramming associated with tissue morphogenesis. Furthermore, NAMPT emerged as a key regulator of embryonic-like stemness, glandular morphogenesis, and structural expansion. Together, these findings reveal that therapeutic stress activates a PGCC life cycle capable of generating two divergent outcomes: resistant tumor regeneration through clonal selection of undifferentiated tumor cells and organized tissue differentiation through spatial nuclear reprogramming. Our study establishes a conceptual framework linking therapy-induced polyploidization, developmental plasticity, and resistance generation at both cellular and tissue levels.
中文摘要:为阐明治疗诱导耐药的机制,研究观察了微管去稳定剂长春新碱(VCR)处理后多倍体巨癌细胞(PGCC)生命周期的时序动态。纵向活细胞荧光成像显示,VCR诱导的有丝分裂抑制激活了一种独特的PGCC生命周期,其特征为核扩增和渐进性细胞重编程。在细胞水平,PGCC进入衰老样状态,伴随衰老相关分泌表型(SASP)增强、上皮间质转化(EMT)增加、早期胚胎样特征获得,以及向外胚层、中胚层和内胚层分化的多谱系潜能。PGCC来源子代的增殖行为呈剂量和时间依赖性变化,体外表现侵袭性表型,体内致瘤潜能随时间变化。在组织水平,PGCC还发生空间核重组并自组织形成形态学明确的腺上皮结构,表现出不同程度的组织成熟,类似早期胚胎发育。沉默IL1β、IL6或IL8,或药理学抑制其受体,可抑制PGCC形成、出芽、EMT以及与组织形态发生相关的胚胎样重编程。NAMPT成为胚胎样干性、腺体形态发生和结构扩展的关键调控因子。这些发现表明,治疗应激激活的PGCC生命周期可产生两种不同结局:通过未分化肿瘤细胞的克隆选择实现耐药性肿瘤再生,以及通过空间核重编程实现有序组织分化。该研究建立了联系治疗诱导多倍体化、发育可塑性和细胞及组织水平耐药产生的概念框架。
Cancer research IF 22.6 2026-10-29 PMID: 42954743
Vasculogenic mimicry (VM) is a process in which malignant cells acquire endothelial-like functions to generate perfusable vascular channels independent of endothelial cells. VM represents a major barrier to effective vascular endothelial growth factor A (VEGFA)-targeted therapy in cancer. In this study, we used organ-scale vascular imaging that identified a mechanism of VM in glioblastoma (GBM) mediated by alpha-L-fucosidase 1 (FUCA1). FUCA1 was preferentially expressed in glioblastoma stem-like cells (GSCs) with high CD44 expression. FUCA1 functioned as a key regulator of GSC-mediated VM by stabilizing LDHA protein and promoting a metabolic shift toward glycolysis. Elevated glycolytic flux increased lactate production and enhanced histone H3 lysine 18 lactylation (H3K18la), which in turn activated SERPINF1 transcription and drove VM in GSCs. In preclinical models, the FUCA1 inhibitor deoxyfuconojirimycin hydrochloride (DFH) significantly reduced GSC tumorigenicity and VM in vivo and exhibited robust antitumor activity when combined with anti-VEGFA therapy. Collectively, these findings define a FUCA1-mediated histone lactylation pathway that enhances GSC VM and highlight a therapeutically targetable mechanism to improve the efficacy of current anti-angiogenic strategies in GBM.
中文摘要:血管生成拟态(VM)是恶性肿瘤细胞获得内皮样功能、不依赖内皮细胞形成可灌注血管通道的过程。VM是癌症中VEGFA靶向治疗有效性的主要障碍。本研究利用器官尺度血管成像,发现胶质母细胞瘤(GBM)中由α-L-岩藻糖苷酶1(FUCA1)介导的VM机制。FUCA1在CD44高表达的胶质母细胞瘤干细胞样细胞(GSCs)中优先表达。FUCA1通过稳定LDHA蛋白并促进代谢向糖酵解转变,作为GSC介导VM的关键调控因子发挥作用。糖酵解通量升高增加乳酸生成并增强组蛋白H3第18位赖氨酸乳酰化(H3K18la),进而激活SERPINF1转录并驱动GSCs中的VM。在临床前模型中,FUCA1抑制剂脱氧岩藻野尻霉素盐酸盐(DFH)显著降低GSC的体内致瘤性和VM,与抗VEGFA治疗联合时表现出强效抗肿瘤活性。这些发现界定了一条增强GSC VM的FUCA1介导组蛋白乳酰化通路,并提示了一个可治疗靶向的机制,以提高GBM现有抗血管生成策略的疗效。
Medicinal research reviews IF 13.6 2026-10-29 PMID: 42952330
Limonoids are an important class of highly oxygenated triterpenoids containing a distinctive 4,4,8-trimethyl-17-furanylsteroid skeleton. To date, over 2700 members, including azadirachtin, toosendanin, limonin, obacunone, nomilin, harrisonin, nimbolide, gedunin, salannin, nimbin, khayanolide, xylocarpin, swietenine, rocaglamide, trichilin, vilasinin, etc., have been isolated from citrus fruits and the plants of the Rutaceae and Meliaceae families. They play a significant role in the discovery of novel drug and pesticide candidates owing to their wide range of biological activities, such as protective, anti-inflammatory, anti-cancer, antimicrobial, and insecticidal properties. Therefore, their potential, challenges, and insights into the chemistry and biology of triterpenoid-type limonoids have recently garnered much attention. The focus of this review is not only to summarize the isolation, total synthesis, and structural modifications of limonoid-type natural products as potential therapeutic and pesticidal agents, but also to highlight the underlying mechanisms of their pharmacological effects from 2017 to 2025. Noteworthily, perspectives were given on the limonoid-type compounds as leads for further development of novel drugs and agrochemicals, and their applications in the future. Hopefully, this review can serve as a comprehensive reference for future research on limonoids and their derivatives in the pharmaceutical and agricultural fields.
中文摘要:柠檬苦素类是一类重要的高度含氧三萜类化合物,具有特征性的4,4,8-三甲基-17-呋喃甾体骨架。迄今为止,已从柑橘类果实及芸香科和楝科植物中分离得到超过2700个成员,包括印楝素、川楝素、柠檬苦素、黄柏酮、诺米林、harrisonin、nimbolide、gedunin、salannin、nimbin、khayanolide、xylocarpin、swietenine、rocaglamide、trichilin、vilasinin等。由于具有保护、抗炎、抗癌、抗菌和杀虫等多种生物活性,它们在新型药物和农药候选物的发现中发挥重要作用。因此,三萜类柠檬苦素在化学和生物学方面的潜力、挑战与启示近来受到广泛关注。本综述不仅总结柠檬苦素类天然产物作为潜在治疗剂和杀虫剂的分离、全合成及结构修饰,还重点阐述2017年至2025年间其药理作用的内在机制。文中还就柠檬苦素类化合物作为先导物用于进一步开发新型药物和农用化学品及其未来应用给出展望。希望本综述能为柠檬苦素及其衍生物在医药和农业领域的未来研究提供全面参考。
Cell IF 45.1 2026-10-29 PMID: 42641604
Three-dimensional genome organization shapes transcriptional regulation, yet measuring its spatial coordination in situ within intact tissues remains challenging. We present Spatial Hi-C-RNA, a multimodal platform that simultaneously maps genome-wide chromatin contacts and transcriptomes from the same tissue section at near-single-cell resolution. Across the mouse brain, developing embryos, and human melanoma, Spatial Hi-C-RNA generated multimodal maps that aligned with tissue anatomy while revealing complementary chromatin- and RNA-defined spatial patterns. Multiscale features, including A/B compartments, topologically associating domains, and chromatin loops, were associated with region- and cell-type-specific transcriptional programs. In mouse embryos, Spatial Hi-C-RNA resolved coordinated chromatin and transcriptional remodeling during neuronal maturation across developmental stages. In human melanoma, chromatin architecture delineated intratumoral subregions not detected by RNA alone and linked tumor-state transitions to changes in compartments, domain boundaries, and regulatory programs. Spatial Hi-C-RNA thus provides a broadly applicable framework for investigating genome structure-function relationships in development and disease within native tissue environments.
中文摘要:三维基因组组织塑造转录调控,但在完整组织中原位测量其空间协调仍具挑战。我们提出 Spatial Hi-C-RNA,一种多模态平台,可在同一组织切片上以接近单细胞分辨率同时绘制全基因组染色质接触和转录组。在小鼠脑、发育中的胚胎和人黑色素瘤中,Spatial Hi-C-RNA 生成的多模态图谱与组织解剖结构对齐,同时揭示由染色质和 RNA 定义的互补空间模式。A/B 区室、拓扑关联结构域和染色质环等多尺度特征与区域和细胞类型特异的转录程序相关。在小鼠胚胎中,Spatial Hi-C-RNA 解析了不同发育阶段神经元成熟过程中协调的染色质和转录重塑。在人黑色素瘤中,染色质架构划分出仅凭 RNA 未检测到的瘤内亚区,并将肿瘤状态转变与区室、结构域边界和调控程序的变化联系起来。Spatial Hi-C-RNA 为在天然组织环境中研究发育和疾病中的基因组结构-功能关系提供了广泛适用的框架。
Blood IF 23.9 2026-10-29 PMID: 42607078
Direct targeting of the oncoprotein MYC has not yet been successful. Here we report a novel dual protein degrader, GT19630, which binds directly to MYC and G1 to S phase transition protein 1 (GSPT1). GT19630 disrupts a novel feedforward loop of MYC and GSPT1, in which MYC promotes transcription of GSPT1, and GSPT1 senses the stop codon of MYC to properly terminate its translation. The agent induces an integrated stress response and abrogates oxidative phosphorylation through inhibition of the tricarboxylic acid cycle, resulting in apoptosis. GT19630 has superior activity compared with GSPT1-targeting molecular glues. GT19630 induces profound antiproliferative effects and apoptosis at low nanomolar concentrations in a multitude of leukemia and lymphoma cell lines and primary samples, including those with TP53 mutations. GT19630 is highly active in vivo in models of therapy-resistant hematologic malignancies, including Burkitt lymphoma, acute myeloid leukemia (AML), and multiple myeloma. CD34+ AML blasts overexpress MYC protein compared with normal hematopoietic stem/progenitor cells (HSPCs), and GT19630 induces greater cytotoxicity in AML cells compared with normal HSPCs. Further, GT19630 restores sensitivity to venetoclax and profoundly prolongs survival in vivo in venetoclax-resistant AML. GT19630 was well tolerated in humanized Crbn mice. In conclusion, our data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy for MYC-driven hematologic malignancies.
中文摘要:直接靶向癌蛋白MYC尚未取得成功。这里报告一种新型双重蛋白降解剂GT19630,它可直接结合MYC和G1至S期转换蛋白1(GSPT1)。GT19630破坏MYC与GSPT1之间一条新的前馈环路:MYC促进GSPT1转录,GSPT1识别MYC的终止密码子以正确终止其翻译。该药物诱导整合应激反应,并通过抑制三羧酸循环阻断氧化磷酸化,导致细胞凋亡。与靶向GSPT1的分子胶相比,GT19630活性更优。在多种白血病和淋巴瘤细胞系及原代样本中,包括携带TP53突变的样本,GT19630在低纳摩尔浓度下产生显著的抗增殖作用和细胞凋亡。GT19630在治疗耐药血液肿瘤模型体内高度活跃,包括伯基特淋巴瘤、急性髓系白血病(AML)和多发性骨髓瘤。与正常造血干/祖细胞(HSPCs)相比,CD34+ AML原始细胞过表达MYC蛋白,GT19630对AML细胞的细胞毒性大于正常HSPCs。GT19630还可恢复对维奈克拉的敏感性,并在维奈克拉耐药AML体内模型中显著延长生存期。GT19630在人源化Crbn小鼠中耐受良好。总之,这些数据支持将MYC/GSPT1降解剂GT19630开发为MYC驱动血液肿瘤的治疗策略。
Blood IF 23.9 2026-10-29 PMID: 42418681
Patients with acute leukemias harboring translocations involving gene lysine methyltransferase 2A (KMT2A) have a poor prognosis due to chemotherapy resistance with rapid relapse following standard treatments. The resulting KMT2A fusion proteins dysregulate gene expression, leading to an upregulation of leukemogenic transcription factors such as HOXA9 and MEIS1, which drives leukemic transformation. Although menin inhibitors are proving to be promising new therapeutics for patients with KMT2A-rearranged (KMT2Ar) acute leukemia, resistance mechanisms have already been described and new therapeutic approaches for this patient subgroup must be identified. Here, a genome-wide CRISPR/Cas9 screen in a KMT2Ar B-cell acute lymphoblastic leukemia cell line identified the deubiquitinase ubiquitin-specific peptidase 22 (USP22) as a novel regulator of MEIS1 protein stability. USP22 is a member of the Spt-Ada-Gcn5 acetyltransferase multiprotein complex, which has crucial functions in shaping the chromatin landscape and modulating transcription. Genetic depletion of USP22 impaired cellular growth and proliferation in KMT2Ar acute leukemia models. Chromatin immunoprecipitation revealed cooperative binding between USP22 and MEIS1 at critical oncogenic target genes, suggesting that USP22 safeguards leukemogenic transcription by protecting MEIS1 from proteasomal degradation. Genetic or chemical inhibition of USP22 led to the polyubiquitination of MEIS1, resulting in proteasomal degradation and downregulation of the expression of target genes. Our study identifies USP22 as a novel regulator of MEIS1 protein stability that could potentially be exploited as a therapeutic target in the future in KMT2Ar leukemias.
中文摘要:携带赖氨酸甲基转移酶2A(KMT2A)基因易位的急性白血病患者因化疗耐药且标准治疗后快速复发而预后较差。由此产生的KMT2A融合蛋白使基因表达失调,上调HOXA9和MEIS1等致白血病转录因子,驱动白血病转化。Menin抑制剂正成为KMT2A重排(KMT2Ar)急性白血病有前景的新疗法,但耐药机制已有报道,仍需为该患者亚组寻找新的治疗策略。研究在KMT2Ar B细胞急性淋巴细胞白血病细胞系中进行全基因组CRISPR/Cas9筛选,发现去泛素化酶泛素特异性肽酶22(USP22)是MEIS1蛋白稳定性的新调控因子。USP22是Spt-Ada-Gcn5乙酰转移酶多蛋白复合体成员,该复合体在塑造染色质景观和调节转录中具有关键功能。遗传性缺失USP22会削弱KMT2Ar急性白血病模型的细胞生长和增殖。染色质免疫沉淀显示USP22与MEIS1在关键致癌靶基因处协同结合,提示USP22通过保护MEIS1免受蛋白酶体降解来维持致白血病转录。遗传或化学抑制USP22导致MEIS1多泛素化,引起蛋白酶体降解并下调靶基因表达。该研究确定USP22是MEIS1蛋白稳定性的新调控因子,未来有望作为KMT2Ar白血病的治疗靶点。
Experimental hematology & oncology IF 17.5 2026-10-28 PMID: 42958602
For more than a century after its initial description, glioblastoma (GBM) has remained one of the most therapeutically refractory human malignancies, resembling an almost impregnable fortress against modern oncology. Despite extensive molecular characterization and identification of numerous actionable targets, survival outcomes have improved only marginally. GBM is characterized by profound spatial and cellular heterogeneity, adaptive signaling rewiring, extensive phenotypic plasticity, an immunosuppressive tumor microenvironment, and major pharmacological constraints imposed by the blood-brain barrier. This review examines the resulting disconnect between biological rationale and clinical outcome through three interrelated translational principles that determine whether mechanistically compelling therapies can achieve meaningful clinical benefit in GBM. First, who is treated and what is biologically active: therapeutic efficacy depends on matching patients to functional pathway dependencies beyond static molecular alterations. Second, whether the drug reaches and modulates its intended target: candidate therapies must achieve sufficient intratumoral exposure and demonstrate target modulation. Third, how the tumor adapts under therapeutic pressure: durable efficacy requires accounting for receptor tyrosine kinase switching, phenotypic plasticity, immune adaptation, and spatial escape. By linking these principles to the molecular, spatial, and pharmacological organization of GBM, this review frames the disease as a dynamic tumor ecosystem and provides a framework for interpreting recurrent clinical failure and guiding more biologically informed therapeutic development.
中文摘要:胶质母细胞瘤(GBM)自首次描述后一个多世纪以来,仍是最难治疗的人类恶性肿瘤之一,面对现代肿瘤学几乎像一座难以攻克的堡垒。尽管已开展广泛分子表征并发现众多可干预靶点,生存结局仅略有改善。GBM具有显著的空间与细胞异质性、适应性信号重编程、广泛的表型可塑性、免疫抑制性肿瘤微环境,以及血脑屏障造成的重大药理学限制。本综述通过三条相互关联的转化原则,考察生物学依据与临床结局之间的脱节,这些原则决定机制上有说服力的疗法能否在GBM中取得有意义的临床获益。治疗效能取决于将患者与静态分子改变之外的功能性通路依赖相匹配;候选疗法需达到足够的瘤内暴露并证明靶点调控;持久疗效需考虑受体酪氨酸激酶转换、表型可塑性、免疫适应和空间逃逸。通过将这些原则与GBM的分子、空间和药理学组织联系起来,本综述将这一疾病视为动态肿瘤生态系统,并提供解释反复临床失败、指导更具生物学依据的治疗开发的框架。
Biomarker research IF 14.6 2026-10-28 PMID: 42958559
Targeted protein degradation (TPD) has significantly influenced cancer therapy by enabling the targeting of traditionally undruggable oncogenic drivers such as transcription factors, chromatin remodelers, and mediators of protein-protein interactions, overcoming limitations of conventional inhibitors. This approach harnesses endogenous cellular machinery, specifically the ubiquitin-proteasome system and lysosomal pathways, to achieve precise and efficient elimination of pathogenic proteins. Currently, one degradation-based agent, vepdegestrant, has been approved by FDA, while most agents remain in Phase I or II evaluation, representing significant progress in addressing previously intractable targets in cancers. Nevertheless, a substantial number of disease-relevant proteins remain challenging to modulate effectively. This review focuses on undruggable targets in cancer and distinguishes three target categories: 1) Structurally undruggable targets; 2) Formerly undruggable, now inhibitor-accessible but degradation offers a mechanistic advantage; 3) Non-enzymatic targets. We highlight recent advances in the development of TPD strategies against these elusive targets to a cutoff of 30 September 2026, with the aim of providing a more systematic theoretical foundation for the broader application of the developing TPD in cancer therapeutics.
中文摘要:靶向蛋白降解(TPD)使转录因子、染色质重塑因子以及介导蛋白-蛋白相互作用的分子等传统上难以成药的致癌驱动因子成为可靶向对象,从而突破传统抑制剂的局限,对肿瘤治疗产生了显著影响。该策略利用内源性细胞机制,具体为泛素-蛋白酶体系统和溶酶体途径,实现对致病蛋白的精准高效清除。目前美国FDA已批准一种基于降解的药物vepdegestrant,多数药物仍处于I期或II期评估,在解决癌症中既往难治靶点方面取得明显进展。仍有大量疾病相关蛋白难以被有效调控。综述聚焦癌症中的难成药靶点,将其分为三类:1)结构上难成药靶点;2)曾经难成药、现已可被抑制剂触及但降解具有机制优势的靶点;3)非酶靶点。文中重点介绍截至2026年9月30日针对这些难靶点开发TPD策略的最新进展,旨在为发展中的TPD在癌症治疗中的更广泛应用提供更系统的理论基础。
Biomarker research IF 14.6 2026-10-28 PMID: 42958550
Relapsed/refractory (R/R) lung adenocarcinoma (LUAD) remains a clinical challenge with limited therapies and poor prognosis. CAR‑NK cell therapy has shown promise in solid tumors, but its efficacy is limited by both the availability of effective targets and the immunosuppressive tumor microenvironment. CD73 (NT5E), highly expressed across solid tumors, catalyzes adenosine production to drive immunosuppression, representing both a specific CAR‑NK target and a key leverage point to overcome tumor immune evasion. However, its systematic evaluation as a therapeutically actionable target for CAR‑NK cell therapy in R/R LUAD remains unexplored. We first characterized CD73 expression through integrative analysis of public datasets, primary and relapsed clinical LUAD specimens, and LUAD cell lines derived from primary and metastatic tumors. We then constructed CD73‑CAR‑NK cells and assessed their in vitro cytotoxicity across LUAD cell lines of varying malignancy, as well as their effects on extracellular adenosine and resistance to adenosine‑mediated immunosuppression. Finally, we assessed their antitumor efficacy in a stepwise manner across a tiered panel of in vivo models, including cell line‑derived xenograft (CDX), metastasis, patient‑derived xenograft (PDX), and clinically relevant immune‑humanized PDX models. CD73 expression was elevated in metastasis-derived LUAD cell lines and R/R LUAD specimens. Accordingly, CD73-CAR-NK92 cells exhibited potent cytotoxicity against CD73-high LUAD cells, accompanied by an activated effector phenotype, reduced extracellular adenosine, partial resistance to adenosine-mediated suppression, and limited activity toward normal bronchial epithelial cells. Notably, this enhanced function was consistently observed across multiple NK cell sources including peripheral blood-derived NK (PBNK), umbilical cord blood‑derived NK (UBNK), and iPSC-derived NK (iNK). In vivo, CD73‑CAR‑NK92 cells significantly suppressed tumor growth and metastasis, with enhanced tumor‑site enrichment, prolonged retention, and elevated intratumoral levels of TNF‑α and IFN‑γ. Importantly, in an immune‑humanized PDX mouse model, CD73‑CAR‑NK92 cells significantly reduced the growth of R/R patient‑derived xenografts, accompanied by immune remodeling, without marked systemic inflammation during the observation period. These findings provide preclinical evidence that CD73-CAR-NK cells exhibit potent antitumor efficacy for R/R LUAD through their dual functions of eliminating CD73-high tumor cells and resisting adenosine-mediated immunosuppressive signaling, supporting their therapeutic potential.
中文摘要:复发/难治性肺腺癌(LUAD)仍是临床难题,治疗手段有限、预后较差。CAR-NK细胞治疗在实体瘤中已显示前景,但其疗效受制于有效靶点的可获得性与免疫抑制性肿瘤微环境。CD73(NT5E)在多种实体瘤中高表达,可催化腺苷生成而驱动免疫抑制,因而是兼具特异性的CAR-NK靶点,也是克服肿瘤免疫逃逸的关键切入点。但将其作为复发/难治性LUAD的CAR-NK治疗可干预靶点进行系统评价,此前尚未开展。研究者先通过整合分析公共数据集、原发与复发临床LUAD标本以及源自原发与转移灶的LUAD细胞系,刻画了CD73的表达特征。随后构建CD73-CAR-NK细胞,评估其对不同恶性程度LUAD细胞系的体外细胞毒性,以及对细胞外腺苷水平的影响和对腺苷介导免疫抑制的抵抗能力。最后按逐步递进的方式,在一组分层体内模型中评估抗肿瘤效果,包括细胞系来源异种移植(CDX)、转移模型、患者来源异种移植(PDX)以及具有临床相关性的免疫人源化PDX模型。CD73表达在转移灶来源的LUAD细胞系和复发/难治性LUAD标本中升高。相应地,CD73-CAR-NK92细胞对CD73高表达LUAD细胞表现出强效细胞毒性,伴随效应表型活化、细胞外腺苷减少、对腺苷介导抑制的部分抵抗,而对正常支气管上皮细胞活性有限。这种功能增强在多种NK细胞来源中均一致出现,包括外周血来源NK(PBNK)、脐带血来源NK(UBNK)和iPSC来源NK(iNK)。体内实验中,CD73-CAR-NK92细胞显著抑制肿瘤生长与转移,肿瘤部位富集增强、滞留时间延长,瘤内TNF-α与IFN-γ水平升高。在免疫人源化PDX小鼠模型中,CD73-CAR-NK92细胞显著减小复发/难治性患者来源异种移植瘤的生长,并伴随免疫重塑,观察期内未见明显全身炎症。上述结果为CD73-CAR-NK细胞治疗复发/难治性LUAD提供了临床前证据:其通过清除CD73高表达肿瘤细胞与抵抗腺苷介导的免疫抑制信号双重作用发挥强效抗肿瘤效果,支持其治疗潜力。
Biomarker research IF 14.6 2026-10-28 PMID: 42958372
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with poor prognosis, especially in relapsed/refractory patients. Aberrant PI3K/AKT/mTOR and NOTCH1 signaling converge on c-MYC to drive proliferation and ribosome biogenesis, but single-agent inhibitors targeting these pathways have shown limited clinical efficacy. An FDA-approved drug library screen identified osimertinib as a candidate anti-T-ALL agent. Its efficacy and mechanism were evaluated in four T-ALL cell lines (MOLT-4, Jurkat, CCRF/CEM, and MOLT-3) with different TP53 statuses and in primary T-ALL blasts. Combination studies with selinexor, an exportin 1 (XPO1) inhibitor, were performed. Multi-omics, biochemical, and functional assays were used, and efficacy and toxicity were assessed in T-ALL xenograft models. Osimertinib suppressed leukemic progression in vivo by promoting proteasome-dependent degradation of c-MYC through a non-canonical, EGFR-independent pathway that cannot be fully explained by inhibition of PI3K/AKT/mTOR or NOTCH1 signaling alone. This c-MYC suppression impaired ribosome biogenesis, and combining osimertinib with selinexor further disrupted this process. The combination increased apoptosis at low concentrations (0.5-2 µM osimertinib plus 20 nM selinexor), with clear synergy at 2 µM in all four T-ALL cell lines. Mechanistically, the combination caused nuclear retention of RPS6, nuclear accumulation of RPL5/RPL11, nucleolar stress (fibrillarin dispersal), decreased MDM2 protein levels, p53 stabilization, BAX activation (6A7), cytochrome c release, c-MYC depletion, and translational suppression. In vivo, the combination improved survival and reduced leukemic burden with minimal toxicity to normal cells at low doses. Potential biomarkers include c-MYC dependency and TP53 status as candidate stratification factors, and treatment-induced c-MYC depletion and RPL5/RPL11 nuclear accumulation as candidate pharmacodynamic biomarkers. Osimertinib plus selinexor depletes c-MYC, induces nucleolar stress, and suppresses translation, which together drive T-ALL cell apoptosis. This mechanism-driven combination shows preclinical efficacy with limited toxicity in the normal-cell and xenograft models tested. Further studies incorporating pharmacokinetic monitoring, PDX models, and prospective validation of candidate biomarkers such as c-MYC dependency, TP53 status, and RPL5/RPL11 nuclear accumulation are warranted before clinical translation.
中文摘要:T细胞急性淋巴细胞白血病(T-ALL)是一种侵袭性强、预后差的恶性肿瘤,复发/难治患者尤其如此。异常的PI3K/AKT/mTOR与NOTCH1信号汇聚于c-MYC,驱动增殖和核糖体生物合成,但靶向这些通路的单药抑制剂临床疗效有限。通过FDA已批准药物库筛选,奥希替尼被确定为候选抗T-ALL药物。研究在四种TP53状态不同的T-ALL细胞系(MOLT-4、Jurkat、CCRF/CEM和MOLT-3)及原代T-ALL原始细胞中评估其疗效与机制,并与exportin 1(XPO1)抑制剂塞利尼索开展联合研究。采用多组学、生化与功能实验,并在T-ALL异种移植模型中评估疗效与毒性。奥希替尼通过一种非经典、不依赖EGFR的通路促进c-MYC的蛋白酶体依赖性降解,从而在体内抑制白血病进展,这一作用无法仅用PI3K/AKT/mTOR或NOTCH1信号抑制完全解释。c-MYC受抑损害核糖体生物合成,奥希替尼与塞利尼索联合进一步破坏该过程。联合方案在低浓度(0.5-2 µM奥希替尼加20 nM塞利尼索)下增加凋亡,并在2 µM时于全部四种T-ALL细胞系中显示明确协同作用。机制上,联合处理引起RPS6核滞留、RPL5/RPL11核内蓄积、核仁应激(fibrillarin弥散)、MDM2蛋白水平下降、p53稳定、BAX激活(6A7)、细胞色素c释放、c-MYC耗竭和翻译抑制。体内低剂量联合方案改善生存并降低白血病负荷,对正常细胞毒性很小。潜在生物标志物包括作为候选分层因素的c-MYC依赖性和TP53状态,以及作为候选药效动力学标志物的治疗诱导c-MYC耗竭和RPL5/RPL11核内蓄积。奥希替尼联合塞利尼索耗竭c-MYC、诱导核仁应激并抑制翻译,共同驱动T-ALL细胞凋亡。这一机制驱动的联合方案在所测试的正常细胞和异种移植模型中显示临床前疗效且毒性有限。在临床转化前,仍需开展纳入药代动力学监测、PDX模型以及c-MYC依赖性、TP53状态和RPL5/RPL11核内蓄积等候选生物标志物前瞻性验证的研究。
Molecular biomedicine IF 13.0 2026-10-28 PMID: 42955492
Heterobifunctional compounds (HBCs) that facilitate target protein degradation (TPD) by recruiting an E3 ligase complex have emerged as therapeutic options for cancer. Current screening approaches often prioritize protein degradation over anticancer activity, potentially missing therapeutically relevant compounds. To address this, we developed a viability-based screening strategy using isogenic wild-type, MAP3K1-knockout, and CRBN-knockout cell lines to identify HBCs with target- and E3-ligase-dependent anticancer effects. This approach identified HBC-8, which is > 30-fold more potent than the parent MAP3K1 inhibitor and induces S-phase arrest, growth inhibition, and apoptosis in a MAP3K1- and CRBN-dependent manner. HBC-8 degrades MAP3K1; however, proteome-wide, genome-wide, and large-scale viability-based screens indicate that the anticancer activity of HBC-8 also relies on the disruption of the ubiquitin-proteasome system and protein translation machinery, extending beyond MAP3K1 degradation alone. Target dependence of HBC-8 was established using a large-scale viability screen in 869 cancer cell lines, and the anticancer effects correlated with the expression levels of the target (MAP3K1) and E3 ligase (CRBN). Furthermore, HBC-8 showed antitumor effects in an in vivo orthotopic ovarian cancer model without observable toxicity, supporting the use of isogenic cell lines for chemical genetic screens as a rapid, holistic approach to identify therapeutically relevant HBCs that also degrade the target protein.
中文摘要:通过招募E3泛素连接酶复合物促进靶蛋白降解(TPD)的双功能化合物(HBC)已成为癌症治疗的选择之一。现有筛选方法往往以蛋白降解为优先指标而非抗癌活性,可能漏掉具治疗价值的化合物。为此,研究者建立了基于细胞活力的筛选策略,使用同源的野生型、MAP3K1敲除与CRBN敲除细胞系,识别兼具靶点依赖性与E3连接酶依赖性抗癌作用的HBC。该策略找到HBC-8,其效力比母体MAP3K1抑制剂强30倍以上,并以MAP3K1与CRBN依赖的方式诱导S期阻滞、生长抑制与凋亡。HBC-8可降解MAP3K1;但蛋白质组范围、基因组范围及大规模活力筛选显示,其抗癌活性还依赖对泛素-蛋白酶体系统与蛋白翻译机器的干扰,作用超出单纯的MAP3K1降解。研究者在869株癌细胞系中开展大规模活力筛选,确立了HBC-8的靶点依赖性,抗癌效应与靶点MAP3K1及E3连接酶CRBN的表达水平相关。HBC-8在原位卵巢癌体内模型中显示抗肿瘤作用,未观察到明显毒性,支持将同源细胞系用于化学遗传学筛选,作为快速、整体的方法来找寻既降解靶蛋白又具治疗相关性的HBC。
Journal of the American Chemical Society IF 16.6 2026-10-28 PMID: 42954533
Polymeric micelles (PMs) and coacervate microdroplets (CMs) are both promising delivery vehicles, yet each suffers from distinct limitations. The delivery efficiency of PMs is often hindered by factors, such as limited endosome escape and uncontrolled drug release. On the other hand, CMs are prone to coalescence and aging, which hamper long-term storage and systemic injection. Here, by employing an intracellular morphological transition strategy, these drawbacks can be efficiently addressed without compromising their inherent advantages. The system exists as nanosized PMs during storage and circulation. Upon internalization by the tumor cells, the highly reductive intracellular environment induces the detachment of the poly(ethylene glycol) (PEG) shell and results in in situ formation of CMs. The formed CMs can effectively escape from endosomes by disrupting the endosomal membrane, facilitating the release of drugs into the cytoplasm. Furthermore, the CMs can serve as drug reservoirs, protecting the cargo from burst release and degradation, thus significantly prolonging the retention time and improving systemic delivery efficacy. Notably, the CMs can also sequester free drugs from the surrounding environment, enhancing sequential therapy by increasing the intratumoral accumulation of the temporally staggered agents. Thus, this micelle-to-coacervate transformable platform illuminates new possibilities for both types of drug-delivery systems.
中文摘要:聚合物胶束(PMs)与凝聚层微滴(CMs)都是有前景的递送载体,但各自存在不同局限。PMs的递送效率常受内体逃逸有限和药物释放不受控等因素影响。CMs则易发生聚并和老化,妨碍长期储存和全身注射。这里采用细胞内形态转变策略,在不削弱其固有优势的情况下有效解决这些不足。该系统在储存和循环过程中以纳米级PMs形式存在。被肿瘤细胞内化后,高度还原的细胞内环境诱导聚乙二醇(PEG)外壳脱落,并在原位形成CMs。形成的CMs可通过破坏内体膜有效逃逸内体,促进药物释放进入细胞质。CMs还可作为药物储库,保护载荷免于突释和降解,从而显著延长滞留时间并提高全身递送疗效。CMs也能从周围环境捕获游离药物,通过增加时间错开药物的瘤内蓄积来增强序贯治疗。因此,这种可发生胶束到凝聚层转变的平台为两类药物递送系统提供了新可能。
Journal of the American Chemical Society IF 16.6 2026-10-28 PMID: 42954524
NIR-II fluorescence/photoacoustic dual-modal imaging offers complementary advantages in sensitivity and penetration depth. However, its efficacy is compromised by aggregation, nonspecific binding, and background interference, which persist even with polymeric encapsulation. To address these limitations, we report herein the rationally designed encapsulation-activated triarylmethane dyes (ED5) functionalized with bulky 1,8-bis(2,4,6-trimethylphenoxy)anthracene (1,8-BMPhA) moieties. The judiciously installed bulky substituents not only impart sufficient steric hindrance to repel protein binding and suppress intermolecular π-π stacking but also favor a locally near-coplanar geometry of the conjugated backbone, thereby preserving a high oscillator strength and a large molar extinction coefficient. Upon DSPE-PEG2000 encapsulation, nanoconfinement restricts intramolecular rotation and suppresses nonradiative decay, triggering a marked turn-on response of both fluorescence and photoacoustic signals. The optimized ED5_3@NPs exhibit a 14-fold fluorescence enhancement, a molar extinction coefficient of 71,000 M-1 cm-1, and a photothermal conversion efficiency of 62%. In vivo, they enable sustained high-quality imaging over a 51-h period, achieve crosstalk-free vascular-lymphatic dual-channel visualization, and afford high-contrast orthotopic liver tumor diagnosis against strong background interference. This encapsulation-activated strategy overcomes the long-standing constraints of NIR-II fluorophores, including low molar extinction coefficient, aggregation propensity, poor water solubility, and low photothermal conversion efficiency. It offers a general and well-defined paradigm for high-fidelity deep-tissue imaging and provides a promising strategy for further development of precision diagnostics.
中文摘要:近红外二区荧光/光声双模态成像在灵敏度和穿透深度方面具有互补优势。但聚集、非特异性结合和背景干扰会削弱其效果,即使采用聚合物包封仍存在这些问题。为克服这些限制,我们报道了合理设计的包封激活型三芳基甲烷染料(ED5),其以庞大的1,8-双(2,4,6-三甲基苯氧基)蒽(1,8-BMPhA)基团进行功能化。精心引入的庞大取代基不仅提供足够的空间位阻以排斥蛋白结合并抑制分子间π-π堆积,还促使共轭骨架形成局部近共平面构型,从而保持高振子强度和大的摩尔消光系数。经DSPE-PEG2000包封后,纳米限域作用限制分子内旋转并抑制非辐射衰减,触发荧光和光声信号显著开启响应。优化后的ED5_3@NPs表现为14倍荧光增强、71,000 M⁻¹ cm⁻¹的摩尔消光系数和62%的光热转换效率。在体内,它们可在51小时内实现持续高质量成像,完成无串扰的血管-淋巴双通道可视化,并在强背景干扰下实现高对比度原位肝肿瘤诊断。这种包封激活策略克服了近红外二区荧光团长期存在的限制,包括摩尔消光系数低、易聚集、水溶性差和光热转换效率低。它为高保真深层组织成像提供了一种通用且明确的范式,并为精准诊断的进一步发展提供了有前景的策略。
Journal of the American Chemical Society IF 16.6 2026-10-28 PMID: 42954521
Fluorescence imaging holds theoretical sensitivity for single-cell molecular diagnosis, yet practical performance is limited by residual probe-intrinsic fluorescence arising from incomplete control of intramolecular electron transfer within the probe scaffold. Inspired by natural photosynthesis, where spatially organized pigments enable quantum-coherent excitation transport and precise intermolecular electron transfer, we develop a bioinspired quantum chemistry-guided engineering (BQCE) strategy that programs intermolecular electron transfer to construct molecular assembly based background-eliminating activatable molecule probes (BEAMs). Guided by BQCE, the peroxynitrite-responsive hemicyanine-based BEAM1, despite the intrinsically difficult-to-quench nature of this fluorophore scaffold, achieves near-zero background fluorescence, 103.5-fold activation, and an unprecedented detection limit of 1.3 nM. BEAM1 resolves basal ONOO- fluxes at single-cell resolution, enabling single-cell molecular diagnosis that distinguishes malignant from normal cells based solely on endogenous redox signatures. In vivo, BEAM1 enables detection of lymph nodes containing sparsely distributed metastatic cells, with subsequent ex vivo histological analysis identifying metastatic deposits as small as ∼ 35 μm, extending fluorescence imaging into the regime of single-cell level early cancer detection.
中文摘要:荧光成像在单细胞分子诊断中具有理论灵敏度,但探针骨架内分子内电子转移控制不完全带来的探针固有残余荧光限制了实际性能。受自然光合作用启发——空间有序排列的色素可实现量子相干激发传输和精确的分子间电子转移——我们提出一种仿生量子化学指导工程(BQCE)策略,通过编程分子间电子转移构建基于分子组装的本底消除型可激活分子探针(BEAMs)。在BQCE指导下,响应过氧亚硝酸盐的基于半花菁的BEAM1尽管该荧光团骨架本身难以猝灭,仍实现近零本底荧光、103.5倍激活以及1.3 nM的前所未有的检测限。BEAM1在单细胞分辨率下解析基础ONOO⁻通量,使单细胞分子诊断仅依据内源性氧化还原特征即可区分恶性细胞与正常细胞。在体内,BEAM1可检测含有稀疏分布转移细胞的淋巴结,随后离体组织学分析识别出小至约35 μm的转移灶,将荧光成像拓展至单细胞水平早期癌症检测范围。
Nature IF 56.1 2026-10-28 PMID: 42951962
The BAF (also known as mammalian SWI/SNF) chromatin remodelling complexes are essential regulators of nucleosome positioning and transcription factor binding1,2. Loss-of-function (LOF) mutations in genes encoding components of the BAF complexes are among the most frequent across cancer types3. However, a unifying mechanism that explains their widespread disruption remains unclear. Here we disrupted BAF function through pharmacological inhibition and ARID1A deletion across various mammalian cell types and tissues and observed a conserved chromatin response: increased accessibility at CTCF-binding sites. ARID1A LOF alone was sufficient to drive these changes, which demonstrates that canonical BAF (cBAF) disruption is the key driver of CTCF gain. Genomic profiling showed increased CTCF and SMC3 occupancy, which reveals an antagonistic relationship between cBAF and CTCF-cohesin complexes. Furthermore, cBAF loss restructured 3D genome organization, which led to a strengthening of topologically associating domain boundaries and subdivision of large domains into smaller insulated structures. Long-range enhancer-promoter loops were replaced by shorter, promoter-proximal loops anchored at CTCF-enriched sites. To determine how CTCF function is enabled following cBAF loss, we profiled CTCF-interacting cofactors and found that CTCF binds directly to fully assembled PBAF. After cBAF depletion, PBAF was recruited to sites of increased CTCF occupancy, which demonstrates that there is an antagonistic switch between SWI/SNF subcomplexes. In vivo, conditional Arid1a deletion in primary mouse cells resulted in the expansion of a highly proliferative population marked by elevated accessibility at CTCF sites. This phenotype was fully reversed by either Ctcf or Pbrm1 deletion, which establishes that cBAF and the activity of CTCF and PBAF have contrasting roles.
中文摘要:BAF(又称哺乳动物SWI/SNF)染色质重塑复合物是核小体定位和转录因子结合的重要调控者。编码BAF复合物组分的基因发生功能缺失(LOF)突变,是多种癌症中最常见的突变之一,但解释其广泛破坏的统一机制仍不清楚。我们通过药物抑制和ARID1A缺失,在多种哺乳动物细胞类型和组织中破坏BAF功能,观察到一种保守的染色质反应:CTCF结合位点可及性增加。仅ARID1A LOF就足以驱动这些变化,表明经典BAF(cBAF)破坏是CTCF获得的关键驱动因素。基因组分析显示CTCF和SMC3占据增加,揭示cBAF与CTCF-cohesin复合物之间的拮抗关系。cBAF缺失重塑了三维基因组组织,导致拓扑关联结构域边界增强,并将大结构域细分为更小的绝缘结构。长距离增强子-启动子环被锚定在CTCF富集位点的较短启动子近端环所取代。为确定cBAF缺失后CTCF功能如何被启用,我们分析了CTCF相互作用的辅因子,发现CTCF直接结合完整组装的PBAF。cBAF耗竭后,PBAF被招募到CTCF占据增加的位点,表明SWI/SNF亚复合物之间存在拮抗性转换。在体内,原代小鼠细胞中条件性Arid1a缺失导致一个高度增殖群体扩增,该群体以CTCF位点可及性升高为标志。这一表型可被Ctcf或Pbrm1缺失完全逆转,确立cBAF与CTCF及PBAF活性具有相反作用。
Nature communications IF 18.1 2026-10-28 PMID: 42951897
Efficient DNA replication requires coordinated use of replicative and error-prone polymerases, which provide flexibility at the cost of mutagenesis. DNA polymerase η (Pol η) tolerates UV-induced lesions via translesion synthesis (TLS), but may contribute more broadly to DNA synthesis. Using polymerase usage sequencing (Pu-seq), we map Pol η activity genome-wide during unperturbed replication in human cells. Pol η preferentially participates in lagging strand replication, as in budding yeast. This bias requires direct PCNA interaction, suggesting stochastic engagement of PCNA-bound intermediates at replication forks. Pol η usage also varies across S phase, with PCNA ubiquitylation-dependent enrichment in late-replicating domains. In cancer genomes, characteristic Pol η mutations are enriched in late-replicating regions and correlate with RAD18 expression, linking PCNA ubiquitylation to Pol η-mediated mutagenesis. Thus, Pol η usage is biased by strand and replication timing during unperturbed replication and may contribute to mutational burden in human genomes.
中文摘要:高效的DNA复制需要复制型聚合酶与易错聚合酶协同使用,后者在提供灵活性的同时以诱变为代价。DNA聚合酶η(Pol η)通过跨损伤合成(TLS)耐受紫外诱导的损伤,但可能更广泛地参与DNA合成。采用聚合酶使用测序(Pu-seq),我们绘制了人细胞未受扰动复制过程中Pol η活性的全基因组图谱。Pol η优先参与后随链复制,与芽殖酵母中相同。这种偏好需要直接的PCNA相互作用,提示复制叉处PCNA结合的中间体以随机方式被利用。Pol η的使用在S期不同阶段也有变化,在晚复制结构域中呈PCNA泛素化依赖的富集。在癌症基因组中,Pol η特征性突变富集于晚复制区域,并与RAD18表达相关,将PCNA泛素化与Pol η介导的诱变联系起来。在未受扰动复制中,Pol η的使用受链别与复制时序影响,并可能贡献于人类基因组的突变负荷。
Pharmacological research IF 12.2 2026-10-28 PMID: 42951120
Paclitaxel-induced peripheral neuropathy (PIPN) is a dose-limiting complication of cancer chemotherapy driven by macrophage-mediated NLRP3 inflammasome activation. While suppressing TLR-NF-κB-dependent priming can limit neuroinflammation by reducing both NLRP3 induction and downstream inflammasome activation, such upstream intervention may also affect broader immune transcriptional programs in vulnerable oncology patients. Here, we identify a structural division of labor within histone deacetylase 6 (HDAC6) that pharmacologically uncouples the priming and assembly steps of NLRP3 activation. In a murine PIPN model, we demonstrate that paclitaxel directly primes macrophages. Complementary ND7/23-BMDM experiments support a model in which ATP released from paclitaxel-stressed neuronal cells provides a second signal for inflammasome assembly. By integrating domain-selective pharmacology with genetic knockdown-rescue using catalytically inactive and ZnF-UBP-deletion mutants, we reveal that the catalytic domain of HDAC6 governs upstream TLR4-NF-κB-dependent priming. In contrast, the non-catalytic ZnF-UBP domain is required for downstream HDAC6-NLRP3-ASC complexation and ASC speck assembly, ultimately driving caspase-1 activation, GSDMD cleavage, and IL-1β release. In vivo, targeting the ZnF-UBP domain with CP31 effectively alleviated paclitaxel-evoked pain hypersensitivity and dorsal root ganglion (DRG) neuroinflammation without altering canonical α-tubulin acetylation. By reframing HDAC6 into domain-separable intervention points, we provide a pathway-restricted therapeutic strategy for PIPN that precisely disarms downstream pathological inflammasome assembly while largely preserving the measured upstream priming responses.
中文摘要:紫杉醇诱导的周围神经病变(PIPN)是癌症化疗的剂量限制性并发症,由巨噬细胞介导的NLRP3炎症小体激活驱动。抑制TLR-NF-κB依赖的启动可通过减少NLRP3诱导及下游炎症小体激活来限制神经炎症,但这类上游干预也可能影响易感受肿瘤患者更广泛的免疫转录程序。本研究发现组蛋白去乙酰化酶6(HDAC6)内部存在结构分工,可在药理学上解偶联NLRP3激活的启动与组装步骤。在小鼠PIPN模型中,紫杉醇直接启动巨噬细胞。ND7/23-BMDM互补实验支持如下模型:紫杉醇应激的神经元细胞释放ATP,为炎症小体组装提供第二信号。将结构域选择性药理与使用催化失活及ZnF-UBP缺失突变体的基因敲低-回补相结合,发现HDAC6催化结构域调控上游TLR4-NF-κB依赖的启动。相比之下,非催化性ZnF-UBP结构域是下游HDAC6-NLRP3-ASC复合物形成及ASC斑点组装所必需,并最终驱动caspase-1激活、GSDMD剪切和IL-1β释放。在体内,用CP31靶向ZnF-UBP结构域可有效缓解紫杉醇引起的痛觉过敏和背根神经节(DRG)神经炎症,且不改变经典α-微管蛋白乙酰化。通过将HDAC6重新界定为可按结构域分离的干预靶点,我们为PIPN提供了一种通路受限的治疗策略,该策略精确解除下游病理性炎症小体组装,同时大体保留所测定的上游启动反应。
Cell metabolism IF 37.0 2026-10-28 PMID: 42950831
Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment of hematological malignancies, but cytokine release syndrome (CRS) remains a major toxicity. Fever-a hallmark of CRS-has been understudied as a modifier of therapeutic efficacy. In a retrospective cohort of patients with B cell acute lymphoblastic leukemia treated with CD22-directed CAR T cells (NCT02315612), sustained high-grade fever inversely correlated with clinical response. Mechanistically, experimental hyperthermia impaired proximal CAR signaling, reduced cytotoxicity, and compromised metabolic fitness through dysregulated arginine metabolism. Arginine supplementation restored CAR T cell function following hyperthermic stress and enhanced cytotoxicity under normothermic conditions. This effect required mTOR-dependent recruitment of the eIF4F translation-initiation complex and downstream c-MYC-driven metabolic reprogramming. Importantly, arginine enhanced good manufacturing practice (GMP)-manufactured CAR T cell function under normothermia, while oral supplementation improved in vivo efficacy. These findings identify metabolic control of translation as a fever-sensitive checkpoint and establish arginine supplementation as a tractable strategy to enhance CAR T cell efficacy.
中文摘要:嵌合抗原受体(CAR)T细胞疗法改变了血液系统恶性肿瘤的治疗格局,但细胞因子释放综合征(CRS)仍是主要毒性。发热是CRS的标志,却较少作为疗效修饰因素受到研究。在一项接受CD22靶向CAR T细胞治疗(NCT02315612)的B细胞急性淋巴细胞白血病患者回顾性队列中,持续高热与临床反应呈负相关。机制上,实验性高热损害近端CAR信号、降低细胞毒性,并通过精氨酸代谢失调破坏代谢适应性。补充精氨酸可在热应激后恢复CAR T细胞功能,并在常温条件下增强细胞毒性。该效应依赖mTOR介导的eIF4F翻译起始复合物募集及下游c-MYC驱动的代谢重编程。精氨酸可增强常温下按良好生产规范(GMP)制造的CAR T细胞功能,口服补充则改善体内疗效。这些发现将翻译的代谢控制识别为对发热敏感的检查点,并将精氨酸补充确立为增强CAR T细胞疗效的可行策略。
ACS sensors IF 10.9 2026-10-28 PMID: 42950174
Quantum sensing technologies offer unprecedented detection sensitivities down to single-molecule, attomolar detection limits and thus are emerging as transformative tools for ultra-sensitive biomarker detection in biomedical diagnostics. This comprehensive review synthesizes insights from over 380 plus studies to provide recent advances in quantum sensor platforms, examining the fundamental quantum mechanical principles that enable enhanced sensitivity, and surveys a diverse range of quantum sensing technologies along with their applications across the biomedical field. Specifically, nitrogen-vacancy (NV) centers in diamond, quantum dots, superconducting quantum interference devices (SQUIDs), and other quantum sensing modalities applied to biomarker detection for cancer diagnostics, cardiovascular disease, neurological disorders, and infectious disease detection are reviewed. Further, the key technical challenges that hurdle their clinical translation are critically evaluated. The review results demonstrate that quantum-enhanced biosensors have achieved detection limits of the order of magnitude below conventional methods. Intrinsic to their capabilities, several quantum sensing platforms have progressed to clinical testing and early commercialization efforts. Specifically, for point-of-care diagnosis, early disease detection, and personalized medicine.
中文摘要:量子传感技术可提供低至单分子、阿摩尔级的检测灵敏度,正在成为生物医学诊断中超灵敏生物标志物检测的变革性工具。基于380余项研究,本文汇总量子传感器平台的最新进展,考察带来灵敏度提升的基本量子力学原理,并梳理多种量子传感技术及其在生物医学领域的应用。具体而言,综述了金刚石中的氮空位(NV)色心、量子点、超导量子干涉器件(SQUID)及其他量子传感模式在癌症、心血管疾病、神经系统疾病和感染性疾病生物标志物检测中的应用。同时,对阻碍其临床转化的关键技术挑战进行了批判性评估。综述结果表明,量子增强生物传感器已达到比传统方法低约一个数量级的检测限。若干量子传感平台依托其内在能力已进入临床测试和早期商业化阶段,具体面向即时诊断、疾病早期发现和个性化医疗。
Blood IF 23.9 2026-10-28 PMID: 42950083
EBV activation specifically occurs in a subset of patients following CD7 CAR-T therapy, subsequently leading to EBV-positive lymphoproliferative disorder (EBV+ LPD), descriptively referred to as post-CD7 CAR-T lymphoproliferative disorder (PCLD) in this study. To comprehensively characterize PCLD, we employed single-nucleus RNA sequencing, ATAC sequencing, and Stereo-seq to perform multi-omic spatial profiling of PCLD, and compared it with classical post-transplant lymphoproliferative disorder (PTLD), EBV-negative diffuse large B-cell lymphoma (EBV- DLBCL) and normal lymph nodes. Infiltrating T cells in PCLD are uniquely characterized by CD7 negativity, exhibiting limited proliferation upon infection stimulation and impaired antiviral activity against EBV. Macrophages are recruited in an attempt to sustain viral clearance; however, the Macro_IDO1 subset emerges as the dominant macrophage population, exhibiting an immunosuppressive phenotype marked by elevated IDO1 expression. Spatially, macrophages, predominantly Macro_IDO1, aggregate to form an immunosuppressive niche that restricts T-cell infiltration and is enriched for inhibitory ligand-receptor interactions, including the PD-1/PD-L1 axis. T-cell function is further compromised, enabling sustained EBV infection of B cells and driving malignant transformation. EBV-driven B cells undergo plasmacytic differentiation and sustained proliferation, actively remodeling the microenvironment. This study provides a comprehensive molecular characterization of lymphoproliferative disorder following CD7 CAR-T therapy, elucidates spatial tumor-immune interactions, mechanisms of EBV-driven B-cell transformation and potential intervention strategies.
中文摘要:CD7 CAR-T治疗后,部分患者可出现EBV激活,并进一步发展为EBV阳性淋巴增殖性疾病(EBV+ LPD),本研究将其描述性地称为CD7 CAR-T后淋巴增殖性疾病(PCLD)。为全面刻画PCLD,我们采用单核RNA测序、ATAC测序和Stereo-seq对PCLD开展多组学空间图谱分析,并与经典型移植后淋巴增殖性疾病(PTLD)、EBV阴性弥漫大B细胞淋巴瘤(EBV- DLBCL)以及正常淋巴结进行比较。PCLD中浸润的T细胞以CD7阴性为特征,感染刺激下增殖能力有限,针对EBV的抗病毒活性受损。巨噬细胞被募集以试图维持病毒清除,但Macro_IDO1亚群成为优势巨噬细胞群体,呈现以IDO1表达升高为标志的免疫抑制表型。空间上,以Macro_IDO1为主的巨噬细胞聚集形成免疫抑制生态位,限制T细胞浸润,并富集抑制性配体-受体相互作用,包括PD-1/PD-L1轴。T细胞功能进一步受损,使EBV得以持续感染B细胞并推动恶性转化。EBV驱动的B细胞发生浆细胞样分化并持续增殖,主动重塑微环境。该研究对CD7 CAR-T治疗后淋巴增殖性疾病给出了系统的分子层面刻画,阐明了空间上的肿瘤-免疫相互作用、EBV驱动B细胞转化的机制以及潜在干预策略。
Critical reviews in food science and nutrition IF 10.6 2026-10-28 PMID: 42949652
Cruciferous vegetables are rich in glucosinolates (GSLs) with diverse R-group side chains. Hydrolysis of GSLs yields various isothiocyanates (ITCs), including sulforaphane (SFN), which possesses anti-cancer and antioxidant activities. However, the pungent odor of SFN limits consumer acceptance. Probiotic fermentation effectively improves flavor and nutritional value. Single-strain fermentation may result in relatively monotonous flavors, whereas co-fermentation enriches flavor but may impair SFN stability. Microbial metabolism in co-fermentation can disrupt SFN-stabilizing acidic conditions and accelerate its degradation. Nevertheless, major research gaps still exist, including unclear microbial interactions in co-fermentation systems and bottlenecks for industrial-scale application. Based on GSL hydrolysis mechanisms, this review systematically compares single-strain and co-fermentation in terms of flavor and SFN content, and analyzes the mechanisms by which these two approaches improve the flavor of SFN-rich cruciferous vegetable juices. Furthermore, to quantify functional and flavor attributes under different fermentation processes and optimize product quality, we systematically summarize conventional and advanced detection techniques for flavor compounds and SFN. Meanwhile, the association between probiotic biotransformation and sensory quality in SFN-rich systems is specifically discussed, aiming to offer theoretical reference and practical insights for the quality improvement and product development of fermented cruciferous vegetable beverages.
中文摘要:十字花科蔬菜富含具有多样R基侧链的硫苷(GSLs)。硫苷水解产生多种异硫氰酸酯(ITCs),包括具有抗癌和抗氧化活性的萝卜硫素(SFN)。但SFN的辛辣气味限制了消费者接受度。益生菌发酵能有效改善风味和营养价值。单菌株发酵可能造成风味相对单一,而共发酵虽丰富风味,却可能损害SFN稳定性。共发酵中的微生物代谢会破坏稳定SFN的酸性条件并加速其降解。仍存在重要研究空白,包括共发酵体系中微生物相互作用不明确以及工业规模应用的瓶颈。基于GSL水解机制,该综述系统比较单菌株发酵与共发酵在风味和SFN含量方面的差异,并分析这两种方式改善富含SFN十字花科蔬菜汁风味的机制。为量化不同发酵工艺下的功能与风味属性并优化产品质量,系统总结风味化合物和SFN的常规与先进检测技术。同时,专门讨论富含SFN体系中益生菌生物转化与感官品质的关联,旨在为发酵十字花科蔬菜饮料的品质提升和产品开发提供理论参考与实践启示。
Cellular & molecular immunology IF 23.9 2026-10-28 PMID: 42946800
Macrophages are versatile immune cells that maintain tissue homeostasis and shape disease progression through continuous adaptation to the local environment. Recent advances in single-cell, spatial, and multiomics technologies have revealed extensive diversity in tissue-specific macrophage identities and their adaptation to physiological and pathological contexts. Emerging evidence indicates that macrophage behavior emerges from the coordinated integration of ontogenetic imprinting, environmental sensing, metabolic rewiring, and epigenetic remodeling. These interconnected layers collectively determine macrophage responses in inflammatory diseases, neurodegeneration, and cancer, creating both challenges and opportunities for therapeutic intervention. In this review, we provide an overview of recent mechanistic insights into the molecular circuits governing macrophage plasticity and function and discuss how this evolving framework can inform next-generation macrophage-based therapeutic strategies to restore immune homeostasis and improve disease outcomes.
中文摘要:巨噬细胞是一类具有多种功能的免疫细胞,通过对局部环境的持续适应维持组织稳态并影响疾病进展。单细胞、空间和多组学技术的最新进展揭示了组织特异性巨噬细胞身份的广泛多样性,以及它们对生理和病理环境的适应。新出现的证据表明,巨噬细胞行为源于个体发育印记、环境感知、代谢重编程和表观遗传重塑的协同整合。这些相互关联的层面共同决定巨噬细胞在炎症性疾病、神经退行性疾病和癌症中的反应,为治疗干预带来挑战与机会。本综述概述了调控巨噬细胞可塑性和功能的分子回路的最新机制认识,并讨论这一不断演进的框架如何为下一代基于巨噬细胞的治疗策略提供依据,以恢复免疫稳态并改善疾病结局。
Cell death and differentiation IF 13.6 2026-10-28 PMID: 42946759
The cohesin complex is well recognized for maintaining sister chromatid cohesion during mitosis and meiosis, as well as for its role in genome organization through chromatin loop formation. Recent studies indicate that cohesin can be co-opted in cancer by aiding DNA repair processes to promote cancer cell proliferation. However, the mechanisms, protein partners, and functions by which cohesin is involved in DNA repair remain unclear. Here, we uncover a novel function of cohesin core subunits (RAD21, STAG1/2) in promoting transcription-coupled homologous recombination (TC-HR) at sites of R-loops. We demonstrate that cohesin (SMC1/3, RAD21, STAG1) preferentially localizes to R-loops in vitro and localize to DNA damage-induced R-loops in cells. Through a screen of chromatin remodelers, we identify that chromatin remodeler SMARCA5 recruits RAD21 and STAG at R-loop sites. SMARCA5 forms a complex with RAD21 via its SLIDE domain and is recruited to R-loops, providing a dual mechanism to promote the R-loop localization of the cohesin core subunits. The ATPase activity of SMARCA5 facilitates the localization of RAD21 and RAD51 at sites of R-loops to promote TC-HR and timely resolution of R-loops. Depletion of either core subunits of cohesin or SMARCA5, both of which are overexpressed in a subset of cancers, leads to aberrant R-loop accumulation, stalled replication fork progression, and elevated transcription-replication collision (TRC) events induced cell death. These findings shed new light on a previously unknown function of SMARCA5 through regulating cohesin core subunits RAD21/STAG at R-loops and established their potential as therapeutic targets in treating cancer.
中文摘要:黏连蛋白复合体因在有丝分裂和减数分裂中维持姐妹染色单体黏连、并通过染色质环形成参与基因组组织而广为人知。近期研究表明,癌细胞可利用黏连蛋白协助DNA修复过程,从而促进癌细胞增殖。但黏连蛋白参与DNA修复的机制、蛋白伙伴及功能仍不清楚。本研究发现黏连蛋白核心亚基(RAD21、STAG1/2)在R-loop位点促进转录偶联同源重组(TC-HR)的新功能。研究显示,黏连蛋白(SMC1/3、RAD21、STAG1)在体外优先定位于R-loop,并在细胞中定位于DNA损伤诱导的R-loop。通过对染色质重塑因子的筛选,研究鉴定出染色质重塑因子SMARCA5在R-loop位点招募RAD21和STAG。SMARCA5通过其SLIDE结构域与RAD21形成复合体并被招募至R-loop,提供促进黏连蛋白核心亚基R-loop定位的双重机制。SMARCA5的ATP酶活性促进RAD21和RAD51在R-loop位点的定位,从而促进TC-HR和R-loop的及时解析。耗竭黏连蛋白核心亚基或SMARCA5(二者在一部分癌症中过表达)会导致异常R-loop积累、复制叉进程停滞以及转录-复制碰撞(TRC)事件升高所诱导的细胞死亡。这些发现揭示了SMARCA5通过调控R-loop处黏连蛋白核心亚基RAD21/STAG的一个此前未知功能,并确立其作为癌症治疗靶点的潜力。
Endocrine reviews IF 23.9 2026-10-28 PMID: 42946681
Emerging evidence highlights a strong association between type 2 diabetes (T2D) and increased cancer risk, with partially overlapping metabolic disruptions potentially driving both diseases. Chronic hyperglycemia, a hallmark of T2D, disrupts glycolytic flux and contributes to the accumulation of toxic intermediates, driving cellular damage and diabetic complications. Specifically, dysregulation of glycolytic enzymes diverts metabolites into harmful pathways, promoting oxidative and glycative stress across multiple cell types. Similar metabolic disturbances support cancer development and progression by fueling rapid tumor cell proliferation. This review explores the role of abnormal glycolysis as a potential mechanistic link between T2D and cancer, detailing shared enzymatic alterations and metabolic pathway shifts. Additionally, it discusses pharmacological therapeutic strategies targeting glycolysis-related abnormalities common to both diseases, emphasizing the need for balanced metabolic modulation.
中文摘要:新出现的证据表明2型糖尿病(T2D)与癌症风险升高密切相关,部分重叠的代谢紊乱可能共同驱动这两种疾病。慢性高血糖是T2D的标志,会扰乱糖酵解通量并促使毒性中间产物蓄积,造成细胞损伤和糖尿病并发症。具体而言,糖酵解酶失调使代谢物转向有害途径,在多种细胞类型中促进氧化应激和糖化应激。类似的代谢紊乱通过为肿瘤细胞快速增殖提供燃料,支持癌症发生和进展。该综述探讨异常糖酵解作为T2D与癌症之间潜在机制联系的作用,详述二者共有的酶改变和代谢通路偏移。综述还讨论针对两种疾病共有的糖酵解相关异常的药物治疗策略,强调需要进行平衡的代谢调节。
Cancer letters IF 11.8 2026-10-28 PMID: 42679918
Hepatobiliary cancers are highly heterogeneous malignant tumors, and the drug resistance frequently emerges at advanced stages. Patient-derived organoids (PDOs) are three-dimensional ex vivo cultures. They can reproduce essential biological aspects of primary tumors, and play a key role in personalized oncology. With advances in methodology and technology, PDOs are increasingly being used in hepatobiliary cancer research at both the fundamental and translational levels. This review summarizes recent advances in patient-derived organoids, including culture matrices, microenvironment reconstruction, and organoid-on-chips. We also discuss the applications of PDOs in hepatobiliary cancer modeling and organoid biobank construction. Hepatobiliary cancer organoids hold promise for drug development and may serve as complementary tools for preclinical prediction. Integrating in vitro drug testing, resistance mechanism identification and combination regimen screening, organoid-based workflows can provide platforms for treatment stratification and personalized treatment optimization in hepatobiliary cancers. The incorporation of artificial intelligence may further expand the capabilities of organoid-based platforms. Overall, hepatobiliary cancer organoids represent clinically promising models for overcoming therapeutic resistance and developing personalized treatment strategies. They are powerful tools for precision oncology and clinical translation.
中文摘要:肝胆系统肿瘤是高度异质的恶性肿瘤,晚期常出现耐药。患者来源类器官(PDOs)是三维离体培养物,能够再现原发肿瘤的关键生物学特征,在个体化肿瘤学中发挥重要作用。随着方法学与技术的进步,PDOs 越来越多地用于肝胆肿瘤的基础与转化研究。本综述总结了患者来源类器官的最新进展,涵盖培养基质、微环境重建及类器官芯片。同时讨论 PDOs 在肝胆肿瘤建模与类器官生物样本库构建中的应用。肝胆肿瘤类器官在药物开发方面具有前景,可作为临床前预测的补充工具。将体外药物检测、耐药机制鉴定与联合方案筛选整合起来,基于类器官的工作流程可为肝胆肿瘤的治疗分层与个体化治疗优化提供平台。人工智能的引入可能进一步拓展类器官平台的能力。总体而言,肝胆肿瘤类器官是克服治疗耐药、制定个体化治疗策略方面具有临床前景的模型,也是精准肿瘤学与临床转化的有力工具。
Cancer letters IF 11.8 2026-10-28 PMID: 42641867
Intercellular communication via gap junctions is often lost during cancer development, which may contribute to increased tumor growth and affect how cancer cells respond to radio- and chemotherapy. Gap junction channels comprise transmembrane proteins belonging to the connexin family, of which connexin43 (Cx43) is the most ubiquitously expressed in humans. SMAD ubiquitination regulatory factor 2 (SMURF2), a member of the neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4) family of E3 ubiquitin ligases, often accumulates in the cytoplasm in cancer cells, where it may display oncogenic properties. Here, we demonstrate that SMURF2 interacts with Cx43 and promotes its ubiquitination in HeLa cells, which is associated with loss of Cx43-based gap junctions and reduced levels of Cx43. Moreover, SMURF2 was found to cooperate with two other NEDD4 family members, NEDD4 and ITCH, to regulate Cx43 ubiquitination and degradation. Simultaneous depletion of these three E3 ubiquitin ligases significantly reduced the Cx43 ubiquitination and degradation rate compared with their single depletion. Their combined knockdown was also found to reduce the ubiquitination and degradation of Cx43 following exposure to the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA). Collectively, these data identify SMURF2 as a negative regulator of gap junctional intercellular communication in cancer cells by inducing the loss of Cx43-based gap junctions. The study also establishes that Cx43 ubiquitination and degradation are controlled by the concurrent participation of multiple E3 ubiquitin ligases, both under basal conditions and in response to TPA exposure.
中文摘要:通过间隙连接进行的细胞间通讯在癌症发生过程中常丢失,这可能促进肿瘤生长并影响癌细胞对放疗和化疗的反应。间隙连接通道由连接蛋白家族的跨膜蛋白组成,其中连接蛋白43(Cx43)在人体内表达最广泛。SMAD泛素化调节因子2(SMURF2)是神经前体细胞表达发育下调蛋白4(NEDD4)家族E3泛素连接酶的一员,常在癌细胞胞质中蓄积,并可能表现出致癌特性。研究发现,在HeLa细胞中SMURF2与Cx43相互作用并促进其泛素化,这与基于Cx43的间隙连接丢失及Cx43水平降低相关。SMURF2还可与NEDD4家族另外两个成员NEDD4和ITCH协同调控Cx43的泛素化和降解。与单独敲低相比,同时敲低这三种E3泛素连接酶可显著降低Cx43的泛素化水平和降解速率。联合敲低还可降低暴露于肿瘤促进剂12-O-十四烷酰佛波醇13-乙酸酯(TPA)后Cx43的泛素化和降解。这些数据表明SMURF2通过诱导基于Cx43的间隙连接丢失,成为癌细胞间隙连接细胞间通讯的负调控因子。该研究还确定,在基础条件下以及TPA暴露后,Cx43的泛素化和降解均受多种E3泛素连接酶共同参与的控制。
Cancer letters IF 11.8 2026-10-28 PMID: 42641866
Adrenergic signaling regulates immune homeostasis through neuroendocrine pathways, but its role in hematologic malignancies remains poorly understood. Multiple myeloma (MM) originates in the bone marrow (BM), a highly innervated niche where neural, immune, and stromal signals are integrated. Whether adrenergic stimulation shapes BM immunity and influences myeloma progression is unclear. Using the 5T33MM mouse model, we investigated how adrenergic activation affects tumor growth and the BM immune landscape. Sustained adrenergic signaling was induced in vivo, while pharmacological β-adrenergic stimulation was used to assess effects on tumor-immune interactions. Immune composition and tumor burden were analyzed in BM and spleen, β2-adrenergic receptor expression was examined across murine and human immune populations, and ex vivo assays were performed using murine and patient-derived BM samples treated with adrenergic agonists alone or combined with relevant myeloma immunotherapies. Chronic restraint stress remodeled the BM immune compartment in MM-bearing mice, characterized by expansion of innate effector populations, including neutrophils and natural killer cells, and was associated with a significant reduction in BM tumor burden. These effects were compartment-restricted and not reflected in splenic tumor load or systemic disease markers. Pharmacological β-adrenergic stimulation reproduced these immune alterations and transiently delayed myeloma progression. In contrast, short-term β-adrenergic agonism ex vivo did not alter MM cell viability but consistently reduced the efficacy of MM immunotherapies. In summary, adrenergic signaling exerts context-dependent effects on myeloma progression, restraining tumor growth in vivo while impairing immunotherapy efficacy ex vivo, identifying a BM-specific neuroimmune axis relevant for cancer treatment.
中文摘要:肾上腺素能信号通过神经内分泌通路调节免疫稳态,但其在血液系统恶性肿瘤中的作用仍不清楚。多发性骨髓瘤(MM)起源于骨髓,这是一个神经支配丰富、整合神经、免疫与基质信号的微环境。肾上腺素能刺激是否塑造骨髓免疫并影响骨髓瘤进展尚不明确。我们采用5T33MM小鼠模型研究肾上腺素能激活对肿瘤生长和骨髓免疫格局的影响。在体内诱导持续性肾上腺素能信号,并用药物性β肾上腺素能刺激评估其对肿瘤与免疫相互作用的影响。分析骨髓和脾脏中的免疫组成与肿瘤负荷,检查小鼠及人免疫细胞群中β2肾上腺素能受体的表达,并用小鼠及患者来源骨髓样本进行离体实验,单独给予肾上腺素能激动剂或联合相关骨髓瘤免疫治疗。慢性束缚应激重塑荷瘤小鼠的骨髓免疫区室,表现为中性粒细胞和自然杀伤细胞等固有免疫效应细胞群扩增,并与骨髓肿瘤负荷显著降低相关。这些效应局限于该区室,未反映在脾脏肿瘤负荷或系统性疾病标志物中。药物性β肾上腺素能刺激重现了这些免疫改变,并短暂延缓骨髓瘤进展。相反,离体短期β肾上腺素能激动不改变MM细胞活力,却持续降低MM免疫治疗的疗效。肾上腺素能信号对骨髓瘤进展具有情境依赖性作用,在体内抑制肿瘤生长,而在离体削弱免疫治疗疗效,提示存在与癌症治疗相关的骨髓特异性神经免疫轴。
Cancer letters IF 11.8 2026-10-28 PMID: 42617726
Prostate cancer is a growing global health challenge. To identify new ways to improve patient care, researchers need a variety of preclinical models that faithfully recapitulate human tumours across the disease continuum, from initiation to metastasis. These complementary models include primary cultures of prostate epithelial cells (PrECs), co-cultures, patient-derived explants (PDEs), patient-derived organoids (PDOs) and patient-derived xenografts (PDXs). Collectively, these models enable researchers to study tumour biology and therapeutic responses in clinically relevant contexts. Yet, there is still a need to improve the fidelity of preclinical models to human tumours by integrating diverse cell types from the tumour microenvironment and mimicking biomechanical features. By improving culture methods with matrix components that resemble the tumour microenvironment and new formulations of media that imitate human plasma, in vitro models will more accurately reflect human physiology, nutrient availability, and metabolism. In time this may reduce the reliance on animal testing through organ-on-chip and related techniques. These more complex models are suited to more detailed experimental readouts, including single-cell and spatial analyses. Intravital imaging also enables dynamic visualisation of cell-cell interactions and treatment responses in vivo. Collectively, these approaches are facilitating a shift towards sophisticated models that capture patients' tumour heterogeneity, different cellular niches, and provide opportunities to carefully study tumorigenesis, metastasis, lineage plasticity, and therapy resistance. In this review, we discuss the current progress and future directions for patient-derived models of prostate cancer, highlighting how they can be generated, refined, characterised and shared to accelerate the worldwide effort in translational research.
中文摘要:前列腺癌是全球日益突出的健康挑战。为寻找改善患者诊疗的新途径,研究人员需要多种临床前模型,能够在从起始到转移的疾病连续过程中忠实重现人类肿瘤。这些互补模型包括前列腺上皮细胞原代培养(PrECs)、共培养、患者来源外植体(PDEs)、患者来源类器官(PDOs)和患者来源异种移植(PDXs)。这些模型共同使研究人员能够在临床相关情境中研究肿瘤生物学和治疗反应。临床前模型仍需通过整合肿瘤微环境中的多种细胞类型并模拟生物力学特征,提高对人类肿瘤的还原度。利用类似肿瘤微环境的基质成分和模仿人血浆的新培养基配方改进培养方法,可使体外模型更准确地反映人体生理、营养可利用性和代谢。假以时日,这可能通过器官芯片及相关技术减少对动物实验的依赖。这些更复杂的模型适合更详细的实验读出,包括单细胞和空间分析。活体成像还能够在体内动态观察细胞间相互作用和治疗反应。这些方法共同推动模型向更精细的方向转变,以捕捉患者肿瘤异质性、不同细胞生态位,并为细致研究肿瘤发生、转移、谱系可塑性和治疗耐药提供机会。综述讨论前列腺癌患者来源模型的当前进展和未来方向,重点说明如何生成、改进、表征和共享这些模型,以加速全球转化研究。
Cancer letters IF 11.8 2026-10-28 PMID: 42586305
Ubiquitination regulation is essential for maintaining protein homeostasis. Dysregulated ubiquitination is increasingly recognized to participate in malignant progression. Fbxw11, a substrate-recognition subunit of SCF-type E3 ligases, is involved in tumorigenesis and progression. However, its role and molecular mechanism in acute myeloid leukemia (AML) have not been elucidated. Here we demonstrat that lower levels of Fbxw11 were detected in AML patients and correlated with worse prognosis. Furthermore, overexpression of Fbxw11 delayed AML progression by reducing leukemia stem cell (LSC) frequency and inhibiting leukemia cell migration. Mechanistically‌, quantitative proteomics combined with co-immunoprecipitation and ubiquitination assays identified dihydropyrimidinase-like 2 (Dpysl2) as a direct substrate of Fbxw11, leading to its poly-ubiquitylation and proteasomal degradation. Moreover, overexpression of Dpysl2 reversed the effects of Fbxw11 on LSC levels and migration of AML cells as well as accelerated AML progression in vivo. In addition, inhibition of Dpysl2 with lacosamide, an FDA-approved antiepileptic drug, phenocopied Fbxw11 restoration and delayed AML progression. Lacosamide combined with cytarabine further prolonged the survival of AML mice. Our results suggest Fbxw11 as an intrinsic suppressor in AML progression by regulating the ubiquitination and degradation of Dpysl2, providing new insights into ubiquitination regulation and highlighting the potential of targeting the Fbxw11-Dpysl2 axis as a therapeutic strategy for AML.
中文摘要:泛素化调控对维持蛋白稳态至关重要。泛素化失调参与恶性肿瘤进展的认识不断加深。Fbxw11是SCF型E3泛素连接酶的底物识别亚基,参与肿瘤发生与进展,但其在急性髓系白血病(AML)中的作用及分子机制尚未阐明。AML患者中Fbxw11水平较低,且与更差预后相关。过表达Fbxw11可降低白血病干细胞(LSC)频率并抑制白血病细胞迁移,从而延缓AML进展。机制上,定量蛋白质组学结合免疫共沉淀和泛素化实验确定二氢嘧啶酶样2(Dpysl2)是Fbxw11的直接底物,Fbxw11促进其多聚泛素化及蛋白酶体降解。过表达Dpysl2可逆转Fbxw11对LSC水平及AML细胞迁移的影响,并在体内加速AML进展。使用FDA批准的抗癫痫药拉考沙胺抑制Dpysl2,可模拟Fbxw11恢复的效果并延缓AML进展。拉考沙胺联合阿糖胞苷进一步延长AML小鼠生存。结果提示Fbxw11通过调控Dpysl2泛素化与降解,作为AML进展的内在抑制因子,为泛素化调控提供新认识,并提示靶向Fbxw11-Dpysl2轴可能成为AML治疗策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42551835
Liver metastasis is the leading cause of death in pancreatic ductal adenocarcinoma (PDAC), yet its molecular drivers remain poorly defined. Through integrated transcriptomic and proteomic screening of clinical specimens, we identify the membrane protein Cadherin-Related Family Member 2 (CDHR2) as a key orchestrator of hepatic colonization in PDAC. CDHR2 was upregulated in primary tumors versus adjacent tissues, further elevated in liver metastasis versus matched primary tumors, and markedly enriched in patient-derived plasma extracellular vesicles (EVs), peaking in patients with liver metastasis. Knockdown of CDHR2 in human PDAC cells suppressed proliferation, migration, and invasion, and in orthotopic models attenuated primary tumor growth, remodeled the tumor microenvironment, and reduced liver metastatic burden. Mechanistically, CDHR2 associated with PDK1 and promoted activation of the PDK1-AKT (Thr308) axis to drive proliferation. In turn, AKT activity correlated with the packaging of CDHR2 into EVs, coupling intrinsic signaling to EV cargo loading. Tumor-derived, CDHR2-enriched EVs formed a complex with Aminopeptidase N (ANPEP) on liver sinusoidal endothelial cells (LSECs), disrupting endothelial junctions and enhancing tumor-cell adhesion to enable transendothelial migration. Consistently, ANPEP inhibition or liver-specific knockdown curtailed hepatic colonization, whereas priming with CDHR2+ EVs accelerated it. Finally, systemic delivery of EV-encapsulated siCDHR2 suppressed established primary tumors and markedly reduced liver metastasis. Collectively, our findings define a tumor-intrinsic CDHR2-PDK1-AKT (Thr308) axis coupled to an exosomal CDHR2-ANPEP endothelial-priming program and provide proof-of-concept for exosomal siCDHR2 as a candidate strategy against PDAC liver metastasis.
中文摘要:胰腺导管腺癌(PDAC)肝转移是主要死因,其分子驱动因素仍不明确。通过对临床标本进行整合转录组和蛋白质组筛查,发现膜蛋白Cadherin-Related Family Member 2(CDHR2)是PDAC肝脏定植的关键调控因子。CDHR2在原发肿瘤中较癌旁组织上调,在肝转移灶中较配对原发肿瘤进一步升高,并在患者来源血浆细胞外囊泡(EVs)中明显富集,在肝转移患者中达到峰值。在人PDAC细胞中敲低CDHR2可抑制增殖、迁移和侵袭;在原位模型中可减弱原发肿瘤生长、重塑肿瘤微环境并降低肝转移负荷。机制上,CDHR2与PDK1结合并促进PDK1-AKT(Thr308)轴激活以驱动增殖。AKT活性与CDHR2包装进入EVs相关,将内在信号与EV货物装载偶联。肿瘤来源的CDHR2富集EVs与肝窦内皮细胞(LSECs)上的氨肽酶N(ANPEP)形成复合物,破坏内皮连接并增强肿瘤细胞黏附,从而促进跨内皮迁移。抑制ANPEP或肝脏特异性敲低可减少肝脏定植,而用CDHR2+ EVs预处理则加速定植。全身递送EV包裹的siCDHR2可抑制已建立的原发肿瘤并显著减少肝转移。这些发现定义了肿瘤内在CDHR2-PDK1-AKT(Thr308)轴与外泌体CDHR2-ANPEP内皮预激活程序的偶联,并为外泌体siCDHR2作为对抗PDAC肝转移的候选策略提供概念验证。
Cancer letters IF 11.8 2026-10-28 PMID: 42498074
Chronic inflammation resulting from unresolved tissue injury is a potent driver of tumorigenesis. Macrophages are essential for efferocytosis, the clearance of apoptotic cells, which prevents secondary necrosis and promotes inflammation resolution. However, the epigenetic mechanisms regulating this process under inflammatory stress remain incompletely understood. Here, we identify the m6A methyltransferase METTL3 as a critical regulator of macrophage efferocytosis. Using various models of tissue injury, METTL3 expression was significantly downregulated in macrophages under inflammatory conditions and was associated with defective efferocytosis, the accumulation of apoptotic cells, and exacerbated chronic inflammation. Mechanistically, we reveal that METTL3-mediated m6A modification promotes IGF2BP2/3-dependent stabilization of MFGE8 mRNA, a process that is compromised upon METTL3 deficiency. In a colitis-associated cancer model, the efferocytosis defect associated with Mettl3 deficiency exacerbated chronic inflammatory tissue injury and increased susceptibility to colitis-associated cancer. Ultimately, external administration of recombinant MFGE8 protein effectively rescued the efferocytosis defect, mitigated inflammation, and reduced tumor burden in the AOM/DSS model. Collectively, our findings identify the METTL3-m6A-IGF2BP2/3-MFGE8 pathway as an important regulator of macrophage efferocytosis that may contribute to inflammation-associated carcinogenesis. These results suggest that targeting the METTL3-MFGE8 axis may represent a strategy for restoring efferocytosis and promoting inflammation resolution in chronic inflammatory diseases and inflammation-associated malignancies.
中文摘要:组织损伤持续不愈所致的慢性炎症是肿瘤发生的重要驱动因素。巨噬细胞在胞葬作用(清除凋亡细胞)中起关键作用,该过程可防止继发性坏死并促进炎症消退。炎症应激下调控这一过程的表观遗传机制尚不完全清楚。本研究发现m6A甲基转移酶METTL3是巨噬细胞胞葬作用的关键调控因子。在多种组织损伤模型中,炎症条件下巨噬细胞中METTL3表达显著下调,并与胞葬作用缺陷、凋亡细胞积聚及慢性炎症加重相关。机制上,METTL3介导的m6A修饰促进IGF2BP2/3依赖的MFGE8 mRNA稳定性,而METTL3缺失时该过程受损。在结肠炎相关癌症模型中,Mettl3缺失相关的胞葬缺陷加重了慢性炎症性组织损伤,并提高结肠炎相关癌症的易感性。外源给予重组MFGE8蛋白可有效挽救胞葬缺陷、减轻炎症并降低AOM/DSS模型中的肿瘤负荷。这些结果确定METTL3-m6A-IGF2BP2/3-MFGE8通路是巨噬细胞胞葬作用的重要调控通路,可能参与炎症相关癌变。结果提示,靶向METTL3-MFGE8轴或可成为恢复胞葬作用、促进慢性炎症性疾病及炎症相关恶性肿瘤中炎症消退的策略。
Pharmacological research IF 12.2 2026-10-27 PMID: 42946149
Mitochondrial dysfunction drives diseases, including ischemia-reperfusion injury, neurodegenerative disorders, cardiovascular disease, metabolic syndrome, and inflammation. Conventional mitochondria-targeted strategies offer only partial rescue and are insufficient for severe, irreversible damage. Mitochondrial transplantation (MT)-the delivery of exogenously isolated functional mitochondria to injured cells-has emerged as a promising therapeutic strategy that directly restores mitochondrial bioenergetic function and may subsequently modify the tissue microenvironment. This Review examines the entire MT pipeline, from mitochondrial source selection, isolation and preservation, to in vivo delivery strategies. We critically examine the multiple mechanisms underlying MT's therapeutic efficacy, including cellular uptake and intracellular integration, energy restoration and metabolic reprogramming, redox rebalancing, remodeling of mitochondrial quality control (fusion/fission, mitophagy, biogenesis), and immunomodulation. We summarize preclinical and clinical applications across multiple organ systems-heart, nervous system, liver, kidney, lung, skeletal muscle, retina-as well as in oncology and aging. We analyze five major translational bottlenecks: the lack of standardized manufacturing protocols, undefined dose-response relationships, immunogenicity and long-term safety uncertainties, the decisive impact of mitochondrial heterogeneity, and regulatory ambiguity. We outline future directions-mechanistic deepening, engineered target delivery, individualized mitochondrial medicine, combinatorial regimens, and a phased clinical roadmap. MT is not merely energy supplementation; it may reshape cellular metabolism, quality control networks, and immune microenvironments, representing a shift from pharmacological modulation of mitochondrial function toward organelle replacement strategies. Despite challenges, these advances may facilitate individualized mitochondrial therapies as a proposed future direction.
中文摘要:线粒体功能障碍驱动缺血再灌注损伤、神经退行性疾病、心血管疾病、代谢综合征和炎症等疾病。常规线粒体靶向策略只能带来部分挽救,对严重且不可逆的损伤不足。线粒体移植(MT)——将外源分离的功能性线粒体递送至受损细胞——已成为一种有前景的治疗策略,可直接恢复线粒体生物能量功能,并可能随后改变组织微环境。本综述考察MT全流程,从线粒体来源选择、分离和保存到体内递送策略。我们批判性审视MT疗效的多种机制,包括细胞摄取与胞内整合、能量恢复与代谢重编程、氧化还原再平衡、线粒体质量控制重塑(融合/分裂、线粒体自噬、生物发生)和免疫调节。我们总结多个器官系统的临床前和临床应用——心脏、神经系统、肝脏、肾脏、肺、骨骼肌、视网膜——以及肿瘤学和衰老领域。我们分析五个主要转化瓶颈:缺乏标准化生产方案、剂量反应关系未明确、免疫原性和长期安全性不确定性、线粒体异质性的决定性影响以及监管模糊性。我们概述未来方向——机制深化、工程化靶向递送、个体化线粒体医学、联合方案和分阶段临床路线图。MT不仅是能量补充;它可能重塑细胞代谢、质量控制网络和免疫微环境,代表从药理学调节线粒体功能向细胞器替代策略的转变。尽管存在挑战,这些进展可能促进个体化线粒体治疗,作为提出的未来方向。
Neuron IF 16.9 2026-10-27 PMID: 42945963
Recent studies have identified bi-directional communication between neurons and glioma tumors as a key driver of hyperexcitability and malignant progression. Although much of this work has focused on the activity of excitatory neurons, the roles of inhibitory neurons remain poorly defined. Using in vivo screening approaches in autochthonous glioma models, we found that the loss of a γ-aminobutyric acid (GABA) transporter (Slc6a1) enhanced glioma progression, promoted network hyperactivity, and influenced tonic GABA release by tumors. Mechanistically, we show that glioma tumors influence the activity of inhibitory neurons and that their subsequent stimulation suppresses tumor growth. Further screening of these phenomena identified diazepam binding inhibitor (DBI), a secreted negative allosteric modulator of GABA-A, as a link between glioma-related hyperexcitability and proliferation that functions through modulating inhibitory neuronal signaling. Collectively, our findings indicate that glioma tumors utilize multiple mechanisms to manipulate the activity of inhibitory neurons as a means to drive network hyperactivity, which ultimately facilitates malignant progression.
中文摘要:近期研究发现神经元与胶质瘤之间的双向通讯是过度兴奋和恶性进展的关键驱动因素。相关工作多聚焦于兴奋性神经元活动,抑制性神经元的作用仍不清楚。我们在自发胶质瘤模型中采用体内筛选方法,发现γ-氨基丁酸(GABA)转运体Slc6a1缺失会促进胶质瘤进展、增强神经网络过度兴奋,并影响肿瘤的张力性GABA释放。机制上,胶质瘤会影响抑制性神经元活动,而刺激这些神经元可抑制肿瘤生长。进一步筛选这些现象后,我们发现地西泮结合抑制蛋白(DBI)——一种分泌型GABA-A负性变构调节剂——通过调节抑制性神经元信号,将胶质瘤相关过度兴奋与增殖联系起来。这些结果表明,胶质瘤利用多种机制操控抑制性神经元活动以驱动网络过度兴奋,最终促进恶性进展。
ACS sensors IF 10.9 2026-10-27 PMID: 42945377
Accurate early screening for prostate cancer (PCa) is critical to clinical decision-making. Simultaneous detection of the independent biomarkers sarcosine (Sar) and prostate-specific antigen (PSA) can improve screening accuracy for PCa through cross-validation. However, co-immobilizing the two detection units on the sensor surface causes close intermingling, leading to mutual interference between PSA and Sar detection, which severely reduces detection sensitivity. To address this issue, we adopted a spatial segregation strategy that allows Sar and PSA to be detected inside the pores and on the external surface of the metal-organic framework (MOF) sensors, respectively. First of all, we screened various MOFs through density functional theory calculations and adsorption experiments and found that MOF-74(Ni) outperformed other MOFs in adsorbing Sar. The nanozyme riboflavin (Rf) encapsulated within MOF-74 pores enables intracavity detection of small Sar molecules by size-sieving and cascade reaction. Concurrently, the ferrocene-labeled peptides (Pep-Fc), which are specifically cleavable by PSA, were immobilized on the surface to detect the large PSA molecules excluded from the pores. Finally, the MOF-74/Rf@Pep-Fc electrochemical sensor was constructed for spatial segregation detection. A series of results from adsorption kinetics and anti-interference experiments confirmed that this design can effectively eliminate the mutual interference between Sar and PSA. The sensor demonstrates a limit of detection of 0.78 fg/mL for Sar and 0.065 fg/mL for PSA. Clinical validation in serum showed that the sensor achieved 100% PCa predictive accuracy for PSA > 20 ng/mL, and in the 4-20 ng/mL range, simultaneous detection raised accuracy from < 50% to > 85%, highlighting its clinical potential.
中文摘要:前列腺癌(PCa)的准确早期筛查对临床决策至关重要。同时检测独立生物标志物肌氨酸(Sar)和前列腺特异性抗原(PSA),可通过交叉验证提高PCa筛查准确性。然而,将两个检测单元共固定在传感器表面会造成紧密混合,导致PSA与Sar检测相互干扰,严重降低检测灵敏度。为解决该问题,采用空间分隔策略,使Sar和PSA分别于金属有机框架(MOF)传感器孔内和外表面对应检测。首先,通过密度泛函理论计算和吸附实验筛选多种MOF,发现MOF-74(Ni)对Sar的吸附优于其他MOF。封装于MOF-74孔内的纳米酶核黄素(Rf)通过尺寸筛分和级联反应实现小分子Sar的腔内检测。同时,可被PSA特异性切割的铁茂标记肽(Pep-Fc)固定于表面,用于检测被孔道排除的大分子PSA。最终构建MOF-74/Rf@Pep-Fc电化学传感器进行空间分隔检测。吸附动力学和抗干扰实验的一系列结果证实,该设计可有效消除Sar与PSA之间的相互干扰。传感器对Sar和PSA的检测限分别为0.78 fg/mL和0.065 fg/mL。血清临床验证显示,传感器对PSA > 20 ng/mL的PCa预测准确率为100%,在4–20 ng/mL范围内,同时检测将准确率从< 50%提高至> 85%,显示其临床潜力。
Cancer research IF 22.6 2026-10-27 PMID: 42945304
Metabolic reprogramming is a well-described hallmark of clear cell renal cell carcinoma (ccRCC). Gene copy number variation and altered gene expression data suggest enhanced branched-chain amino acid (BCAA) transamination and reduced BCAA oxidation are highly selected traits in ccRCC. Surprisingly, we found that genetic modulation of BCAA oxidation had little effect on experimental ccRCC cell growth in vitro and in vivo. In contrast, BCAA transamination in ccRCC cells was essential for the generation of glutamate-derived glutathione and cell viability when glutamine was limiting. Thus, BCAA transamination conferred resistance to states of low glutamine or treatment with the glutaminase inhibitor CB-839 by providing glutathione independent of glutamine breakdown. Targeting BCAA transamination in vitro and in vivo sensitized ccRCC to CB-839 mediated glutaminase inhibition by decreasing glutathione biosynthesis and redox homeostasis. These findings reveal that BCAA transamination maintains critical glutamate and glutathione levels in glutamine-deprived ccRCC, explaining why CB-839 treatment has been ineffective in ccRCC clinical trials and demonstrate an approach to treat ccRCC by targeting BCAA transamination to create a vulnerability to glutaminase inhibition.
中文摘要:代谢重编程是透明细胞肾细胞癌(ccRCC)已充分描述的标志。基因拷贝数变异和基因表达改变数据提示,支链氨基酸(BCAA)转氨增强和BCAA氧化减少是ccRCC中高度受选择性的特征。令人意外的是,我们发现遗传调控BCAA氧化对实验性ccRCC细胞在体外和体内的生长影响很小。相反,当谷氨酰胺受限时,ccRCC细胞中的BCAA转氨对生成谷氨酸来源的谷胱甘肽和维持细胞活力是必需的。因此,BCAA转氨通过提供不依赖谷氨酰胺分解的谷胱甘肽,使细胞对低谷氨酰胺状态或谷氨酰胺酶抑制剂CB-839处理产生抵抗。在体外和体内靶向BCAA转氨,可通过降低谷胱甘肽生物合成和氧化还原稳态,使ccRCC对CB-839介导的谷氨酰胺酶抑制敏感。这些发现揭示,BCAA转氨在谷氨酰胺缺乏的ccRCC中维持关键的谷氨酸和谷胱甘肽水平,解释了CB-839治疗在ccRCC临床试验中无效的原因,并展示了一种通过靶向BCAA转氨制造谷氨酰胺酶抑制易感性来治疗ccRCC的方法。
ACS nano IF 17.3 2026-10-27 PMID: 42937556
Inefficient immune synapse formation limits the therapeutic efficacy of T cell-based immunotherapy in both solid tumors and hematological malignancies. Here, we report a fully synthetic, membrane-anchored dual-targeting aptamer engager, AptE 2, that acts as a programmable artificial immunological interface to redirect cytotoxic T cells toward cancer cells without genetic engineering. Constructed entirely from DNA aptamers through optimized bioorthogonal conjugation and enzyme-mediated ligation, AptE 2 integrates multivalent tumor recognition, T cell binding, enhanced nuclease resistance, and prolonged membrane anchoring within a single modular scaffold. In colorectal cancer models, AptE 2 promoted stable T cell-tumor cell engagement, enhanced cytotoxicity and cytokine secretion, and drove pronounced tumor regression with increased intratumoral CD8+ T cell infiltration and minimal systemic toxicity. Importantly, AptE 2 also demonstrated broad applicability in leukemia. In CCRF-CEM cells, AptE 2 exhibited strong surface binding, sustained membrane retention for up to 6 h, and superior resistance to wash-off compared with monovalent aptamers and bivalent controls. AptE 2-prearmed TALL-104 cells markedly enhanced leukemia cell clustering, increased cell lysis to over 90% under optimized coculture conditions, and amplified IFN-γ secretion. In a disseminated CCRF-CEM-Luc leukemia mouse model, AptE 2-mediated T cell therapy suppressed systemic leukemia progression, improved peripheral hematological profiles, and showed favorable tolerability without detectable major organ injury. These findings establish AptE 2 as a generalizable, nonprotein-based and nonviral immune engager platform for programmable T cell redirection across both solid and hematological cancers.
中文摘要:免疫突触形成效率低下限制了基于T细胞的免疫治疗在实体瘤和血液恶性肿瘤中的疗效。研究报告了一种全合成、膜锚定的双靶向适配体衔接器AptE 2,它作为可编程的人工免疫界面,无需基因工程即可将细胞毒性T细胞重定向至癌细胞。AptE 2完全由DNA适配体构建,通过优化的生物正交偶联和酶介导连接,在单一模块化支架中整合了多价肿瘤识别、T细胞结合、增强的核酸酶抗性和延长的膜锚定能力。在结直肠癌模型中,AptE 2促进稳定的T细胞与肿瘤细胞结合,增强细胞毒性和细胞因子分泌,并驱动明显的肿瘤消退,同时增加瘤内CD8+ T细胞浸润且全身毒性很低。AptE 2在白血病中也表现出广泛适用性。在CCRF-CEM细胞中,AptE 2表现出强表面结合、长达6小时的持续膜滞留,以及相较单价适配体和二价对照更强的抗洗脱能力。经AptE 2预武装的TALL-104细胞明显增强白血病细胞聚集,在优化共培养条件下使细胞裂解率超过90%,并提高IFN-γ分泌。在播散性CCRF-CEM-Luc白血病小鼠模型中,AptE 2介导的T细胞治疗抑制全身白血病进展,改善外周血液学指标,耐受性良好且未检测到主要器官损伤。这些结果确立了AptE 2作为一种可推广、非蛋白且非病毒的免疫衔接器平台,可在实体瘤和血液肿瘤中实现可编程T细胞重定向。
ACS nano IF 17.3 2026-10-27 PMID: 42937555
The Golgi apparatus (GA) has emerged as a promising target for cancer therapy. Commonly, therapeutics are guided to the GA by recognizing specific receptors on the GA membrane. However, the low and heterogeneous expression of these receptors often results in suboptimal targeting efficiency. Here, we present an oncolytic virus-like nanoparticle for GA targeting by exploiting sphingomyelin, an abundant component of the GA membrane. This nanoparticle consisted of a polymeric nanocarrier complexed with a plasmid encoding the secreting peptide-deleted α-hemolysin (αHL), a pore-forming protein with high affinity for sphingomyelin. The nanoparticle could transfect cancer cells to induce intracellular expression of αHL, enabling GA targeting through binding to GA-associated sphingomyelin while bypassing the cell membrane. Consequently, the transfected cells exhibited GA structural disassembly and underwent a pyroptosis-like programmed cell death with immunogenic characteristics. Notably, αHL-rich microvesicles were subsequently secreted, effectively killing neighboring tumor cells. Intratumoral administration of this formulation significantly suppressed subcutaneous tumor growth and elicited robust antitumor immunity, preventing tumor rechallenge. Furthermore, by incorporating iRGD-modified polymers, we constructed a tumor-targeting oncolytic virus-like nanoparticle with neutral surface charge. Following intravenous administration, this iRGD-modified nanoparticle could efficiently suppress tumor growth without causing obvious systemic toxicity. Collectively, this work presents a robust strategy for GA-targeting via sphingomyelin recognition, providing a potential approach for GA-targeted anticancer therapeutics.
中文摘要:高尔基体已成为癌症治疗中有前景的靶点。治疗药物通常通过识别高尔基体膜上的特定受体被导向高尔基体,但这些受体表达水平低且异质,常导致靶向效率不理想。该研究利用高尔基体膜的丰富组分鞘磷脂,构建了一种用于高尔基体靶向的溶瘤病毒样纳米颗粒。该纳米颗粒由聚合物纳米载体与编码分泌肽缺失的α-溶血素的质粒复合而成,α-溶血素是一种对鞘磷脂具有高亲和力的成孔蛋白。纳米颗粒可转染癌细胞并诱导α-溶血素在细胞内表达,使其绕过细胞膜并与高尔基体相关鞘磷脂结合,从而实现高尔基体靶向。转染细胞随后出现高尔基体结构解体,并发生具有免疫原性特征的焦亡样程序性细胞死亡。富含α-溶血素的微囊泡随后被分泌,可有效杀伤邻近肿瘤细胞。瘤内给予该制剂显著抑制皮下肿瘤生长,并激发较强的抗肿瘤免疫,阻止肿瘤再攻击。通过引入iRGD修饰聚合物,研究还构建了表面呈中性电荷的肿瘤靶向溶瘤病毒样纳米颗粒。静脉给药后,该iRGD修饰纳米颗粒可有效抑制肿瘤生长,未引起明显的全身毒性。该工作提出了通过鞘磷脂识别靶向高尔基体的策略,为高尔基体靶向抗肿瘤治疗提供了潜在途径。
Signal transduction and targeted therapy IF 81.2 2026-10-27 PMID: 42934234
Adenosine 5'-monophosphate-activated protein kinase (AMPK), a highly conserved energy-sensing kinase, plays a central role in maintaining cellular metabolic homeostasis, such as glucose/lipid metabolism, mitochondrial biogenesis, and autophagy, to counteract energetic stress. Beyond the canonical adenylate-dependent activation of AMPK by sensing the ATP:AMP/ADP ratio, emerging evidence reveals noncanonical activation mechanisms. Proper AMPK signaling is essential for physiological functions, whereas its dysregulation underlies various pathologies, including metabolic diseases, immune disorders, and cancer. This review systematically recapitulates the historical background and landmark discoveries of the AMPK field, including the discovery of AMPK, the structure of AMPK complex, upstream regulators and downstream substrates, and the transcriptional/posttranscriptional and posttranslational regulatory mechanisms. Furthermore, we delineate its roles in maintaining metabolic equilibrium, mitochondrial integrity, and immune competence across organ systems and highlight how dysregulated AMPK activity contributes to pathological diseases, encompassing alterations in its expression levels, intrinsic kinase activity, subcellular localization or upstream regulatory signaling cascades. Specifically, we focus on knock-in or knockout mouse models utilized to study AMPK-associated human diseases and the translational potential of AMPK-targeting agonists or antagonists across diverse pathological conditions. A deep understanding of the multidimensional regulatory network of AMPK and mechanistic insights with therapeutic innovations that we provide with this review will help address the challenges of complex metabolic diseases.
中文摘要:AMPK(腺苷5'-单磷酸激活蛋白激酶)是一种高度保守的能量感受激酶,在维持细胞代谢稳态中起核心作用,包括葡萄糖/脂质代谢、线粒体生物发生和自噬,以应对能量应激。除通过感受ATP:AMP/ADP比值实现经典的腺苷酸依赖性激活外,新证据揭示了非经典激活机制。正常的AMPK信号对生理功能至关重要,而其失调构成多种病理过程的基础,包括代谢性疾病、免疫紊乱和癌症。该综述系统回顾AMPK领域的历史背景和里程碑发现,包括AMPK的发现、AMPK复合物结构、上游调节因子和下游底物,以及转录/转录后和翻译后调控机制。文章进一步描述其在各器官系统中维持代谢平衡、线粒体完整性和免疫能力的作用,并强调AMPK活性失调如何促成病理性疾病,涵盖其表达水平、内在激酶活性、亚细胞定位或上游调控信号级联的改变。具体而言,文章关注用于研究AMPK相关人类疾病的敲入或敲除小鼠模型,以及AMPK靶向激动剂或拮抗剂在不同病理条件下的转化潜力。该综述提供的对AMPK多维调控网络的深入理解及机制见解与治疗创新,将有助于应对复杂代谢疾病的挑战。
Medical image analysis IF 14.0 2026-10-26 PMID: 42956511
Survival prediction is critical in cancer research for forecasting patient outcomes and optimizing treatment strategies. While integrating histopathology whole-slide images (WSIs) with genomic profiles holds promise for improved predictive accuracy, two major challenges persist: (1) the inherent low signal-to-noise ratio in gigapixel WSIs, where task-irrelevant background patches often dominate standard Multi-Instance Learning (MIL) bags, and (2) the instability of unsupervised prototype initialization (e.g., K-means), which frequently converges to non-informative morphological patterns. To address these challenges, we propose DP-VIB (Discriminative Prototypes via Variational Information Bottleneck), a hierarchical framework that leverages the information bottleneck principle to learn survival-relevant prototypes in a coarse-to-fine manner. Unlike traditional approaches, DP-VIB first employs a survival-supervised Global VIB Module to learn a discriminative latent representation, filtering out nuisance variations through an information bottleneck constraint. Subsequently, Gaussian Mixture Model (GMM) priors derived from this purified latent representation serve as robust initializations for fine-grained patch-level prototypes, significantly enhancing convergence and semantic quality. Finally, we introduce a tri-branch Histology-Genomics(HG) encoder followed by a cross-modal fusion mechanism to deeply fuse these VIB-guided prototypes with genomic pathway embeddings, enabling analysis of model-derived prototype-pathway associations. Extensive validation on five TCGA cancer cohorts demonstrates that DP-VIB consistently outperforms strong baselines in Concordance Index (C-index), achieving superior robustness and accuracy in individualized survival prediction.
中文摘要:生存预测在癌症研究中用于预测患者结局和优化治疗策略。将组织病理全切片图像(WSIs)与基因组图谱整合有望提高预测准确性,但仍存在两个主要挑战:一是千兆像素WSIs固有的低信噪比,任务无关的背景图像块常主导标准多实例学习(MIL)包;二是无监督原型初始化(如K-means)不稳定,常收敛到无信息量的形态学模式。为应对这些挑战,我们提出DP-VIB(基于变分信息瓶颈的判别性原型),一个分层框架,利用信息瓶颈原理以由粗到细的方式学习与生存相关的原型。与传统方法不同,DP-VIB先采用生存监督的全局VIB模块学习判别性潜在表示,通过信息瓶颈约束过滤干扰性变异。随后,由该净化潜在表示得到的高斯混合模型(GMM)先验作为细粒度图像块级原型的稳健初始化,显著提升收敛性和语义质量。我们还引入三分支组织学-基因组(HG)编码器及跨模态融合机制,将这些VIB引导的原型与基因组通路嵌入深度融合,从而分析模型导出的原型-通路关联。在五个TCGA癌症队列上的广泛验证表明,DP-VIB在一致性指数(C-index)上持续优于强基线,在个体化生存预测中具有更好的稳健性和准确性。
Journal of hematology & oncology IF 47.8 2026-10-26 PMID: 42934771
The development of tyrosine kinase inhibitors (TKIs) has markedly improved outcomes in Philadelphia chromosome-positive leukemias; however, resistance mediated by BCR::ABL1 kinase domain (KD) mutations remains a major challenge. While the third-generation TKIs ponatinib and asciminib can suppress many resistant mutations including the gatekeeper mutation T315I, their use may be limited by vascular toxicity and emerging resistance, respectively. Compound mutations (CMs), particularly those involving T315I, are frequent in advanced chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia and are largely refractory to approved TKIs when used as monotherapy. Vamotinib (formerly PF-114), a structural analogue of ponatinib with a narrower kinase inhibition profile avoiding vascular endothelial growth factor receptor-2 (VEGFR-2) inhibition, was developed to retain broad anti-BCR::ABL1 activity while reducing toxicity. Here, we evaluated the in vitro activity of vamotinib against a comprehensive panel of BCR::ABL1 KD mutants using drug concentrations corresponding to clinically relevant dosing regimens and compared the results with available clinical data from a phase-1 trial. Our findings indicate that, even at effective average plasma concentrations corresponding to the maximum tolerated dose, vamotinib exhibits a resistance profile comparable to that of a well-performing second-generation TKI. Notably, high-level resistance persisted for T315I and several P-loop mutations. Clinical responses in mutation-positive patients were largely concordant with these observations. Collectively, these data suggest that vamotinib may not meet the criteria for classification as a third-generation TKI but could have utility in selected patient populations or in rational combination strategies.
中文摘要:酪氨酸激酶抑制剂(TKI)的发展明显改善了费城染色体阳性白血病的结局,但由BCR::ABL1激酶结构域(KD)突变介导的耐药仍是主要挑战。第三代TKI帕纳替尼和阿西米尼可抑制包括门控突变T315I在内的多种耐药突变,但前者受血管毒性限制,后者面临新出现的耐药。复合突变(CM),尤其是涉及T315I者,在晚期慢性髓性白血病(CML)和费城染色体阳性急性淋巴细胞白血病中较常见,单药使用已获批TKI时大多难治。Vamotinib(原PF-114)是帕纳替尼的结构类似物,激酶抑制谱更窄,不抑制血管内皮生长因子受体-2(VEGFR-2),其开发目标是保留广泛的抗BCR::ABL1活性并降低毒性。本研究在对应临床相关给药方案的药物浓度下,用一套覆盖较全面的BCR::ABL1 KD突变体评价vamotinib的体外活性,并与1期试验中可获得的临床数据进行比较。结果显示,即使在与最大耐受剂量相对应的有效平均血浆浓度下,vamotinib的耐药谱也与表现良好的第二代TKI相当。T315I及若干P环突变仍呈高水平耐药。突变阳性患者的临床反应与这些观察基本一致。这些数据提示,vamotinib可能不符合第三代TKI的分类标准,但可能在特定患者人群或合理的联合策略中具有价值。
Cellular & molecular immunology IF 23.9 2026-10-26 PMID: 42934289
DC development requires balanced signaling from cytokines, such as Fms-like tyrosine kinase 3 ligand (Flt3L) and macrophage colony-stimulating factor (M-CSF), but how these pathways are integrated to control lineage fate is not fully understood. Using a murine genetic model, we identified the kinase p38α as a central node that orchestrates this balance. We demonstrated that p38α, which acts as a critical effector downstream of Flt3L, is indispensable for plasmacytoid DC (pDC) differentiation. Mechanistically, the Flt3L-p38α pathway sustains the expression of the E3 ubiquitin ligase Nedd4, which mediates the degradation of the M-CSF receptor (CD115). Consequently, genetic deletion of p38α disrupts this primary Flt3L signaling cascade, leading to Nedd4 downregulation and triggering compensatory upregulation of surface CD115 expression on hematopoietic progenitors. This paradoxically enhanced their differentiation potential, leading to a numerical compensation of pDCs and increased overall myeloid repopulation; the resulting DCs were functionally impaired and exhibited defective production of type I/III interferons and IL-12. Crucially, this functional collapse abrogated their ability to orchestrate antitumor immunity. As a direct consequence, mice with p38α-deficient hematopoiesis failed to mount effective IFN-γ+CD8+ T-cell responses and were unable to control tumor growth. Our study reveals a novel p38α-Nedd4 molecular switch that integrates signaling from Flt3L and M-CSF to balance the quantity and functional quality of DCs, highlighting p38α as a key determinant of effective cancer immunosurveillance in a murine system.
中文摘要:DC发育需要Flt3L与M-CSF等细胞因子信号的平衡,但这些通路如何整合以控制谱系命运仍不清楚。利用小鼠遗传模型,我们发现激酶p38α是协调这一平衡的核心节点。p38α作为Flt3L下游的关键效应分子,对浆细胞样DC(pDC)分化不可或缺。机制上,Flt3L-p38α通路维持E3泛素连接酶Nedd4的表达,Nedd4介导M-CSF受体(CD115)降解。因此,p38α基因缺失破坏这一主要Flt3L信号级联,导致Nedd4下调,并触发造血祖细胞表面CD115代偿性上调。这反而增强其分化潜能,造成pDC数量补偿和总体髓系重建增加;所得DC功能受损,I/III型干扰素及IL-12产生缺陷。这一功能崩溃削弱其协调抗肿瘤免疫的能力。直接后果是,p38α缺陷造血的小鼠无法产生有效IFN-γ+CD8+ T细胞应答,不能控制肿瘤生长。这些结果揭示一个新的p38α-Nedd4分子开关,整合Flt3L与M-CSF信号,平衡DC数量与功能质量,并提示p38α是小鼠系统中有效癌症免疫监视的关键决定因素。
Journal for immunotherapy of cancer IF 11.7 2026-10-26 PMID: 42933888
Chimeric antigen receptor T cells (CAR T) targeting CD19 can cure patients with aggressive B cell malignancies. Relapse due to CD19 loss and infections from B cell aplasia remain major causes of death after CD19 CAR T. We demonstrate that CD83 is a clinically relevant target for CAR T therapy in B cell malignancies, overcoming limitations of CD19 CAR T. We evaluate CD83 expression among B cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), and circulating healthy B cells, compared with CD19, CD20, and CD22. We test the activity of CD19 and CD83 CAR T against Raji and Nalm6 target cells using in vitro and in vivo preclinical models. Functional and immunophenotypic aspects of CD19 and CD83 CAR T are investigated to compare potency. Further, we evaluate CD19 and CD83 expression on B cell ALL after prior CD19-directed therapy, revealing a propensity for CD19 antigen loss. To simulate CD19 antigen loss, we test CD19 and CD83 CAR T against CD19 knock-out Nalm6 cells. CD83 is expressed on B-cell ALL, MCL, and DLBCL, with negligible expression on circulating B cells and CLL. B cell ALL expresses CD83 at diagnosis and on relapse following CD19-directed therapy, when CD19 is decreased. CD83 CAR T kills B cell leukemia/lymphoma cell lines in vitro, providing efficacy after CD19 antigen loss. We show CD83 CAR T is effective as monotherapy in mice. Exploratory experiments suggest CD83 CAR T may offer enhanced efficacy when administered sequentially after CD19 CAR T. Our preclinical evidence justifies further translational investigation of CD83 CAR T in B cell leukemia and lymphoma. The benefits of CD83 CAR T include a low risk for B cell aplasia and efficacy after exposure to CD19 CAR T.
中文摘要:靶向CD19的嵌合抗原受体T细胞(CAR T)可治愈侵袭性B细胞恶性肿瘤患者。CD19丢失所致复发及B细胞发育不全所致感染仍是CD19 CAR T治疗后主要死亡原因。我们证明CD83是B细胞恶性肿瘤CAR T治疗的临床相关靶点,可克服CD19 CAR T的局限。我们评估CD83在B细胞急性淋巴细胞白血病(ALL)、慢性淋巴细胞白血病(CLL)、套细胞淋巴瘤(MCL)、弥漫性大B细胞淋巴瘤(DLBCL)及循环健康B细胞中的表达,并与CD19、CD20和CD22比较。我们利用体外和体内临床前模型检测CD19与CD83 CAR T对Raji和Nalm6靶细胞的活性。研究CD19与CD83 CAR T的功能和免疫表型特征以比较效力。进一步评估既往接受CD19靶向治疗后B细胞ALL中CD19和CD83的表达,发现CD19抗原丢失倾向。为模拟CD19抗原丢失,我们检测CD19与CD83 CAR T对CD19敲除Nalm6细胞的作用。CD83表达于B细胞ALL、MCL和DLBCL,在循环B细胞和CLL上表达可忽略。B细胞ALL在诊断时及CD19靶向治疗后复发时表达CD83,此时CD19降低。CD83 CAR T在体外杀伤B细胞白血病/淋巴瘤细胞系,在CD19抗原丢失后仍提供疗效。我们显示CD83 CAR T作为单药在小鼠中有效。探索性实验提示,在CD19 CAR T之后序贯给予CD83 CAR T可能增强疗效。我们的临床前证据支持对CD83 CAR T在B细胞白血病和淋巴瘤中的进一步转化研究。CD83 CAR T的优势包括B细胞发育不全风险低,以及在暴露于CD19 CAR T后仍有效。
ACS sensors IF 10.9 2026-10-26 PMID: 42932496
In line with the Food and Drug Administration's (FDA's) initiative to reduce, refine, and potentially replace animal testing in drug development through New Approach Methodologies, including toxicity testing, cancer organoids are emerging as human-relevant platforms for preclinical drug screening. By enabling direct, quantitative multiplex imaging of multiple protein targets in cell-line-derived organoids, our lanthanide imaging toolkit (LIT) extends analysis from conventional monolayer cultures to physiologically relevant three-dimensional models and offers a scalable tool for mechanistic studies, drug screening, and preclinical development with reduced reliance on animals.
中文摘要:为响应美国食品药品监督管理局(FDA)通过新方法学减少、优化并可能替代药物开发中动物试验(包括毒性测试)的倡议,癌症类器官正成为与人体相关的临床前药物筛选平台。我们的镧系成像工具包(LIT)可对细胞系来源类器官中的多种蛋白靶点进行直接、定量多重成像,将分析从传统单层培养扩展到生理相关的三维模型,并为机制研究、药物筛选和减少动物依赖的临床前开发提供可扩展工具。
Nucleic acids research IF 15.0 2026-10-26 PMID: 42929183
Non-coding RNAs (ncRNAs) can function as competing endogenous RNAs (ceRNAs) to sequester microRNAs, assembling complex regulatory networks that exert critical roles in diverse diseases. Although experimentally validated ceRNA interactions have rapidly accumulated, few resources systematically curate disease-associated ceRNA networks across multi-scale biological contexts. Here, we present LncACTdb 4.0 (https://bio-bigdata.hrbmu.edu.cn/LncACTdb), an updated repository housing manually curated, experimentally supported ceRNA interactions and multi-level regulatory networks for precision oncology. This release includes major data expansions: 15 008 high-confidence ceRNA-disease associations, 18 974 cancer-related biomarkers, as well as transcriptomic profiles from >60 000 individuals and ∼600 000 single cells covering 69 tissues. It implements a four-tier data architecture spanning tissue, cell line, organoid, and single-cell levels and provides a panel of 12 web-based tools to perform bulk-cohort, single-sample, and single-cell ceRNA analyses, with specialized single-cell modules supporting quantification, clustering, trajectory reconstruction, and cell-state annotation. Featuring a user-friendly interface and integrative analytical utilities, LncACTdb 4.0 enables investigation of ceRNA regulatory mechanisms ranging from tissue architecture to cellular resolution and facilitates biomarker mining for precision oncology research.
中文摘要:非编码RNA(ncRNA)可作为竞争性内源RNA(ceRNA)隔离microRNA,形成复杂调控网络,在多种疾病中发挥关键作用。尽管经实验验证的ceRNA相互作用迅速积累,系统整理跨多尺度生物学背景的疾病相关ceRNA网络的资源仍较少。LncACTdb 4.0(https://bio-bigdata.hrbmu.edu.cn/LncACTdb)是一个更新后的数据库,收录人工整理、经实验支持的ceRNA相互作用及面向精准肿瘤学的多层次调控网络。本次发布包含主要数据扩展:15008条高置信度ceRNA-疾病关联、18974个癌症相关生物标志物,以及来自超过60000个个体和约600000个单细胞、覆盖69种组织的转录组图谱。该数据库采用组织、细胞系、类器官和单细胞四个层级的数据架构,提供12个网络工具用于批量队列、单样本和单细胞ceRNA分析,专用单细胞模块支持定量、聚类、轨迹重建和细胞状态注释。LncACTdb 4.0具有友好的用户界面和整合分析功能,可用于从组织结构到细胞分辨率研究ceRNA调控机制,并促进精准肿瘤学研究中的生物标志物挖掘。
Medicinal research reviews IF 13.6 2026-10-25 PMID: 42927615
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway plays a fundamental role in innate immune signaling and has emerged as a therapeutically relevant pathway across cancer, inflammatory, and autoimmune diseases. Herein, we provide a comprehensive medicinal chemistry-focused overview of both activation and inhibition of the cGAS-STING pathway, focusing on three druggable therapeutic targets, cGAS, STING, and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). The translational maturity of these targets differs substantially, with STING being the most clinically advanced, whereas cGAS and ENPP1 remain emerging targets supported predominantly by preclinical evidence, with the advancement of a few inhibitors into early-stage clinical trials. The biological rationale for pathway modulation, along with modulators, is discussed with emphasis on active site interactions, scaffold diversity, their activity profiles, structure-activity relationships, species selectivity, and in vivo efficacy. The particular focus is on patent literature and advanced-stage molecules, discussing their ADME properties, pharmacokinetics, and clinical development status. Although STING agonists have achieved a larger reach in clinical trials within this pathway, recent developments suggest that cGAS inhibitors and ENPP1 inhibitors hold a greater promise for future clinical success. In summary, this review provides insights into medicinal chemistry and translational challenges and future opportunities for rational drug design to guide next-generation modulators of the cGAS-STING-ENPP1 axis.
中文摘要:环鸟苷酸-腺苷酸合成酶(cGAS)-干扰素基因刺激因子(STING)通路在天然免疫信号传导中起基础性作用,已成为癌症、炎症性疾病和自身免疫性疾病中具有治疗相关性的通路。该综述围绕cGAS-STING通路的激活与抑制,聚焦cGAS、STING和胞外核苷酸焦磷酸酶/磷酸二酯酶1(ENPP1)三个可成药治疗靶点,提供以药物化学为重点的全面概述。这些靶点的转化成熟度差异明显,STING在临床进展上最成熟,cGAS和ENPP1仍属新兴靶点,主要由临床前证据支持,仅有少数抑制剂进入早期临床试验。文中讨论通路调控的生物学依据及调控剂,重点涉及活性位点相互作用、骨架多样性、活性谱、构效关系、种属选择性和体内疗效。特别关注专利文献和后期分子,讨论其ADME性质、药代动力学和临床开发状态。尽管STING激动剂在该通路中已取得更广泛的临床试验进展,近期发展提示cGAS抑制剂和ENPP1抑制剂在未来临床成功方面更具前景。该综述为cGAS-STING-ENPP1轴的合理药物设计提供药物化学与转化挑战及未来机会的见解,以指导下一代调控剂。
Nucleic acids research IF 15.0 2026-10-24 PMID: 42960509
The chromatin remodeler HELLS acts as a pleiotropic guardian of genomic integrity, orchestrating critical processes from DNA replication to DNA damage repair. In anaplastic large cell lymphoma (ALCL), HELLS functions as a transcriptional sentinel, fine-tuning chromatin accessibility and RNA polymerase II kinetics to sustain the oncogenic transcriptional landscape essential for lymphomagenesis. Here we show that HELLS preserves genomic stability and sustains ALK-negative ALCL proliferation by preventing transcription-replication conflicts. HELLS acts as a global regulator of R-loop homeostasis while transcriptionally sustaining MCM5, a core subunit of the replicative MCM2-7 complex, which locally restrains replication-transcription collisions at actively transcribed loci. Mechanistically, HELLS loss reduces MCM5 levels, triggering aberrant firing of origins within transcriptionally active regions and consequent collisions between replication forks and the transcription machinery. Being positioned distally from R-loop-enriched sites, HELLS and MCM5 cooperate to preserve genome integrity, with MCM5 acting as the effector that delivers locus-specific protection against replication-associated genomic instability. Pharmacological or genetic disruption of this axis increases R-loop burden and drastically reduces the survival of ALK-negative ALCL cells, providing a rationale for combination therapy. Collectively, the HELLS-MCM5 module emerges as a master coordinator of transcription-replication dynamics and a novel therapeutic vulnerability in aggressive lymphomas.
中文摘要:染色质重塑因子HELLS是基因组完整性的多效守护者,协调从DNA复制到DNA损伤修复的关键过程。在间变性大细胞淋巴瘤(ALCL)中,HELLS作为转录哨兵,微调染色质可及性和RNA聚合酶II动力学,以维持淋巴瘤发生所需的致癌转录格局。研究显示,HELLS通过防止转录-复制冲突来维持基因组稳定性并支持ALK阴性ALCL增殖。HELLS是R-loop稳态的全局调节因子,同时在转录层面维持MCM5——复制性MCM2-7复合物的核心亚基——的表达,MCM5在活跃转录位点局部限制复制-转录碰撞。机制上,HELLS缺失降低MCM5水平,触发转录活跃区域内复制起点的异常激活,并导致复制叉与转录机器之间的碰撞。HELLS与MCM5定位于R-loop富集位点的远端,协同维持基因组完整性,其中MCM5作为效应分子,对复制相关基因组不稳定性提供位点特异性保护。药理学或遗传学破坏该轴会增加R-loop负荷,并大幅降低ALK阴性ALCL细胞的存活,为联合治疗提供依据。HELLS-MCM5模块成为转录-复制动力学的核心协调者,也是侵袭性淋巴瘤的新治疗脆弱点。
Nucleic acids research IF 15.0 2026-10-24 PMID: 42960508
The nucleolus is a membrane-less organelle essential for ribosomal DNA (rDNA) transcription and ribosome biogenesis, yet the mechanisms regulating its dynamic assembly remain incompletely understood. Here, we identify the phosphatase protein phosphatase magnesium-dependent 1 delta (PPM1D) as a key regulator of the nucleolar architecture via dephosphorylation of the scaffold protein TCOF1. By combining super-resolution microscopy and domain mapping, we show that PPM1D localizes to the nucleolus through a conserved motif at the C-terminus. Phosphoproteomic analysis and structural modeling revealed that PPM1D targets casein kinase 2 (CK2)-phosphorylated sites within the low-complexity repeat domain of TCOF1, which impacts its interaction with RNA polymerase I (Pol I), immobilization in the fibrillar centres, and nucleolar condensation. Disruption of the phosphorylation balance by loss of PPM1D or inhibition of CK2 leads to nucleolar disorganization and reduced rDNA transcription. Finally, we demonstrate that pharmacological inhibition of PPM1D sensitizes cells to RNA Pol I inhibitors, in both p53-dependent and -independent contexts. Together, we uncover a reversible phosphorylation switch that governs TCOF1 dynamics and its nucleolar function, with potential implications for targeting ribosome biogenesis in cancer.
中文摘要:核仁是无膜细胞器,对rDNA转录和核糖体生物合成必不可少,但其动态组装调控机制仍不完全清楚。研究确认磷酸酶PPM1D通过去磷酸化支架蛋白TCOF1调控核仁结构。结合超分辨显微成像与结构域作图,PPM1D借助C端保守motif定位于核仁。磷酸化蛋白质组分析和结构建模显示,PPM1D作用于TCOF1低复杂度重复区内被CK2磷酸化的位点,影响TCOF1与RNA聚合酶I的相互作用、其在纤维中心的固定以及核仁凝聚。PPM1D缺失或CK2抑制打破磷酸化平衡,导致核仁结构紊乱、rDNA转录下降。药理抑制PPM1D可在p53依赖与非依赖背景下增强细胞对RNA Pol I抑制剂的敏感性。这些结果揭示了一个可逆磷酸化开关,控制TCOF1动态变化及其核仁功能,对以核糖体生物合成为靶点的肿瘤治疗具有潜在意义。
Nucleic acids research IF 15.0 2026-10-24 PMID: 42953963
FET family proteins (FUS, EWSR1, and TAF15) have garnered significant attention due to their involvement in oncogenic fusions and mutations in various cancers and neurodegenerative disorders. Although these highly conserved RNA-binding proteins are widely described as multifunctional regulators of gene expression, their precise molecular functions remain incompletely understood. Here, we uncover a previously unrecognized role for EWSR1 as a selective translational repressor in cancer cells. EWSR1 specifically targets mRNAs involved in lipid metabolism and endoplasmic reticulum (ER) homeostasis. Loss of EWSR1 disrupts ER morphology and impairs activation of the unfolded protein response of the ER (UPRER). Mechanistically, EWSR1 represses translation upon association with target mRNAs, and its conserved region spanning two arginine-glycine-glycine (RGG) boxes contributes to association with the 40S ribosomal subunit. These findings define a novel role for EWSR1 in post-transcriptional gene regulation and suggest that perturbations in its translational activity may underlie the pathogenesis of FET-associated diseases.
中文摘要:FET家族蛋白(FUS、EWSR1和TAF15)因参与多种癌症和神经退行性疾病中的致癌融合与突变而受到关注。这些高度保守的RNA结合蛋白常被描述为基因表达的多功能调控因子,但其确切分子功能仍未完全阐明。我们发现EWSR1在癌细胞中具有此前未被认识的选择性翻译抑制因子作用。EWSR1特异性靶向参与脂质代谢和内质网稳态的mRNA。EWSR1缺失会破坏内质网形态并削弱内质网未折叠蛋白反应(UPRER)的激活。机制上,EWSR1与靶mRNA结合后抑制翻译,其包含两个精氨酸-甘氨酸-甘氨酸(RGG)框的保守区域参与与40S核糖体亚基的结合。这些发现确立了EWSR1在转录后基因调控中的新作用,并提示其翻译活性的扰动可能是FET相关疾病发病机制的基础。
Nucleic acids research IF 15.0 2026-10-24 PMID: 42953962
This study presents a novel approach to understanding DNA movement dynamics. Chromatin conformation plays a crucial role in controlling gene expression and cellular processes, with abnormalities linked to diseases like cancer and genetic disorders. ​Current single-cell chromatin conformation methods face limitations in cost-effectiveness, accessibility, and capturing dynamic genome architecture.​​ Therefore, we develop ​DropHiChew, a droplet-based, highly efficient chromatin conformation capture method employing 10× Genomics single-cell systems for user-friendly, cost-effective implementation. Combined with our ​loop velocity algorithm-which estimates the speed and direction of cell development by quantifying chromatin movement-this approach accurately gauges the trajectory of DNA motion and cellular states even at shallow sequencing depth (50k contacts per cell). Validation demonstrates its applicability across biological systems, including HEK293T, spermiogenesis, and embryonic development. The integration of DropHiChew and loop velocity offers potential for diverse applications in chromatin capture studies. This paradigm provides a dynamic perspective on genome organization for disease modeling, cellular differentiation, and developmental biology.
中文摘要:本研究提出一种理解DNA运动动力学的新方法。染色质构象在控制基因表达和细胞过程中起关键作用,其异常与癌症和遗传病等疾病相关。当前单细胞染色质构象方法在成本效益、可及性和捕获动态基因组结构方面存在局限。因此,我们开发了DropHiChew,一种基于液滴的高效染色质构象捕获方法,利用10× Genomics单细胞系统实现用户友好且成本有效的实施。结合我们的loop velocity算法——该算法通过量化染色质运动来估计细胞发育的速度和方向——该方法即使在浅测序深度(每个细胞5万个接触)下也能准确评估DNA运动轨迹和细胞状态。验证表明其适用于多种生物系统,包括HEK293T、精子发生和胚胎发育。DropHiChew与loop velocity的整合为染色质捕获研究中的多样应用提供了潜力。这一范式为疾病建模、细胞分化和发育生物学中的基因组组织提供了动态视角。
Pharmacological research IF 12.2 2026-10-24 PMID: 42926078
Differentiation-based cancer therapy is a potentially low-toxicity approach with demonstrated clinical benefits. However, the therapeutic efficacy of differentiation therapy remains limited in tumor types other than acute promyelocytic leukemia (APL). Our previous studies reported that diptoindonesin G (Dip G), a natural compound, can induce differentiation in both acute myeloid leukemia (AML) cells and basal-like breast cancer cells. In this study, we report a crucial role of GABAA receptor-associated protein-like 1 (GABARAPL1) in driving cancer cell differentiation. By utilizing myeloid cell differentiation models and primary leukemic cells, we demonstrate that upregulation of GABARAPL1 expression was crucial for Dip G-induced differentiation and that Dip G upregulated GABARAPL1 expression by targeting nucleolin (NCL). Also, GABARAPL1 promoted differentiation independent of its autophagic function. Both pharmacological and genetic upregulation of GABARAPL1 expression effectively overcame the differentiation blockade in various tumor models, including AML cells. Mechanistically, GABARAPL1 interacted with splicing factor proline and glutamine rich (SFPQ) and recruited MDM2 to promote the degradation of SFPQ by the proteasome. Upon SFPQ depletion, the transcription of linker histone H1.2 gene was repressed, which in turn rescued the transcription of the differentiation-related pathway. Our study not only highlights the contribution of GABARAPL1 to differentiation but also provides a potential therapeutic strategy aimed at expanding the scope of application of differentiation-based cancer therapy.
中文摘要:基于分化的癌症治疗是一种具有低毒性潜力且已显示临床获益的方法。除急性早幼粒细胞白血病(APL)外,分化治疗在其它肿瘤类型中的疗效仍然有限。既往研究报道,天然化合物diptoindonesin G(Dip G)可诱导急性髓系白血病(AML)细胞和基底样乳腺癌细胞分化。GABAA受体相关蛋白样1(GABARAPL1)在驱动癌细胞分化中起关键作用。利用髓系细胞分化模型和原代白血病细胞,研究证明GABARAPL1表达上调对Dip G诱导的分化至关重要,且Dip G通过靶向核仁素(NCL)上调GABARAPL1表达。GABARAPL1促进分化不依赖其自噬功能。药物和遗传学上调GABARAPL1表达均能有效克服包括AML细胞在内的多种肿瘤模型中的分化阻滞。机制上,GABARAPL1与富含脯氨酸和谷氨酰胺的剪接因子(SFPQ)相互作用,并招募MDM2促进蛋白酶体降解SFPQ。SFPQ耗竭后,连接组蛋白H1.2基因转录受到抑制,进而恢复分化相关通路的转录。这些结果不仅强调GABARAPL1对分化的贡献,也提供了一种旨在拓展基于分化的癌症治疗应用范围的潜在治疗策略。
ACS sensors IF 10.9 2026-10-24 PMID: 42921675
The ability to accurately quantify localized neuroinflammatory and neurodegenerative biomarkers in vivo is critical for enabling the early diagnosis of Parkinson's disease (PD). Here, we demonstrate a strategy for localized neuroinflammation quantification using an implantable glass-fiber-based CRISPR/Cas immunosensor. When interfaced with a portable fluorescence detector, our platform enables the spatially resolved multiplex detection of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and alpha-synuclein (α-syn) in the PD rat brain. The sensor surface was modified with functionalized liquid metal nanoparticles to enable antibody immobilization and long-term in vivo operation. This method demonstrated high specificity, excellent linearity in artificial cerebrospinal fluid (R2 > 0.91), sustained surface stability over 28 days, good biocompatibility with PC12 cells, and selective antibacterial activity against Staphylococcus aureus. Following cannula implantation into the substantia nigra pars compacta (SNc) of a 6-hydroxydopamine-induced PD rat model, the functionalized glass fiber enabled repeated, minimally invasive biomarker sampling at 6, 12, and 24 h postimplantation. Systemic inflammation induced by lipopolysaccharide (LPS) triggered marked elevations in TNF-α, IL-6, and α-syn, peaking at 6 h post-LPS. This implantable fiber-based biosensing method offers a promising reliable approach for early PD diagnosis, disease progression tracking, and investigation of neuroimmune interactions in neurodegenerative diseases in a point-of-care scenario.
中文摘要:在体内准确定量局部神经炎症和神经退行性生物标志物,对帕金森病早期诊断具有重要意义。本工作展示了一种基于可植入玻璃纤维的CRISPR/Cas免疫传感器,用于局部神经炎症定量。该平台与便携式荧光检测器连接后,可在帕金森病大鼠脑内对肿瘤坏死因子α、白细胞介素6和α-突触核蛋白进行空间分辨的多重检测。传感器表面经功能化液态金属纳米颗粒修饰,以实现抗体固定和体内长期运行。该方法表现出高特异性,在人工脑脊液中具有良好线性(R2 > 0.91),表面稳定性可维持28天,对PC12细胞具有良好生物相容性,并对金黄色葡萄球菌具有选择性抗菌活性。将功能化玻璃纤维经套管植入6-羟基多巴胺诱导的帕金森病大鼠模型黑质致密部后,可在植入后6、12和24小时重复进行微创生物标志物采样。脂多糖诱导的系统性炎症引起肿瘤坏死因子α、白细胞介素6和α-突触核蛋白明显升高,并在脂多糖处理后6小时达到峰值。这种可植入纤维生物传感方法为帕金森病早期诊断、疾病进展追踪以及神经退行性疾病中神经免疫相互作用研究提供了一种有前景的可靠途径,适用于即时检测场景。
ACS sensors IF 10.9 2026-10-24 PMID: 42921661
Precise intraoperative delineation of melanoma margins remains a clinical challenge; incomplete resection causes recurrence, whereas over-excision compromises aesthetic and functional outcomes. While surface-enhanced Raman spectroscopy (SERS) provides chemically rich vibrational fingerprints, accurate intraoperative quantification is hindered by complex, coupled full-spectrum responses. Herein, we report a chemistry-informed artificial intelligence (AI)-SERS platform designed to support melanoma margin assessment via the detection of tumor-associated metabolic acidification. A pH-responsive HemS-SERS microarray was developed to translate the phenolic protonation/deprotonation of a hemicyanine-xanthene reporter into coordinated intensity redistributions across multiple Raman bands. Guided by this acid-base chemistry, our AI model (CIMPA-pH) encodes these pH-responsive vibrational anchors as learnable directional chemical priors, integrating full-spectrum attention with Henderson-Hasselbalch-guided prediction. This global decoding strategy accurately captures coupled pH responses, reducing prediction errors by approximately 85% and 54-78% compared to manual peak-ratio features and conventional deep-learning baselines, respectively, while a quality-control risk metric further reduces high-error readouts by 29.1%. Providing rapid (10 s) pointwise pH measurements, the platform distinguishes melanomas from normal skin with distinct pigmentation phenotypes in animal models and shows preliminary applicability for assessing melanoma-associated regions, including grossly atypical areas, in human resection specimens. Ultimately, this chemical-prior-guided SERS decoding strategy provides an interpretable framework with potential for metabolism-guided intraoperative margin assessment.
中文摘要:黑色素瘤切缘的术中精准界定仍是临床难题;切除不彻底会导致复发,过度切除则损害美观与功能。表面增强拉曼光谱(SERS)可提供化学信息丰富的振动指纹,但复杂且耦合的全光谱响应阻碍了术中准确定量。我们报道一个化学信息引导的人工智能(AI)-SERS平台,通过检测肿瘤相关代谢酸化来支持黑色素瘤切缘评估。开发pH响应性HemS-SERS微阵列,将半花菁-氧杂蒽报告分子的酚羟基质子化/去质子化转化为多个拉曼谱带之间协同的强度重分布。在这一酸碱化学原理指导下,AI模型(CIMPA-pH)将这些pH响应性振动锚点编码为可学习的方向性化学先验,整合全光谱注意力与Henderson-Hasselbalch引导的预测。该全局解码策略准确捕捉耦合的pH响应,与人工峰比特征和常规深度学习基线相比,预测误差分别降低约85%和54–78%,质量控制风险指标进一步将高误差读数减少29.1%。该平台可在10秒内提供逐点pH测量,在动物模型中区分黑色素瘤与具有不同色素表型的正常皮肤,并在人切除标本中显示出评估黑色素瘤相关区域(包括大体非典型区域)的初步适用性。最终,这种化学先验引导的SERS解码策略提供了一个可解释框架,有望用于代谢引导的术中切缘评估。

2肿瘤免疫/微环境 (64篇)

临床研究 (10篇)

ESMO open IF 10.6 2026-10-30 PMID: 42962562
Chemoimmunotherapy has become the standard first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). However, the role and optimal timing of locoregional radiotherapy in dmNPC in the chemoimmunotherapy era remain unclear. This study aims to evaluate whether salvage locoregional radiotherapy (SLRRT), deferred until locoregional progression in patients with well-controlled distant metastases, compromises survival compared with immediate locoregional radiotherapy (ILRRT) in responders to first-line chemoimmunotherapy. This retrospective cohort study included consecutive patients with dmNPC who achieved a complete or partial response after first-line platinum-based chemotherapy combined with anti-programmed cell death protein 1 therapy. The primary endpoint was overall survival (OS). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline characteristics. Survival outcomes were assessed using Kaplan-Meier analyses and a multivariate Cox regression model. A total of 439 patients were included, with a median follow-up of 35.0 months (interquartile range, 24.0-45.2). Of these, 331 patients were assigned to the ILRRT cohort and 108 to the SLRRT cohort. After IPTW adjustment, SLRRT was not associated with inferior OS compared with ILRRT [2-year OS, 97.4% versus 90.1%; hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.54-1.59, P = 0.78]. SLRRT was associated with worse locoregional control (HR 4.78, 95% CI 2.98-7.66, P < 0.001) but better distant control (HR 0.62, 95% CI 0.41-0.95, P = 0.03). Radiotherapy-related adverse effects were substantially more frequent in the ILRRT cohort. Deferring SLRRT until locoregional progression did not compromise survival among responders to first-line chemoimmunotherapy. These findings support a response-adapted, de-escalated treatment strategy that may reduce treatment-related toxicities and improve quality of life without adversely affecting survival.
中文摘要:在初诊转移性鼻咽癌中,化疗联合免疫治疗已成为一线标准治疗,但局部区域放疗的作用及最佳时机仍不明确。本研究评估在一线化疗联合免疫治疗缓解者中,对远处转移控制良好者将挽救性局部区域放疗推迟至出现局部区域进展时,是否较即刻局部区域放疗损害生存。这项回顾性队列研究纳入连续初诊转移性鼻咽癌患者,均在一线铂类化疗联合抗PD-1治疗后达到完全或部分缓解。主要终点为总生存期。采用逆概率治疗加权调整基线特征,通过Kaplan-Meier分析和多因素Cox回归模型评估生存结局。共纳入439例患者,中位随访35.0个月(四分位距24.0-45.2)。331例进入即刻局部区域放疗队列,108例进入挽救性局部区域放疗队列。逆概率治疗加权调整后,挽救性局部区域放疗与即刻局部区域放疗相比未显示总生存劣效(2年总生存率97.4%对90.1%;风险比0.93,95%置信区间0.54-1.59,P=0.78)。挽救性局部区域放疗与更差的局部区域控制相关(风险比4.78,95%置信区间2.98-7.66,P<0.001),但与更好的远处控制相关(风险比0.62,95%置信区间0.41-0.95,P=0.03)。即刻局部区域放疗队列的放疗相关不良反应明显更常见。在一线化疗联合免疫治疗缓解者中,将挽救性局部区域放疗推迟至局部区域进展并未损害生存。这些结果支持按缓解情况调整、降低治疗强度的策略,可能在不影响生存的情况下减少治疗相关毒性并改善生活质量。
Annals of the rheumatic diseases IF 24.0 2026-10-29 PMID: 42957459
B-cell-directed immune-reset therapies are emerging as transformative approaches in autoimmune diseases, but their impact on long-term humoral immunity remains uncertain. These strategies encompass a broad range of B-cell targets and therapeutic modalities, the most clinically established targets include CD19, CD20, and B-cell maturation antigen (BCMA), with T-cell-redirecting approaches, particularly chimeric antigen receptor T-cell therapies and bispecific T-cell engagers, among the most validated modalities. Here, we aim to provide a practical framework for revaccination in patients with autoimmune diseases. We examine existing clinical evidence on the effects of BCMA-targeting therapies with respect to antivaccine titres to provide a revaccination framework in autoimmunity. Current clinical evidence suggests that BCMA-targeting therapies reduce vaccine-specific antibody titres along with total immunoglobulin levels. Insights from oncology studies provide a framework for understanding antivaccine responses in the context of profound BCMA-directed cell depletion, with the caveat that important differences exist between patients with autoimmunity and those with malignancies, including the magnitude and duration of immunosuppressive treatment. We propose a pragmatic revaccination approach after BCMA-targeting therapies in adult patients with autoimmune diseases, utilising minimal serologic monitoring. Future studies of these novel drugs will refine our understanding of the optimal timing and need for revaccinations in this population.
中文摘要:B细胞导向的免疫重置疗法正在成为自身免疫病的变革性手段,但其对长期体液免疫的影响仍不确定。这些策略覆盖广泛的B细胞靶点和治疗方式,临床证据最充分的靶点包括CD19、CD20和B细胞成熟抗原(BCMA),T细胞重定向方法中以嵌合抗原受体T细胞疗法和双特异性T细胞衔接器验证较多。我们旨在为自身免疫病患者的重接种提供实用框架。我们梳理BCMA靶向治疗对抗疫苗滴度影响的现有临床证据,以形成自身免疫病中的重接种框架。现有临床证据提示,BCMA靶向治疗在降低总免疫球蛋白水平的同时也降低疫苗特异性抗体滴度。肿瘤学研究中的见解有助于理解BCMA导向的深度细胞耗竭背景下的抗疫苗反应,但需注意自身免疫病患者与恶性肿瘤患者存在重要差异,包括免疫抑制治疗的强度和持续时间。我们提出一种用于成人自身免疫病患者接受BCMA靶向治疗后重接种的务实方案,采用最少化的血清学监测。对这些新药的后续研究将进一步明确该人群中重接种的最佳时机和需求。
Cell IF 45.1 2026-10-29 PMID: 42805174
Chimeric antigen receptor (CAR)-T cell therapy has transformed hematological cancer treatment, yet nearly half of patients still relapse or progress. Increasing evidence implicates the gut microbiome and antibiotic exposure as key modulators of clinical outcomes. In a cohort of 129 patients across three German centers, shotgun metagenomics and targeted mass spectrometry revealed that reduced short-chain fatty acids, particularly valeric acid, prior to CAR-T cell therapy correlated with increased risk of disease progression. Conversely, high levels of indole metabolites, including indole-3-carboxaldehyde and indole-3-acetic acid as well as the branched-chain fatty acid isovaleric acid, were linked to adverse outcomes. Functional validation in human and murine CAR-T cell models demonstrated that valeric acid supplementation enhanced, while indole-3-carboxaldehyde and isovaleric acid impaired, CAR-T cell efficacy. These findings reveal the opposing roles of immunomodulatory metabolites on CAR-T cell therapy, carrying significant implications for the design of metabolite-guided, microbiome-based therapeutics.
中文摘要:嵌合抗原受体(CAR)-T细胞疗法已改变血液肿瘤的治疗格局,但仍有近半数患者出现复发或疾病进展。越来越多证据提示,肠道微生物组和抗生素暴露是临床结局的重要调节因素。在一项纳入德国三个中心129例患者的队列中,鸟枪法宏基因组学和靶向质谱分析显示,CAR-T细胞治疗前短链脂肪酸(尤其戊酸)水平降低与疾病进展风险升高相关。相反,吲哚类代谢物(包括吲哚-3-甲醛和吲哚-3-乙酸)以及支链脂肪酸异戊酸水平较高与不良结局相关。在人源和小鼠CAR-T细胞模型中的功能验证表明,补充戊酸可增强CAR-T细胞疗效,而吲哚-3-甲醛和异戊酸则削弱其疗效。这些发现揭示了免疫调节代谢物对CAR-T细胞疗法的相反作用,对设计以代谢物为导向、基于微生物组的治疗策略具有重要意义。
Biomarker research IF 14.6 2026-10-28 PMID: 42958364
The immune checkpoints and their inhibitors are revolutionary advances in tumour immunotherapy. Immune checkpoints, however, have a broad spectrum effect. They not only contribute to tumour immune escape, but also are involved in the regulation of the pathopathological processes of numerous inflammatory illnesses, such as sepsis, autoimmune diseases, organ transplant rejection, and viral infections, among others. Today, a considerable gap in knowledge remains regarding immune checkpoints and immune checkpoint inhibitors in non-tumour inflammatory diseases, which remains largely unaddressed. At the same time, the emergence of immune-related adverse events and resistance challenges related to the clinical use of immune checkpoint inhibitors is becoming increasingly prominent, posing a significant obstacle to their application across various diseases. To overcome such issues, this narrative review establishes a systematic framework that links immune checkpoints to various inflammatory diseases and explores the associated therapeutic and clinical challenges. These diseases pose therapeutic and clinical challenges of immune checkpoint inhibitors, which we explore. The paper not only thoroughly describes the clinical picture, pathophysiology, and interventions in immunologic adverse events but also suggests a prospective strategy to confront the existing problems with immune checkpoint inhibitors in 3 dimensions: evaluation, management, and prevention. It will attempt to present a new conceptual framework for a comprehensive understanding of the dual role of immune checkpoints (in maintaining immune homeostasis and facilitating disease progression) and to provide a solid theoretical foundation for the development of safer and more effective cross-disease immunotherapy.
中文摘要:免疫检查点及其抑制剂是肿瘤免疫治疗领域的革命性进展。免疫检查点具有广谱效应,既参与肿瘤免疫逃逸,也参与脓毒症、自身免疫病、器官移植排斥和病毒感染等多种炎症性疾病病理过程的调控。当前对免疫检查点及免疫检查点抑制剂在非肿瘤炎症性疾病中的认识仍存在明显空白,且相关研究大多尚未展开。与此同时,免疫相关不良事件以及免疫检查点抑制剂临床使用中的耐药问题日益突出,成为其跨疾病应用的重要障碍。为应对这些问题,该叙述性综述建立了一个将免疫检查点与多种炎症性疾病联系起来的系统框架,并探讨相关的治疗与临床挑战。文章不仅详细描述免疫不良事件的临床图景、病理生理机制和干预措施,也从评估、管理和预防三个维度提出应对免疫检查点抑制剂现有问题的前瞻性策略。文章尝试提供新的概念框架,以全面理解免疫检查点在维持免疫稳态和促进疾病进展中的双重作用,并为开发更安全、更有效的跨疾病免疫治疗提供理论基础。
Cancer cell IF 56.1 2026-10-27 PMID: 42945960
The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunotherapy are expanding, this issue represents a global challenge in oncology. Here, we paint an updated and comprehensive landscape of antibiotic exposure in immuno-oncology, provide actionable clinical recommendations, and envision future avenues for improvement. First, we describe the biological mechanisms by which antibiotic-induced dysbiosis contributes to ICI resistance. Next, through an updated meta-analysis of 116 cohorts and 97,850 cancer patients treated with ICI, we found a significant association between antibiotic exposure and survival outcomes (overall survival, hazard ratio [HR]: 1.49, 95% confidence interval [CI]: 1.34-1.65; progression-free survival, HR: 1.44, 95% CI: 1.31-1.58). Finally, we discuss antibiotics stewardship and microbiome-centered strategies to prevent, diagnose, and/or repair dysbiosis.
中文摘要:肠道微生物组是免疫检查点抑制剂治疗反应的可调节决定因素,使抗生素暴露成为免疫肿瘤学中一个关键但认识不足的生存不良风险因素。近30%接受免疫检查点抑制剂治疗的患者使用抗生素,而肿瘤免疫治疗适应证不断扩大,该问题已成为全球肿瘤学挑战。本文描绘抗生素暴露在免疫肿瘤学中的最新综合图景,提供可操作的临床建议,并展望改进方向。抗生素诱导的菌群失调通过哪些生物学机制导致免疫检查点抑制剂耐药,文中对此进行了描述。基于116个队列、97,850例接受免疫检查点抑制剂治疗的癌症患者的最新荟萃分析发现,抗生素暴露与生存结局显著相关:总生存期风险比1.49,95%置信区间1.34-1.65;无进展生存期风险比1.44,95%置信区间1.31-1.58。文中还讨论抗生素管理和以微生物组为中心的策略,用于预防、诊断和修复菌群失调。
Cancer discovery IF 29.5 2026-10-27 PMID: 42944548
Results from two phase III trials, CLARITY-Gastric01 and G-HOPE-001, indicate that the investigational CLDN18.2-targeting antibody-drug conjugates sonesitatug vedotin and arcotatug tavatecan could be effective third- or later-line treatments for patients with CLDN18.2-positive gastric or gastroesophageal carcinomas. Both ADCs improved overall survival, which is welcome news for a population whose options are otherwise very limited.
中文摘要:两项III期试验CLARITY-Gastric01和G-HOPE-001的结果表明,研究中的靶向CLDN18.2的抗体偶联药物sonesitatug vedotin和arcotatug tavatecan可能成为CLDN18.2阳性胃或胃食管癌患者的三线或更后线有效治疗。两种ADC均改善了总生存期,这对其他选择非常有限的人群是好消息。
Nature medicine IF 52.5 2026-10-26 PMID: 42934326
The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvant chemoimmunotherapy guided by multidisciplinary team assessments during the neoadjuvant period. The primary endpoint was the overall resection rate (descriptive with no formal hypothesis testing). Secondary endpoints included event-free survival, progression-free survival, pathological complete response rate (resectable patients cohort), circulating tumor DNA clearance between baseline and presurgery/pre-CRT and safety. Overall, 142 patients received neoadjuvant treatment; 64.8% and 35.2% were deemed resectable and borderline resectable at baseline, respectively. The overall resection rate (95% confidence interval) was 74.6% (66.7‒81.6) in a population that included more than one-third of patients with borderline resectable disease. R0 resection rate was 96.2% (90.6‒99.0) in those who underwent surgery. Overall, 131 (92.3%) patients had surgery (n = 106) or CRT (n = 25) after neoadjuvant treatment, and 117 (82.4%) patients received adjuvant (n = 94) or consolidation (n = 23) durvalumab. During adjuvant or consolidation durvalumab, maximum grade 3/4 adverse events occurred in 7.4% of resected patients and 17.4% of CRT-treated patients, with 8.5% and 13.0% discontinuing treatment due to adverse events. This multidisciplinary team-guided approach was feasible and enabled delivery of curative-intent treatment (surgery or CRT), followed by durvalumab in most patients, and demonstrated encouraging preliminary efficacy with a manageable adjuvant or consolidation safety profile that was consistent with prior studies. ClinicalTrials.gov identifier: NCT05925530 .
中文摘要:2期MDT-BRIDGE研究在可切除和临界可切除非小细胞肺癌中评估围手术期度伐利尤单抗联合新辅助化疗(AEGEAN方案),并在新辅助化疗联合免疫治疗后经新辅助期多学科团队评估转为不可切除的患者中评估放化疗(CRT)后巩固度伐利尤单抗(PACIFIC方案)。主要终点为总体切除率(描述性,未进行正式假设检验)。次要终点包括无事件生存期、无进展生存期、病理完全缓解率(可切除患者队列)、基线至术前或CRT前循环肿瘤DNA清除以及安全性。共142例患者接受新辅助治疗;基线时分别有64.8%和35.2%被判定为可切除和临界可切除。总体切除率(95%置信区间)为74.6%(66.7–81.6),该人群中有超过三分之一为临界可切除疾病。在接受手术者中,R0切除率为96.2%(90.6–99.0)。新辅助治疗后,131例(92.3%)接受手术(n=106)或CRT(n=25),117例(82.4%)接受辅助(n=94)或巩固(n=23)度伐利尤单抗。在辅助或巩固度伐利尤单抗期间,最大3/4级不良事件发生率在手术切除患者中为7.4%,在CRT治疗患者中为17.4%;因不良事件停药的比例分别为8.5%和13.0%。这种多学科团队引导的方法可行,使大多数患者能够接受根治性治疗(手术或CRT)并随后接受度伐利尤单抗,显示出令人鼓舞的初步疗效,辅助或巩固治疗安全性可控,与既往研究一致。ClinicalTrials.gov标识符:NCT05925530。
Cancer discovery IF 29.5 2026-10-26 PMID: 42932175
The antibody-drug conjugate field is increasingly looking to go after more than one target at a time. Preliminary efficacy data suggest that B7-H3-targeting elfetabart drozuntecan plus the PD-L1-VEGF-A bispecific pumitamig could be a potential combination strategy. As well, two bispecific ADCs, respectively targeting EGFR-c-MET and EGFR-B7-H3, appear active against multiple solid tumor types.
中文摘要:抗体偶联药物领域正日益寻求同时作用于多个靶点。初步疗效数据提示,靶向B7-H3的elfetabart drozuntecan联合PD-L1-VEGF-A双特异性抗体pumitamig可能成为一种潜在联合策略。另外,两种双特异性ADC分别靶向EGFR-c-MET和EGFR-B7-H3,似乎对多种实体瘤类型具有活性。
Cancer discovery IF 29.5 2026-10-26 PMID: 42929716
Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.
中文摘要:III期INTerpath-0001试验结果显示,黑色素瘤术后在PD-1抑制剂帕博利珠单抗基础上加用mRNA个体化新抗原疫苗intismeran autogene,可将疾病复发或死亡风险降低42%。相关数据在2026年10月23日至27日于西班牙马德里举行的ESMO大会上公布。
Cancer treatment reviews IF 10.6 2026-10-24 PMID: 42945772
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of several malignancies; however, their efficacy in platinum-resistant ovarian cancer (PROC) remains limited. The immunosuppressive tumor microenvironment (TME) in ovarian cancer constitutes a major barrier to effective antitumor immunity, prompting the development of various strategies to enhance responsiveness to ICIs. This narrative review examines current therapeutic approaches targeting the TME to overcome resistance to ICIs in PROC, with a focus on angiogenesis, innate immunity, and adaptive immune pathways. Despite a strong biological rationale, most chemotherapy-free ICI-based combinations targeting specific immune or stromal components have shown limited and inconsistent clinical benefit. The most notable clinical activity has been observed when ICIs are combined with chemotherapy, particularly in regimens that include anti-angiogenic agents. Recent positive results from a single phase 3 trial evaluating pembrolizumab in combination with weekly paclitaxel, with or without bevacizumab, mark a notable deviation from the predominantly negative outcomes of earlier studies. Nevertheless, it remains uncertain whether this result represents a true paradigm shift or a context-specific effect. Currently, no validated predictive biomarkers exist to reliably identify patients most likely to benefit from ICI-based strategies. The discrepancy between the isolated success of chemo-immunotherapy combinations and the failure of most previous trials highlights the need for further investigation into TME biology. A more comprehensive understanding of TME dynamics and the development of biomarker-driven patient selection strategies will be essential to define the role of ICIs in this challenging clinical context.
中文摘要:免疫检查点抑制剂(ICIs)已改变多种恶性肿瘤的治疗格局,但在铂耐药卵巢癌(PROC)中的疗效仍然有限。卵巢癌的免疫抑制性肿瘤微环境(TME)是有效抗肿瘤免疫的主要障碍,促使多种策略被开发以增强对ICIs的应答。这篇叙述性综述考察当前针对TME以克服PROC中ICI耐药的多种治疗策略,重点涉及血管生成、固有免疫和适应性免疫通路。尽管生物学依据充分,大多数针对特定免疫或基质成分的不含化疗的ICI联合方案临床获益有限且不一致。最显著的临床活性出现在ICIs与化疗联合时,尤其是包含抗血管生成药物的方案。近期一项3期试验评估帕博利珠单抗联合每周紫杉醇,联合或不联合贝伐珠单抗,获得阳性结果,这与既往研究多为阴性结局形成明显差异。该结果是否代表真正的范式转变或仅为特定背景下的效应仍不确定。目前尚无经过验证的预测性生物标志物可可靠识别最可能从ICI策略中获益的患者。化疗-免疫联合方案的孤立成功与既往大多数试验失败之间的差异,凸显了进一步研究TME生物学的必要性。更全面地理解TME动态并建立生物标志物驱动的患者选择策略,对于界定ICIs在这一具有挑战性的临床情境中的作用至关重要。

基础研究 (54篇)

Medicinal research reviews IF 13.6 2026-10-30 PMID: 42963587
SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis, immunosuppression, and telomere extension. SHP2 acts as a convergent node of oncogenic signaling pathways including MAPK, PI3K-AKT, VEGF, JAK-STAT making it an attractive target for cancer therapeutics. Preclinical studies demonstrate that SHP2 allosteric inhibitors in combination with EGFR, PD-1, KRAS, or MEK inhibitors, show potent antitumour activity and effectively overcome adaptive resistance beyond conventional therapies. Multiple SHP2 allosteric inhibitors are currently in clinical trials to assess their effectiveness, safety, and tolerability in treating various malignancies. Despite these advancements, SHP2's complex role presents challenges for the efficacy of SHP2 monotherapy and in the context of SHP2 mutants. Current allosteric inhibitors lack a well-defined mode of action for selectively targeting hyperactive SHP2 in malignancies. Moreover, a deeper understanding of SHP2's regulatory mechanisms and its interactions within the tumor microenvironment is needed to optimize SHP2-directed therapies. This review highlights these challenges, with a focus on SHP2 regulation, disease-associated mutants, its role in cancer cells and the tumor microenvironment, current and future therapeutic prospects.
中文摘要:SHP2是一种酪氨酸磷酸酶,通过一对src同源2(SH2)结构域介导跨膜受体下游的细胞内信号传导。其过表达和突变通过影响多种癌症的基本特征,如转移、DNA修复、血管生成、免疫抑制和端粒延长,在驱动肿瘤进展中起关键作用。SHP2作为MAPK、PI3K-AKT、VEGF、JAK-STAT等致癌信号通路的汇聚节点,使其成为有吸引力的癌症治疗靶点。临床前研究表明,SHP2变构抑制剂与EGFR、PD-1、KRAS或MEK抑制剂联合应用可表现出强效抗肿瘤活性,并有效克服传统疗法之外的适应性耐药。多种SHP2变构抑制剂目前正在临床试验中评估其治疗多种恶性肿瘤的有效性、安全性和耐受性。尽管取得这些进展,SHP2的复杂作用仍给SHP2单药治疗以及SHP2突变背景下的疗效带来挑战。现有变构抑制剂缺乏明确的作用模式来选择性靶向恶性肿瘤中过度活跃的SHP2。需要更深入理解SHP2的调控机制及其在肿瘤微环境中的相互作用,以优化SHP2导向疗法。这些挑战是讨论重点,关注SHP2调控、疾病相关突变体、其在癌细胞和肿瘤微环境中的作用,以及当前和未来的治疗前景。
Nature cancer IF 28.0 2026-10-30 PMID: 42963425
Chimeric antigen receptor T (CAR-T) cell therapy shows limited efficacy in solid tumors, partly owing to poorly defined tumor-intrinsic resistance mechanisms. Here we show that the epigenetic regulator BAZ2A drives resistance to CD70-targeted CAR-T therapy by reprogramming tumor lipid metabolism. Using an in vivo CRISPR screen in a mouse renal cell carcinoma model, we identify BAZ2A as a key mediator that promotes the production and accumulation of palmitic acid, a saturated fatty acid in the tumor microenvironment. Excess palmitic acid is taken up by CAR-T cells and impairs mitochondrial fitness by inhibiting PGC-1α activity, thereby enforcing a dysfunctional state. Pharmacologic inhibition of BAZ2A reduces lipid accumulation and restores CAR-T cell activity in vivo. These findings reveal an epigenetic-metabolic mechanism of immune resistance and suggest that targeting tumor lipid remodeling represents a therapeutic strategy to overcome CAR-T resistance in solid tumors.
中文摘要:嵌合抗原受体T细胞(CAR-T)疗法在实体瘤中的疗效有限,部分原因在于肿瘤内在的耐药机制尚不明确。研究显示,表观遗传调控因子BAZ2A通过重编程肿瘤脂质代谢驱动对CD70靶向CAR-T治疗的抵抗。在小鼠肾细胞癌模型中开展体内CRISPR筛选,发现BAZ2A是促进棕榈酸产生并在肿瘤微环境中积累的关键介导因子。过量棕榈酸被CAR-T细胞摄取,通过抑制PGC-1α活性损害线粒体适应性,使CAR-T细胞进入功能障碍状态。药物抑制BAZ2A可减少脂质积累并在体内恢复CAR-T细胞活性。这些发现揭示了免疫抵抗的表观遗传—代谢机制,提示靶向肿瘤脂质重塑可作为克服实体瘤CAR-T抵抗的治疗策略。
Pharmacological research IF 12.2 2026-10-30 PMID: 42963013
Microsatellite-stable colorectal cancer (MSS-CRC) remains broadly refractory to immune checkpoint blockade, underscoring the need for strategies that convert immunologically "cold" tumors into therapy-responsive states. Here, we identify 4-hydroxyphenylpyruvate dioxygenase (HPD), the rate-limiting enzyme in tyrosine catabolism, as a modulator of sorafenib sensitivity in MSS-CRC. Pharmacological inhibition of HPD by the FDA-approved orphan drug nitisinone synergized with sorafenib across patient-derived organoids, human PBMC-tumor co-cultures, and immunocompetent orthotopic models. Mechanistically, nitisinone imposes strict glutaminolysis dependency, whereas sorafenib disrupts cRaf-MEK-ERK signaling to trigger proteasomal cMYC degradation and transcriptional repression of GLS1, thereby ablating compensatory glutamine anaplerosis. This dual metabolic blockade creates a synthetic lethal trap, provoking irreversible mitochondrial collapse and mtDNA release, which activates the cGAS-STING pathway and drives intratumoral infiltration of cytotoxic NK and CD8+ T cells. Critically, ρ⁰ cells and STING-deficient models confirm mitochondrial damage as the "trigger" of cell death and STING as the "amplifier" of antitumor immunity. In TCGA MSS-CRC cohorts, a double-low glutamine/tyrosine metabolic signature was associated with prolonged survival, enhanced cGAS-STING signaling, and immune-hot tumor features, findings corroborated by single-cell RNA-seq analyses. Finally, the triple combination of nitisinone, sorafenib, and anti-PD-1 therapy achieved superior antitumor efficacy with favorable tolerability in vivo. Collectively, our findings delineate a metabolic-mitochondrial-STING axis and support repurposing nitisinone as a promising translational strategy to sensitize MSS-CRC to immunotherapy.
中文摘要:微卫星稳定型结直肠癌(MSS-CRC)对免疫检查点阻断普遍耐药,需要将免疫「冷」肿瘤转化为治疗响应状态的策略。研究识别出酪氨酸分解代谢限速酶4-羟苯基丙酮酸双加氧酶(HPD)是MSS-CRC中索拉非尼敏感性的调节因子。用FDA批准的孤儿药尼替西农抑制HPD,可在患者来源类器官、人PBMC-肿瘤共培养和免疫健全原位模型中与索拉非尼协同。机制上,尼替西农造成严格的谷氨酰胺分解依赖,索拉非尼破坏cRaf-MEK-ERK信号,触发蛋白酶体途径的cMYC降解并转录抑制GLS1,从而消除代偿性谷氨酰胺回补。双重代谢阻断形成合成致死陷阱,引起不可逆的线粒体崩溃和mtDNA释放,激活cGAS-STING通路,并促进细胞毒性NK细胞和CD8+ T细胞向瘤内浸润。ρ⁰细胞和STING缺陷模型证实线粒体损伤是细胞死亡的「触发因素」,STING是抗肿瘤免疫的「放大器」。在TCGA MSS-CRC队列中,谷氨酰胺/酪氨酸双低代谢特征与较长生存、增强的cGAS-STING信号及免疫热肿瘤特征相关,单细胞RNA-seq分析支持这些发现。尼替西农、索拉非尼和抗PD-1三联方案在体内取得更优抗肿瘤疗效且耐受性良好。这些结果勾勒出代谢-线粒体-STING轴,支持将尼替西农重定位为增敏MSS-CRC免疫治疗的有转化前景的策略。
Acta biomaterialia IF 10.4 2026-10-30 PMID: 42962841
The synergistic combination of oncolytic adenovirus (oAd) and paclitaxel chemodrug holds great potential for cancer therapy as it can enhance cell apoptosis, the viral replication in cancer cells, and induce a potent antitumor effect. However, clinical output is insufficient because of the rapid blood clearance and inactivation of viral activity within high-reactive oxygen species (ROS) tumor microenvironment (TME). In this regard, we have developed an ROS responsive supramolecular hydrogel (mPEG-b-PCL-DPMP/α-cyclodextrin (DPMP/α-CD hydrogel)) system to protect oAd bioactivity while providing sustained, localized co-delivery of paclitaxel (PTX). The amount of ROS was evaluated by fluorescence measurements using H2DCFDA as a probe and confirmed that there was a significant decrease in ROS level by DPMP/α-CD hydrogel. An in vivo degradation study showed that the hydrogel underwent substantial degradation within one week. Furthermore, oAd and PTX encapsulated in DPMP/α-CD hydrogel were released consistently and retained the viral activity, exhibiting cancer cell killing efficacy under strong tumor microenvironment conditions. In vivo, a single intratumoral injection formed a stable depot that persisted for over a week, leading to superior tumor regression in H460 xenograft models compared to naked oAd or PTX alone. Histological and biochemical analyses confirmed no detectable histopathological abnormalities in the examined major organs or elevations in the measured serum liver and kidney injury markers under the conditions evaluated. Altogether, this ROS-responsive shield-and-release injectable supramolecular hydrogel platform loaded with oAd/PTX exhibits downregulated ROS level at tumor microenvironment and enhanced anti-tumor effect. STATEMENT OF SIGNIFICANCE: • An active shield-scavenge-release hydrogel was engineered to enhance oncolytic adenovirus/paclitaxel (oAd/PTX) combination therapy. • The hydrogel protects oxidation-sensitive adenovirus while enabling sustained local viral release. • ROS-responsive dipentaerythritol hexakis(3-mercaptopropionate) (DPMP) segments convert the oxidative tumor microenvironment into a therapeutic release trigger. • PTX-loaded hydrophobic domains support prolonged chemotherapy without disrupting hydrogel architecture. • Sustained oAd/PTX co-release amplifies viral replication, tumor cell killing, and antitumor efficacy. • A single intratumoral administration achieves durable tumor suppression with minimal systemic toxicity.
中文摘要:将溶瘤腺病毒(oAd)与紫杉醇化疗药联用具有协同增强细胞凋亡、促进病毒在癌细胞中复制并诱导强抗肿瘤效应的潜力。但病毒在血液中快速清除以及在高活性氧(ROS)肿瘤微环境(TME)中活性失活,使临床效果不足。为此,构建了ROS响应性超分子水凝胶(mPEG-b-PCL-DPMP/α-环糊精,DPMP/α-CD水凝胶)系统,用于保护oAd生物活性并实现紫杉醇(PTX)持续、局部共递送。以H2DCFDA为探针通过荧光测定评估ROS量,确认DPMP/α-CD水凝胶显著降低ROS水平。体内降解研究显示水凝胶在一周内发生明显降解。包载于DPMP/α-CD水凝胶中的oAd与PTX能够持续释放并保持病毒活性,在强肿瘤微环境条件下仍表现出杀伤癌细胞的效果。体内单次瘤内注射形成稳定储库并维持超过一周,在H460异种移植模型中较裸oAd或单用PTX带来更优的肿瘤消退。组织学和生化分析显示,在所评估条件下,受检主要器官未检测到组织病理学异常,所测血清肝肾功能损伤标志物也未升高。该负载oAd/PTX的ROS响应性屏蔽-释放可注射超分子水凝胶平台可下调肿瘤微环境ROS水平并增强抗肿瘤效果。其意义在于:构建了主动屏蔽-清除-释放水凝胶以增强oAd/PTX联合治疗;水凝胶保护对氧化敏感的腺病毒并实现病毒持续局部释放;ROS响应性DPMP链段将氧化性肿瘤微环境转化为治疗释放触发条件;负载PTX的疏水结构域支持延长化疗而不破坏水凝胶结构;oAd/PTX持续共释放放大病毒复制、肿瘤细胞杀伤和抗肿瘤疗效;单次瘤内给药实现持久肿瘤抑制且全身毒性低。
Science advances IF 13.9 2026-10-30 PMID: 42962039
Aberrant glutamine metabolism undermines the efficacy of cancer radiotherapy (RT) by promoting DNA repair, increasing oxygen consumption, and imposing metabolic stress that compromises the viability and function of cytotoxic T lymphocytes (CTLs). Here, we report a mitochondria-enriched, metabolism-regulating monolayered metal-organic framework (MOF) nanoplatform, Hf-Ir/DON, constructed by incorporating the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) into a radiosensitizing hafnium-iridium (Hf-Ir) MOF to inhibit glutaminolysis. This design markedly sensitizes tumor cells to RT and, upon x-ray irradiation, enables mitochondria-targeted RT-radiodynamic therapy with substantially enhanced reactive oxygen species accumulation. The resulting oxidative stress induces extensive DNA damage, mitochondrial dysfunction, and immunogenic tumor cell pyroptosis. Concurrently, Hf-Ir/DON alleviates metabolic constraints on activated T cells, preserving CTL viability while sustaining effector and memory functions. In a murine colon cancer model, low-dose RT combined with Hf-Ir/DON achieved >95% tumor growth inhibition. Further combination with anti-PD-L1 therapy induced regression of bilateral triple-negative breast tumors and prevented lung metastasis. These results establish a radiometabolic MOF nanoplatform that potentiates RT while promoting durable antitumor immunity.
中文摘要:异常谷氨酰胺代谢会促进DNA修复、增加耗氧,并造成代谢应激,削弱细胞毒性T淋巴细胞(CTL)的存活与功能,从而降低癌症放疗(RT)疗效。报道了一种线粒体富集、可调控代谢的单层金属有机框架(MOF)纳米平台Hf-Ir/DON,其构建方式是将谷氨酰胺拮抗剂6-重氮-5-氧代-L-正亮氨酸(DON)引入具有放射增敏作用的铪-铱(Hf-Ir)MOF,以抑制谷氨酰胺分解。该设计显著增强肿瘤细胞对RT的敏感性,并在X射线照射下实现靶向线粒体的RT-放射动力治疗,使活性氧积累明显增加。由此产生的氧化应激引起广泛DNA损伤、线粒体功能障碍和免疫原性肿瘤细胞焦亡。同时,Hf-Ir/DON减轻活化T细胞所受的代谢限制,维持CTL存活并保持效应与记忆功能。在小鼠结肠癌模型中,低剂量RT联合Hf-Ir/DON实现超过95%的肿瘤生长抑制。进一步联合抗PD-L1治疗可使双侧三阴性乳腺癌消退,并阻止肺转移。这些结果建立了一个放射代谢MOF纳米平台,可增强RT并促进持久抗肿瘤免疫。
Science advances IF 13.9 2026-10-30 PMID: 42962034
Whole-genome doubling (WGD) occurs frequently in human cancer and influences tumor evolution, metastasis, and treatment response. Here, we integrate bulk, single-cell, and spatial data to dissect the subclonal dynamics of WGD. Single-cell data analysis shows that WGD cells are prevalent even in tumors that are classified as non-WGD (nWGD). WGD subclones actively acquire somatic copy number alterations as they expand, suggesting ongoing evolution. We developed and rigorously validated a gene expression-based method, WAGES, to map WGD cell clonal fraction in bulk tumors. Applying WAGES to nWGD tumors, we reveal genomic correlates including TP53 mutations and chromosomal instability that are consistent with the presence of WGD subclones. Clinically, WAGES scores are strongly correlated with tumor metastatic potential, response to treatments including chemotherapy and immunotherapy, and patient prognosis. These findings reveal widespread WGD subclones in nWGD tumors and demonstrate their substantial impact on cancer evolution and therapeutic outcomes.
中文摘要:全基因组加倍(WGD)在人类癌症中频繁发生,并影响肿瘤演化、转移和治疗反应。该研究整合 bulk、单细胞和空间数据,解析 WGD 的亚克隆动态。单细胞数据分析显示,即使在被归类为非 WGD(nWGD)的肿瘤中,WGD 细胞仍普遍存在。WGD 亚克隆在扩增过程中不断获得体细胞拷贝数改变,提示演化仍在进行。研究开发并严格验证了一种基于基因表达的方法 WAGES,用于在 bulk 肿瘤中推断 WGD 细胞的克隆比例。将 WAGES 应用于 nWGD 肿瘤后,研究揭示了与 WGD 亚克隆存在相一致的基因组相关特征,包括 TP53 突变和染色体不稳定性。在临床上,WAGES 评分与肿瘤转移潜能、包括化疗和免疫治疗在内的治疗反应以及患者预后密切相关。这些发现表明 nWGD 肿瘤中广泛存在 WGD 亚克隆,并显示其对癌症演化和治疗结局具有实质影响。
Science advances IF 13.9 2026-10-30 PMID: 42962000
Regulatory T cell (Treg) accumulation within the tumor microenvironment is a major contributor to immune evasion and immunotherapy resistance. However, the metabolic signals orchestrating Treg lineage commitment remain poorly defined. We identify that the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC), produced by Vimentin+ stromal cells, acts through GPR183 to promote Treg differentiation and suppressive identity. In patients with gastric cancer (GC), GPR183+ Treg infiltration correlates with advanced disease and poor survival. In syngeneic tumor models, conditional GPR183 deletion, specifically in CD4+ T cells or Treg cells, demonstrates its cell-intrinsic requirement for high-cholesterol-diet-induced Treg expansion and tumor growth, thereby abrogating immune evasion and restoring CD8+ T cell effector function. Mechanistically, 7α,25-OHC-GPR183 signaling activates the AXL-JAK2-STAT5 pathway to reinforce Foxp3 expression. Last, GPR183 antagonism modestly enhances anti-PD-1 efficacy in a model-dependent manner and prevents therapy-induced Treg expansion. These findings identify the 7α,25-OHC-GPR183-AXL axis as a potential metabolic checkpoint linking cholesterol metabolism to immune suppression, suggesting a potential therapeutic strategy to enhance antitumor immunity.
中文摘要:肿瘤微环境中调节性T细胞(Treg)积聚是免疫逃逸和免疫治疗耐药的重要驱动因素。调控Treg谱系定向的代谢信号仍不清楚。研究发现,Vimentin+基质细胞产生的氧固醇7α,25-二羟基胆固醇(7α,25-OHC)通过GPR183促进Treg分化及抑制性特征。胃癌患者中GPR183+ Treg浸润与疾病进展和较差生存相关。在同基因肿瘤模型中,CD4+ T细胞或Treg细胞条件性敲除GPR183表明,GPR183是细胞内在性的、高胆固醇饮食诱导Treg扩增和肿瘤生长所必需,并因此削弱免疫逃逸、恢复CD8+ T细胞效应功能。机制上,7α,25-OHC-GPR183信号激活AXL-JAK2-STAT5通路,强化Foxp3表达。GPR183拮抗以模型依赖方式适度增强抗PD-1疗效,并阻止治疗诱导的Treg扩增。这些结果将7α,25-OHC-GPR183-AXL轴确定为连接胆固醇代谢与免疫抑制的潜在代谢检查点,提示增强抗肿瘤免疫的潜在治疗策略。
Cancer research IF 22.6 2026-10-30 PMID: 42961778
Cellular senescence contributes dynamically to fibrosis and cancer depending on the senescent cell type and its tissue remodeling senescence-associated secretory phenotype; however, current senotherapies lack specificity in targeting pathogenic senescent cells and have limiting toxicities. In a recent issue of Science, Hinterleitner and colleagues designed P-selectin-directed nanoparticles (SMNPs) capable of delivering senotherapies specifically to pathogenic P-selectin+ senescent macrophages in fibrotic tissues while preventing uptake in beneficial senescent endothelial cells. Precision targeting by SMNPs resolved fibrosis and restored organ function in the lung and liver and minimized senotherapeutic toxicity in mice. In tumor models, SMNP targeting of this small senescent macrophage subset was sufficient to overcome fibrosis-mediated immune exclusion and sensitize liver and lung cancers to T cell-directed immunotherapy. P-selectin+ macrophages with senescent features were also enriched in fibrotic human tissues and treatment-refractory cancer patient samples. Overall, this study provides a platform for reducing the toxicity and enhancing the specificity of senotherapies necessary to advance their clinical development for treating chronic disease.
中文摘要:细胞衰老对纤维化和癌症的贡献随衰老细胞类型及其组织重塑相关衰老相关分泌表型而动态变化;现有衰老细胞治疗缺乏对致病性衰老细胞的靶向特异性,并存在毒性限制。在近期《Science》发表的工作中,Hinterleitner等设计了P-选择素导向纳米颗粒(SMNPs),可将衰老细胞治疗药物特异递送至纤维化组织中致病的P-选择素阳性衰老巨噬细胞,同时避免被有益衰老内皮细胞摄取。SMNPs的精准靶向在小鼠中缓解纤维化并恢复肺和肝脏器官功能,且降低了衰老细胞治疗药物的毒性。在肿瘤模型中,靶向这一小群衰老巨噬细胞足以克服纤维化介导的免疫排斥,并使肝癌和肺癌对T细胞导向免疫治疗敏感。具有衰老特征的P-选择素阳性巨噬细胞也在纤维化人组织和治疗难治性癌症患者样本中富集。该研究提供了一个降低衰老细胞治疗毒性并提高其特异性的平台,为推进其治疗慢性病的临床开发所必需。
Signal transduction and targeted therapy IF 81.2 2026-10-30 PMID: 42957652
Cancer-associated fibroblasts (CAFs) are integral components of the tumor microenvironment (TME) and are increasingly recognized as critical regulators of nearly every hallmark of cancer. Once viewed as a uniform, protumorigenic cell type, it is now clear that CAFs comprise a spectrum of dynamic and plastic functional states with both tumor-promoting and tumor-restraining capacities. This functional duality, conceptualized within the framework of cancer as a "wound that fails to heal", is dictated by their diverse cellular origins, the specific activation pathways engaged (such as TGF-β and PDGF), and the evolving cues from the TME. In this Review, we dissect the multifaceted roles of CAFs, from their promotion of cancer cell proliferation, invasion and angiogenesis through secreted factors and extensive extracellular matrix (ECM) remodeling, to their profound influence on the immune landscape. We detail how distinct CAF subsets, such as myofibroblastic (myCAFs) and inflammatory (iCAFs) CAFs, orchestrate an immunosuppressive niche and contribute to therapeutic resistance. We also explore the compelling evidence for tumor-suppressive CAF functions, which have catalyzed a paradigm shift in therapeutic strategies-moving away from indiscriminate CAF ablation towards nuanced approaches aimed at reprogramming their state. These strategies include modulating key signaling pathways, normalizing the CAF-remodeled ECM, and exploiting unique metabolic vulnerabilities. Finally, we discuss how advances in single-cell and spatial transcriptomics are resolving this complexity, paving the way for the development of precision therapies that can selectively neutralize pro-tumorigenic CAF activities while harnessing their beneficial functions to improve patient outcomes.
中文摘要:癌相关成纤维细胞(CAFs)是肿瘤微环境(TME)的组成部分,日益被视为几乎每个癌症标志的关键调控者。曾被看作单一促瘤细胞类型,现已明确CAFs包含具有促瘤和抑瘤能力的动态、可塑性功能状态谱系。这种功能双重性在癌症作为「无法愈合的伤口」的框架内被概念化,由其多样的细胞来源、所激活的特定通路(如TGF-β和PDGF)以及TME不断演变的信号决定。在这篇综述中,我们剖析CAFs的多方面作用,从通过分泌因子和广泛细胞外基质(ECM)重塑促进癌细胞增殖、侵袭和血管生成,到对免疫格局的深刻影响。我们详述不同CAF亚群,如肌成纤维细胞性(myCAFs)和炎症性(iCAFs)CAFs,如何组织免疫抑制生态位并促成治疗抵抗。我们也探讨抑瘤性CAF功能的证据,这些证据推动了治疗策略的范式转变,从非选择性清除CAF转向旨在重编程其状态的精细方法。这些策略包括调节关键信号通路、使CAF重塑的ECM正常化以及利用独特的代谢脆弱性。单细胞与空间转录组学的进展正在解析这一复杂性,为开发精准疗法铺路,这些疗法能够选择性中和促瘤CAF活性,同时利用其有益功能改善患者结局。
International journal of oral science IF 17.6 2026-10-30 PMID: 42957619
Chronic exposure to severe social and environmental stressors is a major risk factor for tumor initiation and progression, yet the central nervous system (CNS)-driven mechanisms linking stress to cancer immunity remain poorly defined. Here, we identify activation of the hypothalamic-pituitary-bone marrow (HPB) axis as a critical driver of oral squamous cell carcinoma (OSCC). Chronic stress activates hypothalamic paraventricular nucleus (PVN) neurons, inducing pituitary overexpression of POMC and aberrant secretion of α‑MSH. This neuroendocrine activation increases the frequency of PMN-MDSCs in the bone marrow and upregulates the chemokine CXCL13 in the tumor microenvironment. Mechanistic studies show that this stress-responsive neuroendocrine circuit remodels the tumor immune microenvironment by promoting PMN-MDSC recruitment, suppressing CD8⁺ T cell infiltration, and skewing macrophages toward an M2 phenotype, collectively establishing profound immunosuppression. Chronic stress further amplifies this axis, accelerating OSCC progression and recurrence. Therapeutic blockade of MC5R restores antitumor immune surveillance and markedly potentiates PD-1 checkpoint inhibition. These findings delineate a previously underappreciated neuro-immune regulatory pathway governing malignant progression and highlight a tractable target for improving immunotherapy efficacy in stress-associated cancers.
中文摘要:长期暴露于严重社会和环境应激是肿瘤发生和进展的主要危险因素,但中枢神经系统(CNS)驱动应激与肿瘤免疫关联的机制仍不清楚。我们确定下丘脑-垂体-骨髓(HPB)轴的激活是口腔鳞状细胞癌(OSCC)的关键驱动因素。慢性应激激活下丘脑室旁核(PVN)神经元,诱导垂体POMC过表达和α-MSH异常分泌。这种神经内分泌激活增加骨髓中PMN-MDSC频率,并上调肿瘤微环境中的趋化因子CXCL13。机制研究表明,这一应激反应性神经内分泌环路通过促进PMN-MDSC募集、抑制CD8⁺ T细胞浸润以及使巨噬细胞向M2表型偏移来重塑肿瘤免疫微环境,共同建立深度免疫抑制。慢性应激进一步放大该轴,加速OSCC进展和复发。治疗性阻断MC5R可恢复抗肿瘤免疫监视,并显著增强PD-1检查点抑制。这些发现阐明了一条此前未被充分认识的、调控恶性进展的神经免疫调节通路,并突出一个可干预靶点,用于提高应激相关癌症的免疫治疗疗效。
Science advances IF 13.9 2026-10-30 PMID: 42950043
The serine/glycine biosynthesis pathway plays a critical role in tumor progression and has emerged as a promising therapeutic target in cancer. Phosphoserine aminotransferase 1 (PSAT1) is a key enzyme in this pathway and has been implicated in the progression of multiple malignancies. However, the functional significance and underlying mechanisms of PSAT1 in hepatocellular carcinoma (HCC) remain largely undefined. In this study, we identify PSAT1 as a critical determinant of ferroptosis resistance in HCC. Elevated PSAT1 expression was positively associated with ferroptosis resistance and poor clinical outcomes in patients with HCC. Both in vitro and in vivo functional assays demonstrated that PSAT1 promotes HCC cell proliferation and suppresses ferroptosis through an HSPA5-mediated adaptive endoplasmic reticulum response. Mechanistically, PSAT1 interacts with and stabilizes BCLAF1, thereby enhancing HSPA5 messenger RNA stability and translation in HCC cells. In addition, PSAT1 remodels the tumor immune microenvironment by promoting M2 tumor-associated macrophage polarization and regulatory T cell infiltration. PSAT1 up-regulates NRF2 expression, which directly binds to the CCL5 promoter to enhance CCL5 production and secretion by tumor cells, thereby fostering an immunosuppressive microenvironment. Therapeutically, pharmacological inhibition of PSAT1 with aminooxyacetic acid markedly potentiated the antitumor efficacy of anti-PD-1 immunotherapy. Our study reveals a previously unrecognized role of PSAT1 in coordinating ferroptosis resistance and immune escape in HCC and highlights therapeutic targeting of PSAT1 as a promising strategy for HCC treatment.
中文摘要:丝氨酸/甘氨酸生物合成通路在肿瘤进展中起关键作用,并已成为有前景的癌症治疗靶点。磷酸丝氨酸氨基转移酶1(PSAT1)是该通路中的关键酶,已被认为与多种恶性肿瘤的进展有关。PSAT1在肝细胞癌(HCC)中的功能意义及潜在机制仍大多不明确。本研究确认PSAT1是HCC铁死亡抵抗的关键决定因素。PSAT1表达升高与HCC患者的铁死亡抵抗及不良临床结局呈正相关。体外和体内功能实验均表明,PSAT1通过HSPA5介导的适应性内质网反应促进HCC细胞增殖并抑制铁死亡。机制上,PSAT1与BCLAF1相互作用并稳定BCLAF1,从而增强HCC细胞中HSPA5信使RNA的稳定性和翻译。PSAT1还通过促进M2型肿瘤相关巨噬细胞极化和调节性T细胞浸润重塑肿瘤免疫微环境。PSAT1上调NRF2表达,NRF2直接结合CCL5启动子,增强肿瘤细胞产生和分泌CCL5,进而形成免疫抑制微环境。治疗方面,用氨基氧乙酸对PSAT1进行药理抑制,显著增强了抗PD-1免疫治疗的抗肿瘤疗效。该研究揭示了PSAT1在协调HCC铁死亡抵抗与免疫逃逸中的既往未被认识的作用,并强调靶向PSAT1是HCC治疗的有前景策略。
Science bulletin IF 20.7 2026-10-30 PMID: 42791141
Immunotherapy is increasingly reshaping the therapeutic landscape of clinical oncology by inducing effective tumor regression and durable responses in various types of human cancers. However, a substantial fraction of patients resist immunotherapy, or even experience relapse after an initial response. Clinically, the conventional biomarkers often exhibit limited predictive accuracy and poor transferability across tumor types. These limitations highlight the urgent need for more robust, data-driven strategies to decipher tumor-immune dynamics and guide personalized treatment. Recently, artificial intelligence (AI) has emerged as a transformative paradigm in immuno-oncology, offering scalable solutions to decode high-dimensional and heterogeneous biomedical data. The evolution of AI can be broadly divided into six key stages: early machine learning (ML) classifiers, unsupervised representation learning, graph-based modeling of cell-cell interactions, multimodal foundation and biomedical language models, reinforcement and active learning paradigms, and AI virtual cells. At the molecular level, AI facilitates the integration of genomics, transcriptomics, proteomics, and spatially resolved single-cell omics, supporting fine-grained reconstruction of the tumor immune microenvironment (TIME). At the clinical interface, the application of deep learning (DL) in liquid biopsy, digital pathology, and radiologic imaging has advanced response prediction, biomarker discovery, and early detection of immune-related adverse events (irAEs), driving personized immunotherapy. This review synthesizes recent progress in AI-guided precision immunotherapy across molecular, cellular, and phenotypic area. By outlining key methodological advances and translational opportunities, we highlight that multimodal AI frameworks can pave the way toward the more interpretable, robust, and individualized immunotherapy strategies for cancer treatment.
中文摘要:免疫治疗通过诱导有效的肿瘤退缩与持久缓解,正在重塑多种人类癌症的临床肿瘤学治疗格局。但相当一部分患者对免疫治疗耐药,或在初始缓解后出现复发。临床上,传统生物标志物的预测准确性有限,跨瘤种迁移能力不佳。这些局限凸显出迫切需要更稳健、数据驱动的策略,以解析肿瘤-免疫动态并指导个体化治疗。近年来,人工智能(AI)已成为免疫肿瘤学中的变革性范式,为解析高维、异质的生物医学数据提供可扩展的解决方案。AI的演进大致可分为六个关键阶段:早期机器学习(ML)分类器、无监督表征学习、基于图的细胞间相互作用建模、多模态基础模型与生物医学语言模型、强化学习与主动学习范式,以及AI虚拟细胞。在分子层面,AI促进基因组学、转录组学、蛋白质组学与空间分辨单细胞组学的整合,支持对肿瘤免疫微环境(TIME)的精细重建。在临床环节,深度学习(DL)在液体活检、数字病理与影像学中的应用推进了疗效反应预测、生物标志物发现以及免疫相关不良事件(irAEs)的早期识别,促进了个体化免疫治疗。综述梳理了AI引导的精准免疫治疗在分子、细胞与表型层面的近期进展。通过概述关键方法学进展与转化机遇,文章指出多模态AI框架可为更具可解释性、更稳健且更个体化的癌症免疫治疗策略铺平道路。
Trends in immunology IF 13.1 2026-10-29 PMID: 42957456
Biological sex is a major variable associated with cancer incidence and treatment response, but how it affects antitumor immunity is not well understood. This review highlights the multilayered mechanisms driving sex differences in antitumor immunity. At the molecular level, tumor suppressor and oncogene alterations can be sex-biased and lead to the activation of noncanonical, immune-altering pathways. At the tissue level, resident immune niches and the commensal microbiome modulate sex-biased inflammation. Finally, at the organismal level, sex hormones and chromosomes, which act systemically across tissues, drive divergent inflammatory responses. Together, these mechanisms drive sex-specific antitumor responses, including differences in immunotherapy efficacy and toxicity. Further elucidating these mechanisms will advance precision oncology through sex-stratified treatment strategies and improve preclinical and clinical study designs.
中文摘要:生理性别是与癌症发病率和治疗反应相关的重要变量,但其如何影响抗肿瘤免疫仍不清楚。本综述聚焦驱动抗肿瘤免疫性别差异的多层次机制。分子层面上,抑癌基因和癌基因改变可能具有性别偏向,并导致非经典免疫调节通路的激活。组织层面上,驻留免疫微环境和共生微生物组调节性别偏向性炎症。机体层面上,在全身各组织发挥作用的性激素和性染色体驱动不同的炎症反应。这些机制共同造成性别特异的抗肿瘤反应,包括免疫治疗疗效和毒性的差异。进一步阐明这些机制将通过性别分层治疗策略推进精准肿瘤学,并改进临床前和临床研究设计。
Trends in immunology IF 13.1 2026-10-29 PMID: 42957452
Glutamine metabolism is often viewed as a cancer cell dependency, but its biological consequences depend on how glutamine and its carbon- and nitrogen-derived metabolites are used across malignant, immune, and stromal compartments. In this article, we introduce the glutamine metabolic interaction network (GMIN) as an analytical framework that integrates nutrient partitioning, competition, metabolic cooperation, and metabolite-mediated regulation while distinguishing candidate associations from functionally supported interactions. We review the biochemical, spatial, and treatment-dependent determinants of GMIN states, including emerging evidence for metabolic remodeling during immunotherapy resistance. Current clinical evidence neither supports uniform glutaminase 1 dependence nor establishes a single preferred strategy for glutamine-directed intervention. GMIN may therefore provide a framework for identifying context-specific glutamine-centered interactions and prioritizing them for state-resolved therapeutic targeting.
中文摘要:谷氨酰胺代谢常被视为癌细胞依赖,但其生物学后果取决于谷氨酰胺及其碳源和氮源衍生代谢物在恶性、免疫和基质区室中的使用方式。引入谷氨酰胺代谢相互作用网络(GMIN)作为分析框架,整合营养分配、竞争、代谢合作和代谢物介导的调控,同时区分候选关联与有功能支持的相互作用。综述GMIN状态的生化、空间和治疗依赖性决定因素,包括免疫治疗耐药期间代谢重塑的新证据。当前临床证据既不支持谷氨酰胺酶1的普遍依赖,也未确立谷氨酰胺导向干预的单一优选策略。GMIN可提供框架,用于识别情境特异性的谷氨酰胺中心相互作用,并优先将其用于状态分辨的治疗靶向。
Acta biomaterialia IF 10.4 2026-10-29 PMID: 42956951
Acute myeloid leukemia (AML) relapse and drug resistance remain major causes of mortality in hematologic malignancies, driven in part by CXCR4/CXCL12-mediated homing and retention of leukemic cells within the bone marrow niche, as well as immune evasion mechanisms that enable their persistent survival. Here, we report a Cascade Catalysis Fe₃O₄@Pt nanozyme platform co-functionalized with a CXCR4 antagonist and anti-PD-L1 (aPD-L1) antibody for synergistic therapy of drug-resistant AML. This nanoplatform simultaneously disrupts the CXCL12/CXCR4 axis to suppress AML cell homing and bone marrow infiltration, while blocking the PD-1/PD-L1 immune checkpoint to overcome immune evasion and enhance T cell-mediated cytotoxicity against leukemic cells. Following lysosomal internalization, the Fe₃O₄@Pt nanozyme exhibits cascade catalytic activity under mildly acidic conditions, generating highly cytotoxic reactive oxygen species (ROS) to effectively eradicate drug-resistant AML cells while minimizing damage to normal counterparts. In vitro and in vivo studies demonstrate that this nanoplatform effectively suppresses AML progression by preventing bone marrow engraftment and systemic dissemination to peripheral organs, including the spleen, lungs, and liver. Concurrently, it enhances antitumor immune responses via T cell activation, resulting in markedly improved therapeutic efficacy and significantly prolonged survival in AML-bearing mice. Overall, this work presents a nanozyme-based therapeutic strategy that combines microenvironment-responsive catalytic therapy, dual signaling axis blockade, and immune modulation, offering a promising approach for overcoming relapse and drug resistance in AML. STATEMENT OF SIGNIFICANCE: This study presents a multifunctional nanozyme-based immunotherapeutic platform that simultaneously targets leukemia cell survival, bone marrow microenvironment protection, and immune evasion in acute myeloid leukemia (AML). By integrating Fe₃O₄@Pt nanozyme-mediated catalytic ROS generation, CXCR4 blockade, and PD-L1 immune checkpoint inhibition, this system enables coordinated disruption of leukemic niche interactions and restoration of antitumor immunity. The findings provide a generalizable strategy for combining catalytic nanomedicine with microenvironment and immune modulation to overcome relapse and drug resistance in hematological malignancies.
中文摘要:急性髓系白血病(AML)复发和耐药仍是血液系统恶性肿瘤死亡的主要原因,部分由CXCR4/CXCL12介导的白血病细胞在骨髓龛内的归巢与滞留,以及使其持续存活的免疫逃逸机制驱动。我们报道一种级联催化Fe₃O₄@Pt纳米酶平台,共功能化CXCR4拮抗剂和抗PD-L1(aPD-L1)抗体,用于耐药AML的协同治疗。该纳米平台同时破坏CXCL12/CXCR4轴,抑制AML细胞归巢和骨髓浸润,并阻断PD-1/PD-L1免疫检查点,克服免疫逃逸,增强T细胞对白血病细胞的细胞毒性。经溶酶体内化后,Fe₃O₄@Pt纳米酶在弱酸性条件下表现级联催化活性,生成高细胞毒性活性氧(ROS),有效清除耐药AML细胞,同时尽量减少对正常细胞的损伤。体外和体内研究表明,该纳米平台通过阻止骨髓植入和向脾、肺、肝等外周器官的系统性播散,有效抑制AML进展。同时,它通过T细胞激活增强抗肿瘤免疫应答,显著提高治疗效果并明显延长荷AML小鼠的生存期。该工作提出一种基于纳米酶的治疗策略,结合微环境响应性催化治疗、双信号轴阻断和免疫调节,为克服AML复发和耐药提供有前景的方法。意义声明:本研究提出一种多功能纳米酶免疫治疗平台,在急性髓系白血病(AML)中同时靶向白血病细胞存活、骨髓微环境保护和免疫逃逸。通过整合Fe₃O₄@Pt纳米酶介导的催化ROS生成、CXCR4阻断和PD-L1免疫检查点抑制,该系统能够协同破坏白血病龛相互作用并恢复抗肿瘤免疫。研究结果为将催化纳米医学与微环境和免疫调节相结合以克服血液系统恶性肿瘤复发和耐药提供了可推广的策略。
Cancer cell IF 56.1 2026-10-29 PMID: 42956742
Sex differences in glioblastoma (GBM) outcomes are shaped by biological, hormonal, and immune factors, but the mechanisms driving these disparities remain unclear. We identify platelet protease-activated receptor 4 (PAR4) signaling as a regulator of sex-specific anti-tumor immunity. GBM patients exhibit increased platelet reactivity driven by PAR4. In murine models, pharmacologic or genetic inhibition of PAR4 prolongs survival in females, but not males, and is estrogen dependent, persisting in hormonal females regardless of chromosomal sex. The survival advantage is mediated within the tumor microenvironment through enhanced CD8+ T cell infiltration and function. PAR4-activated platelets suppress CD8+ T cell activity, whereas CD8+ T cell depletion abolishes both tumor-induced platelet reactivity and the PAR4-dependent survival advantage. Mechanistically, PAR4 inhibition enhances CD8+ T cell signaling through interaction with estrogen receptor β (ERβ). These findings demonstrate that platelets are critical regulators of sex-specific anti-tumor immunity and identify PAR4 as a promising therapeutic target in cancer.
中文摘要:胶质母细胞瘤(GBM)预后的性别差异由生物学、激素和免疫因素共同塑造,但驱动这种差异的机制仍不清楚。研究确定血小板蛋白酶激活受体4(PAR4)信号是性别特异性抗肿瘤免疫的调控因子。GBM患者的血小板反应性升高,且由PAR4驱动。在小鼠模型中,药物或遗传学抑制PAR4可延长雌性生存期,对雄性无此效应;该效应依赖雌激素,且在激素水平为雌性的个体中持续存在,与染色体性别无关。这一生存优势经由肿瘤微环境内CD8+ T细胞浸润与功能增强所介导。PAR4激活的血小板抑制CD8+ T细胞活性,而清除CD8+ T细胞可同时消除肿瘤诱导的血小板反应性和PAR4依赖的生存优势。机制上,抑制PAR4通过与雌激素受体β(ERβ)相互作用增强CD8+ T细胞信号。这些结果说明血小板是性别特异性抗肿瘤免疫的关键调控者,PAR4是有前景的肿瘤治疗靶点。
Cancer research IF 22.6 2026-10-29 PMID: 42954752
KRAS inhibitors (KRASi) are reshaping the treatment of aggressive tumors such as pancreatic ductal adenocarcinoma (PDAC), but it is appreciated that patients will eventually acquire resistance through multiple pathways. To avoid this outcome, there is much effort to identify combination therapies that take advantage of the 'window-of-opportunity' permitted from KRAS inhibition. Tumor cell-intrinsic targeting - as a result of KRASi - results in altered immune and stromal features within the PDAC tumor site that could allow for improved, non-KRAS-targeted, treatment efficacy. Qiang and colleagues investigate the potential of pairing KRASi with immunotherapy - here, an IL-21 mimic - for therapeutic benefit during this 'open window' phase of the KRASi-induced tumor debulking. IL-21 promotes a CD4 T cell response that requires both conventional type 2 dendritic cells (cDC2s) and interferon (IFN)-γ, but not direct tumor cell recognition via major histocompatibility complex (MHC). This work fits in a series of studies highlighting the ability to drive PDAC tumor rejection through cytokines derived from CD4, but not CD8, T cells. These findings highlight a divergence from more 'traditional' immunotherapeutic responses, where cytotoxic CD8 T cells have historically dominated tumor control. Identifying alternative paths towards targeting PDAC may be beneficial - and points towards cell types and modalities that could be leveraged for clinical benefit as the field identifies potential combinatorial partners for KRASi and more patients start receiving these drugs.
中文摘要:KRAS 抑制剂(KRASi)正在改变胰腺导管腺癌(PDAC)等侵袭性肿瘤的治疗格局,但已知患者最终会通过多种途径获得耐药。为避免这一结局,大量工作致力于寻找可利用 KRAS 抑制所带来「机会窗」的联合治疗。KRASi 导致的肿瘤细胞内在靶向作用会改变 PDAC 肿瘤部位的免疫和基质特征,从而可能提高非 KRAS 靶向治疗的疗效。Qiang 等研究 KRASi 与免疫治疗(此处为 IL-21 模拟物)联用在 KRASi 诱导肿瘤减负荷的「开放窗口」期是否具有治疗获益。IL-21 促进 CD4 T 细胞应答,该应答需要经典 2 型树突状细胞(cDC2)和干扰素(IFN)-γ,但不依赖肿瘤细胞通过主要组织相容性复合体(MHC)被直接识别。这项工作属于一系列研究,这些研究强调可通过源自 CD4 而非 CD8 T 细胞的细胞因子驱动 PDAC 肿瘤排斥。这些发现凸显了与更「传统」免疫治疗应答的差异,后者历史上以细胞毒性 CD8 T 细胞主导肿瘤控制。寻找靶向 PDAC 的替代路径可能有益,并指向可被用于临床获益的细胞类型和模式,尤其是在该领域为 KRASi 确定潜在联合伙伴、更多患者开始接受这些药物之际。
Cell IF 45.1 2026-10-29 PMID: 42735689
Cuproptosis is a recently identified form of copper-dependent cell death implicated in various physiological and pathological processes. However, the executive proteins involved and the role of physiological intracellular copper in cuproptosis remain unclear. Herein, we identified myosin heavy-chain 9 (MYH9) as a cuproptosis executioner. Copper binding induced MYH9 polymerization, which disrupted the actin cytoskeleton and led to cuproptotic cell death. Hexyl 2-(3,4,5-trihydroxy-phenyl) acetate (HThPA) was shown to induce cuproptosis by binding to the nuclear receptor Nur77, leading to depletion of copper chelate glutathione (GSH) and release of free copper from intracellular copper stores. Acetylation of MYH9 by acetyltransferase dihydrolipoamide S-acetyltransferase (DLAT) facilitated copper binding, regardless of its extracellular or intracellular origin. Physiological copper levels were higher in drug-resistant tumor cells and clinical samples, which increased the likelihood of HThPA-induced cuproptosis. These results elucidate the mechanisms underlying cuproptosis, establish MYH9 as an executioner, and propose a treatment strategy for drug-resistant tumors.
中文摘要:铜死亡是近期发现的一种依赖铜的细胞死亡形式,参与多种生理和病理过程。不过,其执行蛋白以及生理性细胞内铜在铜死亡中的作用仍不清楚。我们鉴定肌球蛋白重链9(MYH9)为铜死亡执行蛋白。铜结合诱导MYH9聚合,破坏肌动蛋白细胞骨架并导致铜死亡。Hexyl 2-(3,4,5-trihydroxy-phenyl) acetate(HThPA)通过结合核受体Nur77诱导铜死亡,造成铜螯合型谷胱甘肽(GSH)耗竭,并从细胞内铜库释放游离铜。乙酰转移酶二氢硫辛酰胺S-乙酰转移酶(DLAT)对MYH9的乙酰化促进铜结合,无论铜来源于细胞外还是细胞内。耐药肿瘤细胞和临床样本中的生理性铜水平较高,增加了HThPA诱导铜死亡的可能性。这些结果阐明了铜死亡的机制,确立MYH9为执行蛋白,并提出一种针对耐药肿瘤的治疗策略。
Blood IF 23.9 2026-10-29 PMID: 42520200
Immunotherapy has revolutionized the treatment of solid cancers in recent years. However, T-cell non-Hodgkin lymphomas (T-NHL) originate from immune cells themselves and are biologically heterogeneous, rendering investigations of immune checkpoint inhibitor (ICI) mechanisms of action complex. Although case reports and individual anaplastic large cell lymphoma (ALCL) patients enrolled in T-NHL trials demonstrated favorable responses to ICIs, hyperprogression was observed in other T-NHL subtypes. We therefore used a syngeneic mouse model of anaplastic lymphoma kinase positive (ALK+) ALCL to investigate immune surveillance and ICI-induced immune response. Transplantation experiments combined with the depletion of relevant immune axes revealed that ALCL immune surveillance is mediated by CD4+ T cells and natural killer cells. Innate and adaptive immune cell infiltration was confirmed in a large series of primary human ALK+ ALCL samples. ICI monotherapy demonstrated robust efficacy in murine ALCL, inducing complete remissions in ∼50% of treated animals. Mechanistically, PD-L1 blockade reversed regulatory T cell-mediated immunosuppression and increased the frequency of circulating effector CD8+ T lymphocytes, thereby significantly prolonging survival. Importantly, CD4+ T cells proved indispensable for driving and sustaining immunotherapy-induced antitumor responses in murine ALCL. CD4+ T cells of nonresponder animals exhibited an exhausted phenotype and a transcriptomic T helper 22-like signature, implicating persistent T-cell exhaustion and polarization as a meaningful immune evasion mechanism. Our findings uncover CD4+ T cells as key players in spontaneous and immunotherapy-mediated anti-T-cell lymphoma immunity, which demonstrates the critically needed preclinical proof-of-concept for the safe and effective use of immunotherapy for ALCL.
中文摘要:近年来免疫治疗改变了实体癌的治疗格局。T细胞非霍奇金淋巴瘤(T-NHL)起源于免疫细胞本身,生物学异质性强,使免疫检查点抑制剂(ICI)作用机制的研究较为复杂。个案报道以及纳入T-NHL试验的部分间变性大细胞淋巴瘤(ALCL)患者对ICI表现出良好反应,其他T-NHL亚型中却观察到超进展。为此,我们采用ALK阳性(ALK+)ALCL同基因小鼠模型研究免疫监视及ICI诱导的免疫应答。移植实验结合相关免疫轴清除显示,ALCL免疫监视由CD4+ T细胞和自然杀伤细胞介导。在一大批原发人ALK+ ALCL样本中证实了固有免疫和适应性免疫细胞浸润。ICI单药治疗在小鼠ALCL中显示强效,约50%治疗动物获得完全缓解。机制上,PD-L1阻断逆转调节性T细胞介导的免疫抑制,提高循环效应CD8+ T淋巴细胞频率,显著延长生存。CD4+ T细胞对驱动和维持小鼠ALCL免疫治疗诱导的抗肿瘤应答不可或缺。无应答动物的CD4+ T细胞呈耗竭表型及辅助性T细胞22样转录组特征,提示持续性T细胞耗竭和极化是有意义的免疫逃逸机制。研究发现CD4+ T细胞是自发性和免疫治疗介导的抗T细胞淋巴瘤免疫的关键参与者,为ALCL安全有效使用免疫治疗提供了亟需的临床前概念验证。
Experimental hematology & oncology IF 17.5 2026-10-28 PMID: 42958443
Human epidermal growth factor receptor 2 (HER2) is a well-established oncogenic driver in multiple solid tumors, most prominently in breast and gastric cancers. Beyond gene amplification-driven signaling through canonical PI3K/AKT and RAS/MAPK pathways, emerging evidence reveals that HER2 functions within a highly dynamic and context-dependent tumor ecosystem. Interactions between HER2-positive tumor cells and immune and stromal compartments actively shape the tumor microenvironment, contributing to immune evasion, therapeutic resistance and disease progression. A central challenge in the clinical management of HER2-altered cancers is pronounced spatial and temporal heterogeneity, which undermines both diagnostic accuracy and the durability of targeted therapies. In response, advances in multi-omics profiling, liquid biopsy technologies and artificial intelligence-assisted analytics are redefining HER2 assessment, shifting it from static tissue-based classification towards dynamic, minimally invasive monitoring. In parallel, the therapeutic landscape has evolved from single-agent HER2 blockade to rational combination strategies. In particular, antibody-drug conjugates have emerged as a transformative modality, extending the therapeutic reach of HER2 targeting beyond traditional indications and offering new opportunities to overcome heterogeneity and drug resistance. This review synthesizes current insights into the molecular and microenvironmental biology of HER2-altered solid tumors and discusses how these advances are reshaping next-generation precision oncology.
中文摘要:人表皮生长因子受体2(HER2)是多种实体瘤中已明确的致癌驱动因子,在乳腺癌和胃癌中尤为突出。除基因扩增驱动经经典PI3K/AKT与RAS/MAPK通路传导信号外,新证据显示HER2在一个高度动态且依赖情境的肿瘤生态系统中发挥作用。HER2阳性肿瘤细胞与免疫及基质成分之间的相互作用会主动塑造肿瘤微环境,促进免疫逃逸、治疗耐药和疾病进展。HER2异常肿瘤临床管理中的核心难题是显著的空间与时间异质性,这既削弱诊断准确性,也影响靶向治疗的持久性。多组学分析、液体活检技术和人工智能辅助分析的发展正在重新定义HER2评估,使其从静态的组织分类转向动态、微创监测。治疗格局也从单药HER2阻断演变为合理的联合策略。抗体偶联药物成为具有变革意义的治疗方式,把HER2靶向的治疗范围扩展到传统适应证之外,为克服异质性和耐药提供新机会。本综述梳理HER2异常实体瘤分子与微环境生物学的最新认识,并讨论这些进展如何重塑下一代精准肿瘤学。
Biomarker research IF 14.6 2026-10-28 PMID: 42958375
Solid tumors remain challenging for cellular immunotherapy, and CAR-T or CAR-M cells alone often have limited efficacy. Combining these approaches may improve therapeutic activity; however, our previous in vitro study observed increased IL-6, while extracellular matrix (ECM) barriers can restrict immune-cell access. We engineered IL6-CD147 CAR-M, a synthetic IL-6-responsive macrophage construct designed to couple an IL-6-binding scFv to a CD147-containing module. Following IL-6 stimulation, IL6-CD147 CAR-M showed increased MMP-2, MMP-9, MMP-11, and MMP-13 transcripts and proteins. A CD147-deletion control did not reproduce the enhanced MMP transcriptional response, and GM6001 reduced CAR-T cell migration through Matrigel toward IL6-CD147 CAR-M-conditioned medium. In defined 80:20 mixed-antigen tumor models, IL6-CD147 CAR-M plus CAR-T increased tumor killing and inflammatory/cytotoxic mediators while reducing detectable extracellular IL-6. In vivo, combined therapy reduced tumor burden, prolonged survival, increased immune-cell infiltration, altered immune composition, and was not associated with overt histopathological abnormalities in the examined major organs at the assessed time points. These findings support further evaluation of an IL-6-responsive, CD147-containing CAR-M strategy; proximal receptor signaling and the mechanism underlying reduced extracellular IL-6 remain unresolved.
中文摘要:实体瘤对细胞免疫治疗仍具挑战,单用CAR-T或CAR-M细胞疗效常有限。将两者联合可能提高治疗活性;我们此前体外研究观察到IL-6升高,而细胞外基质屏障可限制免疫细胞进入。我们构建了IL6-CD147 CAR-M,一种合成的IL-6响应型巨噬细胞构建体,设计将IL-6结合scFv与含CD147的模块偶联。IL-6刺激后,IL6-CD147 CAR-M的MMP-2、MMP-9、MMP-11和MMP-13转录本及蛋白升高。CD147缺失对照未重现增强的MMP转录反应,GM6001降低了CAR-T细胞经Matrigel向IL6-CD147 CAR-M条件培养基的迁移。在确定的80:20混合抗原肿瘤模型中,IL6-CD147 CAR-M联合CAR-T提高肿瘤杀伤及炎症/细胞毒性介质,同时降低可检测的细胞外IL-6。体内联合治疗降低肿瘤负荷、延长生存、增加免疫细胞浸润、改变免疫组成,在所评估时间点检查的主要器官未见明显组织病理学异常。这些结果支持进一步评估IL-6响应型、含CD147的CAR-M策略;近端受体信号及细胞外IL-6降低的机制仍未明确。
Nature IF 56.1 2026-10-28 PMID: 42951965
Dynamic interactions between tumours and their microenvironment are crucial for cancer progression and therapeutic outcomes1,2. However, our understanding of these relationships remains limited by the constrained capacity of current human model systems to manipulate diverse cellular components and to interrogate complex tumour-stroma crosstalk. Here we generated combinatorial, mix-and-match tumour assembloids by conditionally reconstituting multiple components of human renal cell carcinoma, including cancer cells, cancer-associated fibroblasts (CAFs) and tumour-infiltrating immune cells. Using genetically engineered renal cell carcinoma assembloids with humanized mouse models, we uncovered mechanisms by which CAFs coordinate interactions between tumour cells and CD8+ T cells to maintain non-cell-autonomous CD8+ T cell stemness and drive responsiveness to anti-PD-1 therapy. These interactions operate through a tumour-CAF-T cell signalling axis in which tumour-derived WNT induces CAF expression of activin A, which enhances CD8+ T cell stemness and sensitivity to PD-1 blockade. In non-responders, we also identified a subset of WNT-unresponsive CAFs that do not produce activin A, which leads to impaired CD8+ T cell stemness and resistance to therapy. Together, these findings establish a tumour-CAF-T cell axis as a key determinant of heterogeneous responses to immune checkpoint inhibitors. Moreover, tumour assembloids provide a versatile platform for mechanistic dissection of the tumour microenvironment and evaluation of personalized immunotherapy strategies.
中文摘要:肿瘤与其微环境之间的动态相互作用对癌症进展和治疗结局至关重要。然而,现有人类模型系统在操控多种细胞组分和解析复杂肿瘤-基质串扰方面的能力有限,限制了对这些关系的理解。我们通过条件性重建人肾细胞癌的多种组分,包括癌细胞、癌相关成纤维细胞(CAF)和肿瘤浸润免疫细胞,构建了可组合、可自由搭配的肿瘤组装体。利用基因工程化肾细胞癌组装体与人源化小鼠模型,我们揭示了CAF协调肿瘤细胞与CD8+ T细胞相互作用以维持非细胞自主性CD8+ T细胞干性并驱动抗PD-1治疗应答的机制。这些相互作用通过肿瘤-CAF-T细胞信号轴运行,其中肿瘤来源WNT诱导CAF表达激活素A,激活素A增强CD8+ T细胞干性和对PD-1阻断的敏感性。在无应答者中,我们还鉴定出一类对WNT无应答且不产生激活素A的CAF亚群,其导致CD8+ T细胞干性受损和治疗抵抗。这些发现确立肿瘤-CAF-T细胞轴是免疫检查点抑制剂异质性应答的关键决定因素。肿瘤组装体也为肿瘤微环境机制解析和个体化免疫治疗策略评估提供了通用平台。
Immunity IF 30.6 2026-10-28 PMID: 42950826
Bispecific antibodies that conditionally engage costimulatory receptors aim to enhance antitumor T cell immunity while limiting systemic toxicity. We investigated mechanisms underlying the clinical performance of a PD-L1×4-1BB bispecific antibody. Therapeutic efficacy of PD-L1×4-1BB was largely independent of PD-L1 expression on malignant cells but waned in Batf3-/- mice or upon depletion of type 1 conventional dendritic cells (cDC1s). cDC1-specific deletion of PD-L1 markedly limited tumor control. PD-L1×4-1BB enhanced proliferation of tumor-antigen-specific CD8+ T cells through mechanisms dependent on cross-presentation, the presence of interleukin (IL)-12, 4-1BB costimulation, and CD40L-mediated cDC1 licensing. PD-L1×4-1BB increased cDC1-T cell contacts, which promoted transcriptional programs associated with T cell activation and proliferation. Treated tumors exhibited increased infiltration and spatial proximity of cDC1s and activated CD8+ T cells. Accordingly, increasing dendritic-cell abundance via Flt3L further enhanced tumor control. Thus, cDC1-T cell interactions are central to PD-L1×4-1BB activity, with antigen cross-presentation, dendritic-cell licensing, and IL-12 and 4-1BB costimulation converging to promote antitumor immunity.
中文摘要:条件性激活共刺激受体的双特异性抗体旨在增强抗肿瘤T细胞免疫,同时限制全身毒性。我们研究了PD-L1×4-1BB双特异性抗体临床表现背后的机制。PD-L1×4-1BB的疗效在很大程度上不依赖恶性细胞上的PD-L1表达,但在Batf3-/-小鼠中或清除1型经典树突状细胞(cDC1)后减弱。cDC1特异性敲除PD-L1明显削弱了肿瘤控制。PD-L1×4-1BB通过依赖交叉呈递、白细胞介素(IL)-12、4-1BB共刺激以及CD40L介导的cDC1活化的机制,增强肿瘤抗原特异性CD8+ T细胞的增殖。PD-L1×4-1BB增加了cDC1与T细胞的接触,促进了与T细胞活化、增殖相关的转录程序。治疗后的肿瘤中cDC1与活化CD8+ T细胞浸润增加且空间上彼此靠近。相应地,用Flt3L增加树突状细胞数量进一步增强了肿瘤控制。可见cDC1与T细胞的相互作用是PD-L1×4-1BB活性的核心,抗原交叉呈递、树突状细胞活化以及IL-12与4-1BB共刺激共同汇聚以促进抗肿瘤免疫。
Immunity IF 30.6 2026-10-28 PMID: 42950825
Germinal center (GC) responses generate humoral immunity through coordinated interactions between B cells and T follicular helper (TFH) and T follicular regulatory (TFR) cells. Despite high expression of PD-1 by TFH and TFR cells, the function of its ligand PD-L1 in the GC is unclear. Here, we show an immunogenic role for PD-L1 via tuning T-B collaboration to promote humoral immunity. Integrated analyses of secondary lymphoid organs (SLOs) revealed that B cell zone reticular cells (BRCs), including follicular dendritic cells (FDCs), expressed PD-L1. BRC expression of PD-L1 facilitated GC formation and enabled loss of B cell tolerance in autoantibody disease. Mechanistically, BRC-specific deletion of PD-L1 enhanced TFH cell production of Sostdc1 and TFR cell differentiation, destabilizing T-B contacts in the GC. Patient-derived tumor biopsies indicated that a tumor-infiltrating TFH SOSTDC1 signature inversely correlated with immunotherapy responsiveness. These findings reveal a non-canonical immunogenic role for PD-L1 in the GC and suggest that augmenting B cell responses could improve the efficacy of PD-L1 blockade.
中文摘要:生发中心(GC)反应通过B细胞与滤泡辅助性T细胞(TFH)及滤泡调节性T细胞(TFR)之间的协同相互作用产生体液免疫。尽管TFH和TFR细胞高表达PD-1,其配体PD-L1在GC中的功能仍不清楚。我们在这里展示PD-L1通过调节T-B协作促进体液免疫的免疫原性作用。对次级淋巴器官(SLOs)的整合分析显示,包括滤泡树突状细胞(FDCs)在内的B细胞区网状细胞(BRCs)表达PD-L1。BRC表达PD-L1促进GC形成,并使自身抗体疾病中的B细胞耐受丢失得以发生。机制上,BRC特异性缺失PD-L1增强TFH细胞产生Sostdc1以及TFR细胞分化,破坏GC中T-B接触的稳定性。患者来源的肿瘤活检表明,肿瘤浸润TFH的SOSTDC1特征与免疫治疗反应性呈负相关。这些发现揭示PD-L1在GC中的非经典免疫原性作用,并提示增强B细胞反应可能提高PD-L1阻断的疗效。
Science translational medicine IF 15.6 2026-10-28 PMID: 42950019
T cell-engaging bispecific antibodies (TCBs) have seen notable successes in hematologic malignancies, and emerging data demonstrate their potential for the treatment of solid tumors. Most oncology applications of TCBs have focused on targeting tumor cells via tumor-specific antigens; however, TCBs have been underutilized for strategic depletion of immunosuppressive cells in the TME. Regulatory T cells (Treg cells) play a crucial role in suppressing antitumor immune responses, making them an attractive target for immune-based therapies. Treg cells express several surface markers that can serve as potential targets for antibody-mediated depletion, including C-C chemokine receptor type 8 (CCR8), which is highly enriched on tumor-infiltrating Treg cells. Monoclonal antibody (mAb)-mediated Treg cell depletion relies on natural killer (NK) cells, which can be scarce in some solid tumors, whereas TCBs can broadly engage the T cell compartment by overwriting antigen specificity and redirecting potent T cell cytotoxicity against target cells. Here, we have developed a CCR8xCD3 TCB and show that it effectively depletes CCR8-expressing Treg cells in a T cell-mediated manner. CCR8xCD3 TCB led to the selective depletion of intratumoral Treg cells from human solid tumor samples in vitro and mediated inhibition of tumor growth in multiple syngeneic tumor models with variable levels of T cell infiltration alone or in combination with anti-PD-L1. In cynomolgus monkeys, CCR8xCD3 TCB was well tolerated without evidence of acute phase inflammation or cytokine release syndrome and led to effective and durable depletion of the CCR8-expressing subset of Treg cells.
中文摘要:T细胞衔接双特异性抗体(TCB)在血液系统恶性肿瘤中已有明显成功,新出现的数据显示其在实体瘤治疗中具有潜力。TCB在肿瘤学中的多数应用聚焦于通过肿瘤特异性抗原靶向肿瘤细胞,但利用TCB策略性清除肿瘤微环境(TME)中的免疫抑制细胞仍未充分发挥。调节性T细胞(Treg细胞)在抑制抗肿瘤免疫应答中起关键作用,是免疫治疗的有吸引力靶点。Treg细胞表达多种可用于抗体介导清除的表面标志物,包括C-C趋化因子受体8型(CCR8),该受体在肿瘤浸润Treg细胞上高度富集。单克隆抗体(mAb)介导的Treg细胞清除依赖自然杀伤(NK)细胞,而NK细胞在某些实体瘤中可能较少;TCB则可广泛衔接T细胞 compartment,通过改写抗原特异性并将强效T细胞细胞毒性重定向至靶细胞。本研究开发了CCR8xCD3 TCB,并显示其以T细胞介导的方式有效清除表达CCR8的Treg细胞。CCR8xCD3 TCB在体外可从人实体瘤样本中选择性清除肿瘤内Treg细胞,并在多个T细胞浸润水平不同的同系肿瘤模型中单独或与抗PD-L1联合介导肿瘤生长抑制。在食蟹猴中,CCR8xCD3 TCB耐受良好,未出现急性期炎症或细胞因子释放综合征证据,并有效且持久地清除表达CCR8的Treg细胞亚群。
ACS sensors IF 10.9 2026-10-28 PMID: 42950010
Ultraviolet B (UVB) radiation is a key environmental risk factor for remodeling the melanoma microenvironment, yet the bidirectional communication mechanisms between keratinocytes and melanoma cells remain incompletely understood. This study developed an in situ monitoring platform integrated with scanning electrochemical microscopy (SECM) and a microfluidic chip. With a fabricated Ca2+ ion-selective electrode as a SECM tip (Ca2+-ISE SECM tip), together with a lactate oxidase-modified Pt microelectrode tip (LOx-μPt tip) and a multi-potential step waveform (MPSW) method, the dynamic monitoring of Ca2+, lactate, and ROS in keratinocyte-melanoma cell communication has been achieved. UVB radiation dose-dependently enhanced A-375 melanoma cell migration in both monoculture and co-culture systems. Mechanistically, UVB induced ROS production and stimulated glycolysis in A-375 cells, resulting in elevated lactate release and autocrine-driven migration enhancement. Notably, in the co-culture system, this pro-migratory effect was significantly amplified, while inhibition by the glycolysis inhibitor 2-deoxy-d-glucose (2-DG) was minimal, suggesting a dominant paracrine signaling mechanism. In situ SECM monitoring further demonstrated that UVB also induced ROS generation, transient Ca2+ release, and significantly increased TGF-β1 secretion in HaCaT keratinocytes. N-acetylcysteine (NAC) treatment blocked Ca2+ release and TGF-β1 secretion in HaCaT cells, thereby inhibiting co-cultured A-375 cell migration. Further studies confirmed that HaCaT-derived TGF-β1 serves as a key paracrine factor, promoting migration by upregulating YB-1 expression in A-375 cells, a process dependent on extracellular Ca2+. Consequently, this work reveals an intercellular signaling axis in the UVB-exposed skin tumor microenvironment: UVB → ROS → Ca2+ release → TGF-β1 secretion → YB-1 activation, providing new mechanistic insights and potential therapeutic targets for microenvironment-dependent melanoma progression.
中文摘要:紫外线B(UVB)辐射是重塑黑色素瘤微环境的关键环境风险因素,但角质形成细胞与黑色素瘤细胞之间的双向通讯机制仍未完全阐明。本研究构建了集成扫描电化学显微镜(SECM)与微流控芯片的原位监测平台。以制备的Ca2+离子选择性电极作为SECM探针(Ca2+-ISE SECM tip),结合乳酸氧化酶修饰的Pt微电极探针(LOx-μPt tip)和多电位阶跃波形(MPSW)方法,实现了对角质形成细胞-黑色素瘤细胞通讯中Ca2+、乳酸和ROS的动态监测。UVB辐射在单培养和共培养体系中均剂量依赖性增强A-375黑色素瘤细胞迁移。机制上,UVB诱导A-375细胞产生ROS并刺激糖酵解,导致乳酸释放升高和自分泌驱动的迁移增强。在共培养体系中,这种促迁移效应显著放大,而糖酵解抑制剂2-脱氧-D-葡萄糖(2-DG)的抑制作用很小,提示旁分泌信号机制占主导。原位SECM监测进一步显示,UVB还诱导HaCaT角质形成细胞产生ROS、瞬时Ca2+释放并显著增加TGF-β1分泌。N-乙酰半胱氨酸(NAC)处理阻断了HaCaT细胞的Ca2+释放和TGF-β1分泌,从而抑制共培养A-375细胞迁移。进一步研究证实,HaCaT来源的TGF-β1是关键旁分泌因子,通过上调A-375细胞中YB-1表达促进迁移,该过程依赖细胞外Ca2+。因此,这项工作揭示了UVB暴露皮肤肿瘤微环境中的细胞间信号轴:UVB → ROS → Ca2+释放 → TGF-β1分泌 → YB-1激活,为微环境依赖的黑色素瘤进展提供了新的机制认识和潜在治疗靶点。
Advanced healthcare materials IF 11.0 2026-10-28 PMID: 42949810
Despite considerable progress in cancer immunotherapy, the therapeutic efficacy of current cancer therapy continues to be hampered by the immunosuppressive tumor microenvironment (ITME), which is characterized by acidification, hypoxia, elevated H2O2 levels, and aberrant angiogenesis. While transition metal-based nanomaterials hold great promise for modulating the ITME, their effectiveness is often constrained by insufficient reactive oxygen species (ROS) generation, low immunogenicity, poor immune cell infiltration, and T-cell exhaustion. To address these issues, we developed a bimetallic Cu/Mn-doped nanoplatform, CMPTL, which further integrates acid-dissociable taurine and the angiogenesis inhibitor lenvatinib for malignant solid tumor therapy. This nanoplatform simultaneously triggers violent ROS and cuproptosis, leading to mitochondrial damage and the release of mitochondrial DNA. The subsequent activation of the cGAS-STING pathway, synergistically enhanced by Mn2+, initiates robust immune responses. Additionally, taurine helps alleviate T-cell exhaustion, while lenvatinib promotes tumor vessel normalization, leading to comprehensive remodeling of the TIME. Together, these multimodal mechanisms endow CMPTL with potent antitumor activity, positioning it as a promising candidate for cancer therapy.
中文摘要:尽管癌症免疫治疗取得了很大进展,现有癌症疗法的疗效仍受免疫抑制性肿瘤微环境(ITME)的限制,其特征包括酸化、缺氧、H2O2水平升高和异常血管生成。基于过渡金属的纳米材料在调控ITME方面很有前景,但其效果常受限于活性氧(ROS)生成不足、免疫原性低、免疫细胞浸润差和T细胞耗竭。为解决这些问题,我们构建了一种双金属Cu/Mn掺杂纳米平台CMPTL,并进一步整合酸可解离的牛磺酸和血管生成抑制剂仑伐替尼,用于恶性实体瘤治疗。该纳米平台同时触发强烈的ROS和铜死亡,导致线粒体损伤和线粒体DNA释放。随后cGAS-STING通路被激活,Mn2+协同增强该过程,启动强免疫应答。牛磺酸有助于缓解T细胞耗竭,仑伐替尼促进肿瘤血管正常化,从而全面重塑TIME。这些多模式机制共同赋予CMPTL强抗肿瘤活性,使其成为有前景的癌症治疗候选者。
Chemical Society reviews IF 48.3 2026-10-28 PMID: 42949705
The early detection of therapy-induced biomolecular changes and the prediction of therapeutic response remain major challenges in oncology. Current clinical methods often assess treatment response through macroscopic or morphological endpoints, whereas molecular alterations associated with sensitivity, resistance, or recurrence may arise earlier and remain undetected. Raman spectroscopy offers a label-free and non-destructive approach to probe the intrinsic biochemical composition of cells, tissues, and biofluids, providing spectral and spatial information that can support therapy response prediction and longitudinal monitoring. This review discusses Raman-based technologies for cancer therapy assessment, from preclinical models to emerging clinical applications. We first outline the clinical need for rapid, non-destructive, and molecularly informative tools, considering tumor heterogeneity, therapy resistance, the tumor microenvironment, and current standards for response evaluation. We then provide a methodological framework for selecting Raman modalities, including spontaneous Raman (SR) spectroscopy, surface-enhanced Raman spectroscopy (SERS), stimulated Raman spectroscopy (SRS), and coherent anti-Stokes Raman spectroscopy (CARS), together with key considerations on acquisition strategies, multimodal integration, experimental design, preprocessing, feature analysis, and machine learning. We summarize Raman spectral biomarkers associated with therapy-induced changes in nucleic acids, proteins, lipids, metabolites, extracellular matrix components, and anticancer drugs, and critically examine studies using Raman spectroscopy to predict or monitor responses to major therapeutic approaches. Finally, we discuss barriers to clinical translation, including acquisition speed, inter-instrument reproducibility, preclinical model limitations, regulatory requirements, workflow integration, clinical trials, and prospective validation. Overall, Raman spectroscopy emerges as a promising platform for molecular phenotyping in precision oncology, provided that future studies progress toward standardized, clinically validated, and actionable workflows.
中文摘要:治疗诱导的生物分子变化的早期检测以及治疗反应的预测仍是肿瘤学中的主要难题。当前临床方法多通过宏观或形态学终点评估治疗反应,而与敏感性、耐药或复发相关的分子改变可能更早出现且未被检出。拉曼光谱提供无标记、非破坏性的方式,用于探测细胞、组织和生物体液的内在生化组成,获得可支持治疗反应预测和纵向监测的光谱与空间信息。本综述讨论用于肿瘤治疗评估的拉曼技术,涵盖临床前模型到新兴临床应用。文章梳理对快速、非破坏性且具有分子信息量的工具的需求,并考虑肿瘤异质性、治疗耐药、肿瘤微环境以及当前反应评价标准。随后给出选择拉曼模态的方法学框架,包括自发拉曼光谱、表面增强拉曼光谱、受激拉曼光谱和相干反斯托克斯拉曼光谱,并讨论采集策略、多模态整合、实验设计、预处理、特征分析和机器学习等关键问题。文章总结与治疗诱导的核酸、蛋白质、脂质、代谢物、细胞外基质成分和抗癌药物变化相关的拉曼光谱生物标志物,并批判性审视利用拉曼光谱预测或监测主要治疗方式反应的研究。文章还讨论临床转化的障碍,包括采集速度、仪器间重现性、临床前模型的局限、监管要求、工作流程整合、临床试验和前瞻性验证。总体而言,拉曼光谱有望成为精准肿瘤学中分子表型分析的平台,前提是未来研究转向标准化、经临床验证且可操作的工作流程。
Cancer discovery IF 29.5 2026-10-28 PMID: 42949540
Breast cancers with a stiff extracellular matrix (ECM) frequently evade immune surveillance through mechanisms that remain incompletely understood. Here, we identify a mechanosensitive immune-evasion pathway governed by the phosphorylation-dependent prolyl isomerase Pin1. We show that ECM rigidity stabilizes Pin1 and promotes its nuclear accumulation in cancer cells, where it preserves heterochromatin organization and nuclear envelope integrity by sustaining HP1α-Lamin interactions, thereby suppressing transposable element (TE) activity. Pin1 loss induces early heterochromatin relaxation and LINE1 reactivation, activating the cGAS/STING/type I interferon pathway. Pin1 depletion further promotes TE-derived neoantigen generation and broadly remodels the tumor immune microenvironment, eliciting innate and adaptive immune responses that enhance tumor clearance. Genetic Pin1 depletion, or pharmacological inhibition with clinically available drugs, sensitizes fibrotic, immune-cold tumors to immune checkpoint blockade. These findings uncover a mechano-genomic mechanism of immune evasion in breast cancer and establish Pin1 as a therapeutic target to restore tumor immunogenicity and improve immunotherapy efficacy.
中文摘要:细胞外基质僵硬的乳腺癌常通过尚未完全清楚的机制逃避免疫监视。研究识别出一条受磷酸化依赖性脯氨酰异构酶Pin1调控的力学敏感免疫逃逸通路。细胞外基质刚性可稳定Pin1并促进其在癌细胞核内积聚,Pin1通过维持HP1α与Lamin相互作用来保持异染色质组织和核膜完整性,从而抑制转座元件(TE)活性。Pin1缺失会诱导早期异染色质松弛和LINE1重新激活,启动cGAS/STING/I型干扰素通路。Pin1耗竭还促进TE来源新抗原生成,并广泛重塑肿瘤免疫微环境,激发固有免疫和适应性免疫应答,增强肿瘤清除。遗传性Pin1缺失或用临床可用药物进行药理抑制,可使纤维化、免疫冷肿瘤对免疫检查点阻断更敏感。这些发现揭示了乳腺癌免疫逃逸的力学-基因组机制,并将Pin1确立为恢复肿瘤免疫原性、提高免疫治疗疗效的治疗靶点。
Advanced healthcare materials IF 11.0 2026-10-28 PMID: 42947610
Metastatic dissemination is the leading cause of cancer-related mortality, yet the early steps in this process remain difficult to study using current experimental models. Although organ-on-a-chip platforms recapitulate key features of the tumor microenvironment (TME), most fail to integrate physiologically relevant invasion, intravasation, and circulation within a single system. Membrane- and pillar-based designs hinder endothelial crossing and imaging, while open-interface approaches often lack stable perfusion and controlled positioning of 3D cell aggregates. Here, an open-port, barrier-free microfluidic device is presented, fabricated via surface treatment-based patterning, for investigating early metastatic progression from a tumor spheroid. The planar device incorporates a centrally confined gel matrix accessible via a top-loading port for precise spheroid placement, flanked by endothelialized lateral channels in direct contact with the matrix and perfusable under defined shear stress. Using MDA-MB-231 breast cancer spheroids, the model recapitulates key aspects of tumor cell migration, tumor-induced endothelial disruption, and intravasation, while enabling flow-mediated downstream recovery of viable intravasated cells. Overall, this device provides a physiologically relevant platform for the integrated, high-resolution, and longitudinal investigation of early metastatic events, providing a foundation for future mechanistic studies and molecular characterization of metastatic cell populations.
中文摘要:转移播散是癌症相关死亡的主要原因,当前实验模型仍难以研究这一过程的早期步骤。器官芯片平台虽能重现肿瘤微环境的关键特征,但多数平台无法在单一系统中整合生理相关的侵袭、血管内渗和循环过程。基于膜和柱的设计会阻碍内皮穿越与成像,开放界面方案则常缺乏稳定灌注和对三维细胞聚集体位置的控制。研究提出一种开放端口、无屏障的微流控器件,通过基于表面处理的图案化方法制备,用于研究肿瘤球体的早期转移进展。该平面器件包含中央受限的凝胶基质,可通过顶部加载端口精确放置球体,两侧为内皮化的侧向通道,直接接触基质并可在设定剪切应力下灌注。使用MDA-MB-231乳腺癌球体,该模型重现了肿瘤细胞迁移、肿瘤诱导的内皮破坏和血管内渗等关键环节,并可通过流动介导在下游回收存活的血管内渗细胞。该器件为早期转移事件的整合、高分辨率和纵向研究提供了生理相关平台,为后续转移细胞群的机制研究和分子表征奠定基础。
Cancer letters IF 11.8 2026-10-28 PMID: 42641868
Loss or lack tumor immunogenicity promotes immune escape and resistance to immunotherapy. Arginine methylation, a key protein post-translational modification, participates in tumor progression and therapy resistance. However, whether arginine methylation directly influences the tumor immunogenicity and thereby modulates antitumor immune responses remains poorly understood. Here, we report that protein arginine methyltransferase 3 (PRMT3) exhibited a significantly negative association with antitumor immune signatures and survival outcomes in multiple cancers. Tumor-intrinsic PRMT3 deletion markedly delays tumor growth by promoting CD8+ T cell infiltration and functional activation through the modulation of type I interferon (IFN) signaling. Mechanistically, PRMT3 catalyzes arginine asymmetric-dimethylation at the conserved Arg364 residue of cGAS, suppressing its capacity to activate the downstream STING signaling, which ultimately affects the tumor immunogenicity and overall antitumor immune responses. Combining PRMT3 deletion or pharmacological inhibition with anti-PD-1 antibody therapy achieved profoundly synergistic tumor control and elicited tumor-specific immunological memory. Collectively, our findings delineate a critical regulatory role of PRMT3 on tumor-intrinsic cGAS-mediated adaptive immunity, proposing immunogenicity-enhanced cancer treatment as a transformative strategy to achieve potentiated antitumor efficacy.
中文摘要:肿瘤免疫原性丢失或缺乏会促进免疫逃逸和对免疫治疗的抵抗。精氨酸甲基化是一种关键蛋白质翻译后修饰,参与肿瘤进展和治疗耐药。精氨酸甲基化是否直接影响肿瘤免疫原性并由此调控抗肿瘤免疫应答仍知之甚少。研究报告显示,蛋白精氨酸甲基转移酶3(PRMT3)在多种癌症中与抗肿瘤免疫特征及生存结局呈显著负相关。肿瘤细胞内在PRMT3缺失通过调节I型干扰素信号促进CD8+ T细胞浸润和功能活化,从而明显延缓肿瘤生长。机制上,PRMT3催化cGAS保守Arg364位点的精氨酸不对称二甲基化,抑制其激活下游STING信号的能力,最终影响肿瘤免疫原性和整体抗肿瘤免疫应答。将PRMT3缺失或药理抑制与抗PD-1抗体治疗联合可产生深度协同的肿瘤控制,并诱导肿瘤特异性免疫记忆。这些发现阐明PRMT3对肿瘤内在cGAS介导的适应性免疫具有关键调控作用,提出增强免疫原性的癌症治疗可作为提升抗肿瘤疗效的变革性策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42617725
The fibroblast growth factor receptor (FGFR) pathway is frequently dysregulated in cancer and contributes to tumor progression and immune evasion; however, the underlying immunosuppressive mechanisms remain incompletely understood. Here, we identify FGFR4 as a key FGFR family member that suppresses antitumor immunity. Mechanistically, FGFR4 promotes GRB2-dependent phosphorylation and inactivation of the deubiquitinase CYLD, leading to ubiquitin-proteasome-mediated degradation of STING and FDX1. Loss of STING attenuates type I interferon signaling and impairs cytotoxic immune responses, while destabilization of FDX1 diminishes sensitivity to cuproptosis. Inhibition of FGFR4 restores CYLD activity, stabilizes STING and FDX1, and enhances responsiveness to the STING agonist diABZI. Notably, CYLD-dependent stabilization of FDX1 potentiates elesclomol-induced cuproptosis, triggering mitochondrial stress and cytosolic mtDNA release, thereby activating the cGAS-STING pathway and amplifying STING-dependent immune signaling. Combination therapy with lenvatinib and elesclomol synergistically suppressed tumor growth in immunocompetent mouse models. Across patient cohorts, FGFR4-high/STING-low tumors were associated with inferior responses to anti-PD-1-based therapy. Together, these findings establish FGFR4 as a central regulator of antitumor immunity and cuproptosis and highlight combined FGFR4 inhibition and cuproptosis induction as a promising therapeutic strategy.
中文摘要:成纤维细胞生长因子受体(FGFR)通路在癌症中经常失调,并促进肿瘤进展与免疫逃逸;其免疫抑制机制仍未完全阐明。研究确认 FGFR4 是抑制抗肿瘤免疫的关键 FGFR 家族成员。机制上,FGFR4 促进 GRB2 依赖的 CYLD 磷酸化并使其失活,进而导致 STING 与 FDX1 经泛素-蛋白酶体途径降解。STING 缺失削弱 I 型干扰素信号并损害细胞毒性免疫应答,FDX1 不稳定则降低对铜死亡的敏感性。抑制 FGFR4 可恢复 CYLD 活性,稳定 STING 和 FDX1,并增强对 STING 激动剂 diABZI 的应答。CYLD 依赖的 FDX1 稳定增强 elesclomol 诱导的铜死亡,引发线粒体应激和胞质 mtDNA 释放,激活 cGAS-STING 通路并放大 STING 依赖的免疫信号。lenvatinib 与 elesclomol 联合治疗在免疫健全小鼠模型中协同抑制肿瘤生长。在患者队列中,FGFR4 高表达/STING 低表达的肿瘤与抗 PD-1 治疗应答较差相关。这些结果确立 FGFR4 是抗肿瘤免疫与铜死亡的核心调控因子,并提示联合抑制 FGFR4 与诱导铜死亡是一种有前景的治疗策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42595076
Inflammatory cancer-associated fibroblasts (iCAFs) are a highly plastic stromal population that critically shape tumor progression, immunosuppression, and therapeutic response in esophageal squamous-cell carcinoma (ESCC). Epithelial-intrinsic programs are increasingly recognized as key determinants of fibroblast reprogramming within the tumor microenvironment, yet the underlying mechanisms remain incompletely understood. Here, we identified hepatoma-derived growth factor (HDGF) as a pivotal epithelial-intrinsic regulator that drives iCAF formation in ESCC. Mechanistically, nuclear HDGF functioned as a transcriptional activator by directly binding the ENO1 promoter, thereby upregulating the expression of the glycolytic enzyme enolase 1, enhancing aerobic glycolysis, and promoting lactate secretion from tumor cells. Tumor-derived lactate was subsequently taken up by CAFs and induced histone H4 lysine 12 lactylation (H4K12la), which epigenetically activated NF-κB signaling and promoted iCAF formation. Functionally, HDGF-induced iCAFs promoted tumor progression through activation of the IL-6/JAK1/STAT3 axis and established an immunosuppressive microenvironment characterized by increased recruitment of regulatory T cells and reduced infiltration of CD8+ T cells, thereby facilitating immune evasion. Therapeutically, blockade of ENO1 effectively disrupted the glycolysis-lactylation cascade, markedly suppressing tumor growth and iCAF formation in vivo. Moreover, ENO1 inhibition reprogrammed the immunosuppressive tumor microenvironment and significantly enhanced the efficacy of anti-PD-1 therapy. Collectively, our findings reveal an HDGF/ENO1/H4K12la/iCAF axis that links tumor metabolic reprogramming, stromal inflammatory activation, and immunosuppression in ESCC, identifying this axis as a promising therapeutic target for overcoming immunotherapy resistance.
中文摘要:炎性癌相关成纤维细胞(iCAF)是高度可塑的基质细胞群体,在食管鳞状细胞癌(ESCC)的肿瘤进展、免疫抑制和治疗反应中起关键塑造作用。上皮内在程序日益被视为肿瘤微环境中成纤维细胞重编程的重要决定因素,但其潜在机制仍未完全阐明。本研究发现肝癌衍生生长因子(HDGF)是驱动ESCC中iCAF形成的关键上皮内在调控因子。机制上,核内HDGF作为转录激活因子直接结合ENO1启动子,上调糖酵解酶烯醇化酶1的表达,增强有氧糖酵解并促进肿瘤细胞分泌乳酸。肿瘤来源乳酸随后被CAF摄取并诱导组蛋白H4赖氨酸12乳酸化(H4K12la),后者在表观遗传层面激活NF-κB信号并促进iCAF形成。功能上,HDGF诱导的iCAF通过激活IL-6/JAK1/STAT3轴促进肿瘤进展,并建立以调节性T细胞募集增加和CD8+ T细胞浸润减少为特征的免疫抑制微环境,从而促进免疫逃逸。治疗上,阻断ENO1可有效破坏糖酵解-乳酸化级联,在体内显著抑制肿瘤生长和iCAF形成。此外,抑制ENO1可重编程免疫抑制性肿瘤微环境,并显著增强抗PD-1治疗疗效。总体而言,这些发现揭示了连接ESCC肿瘤代谢重编程、基质炎性激活和免疫抑制的HDGF/ENO1/H4K12la/iCAF轴,并将该轴确定为克服免疫治疗耐药的有前景治疗靶点。
Cancer letters IF 11.8 2026-10-28 PMID: 42580433
Gastrointestinal (GI) adenocarcinomas pose a significant therapeutic challenge due to highly immunosuppressive tumor microenvironments that limit effective antitumor immune responses. Dense stromal fibrosis, immune exclusion and poor responses to immune checkpoint inhibitors are hallmarks of treatment-resistant malignancies, most notably pancreatic ductal adenocarcinoma (PDAC) and subsets of gastric cancer. In this regard, IL-15 superagonists such as N-803, NIZ985, RLI, and NKTR-255 have emerged as promising immunotherapeutic candidates, as they selectively expand natural killer (NK) cells and CD8+ T-cells without the systemic toxicity and regulatory T-cell activation observed with IL-2 therapy. IL-15 superagonists have emerged as more effective therapeutic agents when used in conjunction with local inhibitors of TGF-β and IL-10, stromal remodeling, and vascular normalization. They are supported by increasingly conclusive mechanistic, preclinical and early clinical data. A combination of these interventions circumvents extracellular matrix-provoked immune barriers, reverses VEGF-induced endothelial dysfunction, and enhances the trafficking of lymphocytes into tumor cores. Moreover, several localized therapeutic delivery strategies, such as endoscopic delivery, implantable depots, biomaterial scaffolds, and nanocarriers, can improve intratumoral cytokine retention and reduce systemic inflammatory toxicity. Together, these advances define a new paradigm for cytokine-immunotherapy: IL-15 superagonists serving as key mediators of reprogramming of the tumor microenvironment. Therapeutic strategies targeting IL-15 have the potential to restore cytotoxic immunity, improve access to immune cells, and promote responsiveness to the checkpoint blockade, making them a promising yet investigational approach to converting immune-cold GI malignancies into more treatment-responsive disease states, though further clinical validation is required.
中文摘要:胃肠道腺癌因高度免疫抑制的肿瘤微环境限制有效的抗肿瘤免疫应答,构成显著的治疗挑战。致密间质纤维化、免疫排斥以及对免疫检查点抑制剂反应不佳是治疗耐药恶性肿瘤的标志,最典型的是胰腺导管腺癌(PDAC)和部分胃癌。在此背景下,N-803、NIZ985、RLI和NKTR-255等IL-15超级激动剂成为有前景的免疫治疗候选物,因为它们选择性扩增自然杀伤(NK)细胞和CD8+ T细胞,而不产生IL-2治疗中观察到的全身毒性和调节性T细胞活化。IL-15超级激动剂与局部TGF-β和IL-10抑制剂、间质重塑及血管正常化联合使用时,已成为更有效的治疗药物。越来越多的机制、临床前和早期临床数据支持这一点。这些干预措施的组合可绕过细胞外基质造成的免疫屏障,逆转VEGF诱导的内皮功能障碍,并增强淋巴细胞向肿瘤核心的迁移。多种局部治疗递送策略,如内镜递送、植入式储库、生物材料支架和纳米载体,可改善瘤内细胞因子滞留并减少全身炎症毒性。这些进展共同定义了细胞因子免疫治疗的新范式:IL-15超级激动剂作为重编程肿瘤微环境的关键介质。靶向IL-15的治疗策略有潜力恢复细胞毒性免疫、改善免疫细胞的可及性并促进对检查点阻断的反应性,使其成为将免疫冷型胃肠道恶性肿瘤转化为治疗反应性更高疾病状态的有前景但仍处于研究阶段的方法,不过仍需进一步临床验证。
Cancer letters IF 11.8 2026-10-28 PMID: 42567470
Gastric adenocarcinoma (GAC) remains a leading cause of cancer-related mortality, particularly in patients with peritoneal carcinomatosis, for whom effective therapies are limited. We investigated the therapeutic efficacy and molecular mechanism of CYD-4-61, a BAX activator, using human GAC cell lines, patient-derived xenograft models, genetically engineered mouse models, and a syngeneic mouse model. CYD-4-61 potently inhibited tumor cell proliferation, induced apoptosis, and suppressed cancer stem cell-like properties, with enhanced activity in radiation-resistant GAC cells. Mechanistically, CYD-4-61 activated the BAX-caspase pathway, leading to SOX9 protein reduction. Integrated bulk and single-cell transcriptomic analyses identified SOX9-dependent transcriptional programs as major targets of CYD-4-61. Functional rescue experiments together with chromatin immunoprecipitation and CUT&RUN analyses supported CDK4 as a SOX9-regulated gene and demonstrated suppression of the SOX9-CDK4 regulatory axis following CYD-4-61 treatment. In multiple preclinical models, CYD-4-61 significantly inhibited tumor growth and improved the therapeutic response to anti-programmed cell death protein 1 (PD-1) therapy while modulating the tumor immune microenvironment. Clinically, co-expression of SOX9 and CDK4 was associated with diffuse-type GAC and poor patient outcomes. These findings identify the BAX-SOX9-CDK4 axis as an important mechanism contributing to the antitumor activity of CYD-4-61 and provide a strong preclinical rationale for its further development as a therapeutic strategy for aggressive GAC.
中文摘要:胃腺癌(GAC)仍是癌症相关死亡的主要原因之一,腹膜癌病患者尤其缺乏有效治疗。本研究利用人GAC细胞系、患者来源异种移植模型、基因工程小鼠模型和同系小鼠模型,考察BAX激活剂CYD-4-61的治疗效果与分子机制。CYD-4-61强效抑制肿瘤细胞增殖、诱导凋亡并抑制癌症干细胞样特性,在放射抵抗性GAC细胞中活性更强。机制上,CYD-4-61激活BAX-caspase通路,导致SOX9蛋白减少。批量与单细胞转录组整合分析显示,SOX9依赖的转录程序是CYD-4-61的主要作用靶点。功能回补实验结合染色质免疫沉淀和CUT&RUN分析支持CDK4为SOX9调控基因,并表明CYD-4-61处理抑制SOX9-CDK4调控轴。在多种临床前模型中,CYD-4-61显著抑制肿瘤生长,调节肿瘤免疫微环境,并提高抗程序性细胞死亡蛋白1(PD-1)治疗的应答。临床上,SOX9与CDK4共表达与弥漫型GAC及患者不良结局相关。这些结果确定BAX-SOX9-CDK4轴是CYD-4-61抗肿瘤活性的重要机制,并为其作为侵袭性GAC治疗策略的进一步开发提供有力的临床前依据。
Cancer letters IF 11.8 2026-10-28 PMID: 42546913
While classical tumor suppressors in colorectal cancer (CRC) are predominantly recognized for restraining cell-autonomous proliferation, their extrinsic mandate in orchestrating the tumor immunometabolic niche remains poorly defined. Clinically, we document that APC membrane recruitment protein 1 (AMER1) downregulation correlates with advanced progression and cytotoxic CD8+ T cell spatial exclusion in CRC patients. Using parallel homograft models in diverse host immune backgrounds, we show that tumoral AMER1 confers robust in vivo tumor-suppressive effects that are dependent on a fully functional immune system. Single-cell RNA sequencing reveals that tumoral AMER1 enrichment actively preserves CD8+ T cell effector stemness by expanding the CXCR5+ precursor exhausted subset (Tpex) across regional lymph nodes and primary tumor microenvironments. Integrated multi-omics and biochemical tracking identify dopamine (DA) as the conserved neurometabolic effector driving this niche remodeling. Mechanistically, AMER1 physically binds and rescues dopa decarboxylase (DDC) from post-translational degradation to sustain tumoral DA secretion; conversely, AMER1 loss creates a localized DA void. Cell-autonomously, tumoral DA accumulation triggers gasdermin D (GSDMD)-dependent tumor pyroptosis. Therapeutically, local DA administration halts multi-lineage carcinoma progression by reversing CD8+ T cell terminal exhaustion and reinforcing central memory differentiation. Collectively, our findings redefine AMER1 as a critical immunometabolic gatekeeper and establish neurotransmitter metabolic bypassing as a promising therapeutic strategy for CRC.
中文摘要:结直肠癌(CRC)中的经典抑癌基因通常被认为主要抑制细胞自主性增殖,但其在塑造肿瘤免疫代谢微环境方面的外源性作用仍不清楚。临床资料显示,AMER1(APC膜募集蛋白1)下调与CRC患者疾病进展及细胞毒性CD8+ T细胞空间排斥相关。利用不同宿主免疫背景下的同源移植模型,我们发现肿瘤AMER1在体内具有强效抑瘤作用,且该作用依赖功能完整的免疫系统。单细胞RNA测序显示,肿瘤AMER1富集通过扩增区域淋巴结和原发肿瘤微环境中的CXCR5+前体耗竭亚群(Tpex),主动维持CD8+ T细胞效应干性。整合多组学与生化追踪确定多巴胺(DA)是驱动该微环境重塑的保守神经代谢效应分子。机制上,AMER1与多巴脱羧酶(DDC)物理结合并使其免于翻译后降解,从而维持肿瘤DA分泌;AMER1缺失则造成局部DA缺乏。在细胞自主层面,肿瘤DA积聚触发gasdermin D(GSDMD)依赖性肿瘤细胞焦亡。治疗上,局部给予DA可通过逆转CD8+ T细胞终末耗竭并促进中枢记忆分化,阻止多谱系癌进展。这些结果将AMER1重新定义为关键的免疫代谢守门因子,并确立神经递质代谢旁路作为CRC的潜在治疗策略。
Biosensors & bioelectronics IF 11.8 2026-10-27 PMID: 42956580
Tumor microenvironment (TME)-responsive theranostic nanosystems hold considerable promise for cancer therapy. However, converting transient therapeutic effects into sustained and amplified antitumor efficacy remains a challenge due to the absence of dynamic feedback mechanisms in conventional strategies. Herein, we construct an activatable self-reinforcing FeMOF-Au@HA nanoplatform to potentiate ferroptosis via starvation and photothermal sensitization for amplified cancer therapy. This nanoplatform is fabricated through a stepwise strategy by anchoring ultrasmall Au NPs onto FeMOF followed by hyaluronic acid (HA) functionalization. Upon encountering tumor cells, the HA shell binds to CD44 receptors, promoting tumor-targeted accumulation and cellular internalization of FeMOF-AH. After cellular uptake, FeMOF-AH initiates Au-catalyzed glucose oxidation, depleting glucose to induce starvation therapy (ST) and the generation of H2O2. Meanwhile, GSH reduces Fe3+ to Fe2+, facilitating the conversion of H2O2 to ·OH. The subsequent GSH exhaustion and ·OH accumulation disrupt redox equilibrium, inducing glutathione peroxidase 4 inactivation and lipid peroxidation buildup that drive ferroptosis. Ferroptosis further provokes mitochondrial dysfunction, depleting ATP and suppressing heat shock protein 70 (HSP70), thereby attenuating thermotolerance and sensitizing tumors to mild photothermal therapy (PTT, 45 °C). Under 808-nm laser irradiation, mild photothermal heating accelerates glucose oxidation and Fenton catalysis, reinforcing ST and ferroptosis. Notably, ST fuels ferroptosis via metabolite supply, and ferroptosis attenuates thermoresistance to potentiate mild PTT that amplifies oxidative damage, establishing a self-reinforcing therapeutic network. Consequently, FeMOF-AH exhibits enhanced tumor-targeted accumulation by in vivo fluorescence imaging and superior antitumor efficacy over monotherapies with a 92.6% tumor inhibition rate under laser irradiation without systemic toxicity. This nanoplatform offers a new avenue for designing feedback-amplified nanomedicines for durable and enhanced cancer therapy.
中文摘要:肿瘤微环境响应性诊疗纳米系统在癌症治疗中具有较大潜力。传统策略缺乏动态反馈机制,瞬态治疗效果难以转化为持续且放大的抗肿瘤疗效。本研究构建可激活自增强的FeMOF-Au@HA纳米平台,通过饥饿治疗和光热增敏增强铁死亡,以实现放大的癌症治疗。该平台采用逐步构建策略,将超小Au纳米颗粒锚定于FeMOF,再进行透明质酸功能化。接触肿瘤细胞后,HA外壳与CD44受体结合,促进FeMOF-AH的肿瘤靶向蓄积和细胞摄取。进入细胞后,FeMOF-AH启动Au催化的葡萄糖氧化,消耗葡萄糖以诱导饥饿治疗并生成H2O2。同时,GSH将Fe3+还原为Fe2+,促进H2O2转化为·OH。随后GSH耗竭和·OH积累破坏氧化还原平衡,诱导谷胱甘肽过氧化物酶4失活并促进脂质过氧化积累,驱动铁死亡。铁死亡进一步引起线粒体功能障碍,耗竭ATP并抑制热休克蛋白70,降低耐热性并使肿瘤对温和光热治疗敏感。808 nm激光照射下,温和光热升温加速葡萄糖氧化和Fenton催化,强化饥饿治疗与铁死亡。饥饿治疗通过代谢物供给为铁死亡提供支持,铁死亡降低耐热性以增强温和光热治疗并放大氧化损伤,形成自增强治疗网络。体内荧光成像显示FeMOF-AH具有增强的肿瘤靶向蓄积,激光照射下抑瘤率达92.6%,疗效优于单药治疗且无全身毒性。该纳米平台为设计反馈放大型纳米药物、实现持久且增强的癌症治疗提供了新途径。
Biosensors & bioelectronics IF 11.8 2026-10-27 PMID: 42956579
Excessive reactive oxygen species (ROS) and hypoxia in the tumor microenvironment (TME) severely limit the efficacy of cancer therapies. Photosynthetic microalgae can supply oxygen to relieve hypoxia, but their therapeutic utility is constrained by poor oxidative stress resistance. To overcome this limitation, we engineered the marine microalga Scrippsiella trochoidea (S.t.) with CuMg bimetallic hexacyanoferrate (CuMgHCF) nanozymes-which exhibit cascade superoxide dismutase (SOD)- and catalase (CAT)-like activities-via electrostatic anchoring, yielding S.t.@CuMgHCF. We also developed a ferrocene-labeled DNA sensor on a platinum nanoelectrode to monitor intracellular ROS dynamics in single cells using fast-scan voltammetry. Under simulated TME conditions, S.t.@CuMgHCF showed markedly lower intracellular ROS and malondialdehyde levels, along with higher chlorophyll a retention, than unmodified algae. In co-cultures with diverse cancer cell lines, S.t.@CuMgHCF sustained light-triggered oxygen production and outperformed native microalgae in both two- and three-dimensional models. By integrating nanozyme-enhanced stress resistance with single-cell electrochemical sensing, this work establishes a strategy to counteract tumor hypoxia and improve therapeutic outcomes.
中文摘要:肿瘤微环境(TME)中过量的活性氧(ROS)和缺氧严重限制癌症治疗疗效。光合微藻可提供氧气以缓解缺氧,但其治疗应用受限于抗氧化应激能力差。为克服这一限制,我们通过静电锚定将具有级联超氧化物歧化酶(SOD)和过氧化氢酶(CAT)样活性的CuMg双金属六氰基铁酸盐(CuMgHCF)纳米酶工程化到海洋微藻Scrippsiella trochoidea(S.t.)上,得到S.t.@CuMgHCF。我们还开发了一种在铂纳米电极上的二茂铁标记DNA传感器,利用快速扫描伏安法监测单细胞内的ROS动态。在模拟TME条件下,S.t.@CuMgHCF的细胞内ROS和丙二醛水平明显低于未修饰藻,叶绿素a保留率更高。与多种癌细胞系共培养时,S.t.@CuMgHCF维持光触发产氧,并在二维和三维模型中均优于天然微藻。通过将纳米酶增强的抗逆性与单细胞电化学传感相结合,这项工作建立了一种对抗肿瘤缺氧并改善治疗结局的策略。
Cellular & molecular immunology IF 23.9 2026-10-27 PMID: 42946799
Failure of cancer vaccines in clinical trials has been linked to poor preclinical translatability, immunosuppressive tumor microenvironments (TMEs), suboptimal antigen delivery to antigen-presenting cells, limited human MHC antigenicity, and insufficiently safe immune adjuvants. Therefore, this study aimed to design an integrated cancer vaccine and evaluate its efficacy in a KPC orthotopic pancreatic cancer model containing the G12D mutation. A novel immune adjuvant, C-VAX, was developed from the natural Toll-like receptor 2/6 agonist UNE-C1 and covalently linked to a KRASG12D neoantigen and WNT5a, a tumor-associated antigen upregulated in resistant tumors. This integrated vaccine enhanced CD8⁺ T-cell infiltration and reduced α-SMA expression in the TME. The therapeutic effects were further enhanced following anti-PD-1 checkpoint blockade. These findings suggest that vaccines targeting tumor antigens and resistance-associated TME components may promote an immune-responsive TME in refractory cancers.
中文摘要:癌症疫苗在临床试验中的失败与临床前可转化性差、免疫抑制性肿瘤微环境(TME)、抗原向抗原呈递细胞递送不理想、人MHC抗原性受限以及免疫佐剂安全性不足有关。本研究旨在设计一种整合型癌症疫苗,并在含G12D突变的KPC原位胰腺癌模型中评价其疗效。研究从天然Toll样受体2/6激动剂UNE-C1开发了新型免疫佐剂C-VAX,并将其与KRASG12D新抗原及WNT5a共价连接;WNT5a是在耐药肿瘤中上调的肿瘤相关抗原。该整合疫苗增强了CD8⁺ T细胞浸润,并降低了TME中α-SMA表达。在抗PD-1检查点阻断后,治疗效果进一步增强。这些发现提示,靶向肿瘤抗原和耐药相关TME组分的疫苗可能促进难治性癌症形成免疫应答型TME。
Advanced healthcare materials IF 11.0 2026-10-27 PMID: 42946672
Melanoma remains highly lethal due to rapid progression and limited response to conventional therapies. Photothermal therapy (PTT) offers precise tumor ablation, yet its efficacy is restricted by shallow light penetration and weak immunogenicity. Here, we develop a multifunctional immuno-photothermal nanoplatform based on bimetallic Au-Pd nanodumbbells coated with a genipin crosslinked ovalbumin (OVA) antigenic shell (AuPd-G-OVA NDs). The bilateral Pd coating enhances NIR-II (1064 nm) absorption and photothermal conversion, enabling effective NIR-II heating. Genipin crosslinking provides stable antigen loading and promotes dendritic cell activation. Upon irradiation, AuPd-G-OVA NDs induce potent photothermal ablation and promote reactive oxygen species (ROS)-mediated oxidative stress with ICD-associated immunogenic damage, facilitating enhanced antigen presentation and OVA-associated T-cell responses. In vivo, this platform significantly suppresses B16-OVA melanoma growth and elicits durable systemic antitumor immunity. These findings demonstrate a synergistic strategy integrating PTT with OVA-associated immunotherapy, offering a promising approach for advanced melanoma treatment.
中文摘要:黑色素瘤进展快、对常规治疗反应有限,致死率仍高。光热治疗可实现精准肿瘤消融,但受浅层光穿透和免疫原性弱的限制。本研究构建了基于双金属Au-Pd纳米哑铃的多功能免疫光热纳米平台,其表面包覆京尼平交联的卵清蛋白抗原壳层(AuPd-G-OVA NDs)。双侧Pd包覆增强了近红外二区1064 nm吸收和光热转换,实现有效的近红外二区加热。京尼平交联提供稳定的抗原负载并促进树突状细胞活化。照射后,AuPd-G-OVA NDs诱导强效光热消融,并促进活性氧介导的氧化应激及与免疫原性细胞死亡相关的免疫原性损伤,增强抗原呈递和OVA相关T细胞应答。体内实验中,该平台显著抑制B16-OVA黑色素瘤生长,并引发持久的全身抗肿瘤免疫。这些结果展示了将光热治疗与OVA相关免疫治疗整合的协同策略,为晚期黑色素瘤治疗提供了有前景的途径。
Cell metabolism IF 37.0 2026-10-27 PMID: 42945967
The tumor-associated microenvironment, shaped by dynamic crosstalk between tumor cells and peritumoral adipose tissue (PAT), has attracted growing attention in recent years. Beyond serving as a passive energy reservoir, PAT actively contributes to tumor progression through metabolic reprogramming, modulation of immune cell function, and remodeling of the stromal vascular fraction. Conversely, tumors induce profound structural and functional reorganization in PAT, including fibrosis, browning, and systemic effects such as cachexia, which further enhances tumor progression. Together, these changes reinforce a tumor-supportive microenvironment. Collectively, these reciprocal interactions underscore the pivotal role of adipose tissue in shaping tumor behavior. This review provides a comprehensive overview of the multifaceted roles of PAT in tumor development, elucidates the mechanisms underlying the bidirectional tumor-adipose interaction, and discusses emerging therapeutic strategies targeting the adipose-tumor axis as a promising avenue for cancer treatment.
中文摘要:肿瘤相关微环境由肿瘤细胞与瘤周脂肪组织(PAT)之间的动态交互塑造,近年来受到越来越多关注。PAT不仅是被动能量储库,还通过代谢重编程、免疫细胞功能调节和基质血管组分重塑主动促进肿瘤进展。反过来,肿瘤诱导PAT发生显著结构和功能重组,包括纤维化、棕色化以及恶病质等全身效应,这些变化进一步促进肿瘤进展。上述改变共同强化支持肿瘤的微环境。这些相互作用凸显脂肪组织在塑造肿瘤行为中的关键作用。本综述全面概述PAT在肿瘤发展中的多重作用,阐明肿瘤与脂肪双向互动的机制,并讨论靶向脂肪-肿瘤轴的新兴治疗策略,作为癌症治疗的有前景途径。
Cancer research IF 22.6 2026-10-27 PMID: 42944699
Oncolytic virotherapy is a promising cancer treatment that elicits antitumor immunity. However, the efficacy of virotherapy is often constrained by tumor-intrinsic immune suppression. To identify conserved virus-induced programs driving immune escape, we applied multi-omics and functional assays across multiple tumor and virus models, uncovering an SLC3A2-driven immunosuppressive metabolic barrier. In oncolytic herpes simplex virus (oHSV)-infected tumors, a biphasic immune trajectory emerged: early CD8+ T cell activation was followed by SLC3A2-mediated methionine and tryptophan uptake, driving T cell exhaustion. Mechanistically, oHSV upregulated SLC3A2 via the m6A-IGF2BP3 axis, while tumor-intrinsic tryptophan metabolism engaged the AHR/ARNT/ICP4 cascade to amplify viral replication and reinforce the immunosuppressive program. Importantly, dietary methionine supplementation disrupted the metabolic checkpoint, restored T cell effector function, and synergized with oHSV expressing anti-PD1 to enhance tumor control in humanized preclinical models. Notably, a parallel SLC3A2-centered metabolic-immunologic circuit operated in vesicular stomatitis virus (VSV) infection. Together, these findings delineate an actionable, conserved metabolic checkpoint and provide a framework for integrating metabolic modulation into cancer viroimmunotherapy.
中文摘要:溶瘤病毒治疗是一种有望激发抗肿瘤免疫的癌症治疗方式,但其疗效常受肿瘤内在免疫抑制的限制。为识别驱动免疫逃逸的保守病毒诱导程序,研究在多种肿瘤和病毒模型中采用多组学与功能实验,发现由SLC3A2驱动的免疫抑制性代谢屏障。在感染溶瘤单纯疱疹病毒(oHSV)的肿瘤中,出现双相免疫轨迹:早期CD8+ T细胞活化之后,SLC3A2介导的甲硫氨酸和色氨酸摄取导致T细胞耗竭。机制上,oHSV通过m6A-IGF2BP3轴上调SLC3A2,而肿瘤内在的色氨酸代谢激活AHR/ARNT/ICP4级联,放大病毒复制并强化免疫抑制程序。膳食补充甲硫氨酸可打破该代谢检查点,恢复T细胞效应功能,并与表达抗PD1的oHSV协同增强人源化临床前模型中的肿瘤控制。类似的以SLC3A2为中心的代谢-免疫回路也出现在水疱性口炎病毒(VSV)感染中。这些结果刻画了一个可干预的保守代谢检查点,并为将代谢调节整合进癌症病毒免疫治疗提供了框架。
ACS nano IF 17.3 2026-10-27 PMID: 42937547
Colorectal cancer (CRC) represents one of the most commonly diagnosed malignancies in which Fusobacterium nucleatum (Fn) infiltration critically drives tumor progression by fostering an immunosuppressive tumor microenvironment (TME) that compromises immunotherapy efficacy. Outer membrane vesicles (OMVs) originating from Escherichia coli Nissle 1917 offer an attractive tumor-targeting drug delivery system, combining intrinsic immunostimulatory properties with drug-loading capacity. We therefore developed an OMV-based dual-function system coencapsulating 5-fluorouracil (5-Fu) and metronidazole (MTZ), designated 5-Fu/MTZ@OMVs. In vitro, this system effectively eliminated both CT26 cells and Fn while promoting DC maturation and driving repolarization of M2 macrophages toward M1 as well as N2 neutrophils toward N1. In vivo, upon administration to an Fn-colonized CT26 model, the system homed to tumors, reduced the Fn burden, and inhibited tumor growth, demonstrating its bactericidal and antitumor efficacy. Notably, it reversed immunosuppressive TME by promoting DC maturation, M1 macrophage, and N1 neutrophil polarization, which enhanced the recruitment and functional activation of CD4+ and CD8+ T cells within the tumor. Thus, by integrating bactericidal, antitumor, and immune remodeling activities into a single OMV platform, our strategy constitutes a viable therapeutic approach for Fn-associated CRC.
中文摘要:结直肠癌是常见恶性肿瘤之一,具核梭杆菌(Fn)浸润通过营造免疫抑制性肿瘤微环境(TME)削弱免疫治疗疗效,从而关键性驱动肿瘤进展。源自大肠杆菌Nissle 1917的细菌外膜囊泡(OMVs)兼具内在免疫刺激特性和载药能力,是有吸引力的肿瘤靶向药物递送系统。因此构建了共包载5-氟尿嘧啶(5-Fu)和甲硝唑(MTZ)的OMV双功能系统,命名为5-Fu/MTZ@OMVs。体外,该系统有效清除CT26细胞和Fn,同时促进树突状细胞成熟,并驱动M2巨噬细胞向M1、N2中性粒细胞向N1复极化。体内,在Fn定植的CT26模型中给药后,系统归巢至肿瘤,降低Fn负荷并抑制肿瘤生长,显示其杀菌和抗肿瘤效力。该系统通过促进树突状细胞成熟、M1巨噬细胞和N1中性粒细胞极化逆转免疫抑制性TME,增强肿瘤内CD4+和CD8+ T细胞的募集与功能活化。通过将杀菌、抗肿瘤和免疫重塑活性整合到单一OMV平台,该策略为Fn相关结直肠癌提供了可行的治疗途径。
Advanced healthcare materials IF 11.0 2026-10-26 PMID: 42935031
Cluster of differentiation 44 (CD44) is highly expressed in ovarian cancer (OC) and plays a critical role in cancer stem cell (CSC) maintenance, tumor initiation, and chemoresistance, making it an attractive therapeutic target. Herein, a CD44-targeted antibody-drug conjugate (ADC), CD44-VC-DOX, is developed by conjugating doxorubicin (DOX) to an anti-CD44 monoclonal antibody using a cathepsin-cleavable MC-VC-PAB linker for selective intracellular drug release in CD44-positive tumor cells. Physicochemical characterization confirms successful conjugation, high stability, and an optimal drug-to-antibody ratio. CD44-VC-DOX exhibit selective binding and rapid internalization in CD44-overexpressing OC cells resulting in potent cytotoxicity, apoptosis induction, and G2/M cell-cycle arrest. Importantly, CD44-VC-DOX effectively suppresses CSC-associated phenotypes, including tumorsphere formation, tumor-initiating frequency, CD44+CD133+ CSC populations, ALDH-positive cells, and stemness-related gene expression. In addition, CD44-VC-DOX reduces hypoxia-associated HIF-1α expression, indicating disruption of the CSC-supportive tumor microenvironment. In vivo, CD44-VC-DOX demonstrates efficient tumor targeting, significant tumor growth inhibition, and minimal systemic toxicity. Transcriptomic profiling further reveals coordinated suppression of CSC-associated and oncogenic pathways, including PI3K/AKT, MYC signaling, E2F targets, DNA repair, and stemness-related transcriptional programs, supporting effective depletion of tumor-initiating CSC populations and reduced tumor adaptability. Collectively, these findings highlight CD44-VC-DOX as a promising precision therapeutic strategy for targeting CSC-driven OC.
中文摘要:CD44在卵巢癌中高表达,并在癌症干细胞维持、肿瘤起始和化疗耐药中起关键作用,因此是有吸引力的治疗靶点。研究开发了CD44靶向抗体药物偶联物CD44-VC-DOX,将多柔比星通过组织蛋白酶可裂解的MC-VC-PAB连接子偶联到抗CD44单克隆抗体,实现CD44阳性肿瘤细胞内选择性药物释放。理化表征证实偶联成功、稳定性高且药物抗体比理想。CD44-VC-DOX在CD44过表达卵巢癌细胞中表现出选择性结合和快速内化,产生强细胞毒性、诱导凋亡并导致G2/M细胞周期阻滞。CD44-VC-DOX有效抑制CSC相关表型,包括肿瘤球形成、肿瘤起始频率、CD44+CD133+ CSC群体、ALDH阳性细胞和干性相关基因表达。CD44-VC-DOX降低缺氧相关HIF-1α表达,提示破坏支持CSC的肿瘤微环境。体内实验中,CD44-VC-DOX实现有效肿瘤靶向、显著抑制肿瘤生长且全身毒性低。转录组分析进一步显示CSC相关和致癌通路协同受抑,包括PI3K/AKT、MYC信号、E2F靶点、DNA修复和干性相关转录程序,支持有效清除肿瘤起始CSC群体并降低肿瘤适应性。这些发现表明CD44-VC-DOX是靶向CSC驱动卵巢癌的有前景的精准治疗策略。
Journal of biomedical science IF 14.5 2026-10-26 PMID: 42934719
Chitinase-3-like-protein 1 (CHI3L1), a low-abundance protein in normal tissues, is markedly upregulated in the pancreatic tumor microenvironment (TME), where it promotes fibrosis and immune evasion. Spatial transcriptomics revealed enrichment of CHI3L1 at tumor-stroma interfaces, suggesting that cell-cell interactions regulate CHI3L1 expression. We employed 2D and 3D multicellular culture models, incorporating pancreatic cancer cells, macrophages, and pancreatic stellate cells (PSCs), to recapitulate TME-mediated CHI3L1 induction. Mechanistic insights were gained through secretome profiling, chromatin immunoprecipitation (ChIP), and methylation-specific PCR. The therapeutic potential of targeting identified axes was evaluated in an orthotopic pancreatic adenocarcinoma (PDAC) mouse model. We identified CCL2, CXCL10, and SPARC as key secreted mediators during tumor-stroma crosstalk that cooperatively induced CHI3L1 expression in cancer cells via activation of NF-κB and STAT3. Specifically, inflammatory cytokines within the TME recruited macrophages to induce CCL2, which, in concert with PSCs, enhances CXCL10 and SPARC secretion. Mechanistically, NF-κB directly bound the CHI3L1 promoter, while STAT3 reduced DNA methyltransferase 1 levels, leading to promoter hypomethylation and epigenetic activation of CHI3L1. Clinically, high CHI3L1 expression correlated with the upregulated stromal CCL2, CXCL10, and SPARC levels, and the combined four-marker signature was an independent prognostic factor for both overall and disease-free survival in multivariable analysis. In vivo, blockade of the upstream stromal pathways (CCR2/CXCR3/TGFβR1) coupled with CHI3L1 neutralization reduced tumor growth and remodeled the immunosuppressive microenvironment in immunocompetent PDAC models. Our findings uncover a cooperative multicellular signaling network that orchestrates CHI3L1 expression in cancer via transcriptional and epigenetic reprogramming. Disrupting these upstream stromal pathways concurrently with CHI3L1 neutralization was associated with reduced T-cell exhaustion, offering a promising combinatorial approach for PDAC immunotherapy.
中文摘要:几丁质酶3样蛋白1(CHI3L1)在正常组织中丰度低,在胰腺肿瘤微环境(TME)中明显上调,并促进纤维化与免疫逃逸。空间转录组显示CHI3L1富集于肿瘤-间质交界处,提示细胞间相互作用调控其表达。我们建立二维与三维多细胞培养模型,纳入胰腺癌细胞、巨噬细胞与胰腺星状细胞(PSC),以重现TME对CHI3L1的诱导。机制线索来自分泌组分析、染色质免疫沉淀(ChIP)与甲基化特异性PCR。靶向所鉴定通路的治疗潜力在原位胰腺导管腺癌(PDAC)小鼠模型中评估。结果显示,CCL2、CXCL10与SPARC是肿瘤-间质串扰中的关键分泌介质,通过激活NF-κB与STAT3协同诱导癌细胞CHI3L1表达。TME中的炎性细胞因子招募巨噬细胞并诱导CCL2,CCL2与PSC共同作用增强CXCL10与SPARC分泌。机制上,NF-κB直接结合CHI3L1启动子,STAT3降低DNA甲基转移酶1水平,引起启动子低甲基化及CHI3L1的表观遗传激活。临床相关分析中,CHI3L1高表达与间质CCL2、CXCL10、SPARC水平上调相关,四标志物联合在多因素分析中为总生存与无病生存的独立预后因素。体内实验中,阻断上游间质通路(CCR2/CXCR3/TGFβR1)联合CHI3L1中和可减小肿瘤生长并重塑免疫抑制微环境,该结果见于免疫健全PDAC模型。上述结果揭示了一个协同的多细胞信号网络,通过转录与表观遗传重编程编排癌细胞的CHI3L1表达。同时干扰上游间质通路并中和CHI3L1与T细胞耗竭减轻相关,为PDAC免疫治疗提供了有前景的联合策略。
Experimental hematology & oncology IF 17.5 2026-10-26 PMID: 42934708
Cancer metabolism-associated immune suppression remains a major barrier to durable therapeutic responses. Indoleamine-2,3-dioxygenase 1 has been pursued as a therapeutic target, but incomplete pathway suppression has limited clinical success. As the aryl hydrocarbon receptor is a ligand-activated transcription factor and downstream effector of tryptophan metabolism, we investigated how myeloid-cell aryl hydrocarbon receptor signaling shapes the tumor immune microenvironment and whether its inhibition can restore antitumor immunity. Conditional aryl hydrocarbon receptor knockout mice targeting dendritic cells or macrophages were used to evaluate the effects of genetic aryl hydrocarbon receptor ablation. Pharmacologic inhibition was assessed using DA-4505 across syngeneic lung, colorectal, and breast cancer models and an immune checkpoint inhibitor-refractory humanized patient-derived xenograft model. Therapeutic efficacy was evaluated alone or in combination with anti-programmed cell death protein 1 therapy, chemotherapy, or surgery. Tumor growth, survival, metastasis, and immune remodeling were analyzed by flow cytometry, multiplex immunohistochemistry, single-cell RNA sequencing, cytokine profiling, and human tumor datasets. Conditional aryl hydrocarbon receptor depletion in macrophages and dendritic cells enhanced innate and adaptive immune activation, increased interferon-γ-producing T cells, and strengthened antitumor immunity. In mouse tumor models, pharmacologic aryl hydrocarbon receptor blockade enhanced macrophage chemotaxis and activation programs, promoted M1-like macrophage polarization, increased interferon-γ-producing CD8⁺ T cells, and reduced regulatory T cells and polymorphonuclear myeloid-derived suppressor cells. These changes promoted robust T-cell activation and durable tumor control. Aryl hydrocarbon receptor inhibition further synergized with chemotherapy, surgery, and immune checkpoint blockade, leading to expansion of effector and memory T-cell populations and sustained antitumor responses. In a humanized lung cancer model, aryl hydrocarbon receptor blockade increased intratumoral CD8⁺ T-cell infiltration and cytotoxic-memory programs while reducing regulatory T-cell enrichment. In human tumor datasets, aryl hydrocarbon receptor-positive macrophages correlated with FOXP3⁺ T-cell infiltration, and higher aryl hydrocarbon receptor inhibition-associated T-cell signatures were associated with improved patient survival.
中文摘要:肿瘤代谢相关免疫抑制仍是持久治疗反应的主要障碍。吲哚胺-2,3-双加氧酶1曾被作为治疗靶点,但通路抑制不充分限制了临床成功。芳香烃受体是配体激活的转录因子,也是色氨酸代谢的下游效应分子,因此研究探讨了髓系细胞芳香烃受体的信号如何塑造肿瘤免疫微环境,以及抑制该受体能否恢复抗肿瘤免疫。研究使用靶向树突状细胞或巨噬细胞的条件性芳香烃受体敲除小鼠评估遗传性芳香烃受体缺失的作用。通过DA-4505在同基因肺癌、结直肠癌和乳腺癌模型以及免疫检查点抑制剂难治的人源化患者来源异种移植模型中评估药物抑制。治疗效果在单药以及与抗程序性细胞死亡蛋白1治疗、化疗或手术联合时进行评估。肿瘤生长、生存、转移和免疫重塑通过流式细胞术、多重免疫组化、单细胞RNA测序、细胞因子谱分析和人类肿瘤数据集分析。巨噬细胞和树突状细胞中的条件性芳香烃受体缺失增强了固有免疫和适应性免疫激活,增加了产生干扰素-γ的T细胞,并增强了抗肿瘤免疫。在小鼠肿瘤模型中,药物阻断芳香烃受体增强了巨噬细胞趋化和激活程序,促进M1样巨噬细胞极化,增加产生干扰素-γ的CD8⁺ T细胞,并减少调节性T细胞和多形核髓源性抑制细胞。这些变化促进了强效T细胞激活和持久肿瘤控制。抑制芳香烃受体还与化疗、手术和免疫检查点阻断产生协同作用,导致效应和记忆T细胞群体扩增以及持续抗肿瘤反应。在人源化肺癌模型中,阻断芳香烃受体增加了瘤内CD8⁺ T细胞浸润和细胞毒性记忆程序,同时减少了调节性T细胞富集。在人类肿瘤数据集中,芳香烃受体阳性巨噬细胞与FOXP3⁺ T细胞浸润相关,较高的芳香烃受体抑制相关T细胞特征与患者生存改善相关。
Journal for immunotherapy of cancer IF 11.7 2026-10-26 PMID: 42933890
Core binding factor acute myeloid leukemia (CBF-AML) driven by the CBFB-MYH11 fusion oncogene is associated with high initial remission rates, yet 30%–50% of patients ultimately relapse. While immune evasion is a recognized hallmark of leukemia progression, the precise mechanisms orchestrated by the CBFB-MYH11 oncogene remain poorly understood. Furthermore, the role of transforming growth factor-beta (TGFβ) in hematological malignancies is highly controversial, often viewed as a tumor suppressor in early hematopoiesis rather than a driver of immune evasion. We used an inducible Cbfb-MYH11 knock-in mouse model and primary AML cell transplantation to profile the immune microenvironment during leukemogenesis. We integrated flow cytometry, bulk and single-cell RNA sequencing (scRNA-seq), CUT&RUN, luciferase reporter assay, ChIP-qPCR, and ChIP-Seq. Functional in vitro T-cell suppression assays and in vivo engraftment using Pdcd1 knockout (PD-1 KO) mice, and treatments with the anti-PD-L1 antibody, TGFβ receptor inhibitor galunisertib, and cytarabine were performed to evaluate immunotherapeutic vulnerabilities. Leukemogenesis in the Cbfb-MYH11 model was accompanied by profound T-cell suppression and exhaustion, and the AML cells effectively inhibited T-cell proliferation in co-culture. Transcriptomic profiling identified marked upregulation of Cd274 (PD-L1) and Tgfb1 in AML cells. Mechanistically, CUT&RUN and ChIP-Seq demonstrated that the CBFβ-SMMHC fusion oncoprotein and its co-factor RUNX1 directly bind to the promoter regions of CD274 and TGFB1 to transcriptionally activate their expression in both murine and human AML models. While genetic ablation of PD-1 in host mice provided only limited survival benefits, pharmacological blockade of TGFβ effectively restored T cell function and delayed AML progression. Importantly, combining cytarabine with galunisertib provided superior disease control, reversed T cell exhaustion, and significantly prolonged survival compared with chemotherapy alone, which can be further enhanced by targeting PD-L1/PD-1. The CBFB-MYH11 oncogene directly orchestrates an immunosuppressive microenvironment by transcriptionally activating PD-L1 and TGFβ. These findings provide more insight into the role of TGFβ in CBF-AML, establishing it as a primary, tumor-derived immunosuppressor directly driven by the fusion oncogene. This provides a strong mechanistic rationale for incorporating TGFβ blockade into standard chemotherapy and immune checkpoint blockade regimens to restore anti-leukemic immunity and prevent relapse.
中文摘要:由CBFB-MYH11融合癌基因驱动的核心结合因子急性髓系白血病(CBF-AML)初始缓解率高,但30%–50%患者最终复发。免疫逃逸是白血病进展的公认特征,CBFB-MYH11癌基因所编排的具体机制仍不清楚。TGFβ在血液恶性肿瘤中的作用争议很大,常被视为早期造血中的抑癌因子,而非免疫逃逸驱动因素。研究采用可诱导Cbfb-MYH11敲入小鼠模型和原代AML细胞移植,在白血病发生过程中分析免疫微环境,整合流式细胞术、bulk与单细胞RNA测序(scRNA-seq)、CUT&RUN、荧光素酶报告基因实验、ChIP-qPCR和ChIP-Seq。通过体外T细胞抑制功能实验、Pdcd1敲除(PD-1 KO)小鼠体内植入,以及抗PD-L1抗体、TGFβ受体抑制剂galunisertib和阿糖胞苷处理,评估免疫治疗脆弱点。Cbfb-MYH11模型白血病发生伴随显著T细胞抑制和耗竭,AML细胞在共培养中有效抑制T细胞增殖。转录组分析显示AML细胞中Cd274(PD-L1)和Tgfb1明显上调。机制上,CUT&RUN和ChIP-Seq显示CBFβ-SMMHC融合癌蛋白及其辅因子RUNX1直接结合CD274和TGFB1启动子区域,在小鼠和人AML模型中转录激活其表达。宿主小鼠PD-1基因敲除仅带来有限生存获益,药理学阻断TGFβ有效恢复T细胞功能并延缓AML进展。阿糖胞苷联合galunisertib较单用化疗提供更优疾病控制,逆转T细胞耗竭并显著延长生存,靶向PD-L1/PD-1可进一步增强。CBFB-MYH11癌基因通过转录激活PD-L1和TGFβ直接编排免疫抑制微环境。这些发现加深了对TGFβ在CBF-AML中作用的认识,将其确立为由融合癌基因直接驱动的主要肿瘤来源免疫抑制因子,为将TGFβ阻断纳入标准化疗和免疫检查点阻断方案以恢复抗白血病免疫并预防复发提供了有力机制依据。
Journal for immunotherapy of cancer IF 11.7 2026-10-26 PMID: 42933889
Melanoma is an aggressive skin cancer with a highly immunosuppressive tumor microenvironment. This study investigated the role of matrix Gla protein (MGP)-high cancer-associated fibroblasts (MGPhi CAFs) in melanoma progression and their potential relevance to immunotherapy. Single-cell RNA sequencing and tissue validation were used to characterize MGP expression, and its association with prognosis was analyzed. In vitro assays and mouse melanoma models were used to investigate the effects of MGPhi CAFs on tumor progression, myeloid-derived suppressor cell (MDSC) recruitment and apoptosis. The role of MDSCs was further examined by adoptive transfer. The antitumor effects of vitamin K2, anti-programmed cell death protein 1 (PD-1) and their combination were evaluated in vivo. Normality was assessed using the Shapiro-Wilk test. Group differences were analyzed using two-tailed paired or unpaired Student’s t-tests or one-way or two-way analysis of variance followed by Tukey’s multiple comparisons test. Survival curves were compared using the log-rank test. MGP expression was reduced in melanoma tissues, and low MGP expression was associated with poor prognosis. MGPhi CAFs inhibited melanoma cell proliferation and migration and suppressed tumor growth. Mechanistically, MGPhi CAFs reduced C-X-C motif chemokine ligand 2/C-X-C motif chemokine receptor 2-mediated MDSC recruitment and promoted MDSC apoptosis by inhibiting tumor necrosis factor receptor 2-cellular FLICE-like inhibitory protein signaling and activating caspase-8. Adoptive transfer of MDSCs reversed the antitumor effects of MGPhi CAFs. Vitamin K2 increased MGP protein levels in CAFs isolated from tumors. Combined vitamin K2 and anti-PD-1 treatment produced greater antitumor activity than either monotherapy. MGPhi CAFs suppress melanoma progression by reducing MDSC recruitment and survival. These findings identify an MGPhi CAF-MDSC regulatory axis and support further evaluation of vitamin K2 combined with anti-PD-1 therapy in melanoma.
中文摘要:黑色素瘤是一种侵袭性皮肤癌,其肿瘤微环境具有高度免疫抑制性。本研究探讨基质Gla蛋白(MGP)高表达癌症相关成纤维细胞(MGPhi CAFs)在黑色素瘤进展中的作用及其与免疫治疗的潜在相关性。研究采用单细胞RNA测序和组织验证刻画MGP表达,并分析其与预后的关联。通过体外实验和小鼠黑色素瘤模型研究MGPhi CAFs对肿瘤进展、髓源性抑制细胞(MDSC)募集和凋亡的影响。通过过继转移进一步考察MDSC的作用。在体内评估维生素K2、抗程序性细胞死亡蛋白1(PD-1)及其联合方案的抗肿瘤效果。采用Shapiro-Wilk检验评估正态性。组间差异采用双尾配对或非配对Student t检验,或单因素或双因素方差分析后行Tukey多重比较检验。生存曲线采用log-rank检验比较。黑色素瘤组织中MGP表达降低,低MGP表达与不良预后相关。MGPhi CAFs抑制黑色素瘤细胞增殖和迁移,并抑制肿瘤生长。机制上,MGPhi CAFs减少C-X-C基序趋化因子配体2/C-X-C基序趋化因子受体2介导的MDSC募集,并通过抑制肿瘤坏死因子受体2-细胞型FLICE样抑制蛋白信号、激活caspase-8促进MDSC凋亡。过继转移MDSC可逆转MGPhi CAFs的抗肿瘤作用。维生素K2提高从肿瘤分离的CAFs中MGP蛋白水平。维生素K2与抗PD-1联合治疗的抗肿瘤活性高于任一单药治疗。MGPhi CAFs通过减少MDSC募集和存活抑制黑色素瘤进展。这些发现识别出MGPhi CAF-MDSC调控轴,并支持进一步评估维生素K2联合抗PD-1治疗黑色素瘤。
Journal of hepatology IF 40.1 2026-10-26 PMID: 42933735
Whether intestinal fungal dysbiosis contributes to hepatocellular carcinoma (HCC) progression and resistance to immune checkpoint inhibitors (ICIs) remains unclear. We investigated how gut Candida albicans influences HCC progression, immune remodeling, and response to ICI therapy. Fecal and tumor samples from patients with HCC, liver cirrhosis, and healthy controls were analyzed using ITS2 sequencing, immune profiling, and correlation analyses. Mechanistic studies focused on four complementary autochthonous murine HCC models and cell-based assays, integrating single-cell and bulk RNA sequencing, genetic and pharmacologic perturbations, Kaede photoconversion, fungal antigen recall assays, antifungal treatment, and anti-PD-1 therapy. Fecal C. albicans abundance was higher in HCC patients and was associated with advanced disease, shorter overall survival, and reduced durable clinical benefit. Across HCC models, C. albicans gavage increased tumor burden and induced a Th17/IL-17A-skewed microenvironment characterized by Trem2+ macrophage accumulation and impaired CD8+ T cell infiltration and function. Antifungal treatment attenuated tumor progression, whereas IL-17A blockade or deficiency largely abrogated C. albicans-associated tumor promotion. Mechanistically, IL-17A induced tumor-derived MCP-1 through ACT1-TRAF6-TAK1 signaling to recruit macrophages and upregulated PAI-1, which activated TGF-β/Smad3 signaling to promote an immunosuppressive Trem2+ macrophage state. These macrophages limited CD8+ T cell recruitment and effector function through coordinated CXCL10 repression and GAL-1 induction, while potentially reinforcing Th17 responses through IL-1β and IL-6. Kaede photoconversion demonstrated enhanced mesenteric lymph node-to-liver Th17 trafficking, while fungal antigen recall assays revealed preferential Th17 responsiveness to C. albicans. C. albicans also impaired anti-PD-1 efficacy in vivo, whereas antifungal treatment partially restored therapeutic responsiveness. Intestinal C. albicans promotes HCC progression and anti-PD-1 resistance through an IL-17A-Trem2+ macrophage circuit, supporting its potential as a biomarker and therapeutic target. Intestinal fungal dysbiosis is increasingly recognized as a component of the gut-liver axis, but its functional contribution to HCC has remained poorly defined. Our study identifies intestinal Candida albicans as a promoter of HCC progression in experimental models and delineates an IL-17A-MCP-1/PAI-1-Trem2+ macrophage circuit that links fungal exposure to impaired CD8+ T-cell immunity and reduced response to PD-1 blockade. These findings are relevant to researchers and clinicians seeking microbiome-associated determinants of HCC progression and immunotherapy resistance. Fecal C. albicans abundance and components of this immune circuit may warrant evaluation as biomarkers for patient stratification and as potential targets for combination therapy. However, the clinical associations reported here are based on modest observational cohorts, and antifungal treatment was tested as a proof-of-concept intervention in mice. Larger prospective studies and more selective therapeutic approaches will therefore be required before these findings can inform clinical management.
中文摘要:肠道真菌失调是否参与肝细胞癌(HCC)进展及免疫检查点抑制剂(ICI)耐药尚不清楚。研究分析了肠道白色念珠菌对HCC进展、免疫重塑和ICI治疗反应的影响。对HCC患者、肝硬化患者和健康对照者的粪便样本及肿瘤样本进行了ITS2测序、免疫谱分析和相关性分析。机制研究采用四种互补的原位小鼠HCC模型和细胞实验,整合单细胞与批量RNA测序、遗传和药物干预、Kaede光转换、真菌抗原回忆试验、抗真菌治疗和抗PD-1治疗。HCC患者粪便中白色念珠菌丰度更高,并与晚期疾病、较短总生存期和持久临床获益降低相关。在多种HCC模型中,灌胃白色念珠菌增加肿瘤负荷,诱导以Trem2+巨噬细胞积聚及CD8+ T细胞浸润和功能受损为特征的Th17/IL-17A偏倚微环境。抗真菌治疗减轻肿瘤进展,而阻断或缺失IL-17A基本消除白色念珠菌相关的促肿瘤作用。机制上,IL-17A通过ACT1-TRAF6-TAK1信号诱导肿瘤来源MCP-1以招募巨噬细胞,并上调PAI-1,后者激活TGF-β/Smad3信号,促进免疫抑制性Trem2+巨噬细胞状态。这些巨噬细胞通过协同抑制CXCL10和诱导GAL-1限制CD8+ T细胞招募及效应功能,并可能通过IL-1β和IL-6增强Th17反应。Kaede光转换显示肠系膜淋巴结向肝脏的Th17迁移增强,真菌抗原回忆试验显示Th17对白色念珠菌具有优先反应性。白色念珠菌在体内还削弱抗PD-1疗效,而抗真菌治疗部分恢复治疗反应性。肠道白色念珠菌通过IL-17A-Trem2+巨噬细胞环路促进HCC进展和抗PD-1耐药,支持其作为生物标志物和治疗靶点的潜力。肠道真菌失调日益被视为肠-肝轴的一部分,但其对HCC的功能贡献仍不明确。实验模型显示肠道白色念珠菌促进HCC进展,并勾勒出IL-17A-MCP-1/PAI-1-Trem2+巨噬细胞环路,将真菌暴露与CD8+ T细胞免疫受损及PD-1阻断反应降低联系起来。这些发现对寻找HCC进展和免疫治疗耐药的微生物组相关决定因素的研究者和临床医生具有意义。粪便白色念珠菌丰度及该免疫环路的组分值得评估作为患者分层生物标志物和联合治疗潜在靶点。但这里报告的临床关联基于规模有限的观察性队列,抗真菌治疗是在小鼠中作为概念验证干预进行测试。因此,需要更大规模的前瞻性研究和更具选择性的治疗策略,这些发现才能用于指导临床管理。
Cancer letters IF 11.8 2026-10-26 PMID: 42933591
Mucin-16 (MUC16) is overexpressed in >60% of pancreatic ductal adenocarcinoma (PDAC) cases and correlates with poor outcomes, yet its role in regulating tumor-immune interactions remains incompletely defined. Using KPC and KPC-MUC16 knockout (KPC-MUC16KO) genetically engineered and orthotopic mouse models, we show that loss of MUC16 markedly reduces tumor burden and reprograms the tumor microenvironment (TME) toward a less immunosuppressive state. MUC16 deficiency significantly decreased CD206+ and Ym1/2+ M2-like macrophages, increased the M1/M2 ratio, and improved survival. Cytokine profiling identified CCL2 and Serpin-E1 as MUC16- dependent secreted factors that promote macrophage recruitment and polarization; neutralization of these cytokines reduced macrophage migration in vitro. Bone marrow-derived macrophages (BMDM) exposed to MUC16-expressing tumor cells or conditioned media adopted a CD206+Arg1+ M2-like phenotype, whereas MUC16KO tumor signals favored inflammatory CD86+iNOS + M1-like polarization. Macrophage depletion using clodronate liposomes significantly impaired tumor growth in MUC16-competent tumors but had minimal effect in KPC-MUC16KO tumors, indicating dependence on macrophage-mediated immunosuppression in the former group. Spatial transcriptomics revealed a globally distinct TME in MUC16KO tumors, including enhanced antigen-presentation programs, increased complement activation, and fibroblast states skewed toward pro-inflammatory signaling. These findings establish MUC16 as a key orchestrator of macrophage-driven immunosuppression in PDAC and support therapeutic strategies combining MUC16-targeted interventions with TME-reprogramming approaches.
中文摘要:Mucin-16(MUC16)在超过60%的胰腺导管腺癌(PDAC)病例中过表达,并与不良预后相关,但其在调控肿瘤-免疫相互作用中的作用仍未完全明确。利用KPC和KPC-MUC16敲除(KPC-MUC16KO)基因工程及原位小鼠模型,研究发现MUC16缺失显著降低肿瘤负荷,并将肿瘤微环境(TME)重编程为免疫抑制较弱的状态。MUC16缺陷显著减少CD206+和Ym1/2+ M2样巨噬细胞,提高M1/M2比值,并改善生存。细胞因子谱分析鉴定出CCL2和Serpin-E1是MUC16依赖的分泌因子,可促进巨噬细胞募集和极化;中和这些细胞因子在体外减少巨噬细胞迁移。暴露于表达MUC16的肿瘤细胞或条件培养基的骨髓来源巨噬细胞(BMDM)获得CD206+Arg1+ M2样表型,而MUC16KO肿瘤信号倾向于促炎性CD86+iNOS+ M1样极化。使用氯膦酸盐脂质体清除巨噬细胞显著抑制了MUC16功能完整肿瘤的生长,而在KPC-MUC16KO肿瘤中影响很小,表明前者依赖巨噬细胞介导的免疫抑制。空间转录组学显示MUC16KO肿瘤具有全局上不同的TME,包括抗原呈递程序增强、补体激活增加以及成纤维细胞状态偏向促炎信号。这些发现确立MUC16是PDAC中巨噬细胞驱动免疫抑制的关键协调者,并支持将MUC16靶向干预与TME重编程策略联合的治疗思路。
Cardiovascular research IF 12.5 2026-10-26 PMID: 42931785
Natural killer (NK) cells are a critical component of the innate immune system and are known for their dual roles in cytotoxicity and immune regulation. While NK cells are extensively studied in infections, transplants, and cancer, their role in cardiovascular pathophysiology remains incompletely defined. Emerging evidence suggests that NK cell dysfunction not only disrupts cardiac homeostasis and contributes to cardiac inflammation, tissue remodeling, and various cardiovascular diseases. This review explores the underlying NK cell biology and function to underscore the contributions of NK cells to the cardiac microenvironment while highlighting their pathological roles and protective potential. Furthermore, we discuss the therapeutic potential of targeting NK cells in heart diseases, including recent advances in immunotherapy and various future strategies to modulate their activity for improved cardiac outcomes. Understanding the complex interplay between NK cells and the various cell types in the heart may unlock novel therapeutic avenues in cardiology.
中文摘要:自然杀伤(NK)细胞是先天免疫系统的重要组成部分,以细胞毒作用和免疫调节的双重角色著称。NK细胞在感染、移植和肿瘤中已被广泛研究,但其在心血管病理生理中的作用仍未完全明确。新出现的证据提示,NK细胞功能障碍不仅会破坏心脏稳态,还参与心脏炎症、组织重塑及多种心血管疾病。本综述梳理NK细胞生物学与功能的基础,以强调NK细胞对心脏微环境的贡献,并突出其病理作用与保护潜力。文章还讨论靶向NK细胞治疗心脏疾病的可能性,包括免疫治疗的最新进展以及通过调节NK细胞活性改善心脏结局的未来策略。理解NK细胞与心脏内多种细胞类型之间的复杂相互作用,可能为心脏病学开辟新的治疗途径。
Advanced healthcare materials IF 11.0 2026-10-26 PMID: 42929240
Developing effective nanomedicines for pulmonary metastasis remains challenging because of systemic clearance and local stromal barriers. Guided by single-cell transcriptomic profiling, we characterized a compartmentalized immunosuppressive network involving PGE2 and provide a biological rationale for coordinated EP2/EP4 antagonism. We therefore engineered an inhalable biomimetic platform (PD-1@E2/4 Exo) comprising PD-1-displaying exosomes co-loaded with EP2 and EP4 antagonists. Compared with intravenous administration, nebulized delivery increased pulmonary exposure of the engineered vesicles. Within the pulmonary tumor setting, surface PD-1 is intended to interfere with PD-1/PD-L1 signaling, while the co-delivered antagonists target the EP2/EP4 immunosuppressive axis. Treatment was associated with macrophage reprogramming, increased oxidative stress, and enhanced ICD-related responses in tumor cells. In the experimental breast-cancer lung-colonization model, the inhaled formulation reduced established pulmonary tumor burden and was accompanied by systemic immune-memory responses. These findings provide a preclinical study for integrating local pulmonary delivery with coordinated metabolic and immune modulation in breast cancer lung disease.
中文摘要:由于全身清除和局部基质屏障,开发有效的肺转移纳米药物仍具挑战。基于单细胞转录组分析,我们刻画了涉及PGE2的分区化免疫抑制网络,并为协同拮抗EP2/EP4提供了生物学依据。因此构建了可吸入仿生平台(PD-1@E2/4 Exo),由展示PD-1的外泌体共载EP2和EP4拮抗剂组成。与静脉给药相比,雾化递送提高了工程化囊泡的肺部暴露。在肺部肿瘤环境中,表面PD-1旨在干扰PD-1/PD-L1信号,共递送的拮抗剂靶向EP2/EP4免疫抑制轴。治疗伴随巨噬细胞重编程、氧化应激增加以及肿瘤细胞中ICD相关反应增强。在实验性乳腺癌肺定植模型中,吸入制剂降低了已形成的肺部肿瘤负荷,并伴随全身免疫记忆反应。这些发现为将局部肺部递送与协同代谢和免疫调节相结合用于乳腺癌肺部疾病提供了临床前研究依据。
Cancer discovery IF 29.5 2026-10-26 PMID: 42929145
T cell exhaustion within the tumor microenvironment poses a major barrier to effective cancer immunotherapy, yet the epigenetic mechanisms that preserve functional states of tumor-infiltrating T cells remain incompletely understood. Here, using an in vivo CRISPR screen, we identify heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) as a regulator of CD8+ T cell fitness. Transcriptomic analyses of cancer patient cohorts reveal that hnRNPA2B1 is preferentially enriched in a proliferative, intermediate exhausted T cell subset associated with favorable clinical outcomes. Genetic ablation of hnRNPA2B1 in CD8+ T cells accelerates terminal exhaustion, impairs antitumor immunity, and diminishes responsiveness to immune checkpoint blockade. Mechanistically, hnRNPA2B1 forms nuclear puncta and stabilizes RNAs involved in chromatin organization, thereby maintaining chromatin accessibility that restrains exhaustion-associated programs while preserving proliferative and cytotoxic potential. Together, these findings establish hnRNPA2B1 as an RNA-mediated epigenetic regulator sustaining functional exhausted T cell states in tumors.
中文摘要:肿瘤微环境中的T细胞耗竭是有效肿瘤免疫治疗的主要障碍,但维持肿瘤浸润T细胞功能状态的表观遗传机制仍未完全清楚。通过体内CRISPR筛选,鉴定异质核糖核蛋白A2/B1(hnRNPA2B1)为CD8+ T细胞适应性的调控因子。对癌症患者队列的转录组分析显示,hnRNPA2B1优先富集于与良好临床结局相关的增殖性中间耗竭T细胞亚群。在CD8+ T细胞中遗传去除hnRNPA2B1会加速终末耗竭,损害抗肿瘤免疫,并降低对免疫检查点阻断的反应性。机制上,hnRNPA2B1形成核内点状结构并稳定参与染色质组织的RNA,从而维持染色质可及性,抑制耗竭相关程序并保留增殖和细胞毒性潜能。这些发现确立hnRNPA2B1是RNA介导的表观遗传调控因子,维持肿瘤中功能性耗竭T细胞状态。
Cancer letters IF 11.8 2026-10-24 PMID: 42926036
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint blockade (ICB), largely because of its immunosuppressive and T-cell-excluded tumor microenvironment. While inducing immunogenic cell death (ICD) offers a promising strategy to enhance tumor immunogenicity, redox-targeted ICD inducers with defined molecular targets remain limited in PDAC. Here, a functional screen of natural compounds identified erianin as a potent ICD inducer in PDAC. Erianin triggered canonical ICD hallmarks, including cell-surface calreticulin exposure, extracellular release of HMGB1 and ATP, thereby promoting dendritic-cell maturation, antigen cross-presentation and CD8+ T-cell activation. Target-engagement assays together with genetic perturbation supported glutathione reductase (GSR) as a functionally important erianin target. Erianin decreased the GSH/GSSG ratio, accompanied by increased oxidative stress and preferential activation of the PERK-eIF2α-ATF4-CHOP branch of the endoplasmic reticulum (ER) stress response. Mutational and rescue experiments identified ARG-233 as an important residue required for GSR-dependent protection against erianin-induced redox stress and ICD. In syngeneic PDAC models, erianin-treated tumor cells elicited protective antitumor immunity in a tumor-challenge setting, while a therapeutic regimen combining erianin with anti-PD-1 antibody suppressed tumor growth and was associated with increased dendritic-cell activation and enhanced cytotoxic CD8+ T-cell infiltration. These findings define a GSR-associated redox-immune axis that links glutathione metabolism to immunogenic ER stress and provide a rationale for combining erianin with PD-1 blockade in immunologically cold PDAC.
中文摘要:胰腺导管腺癌(PDAC)对免疫检查点阻断(ICB)应答不佳,主要与其免疫抑制及T细胞排斥的肿瘤微环境有关。诱导免疫原性细胞死亡(ICD)是增强肿瘤免疫原性的可行策略,但在PDAC中,分子靶点明确的氧化还原型ICD诱导剂仍然有限。通过对天然化合物进行功能筛选,发现毛兰素(erianin)是PDAC中强效的ICD诱导剂。毛兰素触发典型ICD特征,包括细胞表面钙网蛋白暴露、HMGB1和ATP的胞外释放,进而促进树突状细胞成熟、抗原交叉呈递和CD8+ T细胞活化。靶点结合实验结合遗传扰动支持谷胱甘肽还原酶(GSR)是毛兰素功能上重要的靶点。毛兰素降低GSH/GSSG比值,同时氧化应激升高,并优先激活内质网应激反应中的PERK-eIF2α-ATF4-CHOP分支。突变与回补实验确定ARG-233是GSR依赖性地抵御毛兰素诱导的氧化还原应激与ICD所需的重要残基。在同基因PDAC模型中,经毛兰素处理的肿瘤细胞在肿瘤攻击实验中引发保护性抗肿瘤免疫;毛兰素与抗PD-1抗体联合的治疗方案抑制肿瘤生长,并伴随树突状细胞活化增加和细胞毒性CD8+ T细胞浸润增强。这些结果界定了一条GSR相关的氧化还原-免疫轴,将谷胱甘肽代谢与免疫原性内质网应激联系起来,并为在免疫「冷」PDAC中联合毛兰素与PD-1阻断提供依据。

3消化系统肿瘤 (25篇)

临床研究 (9篇)

ESMO open IF 10.6 2026-10-30 PMID: 42962563
Off-label use of anticancer medicines is common. Investigator-initiated trials evaluating off-label indications often do not result in label expansion. Additionally, off-label use is often considered when approved treatments are lacking or exhausted. Such use may lead to uncertain efficacy and safety and poses reimbursement challenges. This study examines the Dutch framework to evaluate off-label indications for population-level reimbursement. We quantify national off-label oncology drug use and analyse its supporting evidence to identify clinical needs and support policy development. We identified reimbursable oncology indication-drug pairs (IDPs) using the World Health Organization Anatomical Therapeutic Chemical classification. Approved and off-label indications were mapped using European Medicines Agency marketing authorisations, European Society for Medical Oncology guidelines, medical literature, and the national medicines database. National 2023 health care registry data were analysed to quantify off-label prescribing and expenditure for high-cost oncology drugs. Evidence supporting selected off-label treatments was evaluated using public assessment reports and clinical guidelines. As of January 2025, 331 of 930 (35.6%) reimbursable oncology IDPs were off-label, mainly involving high-cost drugs (n = 299 of 331, 90.3%). Off-label treatments frequently involved chemotherapy, accounting for 67.1% (n = 163 of 331) of off-label IDPs. Targeted therapies comprised 32.9% (n = 109 of 331). For high-cost drugs, 24.4% (n = 41 238 of 169 043) of prescriptions were off-label in 2023, representing only 2.3% (€30.3 million of €1.3 billion) of total expenditure on these drugs. Targeted therapies posed the largest financial impact, representing 67.7% (€20.5 of €30.3 million) of off-label expenditure. The Dutch framework reimbursed off-label treatments meeting thresholds for clinical benefit. Frequently used off-label treatments were supported by strong evidence. Evidence levels varied for rarer indications. The high prevalence of off-label oncology treatments in The Netherlands underscores the importance of a framework to evaluate off-label indications for reimbursement, ensuring access to effective and financially sustainable treatments. It also highlights the need for policy reform to encourage regulatory approval.
中文摘要:抗癌药物的超说明书使用很常见。评估超说明书适应证的研究者发起试验往往未能带来药品说明书适应证的扩展。在缺乏已批准治疗或已批准治疗用尽时,常会考虑超说明书使用。此类使用可能带来疗效与安全性不确定性,并造成报销难题。本研究考察荷兰对超说明书适应证进行人群层面报销的评估框架,量化全国肿瘤药物超说明书使用情况,并分析其支持性证据,以识别临床需求并支持政策制定。我们使用世界卫生组织解剖治疗化学分类识别可报销的肿瘤适应证-药物配对(IDPs)。已批准与超说明书适应证依据欧洲药品管理局上市许可、欧洲肿瘤内科学会指南、医学文献及国家药品数据库进行映射。分析2023年全国医疗登记数据,以量化高成本肿瘤药物的超说明书处方与支出。利用公开评估报告和临床指南评价所选超说明书治疗的支持证据。截至2025年1月,930个可报销肿瘤IDPs中有331个(35.6%)为超说明书,主要涉及高成本药物(331个中的299个,90.3%)。超说明书治疗常涉及化疗,占超说明书IDPs的67.1%(331个中的163个)。靶向治疗占32.9%(331个中的109个)。对于高成本药物,2023年24.4%的处方(169043个中的41238个)为超说明书,但仅占这些药物总支出的2.3%(13亿欧元中的3030万欧元)。靶向治疗带来的财务影响最大,占超说明书支出的67.7%(3030万欧元中的2050万欧元)。荷兰框架对达到临床获益阈值的超说明书治疗予以报销。常用超说明书治疗有强证据支持。较少见适应证的证据水平存在差异。荷兰肿瘤超说明书治疗的高使用率凸显了建立评估超说明书适应证以进行报销的框架的重要性,确保患者获得有效且财务可持续的治疗。这也凸显了政策改革以鼓励监管批准的必要性。
ACS sensors IF 10.9 2026-10-30 PMID: 42961485
Early diagnosis and accurate staging are essential for improving treatment efficacy and clinical outcomes of pancreatic cancer (PC), but remain challenging because of limited early PC-specific biomarkers and high-performance detection methods. In this paper, we developed a machine learning (ML)-enhanced terahertz (THz)-colorimetric dual-mode metadevice based on metallic nanonetworks for multiplexed microRNA (miRNA) detection and early PC diagnosis. Clinical sample measurements and bioinformatics analysis identified miRNA-21, miRNA-1290, and miRNA-320a as candidate PC biomarkers. Target miRNAs triggered the assembly of DNA-functionalized Fe and Au nanoparticles (NPs) with PEI-modified CuS NPs into ternary Fe/Au/Cu nanonetworks, generating THz and colorimetric signals through their dielectric and peroxidase-like properties. This target-triggered assembly enabled three-miRNA panel analysis without enzyme-mediated nucleic acid amplification and achieved attomolar-level miRNA profiling. Six ML algorithms were integrated to develop predictive models for PC diagnosis and staging. Linear discriminant analysis (LDA) achieved diagnostic accuracies of 97.8% (95% CI: 88.2-99.9%) in the training cohort (n = 45) and 96.7% (95% CI: 82.8-99.9%) in the validation cohort (n = 30), with 100% sensitivity for early PC in both cohorts. Compared with CA19-9, CA125, and CEA, the multiplexed miRNA-based dual-mode metadevice showed higher efficacy (area under the curve, AUC: 1.00 vs 0.905), supporting its potential for clinical miRNA-based liquid biopsy.
中文摘要:胰腺癌(PC)的早期诊断和准确分期对提高疗效和改善临床结局至关重要,但早期PC特异性生物标志物有限且高性能检测方法不足,使这一目标仍具挑战。基于金属纳米网络,构建了机器学习(ML)增强的太赫兹(THz)-比色双模式超器件,用于多重microRNA(miRNA)检测和PC早期诊断。临床样本检测和生物信息学分析确定miRNA-21、miRNA-1290和miRNA-320a为候选PC生物标志物。靶标miRNA触发DNA功能化Fe和Au纳米颗粒(NPs)与PEI修饰CuS NPs组装成三元Fe/Au/Cu纳米网络,并借助其介电性质和类过氧化物酶性质产生THz与比色信号。该靶标触发组装可在无需酶介导核酸扩增的情况下实现三-miRNA组合分析,并达到attomolar级miRNA谱分析。整合六种ML算法建立PC诊断和分期预测模型。线性判别分析(LDA)在训练队列(n=45)中诊断准确率为97.8%(95% CI:88.2-99.9%),在验证队列(n=30)中为96.7%(95% CI:82.8-99.9%),两个队列中早期PC的敏感性均为100%。与CA19-9、CA125和CEA相比,基于多重miRNA的双模式超器件显示出更高效能(曲线下面积,AUC:1.00 vs 0.905),支持其用于临床miRNA液体活检的潜力。
Blood IF 23.9 2026-10-29 PMID: 42413008
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan, aggressive hematologic malignancy characterized by high CD123 expression. Tagraxofusp (TAG), a CD123-directed toxin, is the first approved therapy. Prior studies demonstrated BPDCN dependence on BCL2, sensitivity to venetoclax (VEN), and reversal of TAG resistance with azacitidine (AZA). We conducted a phase 2 study evaluating combination therapy with TAG, AZA, and VEN in patients with BPDCN. Patients with previously untreated (1L) or relapsed/refractory (R/R) BPDCN received 28-day cycles of AZA (75 mg/m2 on days 1-7), VEN (400 mg on days 1-21), and TAG (12 μg/kg on days 4-6). Eligibility followed TAG guidelines to mitigate risk of capillary leak syndrome (CLS). Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range, 21-81). Composite complete remission (composed of: complete remission [CR], CR with incomplete count recovery, and CR clinical) rates were 88% in 1L and 64% in R/R cohorts. Median duration of response was not reached in 1L and was 7.2 months in R/R patients. CLS occurred in 15% of patients, most were grade 2. In the 1L cohort, median overall survival (OS) and progression-free survival (PFS) were not reached; the 2-year OS was 65% and 2-year PFS was 53%. Median OS in R/R patients was 8.4 months. A high proportion of patients proceeded to allogeneic stem cell transplantation in remission (63% in 1L, including 10/11 patients aged ≤75 years; 55% in R/R). TAG-AZA-VEN is highly active in both 1L and relapsed BPDCN with a predictable and manageable safety profile, supporting its use as a new therapeutic option. This trial was registered at www.clinicaltrials.gov as #NCT03113643.
中文摘要:母细胞性浆细胞样树突细胞肿瘤(BPDCN)是一种罕见且侵袭性的血液系统恶性肿瘤,特征是CD123高表达。Tagraxofusp(TAG)是一种靶向CD123的毒素,也是首个获批疗法。既往研究显示BPDCN依赖BCL2,对venetoclax(VEN)敏感,azacitidine(AZA)可逆转TAG耐药。我们开展了一项2期研究,评估TAG、AZA和VEN联合治疗BPDCN患者。既往未治疗(1L)或复发/难治(R/R)BPDCN患者接受28天周期治疗:AZA 75 mg/m2第1-7天,VEN 400 mg第1-21天,TAG 12 μg/kg第4-6天。入组标准遵循TAG指南以降低毛细血管渗漏综合征(CLS)风险。共入组27例患者(16例1L,11例R/R),中位年龄70岁(范围21-81)。复合完全缓解(包括完全缓解[CR]、血细胞计数未完全恢复的CR和临床CR)率在1L队列为88%,在R/R队列为64%。1L队列中位缓解持续时间未达到,R/R患者为7.2个月。15%的患者发生CLS,多为2级。1L队列中位总生存(OS)和无进展生存(PFS)均未达到,2年OS为65%,2年PFS为53%。R/R患者中位OS为8.4个月。较高比例患者在缓解期接受异基因干细胞移植(1L为63%,包括10/11例年龄≤75岁患者;R/R为55%)。TAG-AZA-VEN在1L和复发BPDCN中均高度活跃,安全性可预测且可控,支持其作为新的治疗选择。该试验在www.clinicaltrials.gov注册,编号#NCT03113643。
Journal of hematology & oncology IF 47.8 2026-10-28 PMID: 42958334
Cancer is the second leading cause of death worldwide and disproportionately affects older adults. As population ageing accelerates, the global cancer burden among older adults continues to increase. This study systematically evaluated the latest global cancer burden and its epidemiological characteristics among older adults. Data on the incidence and mortality of 33 malignancies, excluding non-melanoma skin cancer, among adults aged 65 + were extracted from the Global Cancer Observatory (GLOBOCAN) 2024 and Global Burden of Disease Study (GBD) 2023 databases and stratified by age, sex, region, and Human Development Index (HDI). Age-standardized incidence and mortality rates (ASIR and ASMR) were calculated. Annual percentage changes (APC) were used to characterize temporal trends. Decomposition analysis was performed to quantify the contributions of population growth, population aging, and epidemiological changes. Demographic projection methods and generalized additive model (GAM) were applied to forecast the cancer burden through 2050. In 2024, there were 9,966,392 new cancer cases and 6,001,290 cancer deaths among older adults worldwide, accounting for 51.11% and 61.84%, respectively, of all-age totals. Lung, colorectal, stomach, liver, and prostate cancers were leading causes of death. Incidence and mortality were higher in men and increased with age. The Western Pacific Region had the largest burden, whereas Europe Region had the highest ASIR. ASIR correlated positively with HDI (rs = 0.771), while mortality-to-incidence ratio (MIR) correlated negatively (rs = -0.825). From 2000 to 2023, ASIR and ASMR declined, although burden increased, primarily driven by population growth; pancreatic cancer exhibited the most rapid increase. Tobacco use remained the leading risk factor for mortality, while metabolic risks rose in importance. Under a demographic scenario assuming constant 2024 age-specific rates and changes only in population size and age structure, new cancer cases and deaths among older adults are projected to reach approximately 19.8 million and 12.5 million by 2050, roughly double the 2024 figures, with the largest increase in the Eastern Mediterranean region. Cancer burden in older adults is substantial, varying by sex, age, region, and development level. Precision prevention and control are urgently needed, particularly in low- and middle-income regions. REGISTRY AND THE REGISTRATION NO. N/A.
中文摘要:癌症是全球第二大死因,对老年人的影响尤为突出。随着人口老龄化加快,全球老年人群的癌症负担持续上升。该研究系统评估了老年人群最新的全球癌症负担及其流行病学特征。研究从全球癌症观测站(GLOBOCAN)2024和全球疾病负担研究(GBD)2023数据库中提取65岁及以上成年人33种恶性肿瘤(不包括非黑色素瘤皮肤癌)的发病和死亡数据,并按年龄、性别、地区、人类发展指数(HDI)分层。计算年龄标化发病率和死亡率(ASIR和ASMR),采用年度百分比变化(APC)描述时间趋势,通过分解分析量化人口增长、人口老龄化和流行病学变化的贡献,并应用人口学预测方法和广义相加模型(GAM)预测到2050年的癌症负担。2024年,全球老年人群新发癌症病例9,966,392例,癌症死亡6,001,290例,分别占全年龄段总数的51.11%和61.84%。肺癌、结直肠癌、胃癌、肝癌和前列腺癌是主要死亡原因。男性和高龄人群的发病率和死亡率更高。西太平洋地区负担最大,欧洲地区ASIR最高。ASIR与HDI呈正相关(rs=0.771),死亡率与发病率之比(MIR)与HDI呈负相关(rs=-0.825)。2000年至2023年,ASIR和ASMR下降,但负担增加,主要由人口增长驱动;胰腺癌增长最快。烟草使用仍是死亡的首要危险因素,代谢风险的重要性上升。在假设2024年年龄别率不变、仅人口规模和年龄结构变化的人口学情景下,预计到2050年老年人群新发癌症病例和死亡将分别达到约1980万和1250万,约为2024年的两倍,东地中海地区增幅最大。老年人群癌症负担沉重,并随性别、年龄、地区和发展水平而异。迫切需要精准防控,尤其是在中低收入地区。注册信息与注册号:不适用。
ESMO open IF 10.6 2026-10-28 PMID: 42956692
Endometrial cancer with somatic POLE exonuclease domain mutations (EDMs) has a highly favorable prognosis; however, the clinical implications of non-hotspot EDMs in POLE remain unclear. In 793 patients with endometrial cancer enrolled at the National Cancer Center and Juntendo University Hospitals, 25 prespecified variants were screened using the Luminex assay. Whole-exome sequencing (WES) was carried out to evaluate 54 patients with hotspot and non-hotspot EDMs. In patients with endometrial cancer (n = 4864) registered in Genomics Evidence Neoplasia Information Exchange (GENIE), those harboring hotspot EDMs were matched with randomly sampled patients without EDMs, and a polymerase epsilon (POLE) score for gene panel testing was developed. In our cohort, POLE-EDMs, including hotspot (n = 91) and non-hotspot (n = 12) EDMs, were identified in 103 (12.9%) of 793 patients. The prevalence of grade 3 and advanced-stage endometrial cancer was higher in patients with non-hotspot EDMs than in those with hotspot EDMs. WES analysis of 54 patients revealed no significant differences in genomic mutations between the groups, and four non-hotspot EDMs were identified. A POLE-specific mutational signature was observed in tumors with EDM. In addition, the POLE score criteria were developed based on hotspot EDMs using the GENIE cohort, achieving a detection sensitivity of 0.94. Using the established POLE score, we identified nine non-hotspot EDMs. We identified 13 novel candidate non-hotspot EDMs using a newly established POLE score for gene panels and demonstrated an association between non-hotspot EDMs and favorable prognosis. The identification of additional non-hotspot EDMs will facilitate precise molecular classification of endometrial cancer.
中文摘要:伴有体细胞POLE核酸外切酶结构域突变(EDM)的子宫内膜癌预后很好,但POLE非热点EDM的临床意义仍不清楚。研究纳入美国国家癌症中心和顺天堂大学医院的793例子宫内膜癌患者,采用Luminex检测筛查25个预设变异。对54例携带热点或非热点EDM的患者进行全外显子组测序(WES)。在GENIE登记的4864例子宫内膜癌患者中,将携带热点EDM者与随机抽取的无EDM患者匹配,建立用于基因panel检测的POLE评分。在该队列793例患者中,103例(12.9%)检出POLE-EDM,包括热点EDM 91例和非热点EDM 12例。非热点EDM患者中3级和晚期子宫内膜癌的比例高于热点EDM患者。54例患者的WES分析显示,两组基因组突变无显著差异,并鉴定出4个非热点EDM。携带EDM的肿瘤中观察到POLE特异性突变特征。基于GENIE队列中热点EDM建立POLE评分标准,检测灵敏度为0.94。利用已建立的POLE评分,鉴定出9个非热点EDM。利用针对基因panel新建立的POLE评分,鉴定出13个新的候选非热点EDM,并显示非热点EDM与良好预后相关。鉴定更多非热点EDM将有助于子宫内膜癌的精准分子分型。
European journal of heart failure IF 10.3 2026-10-28 PMID: 42485618
Advanced heart failure (AdvHF) remains a major clinical challenge, yet contemporary epidemiological real-world data on AdvHF patients are limited. The aim was to assess 20-year trends in clinical characteristics, outcomes, and use of left ventricular assist devices (LVAD) and heart transplantation (HTx) in patients with AdvHF and reduced ejection fraction (AdvHFrEF) in Sweden. Between 2003 and 2022, 5323 patients (median age 76 [IQR 68-82], 23% females) included in the Swedish HF Registry met adapted ESC-HFA criteria for AdvHF (NYHA III-IV, EF <30%, ≥1 HF hospitalization ≤6 months). Of these, 29% were eligible for AdvHF therapies (median age 63 [IQR 57-67] years, 18% females) according to the following additional criteria: ≤70 years old, no dialysis within ≤5 years, no active cancer within ≤3 years.Unadjusted temporal trends in 1-year outcomes (all-cause, CV and non-CV death, HTx, and LVAD implantation) were presented as estimated annual percent change (eAPC). 1-year all-cause mortality declined significantly in the overall cohort (eAPC -3.8; 95%CI -5.3 to -2.2) as well as in patients eligible for AdvHF therapies (eAPC -3.2; 95%CI -6.3 to -0.1) over the study period. These improvements were largely driven by reductions in CV mortality (overall cohort: eAPC -4.3; 95%CI -6.0 to -2.6; eligible cohort: eAPC -5.6, 95%CI -9.4 to -1.7). Use of LVAD significantly increased over the study period, while HTx showed a modest but non-significant rise. In a large nationwide cohort, all-cause and CV-mortality among AdvHFrEF patients markedly declined over the past 20 years, potentially reflecting improvements in treatments. Despite progress, significant opportunities remain to improve access to and adoption of advanced therapies.
中文摘要:晚期心力衰竭(AdvHF)仍是重要临床挑战,但关于AdvHF患者的当代真实世界流行病学数据有限。研究旨在评估瑞典射血分数降低的晚期心力衰竭(AdvHFrEF)患者20年间临床特征、结局以及左心室辅助装置(LVAD)和心脏移植(HTx)使用的变化趋势。2003年至2022年,瑞典心衰登记中5323例患者(中位年龄76岁,IQR 68-82,女性23%)符合改良ESC-HFA的AdvHF标准(NYHA III-IV级、EF<30%、6个月内至少1次心衰住院)。其中29%符合晚期心衰治疗条件(中位年龄63岁,IQR 57-67,女性18%),额外标准为年龄≤70岁、5年内无透析、3年内无活动性癌症。1年结局(全因死亡、心血管死亡、非心血管死亡、HTx和LVAD植入)的未校正时间趋势以估计年百分比变化(eAPC)表示。研究期间,总体队列1年全因死亡率显著下降(eAPC -3.8;95%CI -5.3至-2.2),符合晚期心衰治疗条件的患者同样下降(eAPC -3.2;95%CI -6.3至-0.1)。这些改善主要来自心血管死亡下降(总体队列eAPC -4.3;95%CI -6.0至-2.6;符合条件队列eAPC -5.6;95%CI -9.4至-1.7)。LVAD使用在研究期间显著增加,HTx呈 modest 但非显著上升。在一个大型全国性队列中,AdvHFrEF患者全因死亡和心血管死亡在过去20年明显下降,可能反映治疗改善。尽管取得进展,改善晚期治疗可及性和采用仍有显著空间。
Cancer research IF 22.6 2026-10-27 PMID: 42944677
Barrett's esophagus (BE) patients require improved cancer risk stratification to identify high-risk individuals while reducing over-treatment in low-risk populations. BE evolution towards adenocarcinoma is likely driven by a combination of genomic and microenvironmental factors, suggesting the potential of predictive models that integrate both. Here, we developed BEACON (Barrett's Esophagus DNA content Abnormality and immune ecology for Cancer Outcome), a spatially aware framework integrating deep learning-based prediction of DNA content and immune architecture from routine histopathology. First, DACOR, a multi-instance learning model that predicts DNA content from histopathology, was trained using 777 BE biopsies with flow cytometry-based DNA content data scanned at two institutions, and it demonstrated strong performance across both validation and test datasets for DNA content abnormality prediction. Patients classified as DNA content abnormal by DACOR demonstrated increased cancer progression. Complementary models for cell classification and tissue segmentation enabled spatial immune ecology metric computations. Abnormal regions exhibited increased lymphoplasmacytic inflammation versus normal regions. Among patients with DNA content abnormality, cancer progressors exhibited increased plasma cell clustering adjacent to abnormal epithelium compared to non-progressors. Finally, a logistic regression model was developed that integrated molecular, immune ecological, and epithelial morphology features for cancer risk stratification. The integrated risk classification model stratified DNA content abnormal patients into high- and low-risk groups that corresponded with progression and patient survival. Overall, BEACON spatially integrates molecular abnormality with immune ecology to stratify BE patients by cancer progression risk using routine pathology images.
中文摘要:Barrett食管(BE)患者需要更完善的癌症风险分层,以识别高风险个体,同时减少低风险人群的过度治疗。BE向腺癌演变可能由基因组与微环境因素共同驱动,提示整合两者的预测模型具有潜力。我们开发了BEACON(Barrett食管DNA含量异常与免疫生态用于癌症结局),一个空间感知框架,整合基于深度学习的DNA含量预测与常规组织病理学中的免疫结构。首先,DACOR——一种从组织病理学预测DNA含量的多实例学习模型——使用来自两家机构扫描的777例BE活检及基于流式细胞术的DNA含量数据进行训练,在验证集和测试集上对DNA含量异常预测均表现出良好性能。被DACOR判定为DNA含量异常的患者癌症进展增加。用于细胞分类和组织分割的互补模型支持空间免疫生态指标的计算。异常区域较正常区域显示淋巴浆细胞性炎症增加。在DNA含量异常患者中,癌症进展者相比未进展者,在异常上皮邻近区域表现出浆细胞聚集增加。最后,开发了一个整合分子、免疫生态和上皮形态特征的逻辑回归模型,用于癌症风险分层。该整合风险分类模型将DNA含量异常患者分为高风险和低风险组,与进展和患者生存相对应。BEACON利用常规病理图像,将分子异常与免疫生态在空间上整合,从而按癌症进展风险对BE患者进行分层。
ACS nano IF 17.3 2026-10-27 PMID: 42937557
Ovarian cancer, the most lethal gynecologic malignancy, urgently demands early and accurate diagnostic methods. Tumor-derived extracellular vesicles (tEVs) hold great promise as noninvasive biomarkers, yet their clinical translation is severely hampered by inherent heterogeneity and the inability of conventional assays to detect multiple types of biomarkers. To break this bottleneck, we developed a novel one-pot, triple-encoding platform that integrates size-fluorescence-encoded beads with a membrane fusion strategy. This enables simultaneous in situ profiling of 11 miRNAs across three distinct EV subpopulations defined by EpCAM/PD-L1 expression. Leveraging machine learning, an 11-miRNA logistic panel achieved tumor versus health discrimination (AUC = 0.995), and a combinatorial signature based on EV subpopulations and miRNA profiles enabled the classification of ovarian cancer subtypes, achieving 78.6% accuracy in the validation cohort. Our work provides a versatile and scalable approach for multiparameter EV analysis, enabling comprehensive EV miRNA profiling and ovarian cancer classification.
中文摘要:卵巢癌是最致命的妇科恶性肿瘤,临床迫切需要早期、准确的诊断方法。肿瘤来源细胞外囊泡(tEVs)作为无创生物标志物具有很大潜力,但其固有异质性以及传统检测方法难以同时检测多类生物标志物,严重限制了临床转化。为突破这一瓶颈,研究建立了一种新的一锅法三重编码平台,将尺寸-荧光编码微珠与膜融合策略整合,可对由EpCAM/PD-L1表达定义的三个EV亚群中的11种miRNA进行同步原位分析。借助机器学习,基于11种miRNA的逻辑回归组合实现了肿瘤与健康样本的区分,AUC为0.995;基于EV亚群和miRNA谱的组合特征标签可对卵巢癌亚型进行分类,在验证队列中准确率为78.6%。该工作为多参数EV分析提供了通用且可扩展的方法,可实现全面的EV miRNA谱分析和卵巢癌分类。
Clinical and molecular hepatology IF 21.7 2026-10-27 PMID: 42935235
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a novel class of anti-diabetic drugs that can treat obesity and type 2 diabetes (T2D). T2D and chronic viral hepatitis (CVH) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the effect of GLP-1RA on liver and non-liver complications among patients with T2D and CVH in the United States. Patients with T2D and CVH initiating GLP-1RA were included (2013-2022) in Merative™ Marketscan® Research Databases. Primary outcomes included (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Cox proportional hazards models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI). A total of 9,499 patients with T2D and CVH were included after 1:4 propensity score matching. Compared with non-GLP-1RA (N=7,366), GLP-1RA use (N=2,133) was associated with significantly lower risks of any liver-related outcomes (HR 0.71, 95% CI 0.57-0.87; P=0.001), HCC (HR 0.53, 95% CI 0.31-0.93; P=0.028), cirrhosis (HR 0.70, 95% CI 0.56-0.86; P<0.001), CKD (HR 0.67, 95% CI 0.53-0.84; P<0.001). A trend toward a lower risk of CVD (HR 0.82, 95% CI 0.66-1.03; P=0.089) and non-liver cancer (HR 0.73, 95% CI 0.53-1.01; P=0.055) was observed among GLP-1RA users, although the association did not reach statistical significance. GLP-1RA use was associated with lower risks of cirrhosis, HCC, and CKD among patients with T2D and CVH, with nonsignificant trends toward lower risks of CVD and non-liver cancer.
中文摘要:胰高血糖素样肽-1受体激动剂(GLP-1RA)是一类新型抗糖尿病药物,可治疗肥胖和2型糖尿病(T2D)。T2D与慢性病毒性肝炎(CVH)常共存,并加重肝脏及非肝脏结局,但有效药物治疗有限。我们旨在评估美国T2D合并CVH患者中GLP-1RA对肝脏和非肝脏并发症的影响。纳入2013—2022年Merative™ Marketscan® Research Databases中起始GLP-1RA治疗的T2D合并CVH患者。主要结局包括(1)肝细胞癌(HCC)和肝硬化,(2)心血管疾病(CVD)、慢性肾病(CKD)和非肝脏癌症。采用Cox比例风险模型估计风险比(HR)和95%置信区间(CI)。经1:4倾向评分匹配后共纳入9,499例T2D合并CVH患者。与非GLP-1RA组(N=7,366)相比,GLP-1RA使用组(N=2,133)与任何肝脏相关结局风险显著降低相关(HR 0.71,95% CI 0.57-0.87;P=0.001)、HCC(HR 0.53,95% CI 0.31-0.93;P=0.028)、肝硬化(HR 0.70,95% CI 0.56-0.86;P<0.001)、CKD(HR 0.67,95% CI 0.53-0.84;P<0.001)。GLP-1RA使用者中观察到CVD(HR 0.82,95% CI 0.66-1.03;P=0.089)和非肝脏癌症(HR 0.73,95% CI 0.53-1.01;P=0.055)风险降低趋势,但未达到统计学显著性。GLP-1RA使用与T2D合并CVH患者肝硬化、HCC和CKD风险降低相关,CVD和非肝脏癌症风险呈非显著降低趋势。

基础研究 (16篇)

Nature cancer IF 28.0 2026-10-30 PMID: 42963427
Vγ9Vδ2 T cells mediate HLA-independent targeting of tumor cells, offering unique opportunities for cancer immunotherapy, yet their therapeutic efficacy remains limited. Here, using a genome-wide CRISPR screen, we identify UDP-galactose 4-epimerase (GALE) as a tumor-intrinsic checkpoint that restricts Vγ9Vδ2 T cell-mediated killing. GALE is a key nucleotide-sugar metabolic enzyme that controls the interconversion of UDP-galactose and UDP-glucose, thereby supporting protein glycosylation and cell-surface glycan remodeling. Mechanistically, GALE promotes complex N-glycosylation of CD155 and CEACAM1, favoring their engagement with the inhibitory receptors TIGIT and TIM3, respectively, while limiting CD155 binding to the activating receptor CD226. GALE loss potentiates Vγ9Vδ2 T cell-mediated tumor killing in multiple mouse models and colorectal cancer patient-derived organoids. Together, these findings reveal how nucleotide-sugar metabolism shapes tumor-immune communication through complex N-glycan remodeling and identify GALE and its downstream receptor-ligand interactions as potential therapeutic targets for enhancing Vγ9Vδ2 T cell antitumor activity.
中文摘要:Vγ9Vδ2 T细胞能以不依赖HLA的方式靶向肿瘤细胞,为肿瘤免疫治疗提供了独特机会,但其疗效仍然有限。通过全基因组CRISPR筛选,我们发现UDP-半乳糖4-差向异构酶(GALE)是限制Vγ9Vδ2 T细胞杀伤作用的肿瘤内在检查点。GALE是控制UDP-半乳糖与UDP-葡萄糖互变的关键核苷酸-糖代谢酶,由此支持蛋白糖基化与细胞表面聚糖重塑。机制上,GALE促进CD155与CEACAM1的复杂N-糖基化,利于它们分别与抑制性受体TIGIT和TIM3结合,同时减少CD155与激活性受体CD226的结合。GALE缺失在多种小鼠模型和结直肠癌患者来源类器官中增强了Vγ9Vδ2 T细胞对肿瘤的杀伤。这些结果揭示了核苷酸-糖代谢如何通过复杂N-聚糖重塑塑造肿瘤与免疫的交流,并将GALE及其下游受体-配体相互作用确定为增强Vγ9Vδ2 T细胞抗肿瘤活性的潜在治疗靶点。
Nature cancer IF 28.0 2026-10-30 PMID: 42963426
In pancreatic ductal adenocarcinoma (PDAC), the fibroblastic stroma constitutes most of the tumor mass and is remarkably devoid of functional blood vessels, leaving unresolved how PDAC cells obtain essential metabolites and water-insoluble lipids. We find that cancer-associated fibroblasts (CAFs) acquire and transfer lipids from blood-borne particles to PDAC cells through trogocytosis of CAF plasma membranes, a process requiring the CAF-expressed phospholipid scramblase anoctamin 6 (ANO6) to promote PDAC cell survival. Cancer cells and CAFs form synapse-like contacts that induce cytosolic calcium influx in CAFs through Orai channels, activating ANO6 and driving phosphatidylserine exposure on CAF membranes, which initiates trogocytosis and transfer of membrane lipids, including cholesterol, to PDAC cells. This ANO6-dependent phosphatidylserine externalization also supports CAF-mediated immunosuppression of cytotoxic T cells through trogocytosis. Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.
中文摘要:在胰腺导管腺癌(PDAC)中,纤维母细胞性间质构成肿瘤主体的大部分,且显著缺乏功能性血管,PDAC细胞如何获得必需代谢物和水不溶性脂质一直未明。研究发现,癌相关纤维母细胞(CAF)通过胞啃作用(trogocytosis)从血液来源颗粒获取脂质并转移给PDAC细胞,该过程需要CAF表达的磷脂爬行酶anoctamin 6(ANO6)来促进PDAC细胞存活。癌细胞与CAF形成突触样接触,经Orai通道诱导CAF胞质钙内流,激活ANO6并驱动CAF膜上磷脂酰丝氨酸外翻,从而启动胞啃作用并将包括胆固醇在内的膜脂转移至PDAC细胞。这种依赖ANO6的磷脂酰丝氨酸外翻还通过胞啃作用支持CAF介导的对细胞毒性T细胞的免疫抑制。阻断ANO6可拮抗肿瘤生长,部分通过破坏向癌细胞的胆固醇递送实现,并减弱免疫抑制,提示ANO6是PDAC的候选治疗靶点。
Advanced healthcare materials IF 11.0 2026-10-29 PMID: 42958452
Nanovaccines have been engineered to co-deliver antigens and adjuvants for robust immune responses. While extensive studies have examined the effect of nanovaccine size, shape, surface charge, and targeting on vaccine efficacy, the impact of antigen density remains underexplored. Here, we systematically optimize the anti-tumor CD8+ T cell response by modulating the antigen density on an M13 phage-based nanovaccine. By fine-tuning the antigen ratio from ∼6.0% to ∼70.4% on the phage capsid, the anti-tumor CD8+ T cell response was enhanced. Further investigation demonstrated that the antigen density affected not only antigen presentation efficacy but also dendritic cell uptake. Applying this strategy to a neoantigen in the MC-38 colorectal cancer model, we achieved up to a ∼7-fold increase in the neoantigen-specific CD8+ T cell frequency, resulting in significant tumor suppression. These findings underscore the critical role of antigen density in nanovaccine design and establish M13 bacteriophage as a universal platform for personalized cancer vaccine applications.
中文摘要:纳米疫苗已被设计用于共递送抗原和佐剂,以诱导强免疫应答。尽管大量研究考察了纳米疫苗尺寸、形状、表面电荷和靶向对疫苗效力的影响,抗原密度的影响仍研究不足。本研究通过调节基于M13噬菌体的纳米疫苗上的抗原密度,系统优化抗肿瘤CD8+ T细胞应答。将噬菌体衣壳上的抗原比例从约6.0%精细调整至约70.4%后,抗肿瘤CD8+ T细胞应答增强。进一步研究表明,抗原密度不仅影响抗原呈递效率,也影响树突状细胞摄取。将该策略应用于MC-38结直肠癌模型中的新抗原,新抗原特异性CD8+ T细胞频率最高增加约7倍,并带来显著肿瘤抑制。这些发现强调抗原密度在纳米疫苗设计中的关键作用,并确立M13噬菌体作为个性化癌症疫苗应用的通用平台。
Nature medicine IF 52.5 2026-10-29 PMID: 42957776
The incidence of early-onset colorectal cancer (EO-CRC; diagnosed before age 50 years) is increasing worldwide. Although current data indicate that EO-CRC may be biologically distinct from average-onset CRC (AO-CRC; diagnosed at age ≥50 years), molecular differences remain poorly defined. To address this knowledge gap, we generated a single-nucleus RNA sequencing (snRNA-seq) atlas from 189 primary CRC tumors (54 EO-CRC, 135 AO-CRC) spanning eight decades of life, with at least 20 tumors in most age decades. Our analyses stratified tumors by microsatellite status and accounted for tumor sidedness, stage, patient sex and neoadjuvant treatment history, modeling age continuously or categorically (EO-CRC versus AO-CRC). Among microsatellite-stable (MSS) tumors, those from younger patients were characterized by increased stromal and decreased epithelial proportions, which we confirmed using multispectral immunofluorescence and machine learning in an external cohort of 712 MSS CRC tumors (18 EO-CRC, 694 AO-CRC). Tumor epithelial cells from young patients exhibited increased expression of long noncoding RNAs and FN1, with a trend toward increased heterogeneity in copy number alterations. MSS left-sided EO-CRC tumors had more cell-cell interactions, with epithelial-to-mesenchymal transition-related signaling pathways (FN1/GDF/ACTIVIN) showing increased, cell type-specific interactions. Our large high-resolution snRNA-seq atlas uncovers age-associated features of CRC and provides a resource for the community to understand EO-CRC biology.
中文摘要:早发性结直肠癌(EO-CRC,50岁前诊断)的发病率在全球上升。现有数据提示EO-CRC在生物学上可能不同于平均发病年龄结直肠癌(AO-CRC,≥50岁诊断),但分子差异仍不明确。为填补这一空白,我们构建了覆盖人生八个十年的189例原发性结直肠癌肿瘤的单核RNA测序图谱(54例EO-CRC,135例AO-CRC),多数年龄十年段至少纳入20例肿瘤。分析按微卫星状态分层,并考虑肿瘤侧别、分期、患者性别和新辅助治疗史,将年龄作为连续变量或分类变量(EO-CRC对AO-CRC)建模。在微卫星稳定(MSS)肿瘤中,年轻患者肿瘤表现为基质比例增加、上皮比例降低,我们在外部712例MSS结直肠癌肿瘤队列(18例EO-CRC,694例AO-CRC)中用多光谱免疫荧光和机器学习证实了这一点。年轻患者肿瘤上皮细胞的长链非编码RNA和FN1表达升高,拷贝数改变异质性呈增加趋势。MSS左侧EO-CRC肿瘤的细胞间相互作用更多,上皮-间质转化相关信号通路(FN1/GDF/ACTIVIN)表现出增加的细胞类型特异性相互作用。这一大规模高分辨率snRNA-seq图谱揭示了结直肠癌的年龄相关特征,并为社区理解EO-CRC生物学提供资源。
Trends in cancer IF 21.6 2026-10-29 PMID: 42957524
The rising incidence of early-onset colorectal cancer (EOCRC) challenges existing paradigms of tumorigenesis. Classical models based on cumulative mutational burden, environmental exposure, and hereditary predisposition fail to explain the emergence of malignancy in individuals under 50 years of age. In this review, we propose that EOCRC may be driven by accelerated biological aging and review how core aging processes are prematurely activated in EOCRC. Importantly, these alterations extend beyond the tumor microenvironment and are present in circulating immune cells and inflammatory mediators. We propose that EOCRC develops prematurely in response to environmental, metabolic, genetic, and related factors that systemically accelerate biological aging. This approach reconciles the origin of EOCRC with traditional models of tumorigenesis, while highlighting novel opportunities for early detection, risk stratification, and therapeutic intervention.
中文摘要:早发性结直肠癌(EOCRC)发病率上升,正在挑战现有的肿瘤发生范式。基于累积突变负荷、环境暴露和遗传易感的经典模型,无法解释50岁以下个体中恶性肿瘤的出现。这篇综述提出,EOCRC可能由加速的生物学衰老驱动,并回顾核心衰老过程如何在EOCRC中提前激活。这些改变并不局限于肿瘤微环境,也存在于循环免疫细胞和炎症介质中。我们提出,环境、代谢、遗传及相关因素系统性加速生物学衰老,EOCRC在此背景下提前发生。这一思路将EOCRC的起源与传统肿瘤发生模型协调起来,同时提示早期检测、风险分层和治疗干预的新机会。
Cancer cell IF 56.1 2026-10-29 PMID: 42956743
KRASG12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRASG12D-targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRASG12D-mutant subset intrinsically resistant to KRASG12D-targeted therapeutics, characterized by marked downregulation of innate immune signaling pathways. Functional validation demonstrates that suppressing interferon signaling in sensitive models induces resistance, whereas activation of interferon signaling, particularly interferon beta (IFN-β), increases sensitivity in resistant models. Combining IFN-β with KRAS inhibitors (MRTX1133, HRS-4642, and RMC-6236) exhibits synergistic antitumor effects in intrinsically resistant pancreatic cancer. Mechanistically, sustained MYC activity is associated with attenuated sensitivity to KRAS inhibition and correlates with repressed interferon signaling, suggesting a potential role in promoting intrinsic resistance. These findings identify interferon signaling as a candidate determinant of KRAS-targeted therapy response and support interferon-based combinations as a potential strategy for intrinsically resistant pancreatic cancer.
中文摘要:KRASG12D是胰腺癌的主要驱动因素,但KRASG12D靶向治疗原发耐药的机制基础仍不明确。对242例患者来源类器官(PDO)及配对肿瘤组织进行基因组学、转录组学和蛋白质组学整合分析,发现一个KRASG12D突变亚群对KRASG12D靶向药物存在内在耐药,其特征是先天免疫信号通路显著下调。功能验证显示,在敏感模型中抑制干扰素信号可诱导耐药,而在耐药模型中激活干扰素信号,尤其是干扰素β(IFN-β),可提高敏感性。将IFN-β与KRAS抑制剂(MRTX1133、HRS-4642和RMC-6236)联合,在内在耐药的胰腺癌中表现出协同抗肿瘤效应。机制上,持续的MYC活性与KRAS抑制敏感性降低相关,并与干扰素信号受抑相关,提示其可能在促进内在耐药中发挥作用。这些发现将干扰素信号确定为KRAS靶向治疗反应的候选决定因素,并支持基于干扰素的联合方案作为内在耐药胰腺癌的潜在策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42660487
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with a poor prognosis, highlighting the urgent need for novel diagnostic and therapeutic targets. In this study, through integrated proteomic profiling, we identify AP4M1 as a potential therapeutic vulnerability for HCC and characterize its upstream regulatory and downstream effector mechanisms. We show that AP4M1 is markedly upregulated in HCC, correlates with unfavorable prognosis, and is functionally involved in driving HCC progression. Mechanistically, the deubiquitinase USP15 stabilizes AP4M1 by removing K11- and K48-linked polyubiquitin chains at lysine 163 (K163). Additionally, MINK1-mediated phosphorylation of AP4M1 at threonine 69 (T69) is critical for its interaction with GPX4. Through upregulating GPX4, AP4M1 reduces intracellular lipid peroxidation, thereby suppressing ferroptosis and facilitating HCC tumorigenesis and progression. Importantly, combined treatment with the USP15 inhibitor USP15-IN-1 and the GPX4 inhibitor RSL3 exhibits potent anti-tumor efficacy in both in vitro and in vivo models, underscoring the therapeutic potential of targeting the AP4M1 axis in HCC. Collectively, this study delineates the USP15/AP4M1/MINK1/GPX4 axis as a previously unrecognized ferroptosis-suppressive pathway that promotes HCC progression, providing a critical theoretical basis for AP4M1-targeted therapeutic strategies in HCC.
中文摘要:肝细胞癌(HCC)侵袭性强、预后差,亟需新的诊断与治疗靶点。本研究通过整合蛋白质组学分析,将AP4M1鉴定为HCC的潜在治疗脆弱点,并阐明其上游调控机制与下游效应机制。结果显示,AP4M1在HCC中显著上调,与不良预后相关,并在功能上参与驱动HCC进展。机制上,去泛素化酶USP15通过去除AP4M1赖氨酸163位点(K163)的K11型和K48型多聚泛素链使其稳定性增强;MINK1介导的AP4M1苏氨酸69位点(T69)磷酸化对其与GPX4的相互作用至关重要。AP4M1通过上调GPX4降低细胞内脂质过氧化水平,从而抑制铁死亡,促进HCC的发生与进展。USP15抑制剂USP15-IN-1与GPX4抑制剂RSL3联合处理在体外与体内模型中均表现出强效抗肿瘤作用,提示靶向AP4M1轴在HCC治疗中具有潜力。本研究将USP15/AP4M1/MINK1/GPX4轴界定为一条此前未被认识的、促进HCC进展的铁死亡抑制通路,为HCC中靶向AP4M1的治疗策略提供了关键理论依据。
Cancer letters IF 11.8 2026-10-28 PMID: 42632514
Pancreatic ductal adenocarcinoma (PDAC) is often burdened by cachexia, a metabolic disorder characterized by extensive and severe adipose tissue wasting and muscle atrophy that shortens life expectancy. While adipose depletion frequently coincides with myopathy, the precise molecular mediators by which remodeled adipocytes drive muscle atrophy remain largely undefined. Here, we delineated a pathogenic 'feed-forward' axis wherein tumor-derived inflammatory stimuli (IL-6/TNF-α) drove adipocytes to secrete extracellular vesicles (EVs) enriched with miR-221-3p. Genetic tracing confirmed that these EVs circulated systemically and were actively taken up by skeletal muscle. At the molecular level, EV-delivered miR-221-3p repressed IRS1, leading to the collapse of the PI3K-AKT survival cascade. Consequently, this inhibition triggered severe metabolic dysregulation by coupling impaired GLUT4-dependent glucose transport with heightened ubiquitin-proteasome activity, ultimately culminating in muscle atrophy. Silencing miR-221-3p via AAV-sponges or antagomirs conferred significant protection against muscle wasting and functional decline in cachectic mice. Importantly, high levels of circulating EV-miR-221-3p not only marked the presence of cachexia but were also significantly associated with reduced overall survival in PDAC patients. Collectively, our findings uncover a pathogenic adipose-to-muscle axis mediated by EV-miR-221-3p, offering a novel therapeutic target and a promising non-invasive biomarker for PDAC-associated cachexia.
中文摘要:胰腺导管腺癌(PDAC)常伴发恶病质,这是一种以广泛而严重的脂肪组织消耗和肌肉萎缩为特征的代谢紊乱,会缩短预期寿命。脂肪耗竭常与肌病同时出现,但重塑脂肪细胞驱动肌肉萎缩的确切分子介导因素仍大多不明确。研究描绘了一条致病性「前馈」轴:肿瘤来源的炎症刺激(IL-6/TNF-α)促使脂肪细胞分泌富含miR-221-3p的细胞外囊泡(EV)。遗传示踪证实这些EV进入体循环并被骨骼肌主动摄取。在分子层面,EV递送的miR-221-3p抑制IRS1,导致PI3K-AKT生存级联崩溃。由此,这一抑制作用将受损的GLUT4依赖葡萄糖转运与增强的泛素-蛋白酶体活性耦联,引发严重代谢失调,最终导致肌肉萎缩。通过AAV海绵或antagomir沉默miR-221-3p,可显著保护恶病质小鼠免受肌肉消耗和功能下降。循环EV-miR-221-3p水平升高不仅提示恶病质的存在,还与PDAC患者总生存期缩短显著相关。这些发现揭示了一条由EV-miR-221-3p介导的致病性脂肪至肌肉轴,为PDAC相关恶病质提供了新的治疗靶点和有前景的无创生物标志物。
Cancer letters IF 11.8 2026-10-28 PMID: 42498073
Gallbladder carcinoma (GBC) is a highly aggressive malignancy characterized by an extremely poor prognosis and limited therapeutic options. N6-methyladenosine (m6A), the most prevalent post-transcriptional modification in eukaryotic mRNA, plays a pivotal role in regulating tumor progression. Screening of an siRNA library targeting YTH-domain family reader proteins identified YTH domain-containing family protein 2 (YTHDF2) as essential for the malignant phenotype of GBC cells. YTHDF2 was aberrantly upregulated in GBC tissues and served as an independent predictor of poor prognosis. Genetic silencing of YTHDF2 markedly suppressed both proliferation and metastatic potential of GBC cells in vitro and in vivo. Mechanistically, YTHDF2 transcription is upregulated through P300 histone acetyltransferase-mediated H3K27ac modification. YTHDF2 promotes mRNA degradation by binding to m6A-modified sites within the transcript encoding the metastasis suppressor non-metastatic protein 1 (NME1), thereby repressing NME1 expression and accelerating GBC malignancy. Co-treatment with the P300 inhibitor C646 and the m6A modification inhibitor STM2457 synergistically inhibited YTHDF2-mediated GBC malignancy. Collectively, these findings establish the P300-YTHDF2-m6A-NME1 axis as a critical driver of GBC progression and indicate that combined C646 and STM2457 treatment represents a novel and promising therapeutic strategy for GBC.
中文摘要:胆囊癌(GBC)是一种侵袭性很强的恶性肿瘤,预后极差,治疗选择有限。N6-甲基腺苷(m6A)是真核mRNA中最常见的转录后修饰,在调控肿瘤进展中起关键作用。通过筛选靶向YTH结构域家族阅读蛋白的siRNA文库,发现含YTH结构域家族蛋白2(YTHDF2)对GBC细胞的恶性表型必不可少。YTHDF2在GBC组织中异常上调,并可作为不良预后的独立预测因素。基因沉默YTHDF2在体外和体内均明显抑制GBC细胞的增殖和转移潜能。机制上,YTHDF2的转录受P300组蛋白乙酰转移酶介导的H3K27ac修饰上调。YTHDF2结合编码转移抑制因子非转移蛋白1(NME1)的转录本内m6A修饰位点,促进该mRNA降解,从而抑制NME1表达并加速GBC恶性进展。P300抑制剂C646与m6A修饰抑制剂STM2457联合处理可协同抑制YTHDF2介导的GBC恶性表型。这些发现确立P300-YTHDF2-m6A-NME1轴是GBC进展的重要驱动因素,并提示C646与STM2457联合治疗是GBC的一种有前景的新型治疗策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42379262
Biliary tract cancers (BTCs) comprise biologically heterogeneous subtypes with limited therapeutic options and variable responses to sorafenib. The biological basis underlying this variability remains unclear. In this study, we compared intrahepatic cholangiocarcinoma (iCCA) and gallbladder cancer (GBC) models under defined sorafenib exposure conditions using transcriptomic profiling, Seahorse-based mitochondrial stress assays, pharmacologic combination analysis, and patient-derived organoid models. In representative iCCA models, 1.25 μM sorafenib increased mitochondrial respiration and ATP production, whereas 10 μM sorafenib suppressed this respiratory adaptation. In contrast, representative GBC models exhibited persistent suppression of mitochondrial respiratory function across the tested conditions and did not display a comparable concentration-dependent shift. Integrated transcriptomic and pharmacologic analyses further identified mitochondrial Complex I as a treatment-relevant vulnerability under sorafenib exposure, with stronger combination interactions observed in iCCA models. These findings indicate that iCCA and GBC differ in their metabolic responses to sorafenib and highlight subtype-specific differences in mitochondrial adaptation under treatment stress.
中文摘要:胆道癌(BTCs)包含生物学上异质性的多个亚型,治疗选择有限,对索拉非尼的反应差异较大,这种差异背后的生物学基础尚不清楚。本研究在设定的索拉非尼暴露条件下,用转录组分析、基于Seahorse的线粒体应激实验、药物联合作用分析以及患者来源类器官模型,比较了肝内胆管癌(iCCA)与胆囊癌(GBC)模型。在代表性iCCA模型中,1.25 μM索拉非尼增强线粒体呼吸与ATP生成,10 μM索拉非尼则抑制这种呼吸适应;代表性GBC模型在所测试条件下表现为线粒体呼吸功能持续受抑,未出现相似的浓度依赖性转变。整合转录组与药理学分析进一步显示,线粒体复合物I是索拉非尼暴露下具有治疗意义的脆弱点,iCCA模型中的联合作用更强。这些结果说明iCCA与GBC对索拉非尼的代谢反应不同,并提示治疗应激下线粒体适应存在亚型特异性差异。
Biomaterials IF 13.6 2026-10-27 PMID: 42950773
Photodynamic therapy (PDT) is limited by the shallow tissue penetration of visible-light excitation and the hypoxic tumor microenvironment, while effective photothermal therapy (PTT) and PDT/PTT synergistic therapy remain difficult to achieve under clinically approved laser power. Here, we report a progressive donor-acceptor (D-A) intensification strategy that, counterintuitively, reveals a critical excited-state phase transition from a charge-transfer (CT)-dominated regime to a balanced localized-excitation (LE)/CT hybrid. At this tipping point, the inherent orthogonality between radiative decay, intersystem crossing, and thermal dissipation is synergistically breached. This process concurrently unlocks NIR-II emission, oxygen-independent Type-I photodynamic activity, and an exceptional photothermal conversion efficiency of 87.4%. Such tri-functional synergy is conspicuously absent in conventional D-A systems with either weak or excessive D-A interactions. Quantitative structure-property relationship analysis establishes the LE/CT composition ratio as a predictive descriptor for triplet-state reactivity, enabling rational rather than trial and error optimization. Guided by this paradigm, the optimal photosensitizer achieves potent antitumor efficacy under mild 808 nm irradiation (0.33 W/cm2), effectively decoupling therapeutic potency from reliance on high-intensity laser exposure. This work thus shifts phototheranostic design from discrete molecular screening to excited-state composition engineering, offering a conceptually transformative roadmap for safe and efficient NIR-II phototheranostics.
中文摘要:光动力治疗受可见光激发组织穿透较浅和肿瘤低氧微环境限制,而在临床批准激光功率下实现有效光热治疗及光动力/光热协同治疗仍较困难。本研究提出逐步增强供体-受体相互作用的策略,意外揭示了从电荷转移主导到局域激发/电荷转移平衡杂化的关键激发态相变。在这一临界点,辐射衰减、系间窜越和热耗散之间固有的正交关系被协同打破,同时解锁近红外二区发光、不依赖氧的I型光动力活性和87.4%的突出光热转换效率。这种三功能协同在供体-受体作用过弱或过强的传统体系中明显缺失。定量构效关系分析将局域激发/电荷转移组成比例确立为三重态反应性的预测描述符,使优化从试错转向理性设计。基于该范式,最优光敏剂在温和的808 nm照射(0.33 W/cm2)下取得较强抗肿瘤效果,使治疗效力不再依赖高强度激光暴露。该工作将光诊疗设计从离散分子筛选推进到激发态组成工程,为安全高效的近红外二区光诊疗提供了具有概念变革意义的路线。
Clinical and molecular hepatology IF 21.7 2026-10-27 PMID: 42935236
Hepatocellular carcinoma (HCC) is characterized by an immunosuppressive tumor microenvironment. Here, we aimed to elucidate the tumor cell-intrinsic functions of ubiquitin-specific protease 22 (USP22) in the immune escape of HCC cells. Autochthonous mouse models of HCC with either genetic Usp22 loss or Trp53 knockdown were used. In vitro and in vivo phagocytosis assays were performed to evaluate the interactions between HCC cells and macrophages. Multicolor fluorescence, spatial transcriptomics, immunoprecipitation and ubiquitination assays were used to explore the potential underlying mechanisms. We observed that tumor cell-intrinsic USP22 inhibits the infiltration and anticancer function of tumoricidal macrophages in HCC. USP22 expression in HCC cells blocks their direct phagocytosis by tumoricidal macrophages. Mechanistically, CD24 (a known phagocytosis checkpoint) mediates USP22-induced suppression of phagocytosis. USP22 promotes the transcriptional expression of CD24 by deubiquitinating and stabilizing the transcription factor E2F7. Furthermore, wild-type p53 downregulates USP22 protein expression, whereas TP53 inactivation markedly upregulates USP22 protein expression. The USP22-E2F7-CD24 axis is responsible for mediating TP53-inactivation-induced phagocytic evasion and hepatocarcinogenesis. Mechanistically, USP22 proteins bind to one another and suppress ubiquitination at the K442 residue. The wild-type p53 protein disrupts this mutual deubiquitination, thereby facilitating USP22 degradation. Moreover, TNF secreted by tumoricidal macrophages promotes USP22 degradation by disrupting its self-stabilizing mechanism in a wild-type p53-dependent manner. Our findings indicate that USP22-E2F7-CD24 axis-mediated phagocytic evasion promotes immune escape in TP53-inactivated HCC.
中文摘要:肝细胞癌(HCC)具有免疫抑制性肿瘤微环境。旨在阐明泛素特异性蛋白酶22(USP22)在HCC细胞免疫逃逸中的肿瘤细胞内在功能。使用Usp22基因缺失或Trp53敲低的原位HCC小鼠模型。采用体外和体内吞噬实验评估HCC细胞与巨噬细胞的相互作用。运用多色荧光、空间转录组学、免疫沉淀和泛素化实验探讨潜在机制。观察到肿瘤细胞内在的USP22抑制HCC中杀肿瘤巨噬细胞的浸润和抗癌功能。HCC细胞中USP22表达阻断杀肿瘤巨噬细胞对其的直接吞噬。机制上,CD24(已知的吞噬检查点)介导USP22诱导的吞噬抑制。USP22通过去泛素化并稳定转录因子E2F7促进CD24的转录表达。野生型p53下调USP22蛋白表达,而TP53失活显著上调USP22蛋白表达。USP22-E2F7-CD24轴介导TP53失活诱导的吞噬逃逸和肝癌发生。机制上,USP22蛋白相互结合并抑制K442位点的泛素化。野生型p53蛋白破坏这种相互去泛素化,从而促进USP22降解。杀肿瘤巨噬细胞分泌的TNF以野生型p53依赖的方式破坏USP22的自稳定机制,促进其降解。研究结果表明,USP22-E2F7-CD24轴介导的吞噬逃逸促进TP53失活HCC的免疫逃逸。
Advanced healthcare materials IF 11.0 2026-10-26 PMID: 42935085
Lipid nanoparticle (LNP)-enabled genetic medicines are reshaping cancer therapy yet remain constrained by liver-biased tropism, dose-limiting toxicities, and limited efficacy in refractory solid tumors such as pancreatic ductal adenocarcinoma (PDAC). Here, exosome-inspired proteolipid nanoparticles (Em-pLNPs) are developed to embed three exosomal membrane proteins within an ionizable lipid matrix to support safe, extrahepatic delivery of combinatorial gene-chemo payloads. Em-pLNPs are generated by one-step microfluidic mixing to incorporate the tetraspanins CD63 and CD81 and the "don't-eat-me" marker CD47 into the lipid shell, co-encapsulate diverse nucleic acid and small-molecule cargos, and enable modular CD44-targeted surface functionalization. Following systemic administration in orthotopic PDAC models, Em-pLNPs exhibit prolonged circulation, preferential extrahepatic tumor accumulation, deep penetration of desmoplastic stroma, and efficient cytosolic delivery, while markedly improving tissue tolerability relative to ligand-decorated clinical LNP benchmarks. Formulated with an RNAi-chemo cocktail (siKRAS, siIL-6, and gemcitabine), Em-pLNPs permit repeated intravenous dosing that drives robust, synergistic tumor regression and mitigates chemoresistance. By coupling exosome-like immune evasion and tissue tropism with the manufacturability and high gene-loading capacity of LNPs, Em-pLNPs define a translational proteolipid platform for safe extrahepatic gene therapy against refractory solid tumors.
中文摘要:脂质纳米颗粒(LNP)赋能的基因药物正在重塑肿瘤治疗,但仍受限于肝偏向性趋向、剂量限制性毒性,以及在胰腺导管腺癌(PDAC)等难治性实体瘤中的疗效有限。受外泌体启发的蛋白脂质纳米颗粒(Em-pLNPs)可将三种外泌体膜蛋白嵌入可电离脂质基质,以支持基因-化疗组合载荷的安全肝外递送。Em-pLNPs通过一步微流控混合制备,将四跨膜蛋白CD63和CD81以及「别吃我」标记CD47嵌入脂质壳层,共同包载多种核酸和小分子载荷,并实现模块化的CD44靶向表面功能化。在原位PDAC模型全身给药后,Em-pLNPs表现出延长循环、优先在肝外肿瘤蓄积、深入穿透促结缔组织增生性间质和高效胞质递送,同时相对配体修饰的临床LNP基准显著改善组织耐受性。以RNAi-化疗鸡尾酒(siKRAS、siIL-6和吉西他滨)配制后,Em-pLNPs支持重复静脉给药,驱动强效协同的肿瘤消退并减轻化疗耐药。通过将类外泌体的免疫逃逸和组织趋向性与LNP的可制造性和高基因装载能力结合,Em-pLNPs构成一个用于难治性实体瘤安全肝外基因治疗的转化型蛋白脂质平台。
Experimental hematology & oncology IF 17.5 2026-10-26 PMID: 42934735
Patient-derived tumor organoids (PDTOs) are strongly influenced by culture medium. We compared OncoPro™ (OP) Tumoroid Culture medium with conventional Wnt/R-spondin/noggin (Wnt) medium. This recently developed OP medium offers a standardized, serum-free alternative to Wnt-based formulations. We compared OP and Wnt media across 36 PDTO lines from various malignancies (colorectal, pancreatic, breast, lung, gastric, gastroesophageal junction, biliary head and neck and unknown primary), assessing establishment success. Selected PDTO models were subjected to downstream characterization, including morphological assessment and bulk transcriptomic profiling with comparison to public single-cell RNA sequencing reference datasets (n = 11), whole-exome sequencing (WES) (n = 9), and pharmacological response profiling to a 33-drug panel (n = 3). Adaptation from Wnt medium to OP succeeded in 83.3% (15/18), whereas de novo establishment favored Wnt (33.3% vs 11.1%). Key oncogenic driver alterations were retained across matched organoid cultures, supporting preservation of tumor-relevant genomic features. Transcriptomic profiling confirmed preserved tumor-identity across media, while revealing different epithelial state programs: Wnt upregulated proliferation/stemness-associated genes (e.g. LGR5) and OP enriched adhesion-associated genes and inflammatory/TGF-β programs. In scRNA databases OP signatures preferentially mapped to malignant epithelial compartments in pancreatic cancer, whereas Wnt signatures were linked to non-malignant epithelium. Similarly, in colon cancer OP signature mapped predominantly to the malignant epithelial compartments. Drug (n = 33) screening in pancreatic- and colorectal cancer PDTOs (n = 3) demonstrated consistent medium-dependent shifts: Wnt-grown PDTOs were globally more sensitive in the screened subset, particularly to MAPK-axis inhibitors and apoptosis-sensitizers, while OP-grown PDTOs exhibited relative resistance. Culture medium composition is a key determinant of PDTO phenotype, transcriptome and drug sensitivity. Wnt medium was associated with drug-sensitive states, whereas OP medium was associated with adhesion- and inflammatory-related programs, relative resistance in the screened subset of 33 drugs and closer alignment with malignant epithelial programs in the analyzed pancreatic / colorectal cancer single-cell atlases.
中文摘要:患者来源肿瘤类器官(PDTO)受培养基影响明显。研究比较 OncoPro™(OP)Tumoroid Culture 培养基与常规 Wnt/R-spondin/noggin(Wnt)培养基,OP 为近期开发的标准化无血清替代方案。研究在来自结直肠癌、胰腺癌、乳腺癌、肺癌、胃癌、胃食管结合部癌、胆道癌、头颈癌及原发不明等多种恶性肿瘤的36株PDTO中比较OP与Wnt的建系成功率。选取PDTO模型进行形态学评估、bulk转录组分析并与公共单细胞RNA测序参考数据集(n=11)比较,开展全外显子测序(WES,n=9),并用33种药物组合进行药敏分析(n=3)。由Wnt培养基转换为OP的成功率为83.3%(15/18),而从头建系更倾向Wnt(33.3% vs 11.1%)。配对类器官培养保留关键致癌驱动改变,提示肿瘤相关基因组特征得以维持。转录组分析显示两种培养基均保留肿瘤身份,但上皮状态程序不同:Wnt上调增殖/干性相关基因(如LGR5),OP富集黏附相关基因及炎症/TGF-β程序。在单细胞数据库中,OP特征主要映射到胰腺癌恶性上皮区室,Wnt特征与非恶性上皮相关;结肠癌中OP特征也主要映射到恶性上皮区室。对胰腺癌和结直肠癌PDTO(n=3)的33种药物筛选显示一致的培养基依赖变化:Wnt培养的PDTO在受筛子集中总体更敏感,尤其对MAPK轴抑制剂和凋亡增敏剂,OP培养的PDTO相对耐药。培养基组成是PDTO表型、转录组和药物敏感性的关键决定因素。Wnt培养基与药物敏感状态相关,OP培养基与黏附及炎症相关程序、33种药物受筛子集中的相对耐药相关,并在所分析的胰腺癌/结直肠癌单细胞图谱中更接近恶性上皮程序。
Advanced healthcare materials IF 11.0 2026-10-26 PMID: 42934174
Cancer cell membrane coating offers a promising strategy for targeted drug delivery, yet its homotypic targeting mechanism and optimization remain insufficiently understood. This study identifies epithelial cell adhesion molecule (EpCAM), rather than Galectin-3, as the pivotal mediator of homologous uptake in hepatocellular carcinoma. Through genetic engineering, HepG2 cells overexpressing EpCAM are generated, and their membranes are used to coat gambogic acid-loaded PLGA nanoparticles. Cellular uptake assays reveal that EpCAM-enriched membranes significantly enhance nanoparticle internalization by homologous cancer cells via clathrin-mediated endocytosis, a process dependent on both clathrin heavy chain and light chain. In vivo biodistribution studies demonstrate that the EpCAM-engineered biomimetic platform markedly improves tumoral drug accumulation and retention, leading to potent antitumor efficacy through BAX/BCL-2-mediated apoptosis without inducing significant systemic toxicity. Mechanistically, this enhanced targeting is attributed to multivalent EpCAM-EpCAM interactions and the preservation of native membrane functionalities, including immune evasion and prolonged circulation. By elucidating the molecular machinery driving membrane-mediated homotypic recognition, this work establishes a rational basis for engineering cell membranes with overexpressed adhesion proteins, thereby enabling a novel and translatable strategy for precision chemotherapy delivery in hepatocellular carcinoma and potentially other epithelial tumors.
中文摘要:癌细胞膜包覆为靶向药物递送提供了有前景的策略,但其同型靶向机制与优化仍未充分阐明。本研究确定上皮细胞黏附分子(EpCAM)而非Galectin-3是肝细胞癌同源摄取的关键介导者。通过基因工程构建过表达EpCAM的HepG2细胞,并用其细胞膜包覆载藤黄酸的PLGA纳米颗粒。细胞摄取实验显示,富含EpCAM的膜通过网格蛋白介导的内吞显著增强同源癌细胞对纳米颗粒的内化,该过程依赖网格蛋白重链和轻链。体内生物分布研究表明,经EpCAM改造的仿生平台明显提高肿瘤内药物蓄积与滞留,并通过BAX/BCL-2介导的凋亡产生较强抗肿瘤效果,且未引起明显全身毒性。机制上,这种增强的靶向性归因于多价EpCAM-EpCAM相互作用以及天然膜功能的保留,包括免疫逃逸和延长循环。通过阐明驱动膜介导同型识别的分子机制,本研究为工程化改造过表达黏附蛋白的细胞膜奠定了合理基础,从而为肝细胞癌及其他潜在上皮性肿瘤的精准化疗递送提供了一种新颖且可转化的策略。
ACS sensors IF 10.9 2026-10-26 PMID: 42932447
The acidic microenvironment in solid tumors is not merely a metabolic byproduct of the Warburg effect but actively promotes disease aggressiveness and treatment failure. Tumor alkalization therapy, which aims to neutralize or alkalinize the TME, has therefore emerged as a promising adjunct to conventional cancer treatments. In this study, we fabricated both SERS nanosensors and microsensors for parallel spatiotemporal monitoring of intracellular pH (pHi) and extracellular pH (pHe) within tumor spheroids derived from three human cancer cell lines: lung adenocarcinoma (H1975), pancreatic cancer (SW1990), and colorectal cancer (SW480). Over a 7-day culture period, distinct pHi and pHe profiles were observed among the different cell types. We then examined the pH modulation elicited by administration of sodium bicarbonate (NaHCO3), a clinically employed alkaline agent. Exposure to 75 mM NaHCO3 for 24 h induced a marked elevation of pHe (∼0.78 units) and a modest increment in pHi (∼0.37 units). This integrated nanosensor-microsensor system, which leverages the size effect for precise spatial localization, offers a versatile approach for elucidating the complex interactions within the tumor microenvironment and helps optimize pH-modulating cancer therapies.
中文摘要:实体瘤的酸性微环境不只是Warburg效应的代谢副产物,还会主动促进疾病侵袭性和治疗失败。肿瘤碱化治疗旨在中和或碱化肿瘤微环境,因而成为传统癌症治疗的一种有前景的辅助策略。本研究制备了SERS纳米传感器和微传感器,用于并行、时空监测由三种人癌细胞系来源的肿瘤球内的细胞内pH(pHi)和细胞外pH(pHe),三种细胞系为肺腺癌H1975、胰腺癌SW1990和结直肠癌SW480。在7天培养期内,不同细胞类型表现出不同的pHi和pHe变化特征。随后检测了临床使用的碱性剂碳酸氢钠(NaHCO3)引起的pH调节。暴露于75 mM NaHCO3 24小时使pHe显著升高约0.78个单位,并使pHi小幅升高约0.37个单位。该纳米传感器-微传感器集成系统利用尺寸效应实现精确空间定位,为阐明肿瘤微环境内的复杂相互作用提供了通用方法,并有助于优化pH调节型癌症治疗。

4临床/流行病学 (18篇)

临床研究 (14篇)

Drugs IF 14.7 2026-10-31 PMID: 42963536
Prostate cancer remains a leading cause of cancer-related mortality in men worldwide. While hormone therapy is effective in the early stages of advanced disease, multimodal approaches are often required as disease progresses, including radiotherapy, hormonal agents and chemotherapy. In metastatic castration-resistant prostate cancer (mCRPC), tumour cells become resistant to hormone therapy, resulting in poor survival outcomes despite systemic treatments. Among emerging therapies, radioligand therapy targeting prostate-specific membrane antigen (PSMA) has shown promise. PSMA is a transmembrane glycoprotein highly expressed in prostate cancer cells, with minimal expression in normal tissues. This selective distribution enables precision targeting and minimises toxicity. The radiotheranostic agent [177Lu]Lu-PSMA-617 combines PSMA-617, a small molecule ligand, with the beta-emitting radioisotope 177Lutetium. This therapy has demonstrated efficacy in patients with mCRPC who have progressed after androgen receptor pathway inhibitors and taxane-based chemotherapy. Its regulatory approval in the USA, UK and Europe marks a pivotal advancement in prostate cancer management. Clinical trials such as TheraP, VISION and PSMAfore have established the role of [177Lu]Lu-PSMA-617 in mCRPC and its potential additive effects with other anti-tumour therapies are under investigation. Strategies to enhance PSMA expression may further improve therapeutic response. With no relevant drug-drug interaction risk, [177Lu]Lu-PSMA-617 may be safely considered for use in combination with other therapies, a key advantage for frail patients with mCRPC on polypharmacy. Post-treatment management remains a challenge and ongoing research aims to optimise long-term outcomes. This review provides a comprehensive update on [177Lu]Lu-PSMA-617 therapy, from molecular mechanisms to clinical application and outlines future directions in the treatment of advanced prostate cancer.
中文摘要:前列腺癌仍是全球男性癌症相关死亡的主要原因之一。晚期疾病早期阶段激素治疗有效,但随疾病进展常需多模式治疗,包括放疗、激素药物和化疗。在转移性去势抵抗性前列腺癌(mCRPC)中,肿瘤细胞对激素治疗产生抵抗,尽管接受系统治疗,生存结局仍较差。在新兴疗法中,靶向前列腺特异性膜抗原(PSMA)的放射配体治疗显示出前景。PSMA是一种跨膜糖蛋白,在前列腺癌细胞中高表达,在正常组织中表达很低。这种选择性分布使精准靶向成为可能并减少毒性。放射诊疗一体化药物[177Lu]Lu-PSMA-617将小分子配体PSMA-617与β发射放射性同位素177镥结合。该疗法在经雄激素受体通路抑制剂和紫杉类化疗后进展的mCRPC患者中显示出疗效。其在美国、英国和欧洲获得监管批准,标志着前列腺癌管理的重要进展。TheraP、VISION和PSMAfore等临床试验确立了[177Lu]Lu-PSMA-617在mCRPC中的作用,其与其他抗肿瘤治疗的潜在叠加效应正在研究中。提高PSMA表达的策略可能进一步改善治疗反应。由于不存在相关药物相互作用风险,[177Lu]Lu-PSMA-617可安全考虑与其他治疗联合使用,这对接受多种药物治疗的虚弱mCRPC患者是一项关键优势。治疗后管理仍是挑战,正在开展的研究旨在优化长期结局。该综述梳理[177Lu]Lu-PSMA-617治疗从分子机制到临床应用的信息,并概述晚期前列腺癌治疗的未来方向。
Journal of hematology & oncology IF 47.8 2026-10-30 PMID: 42963543
Pancreatic ductal adenocarcinoma (PDAC) is a near-universally lethal malignancy, with KRAS mutations driving tumorigenesis in over 90% of cases. For decades considered undruggable, oncogenic KRAS has now been therapeutically engaged across multiple mutational subtypes, a revolution precipitated by allele-specific covalent inhibitors and accelerated by the emergence of RAS(ON) multi-selective inhibitors. The pivotal phase 3 RASolute 302 trial of daraxonrasib, a pan-RAS(ON) inhibitor, demonstrated nearly doubled median overall survival (13.2 versus 6.7 months; HR 0.40; P < 0.0001) over standard chemotherapy in previously treated metastatic PDAC. Concurrently, mutation-selective G12D inhibitors (zoldonrasib, VS-7375, INCB161734), G12D-targeted protein degraders (setidegrasib), G12C-selective RAS(ON) compounds (elironrasib), and next-generation MEK inhibitors (atebimetinib) are advancing through clinical evaluation. This review synthesizes the biological basis of KRAS-driven oncogenesis in the pancreas, the mutational landscape and its prognostic implications, the structural and mechanistic evolution of KRAS inhibitor classes, contemporary and emerging clinical data from recent trials, toxicity profiles and their management, and resistance mechanisms. The field stands at an inflection point: daraxonrasib now redefines second-line PDAC management, while first-line combination regimens with daraxonrasib plus chemotherapy have produced an ORR of 58% in early-phase single-arm data, a result now being tested in the randomized RASolute 303 trial. The challenge ahead lies in translating these results into durable remissions through rational combination therapy and in overcoming acquired resistance.
中文摘要:胰腺导管腺癌(PDAC)是一种几乎普遍致死的恶性肿瘤,超过90%的病例由KRAS突变驱动肿瘤发生。数十年来被认为不可成药,致癌KRAS现已在多种突变亚型中实现治疗性干预,这一转变由等位基因特异性共价抑制剂引发,并因RAS(ON)多选择性抑制剂的出现而加速。daraxonrasib(一种泛RAS(ON)抑制剂)的关键3期RASolute 302试验显示,在既往接受过治疗的转移性PDAC中,其中位总生存期较标准化疗几乎翻倍(13.2个月对6.7个月;HR 0.40;P < 0.0001)。同时,突变选择性G12D抑制剂(zoldonrasib、VS-7375、INCB161734)、靶向G12D的蛋白降解剂(setidegrasib)、G12C选择性RAS(ON)化合物(elironrasib)以及下一代MEK抑制剂(atebimetinib)正在推进临床评价。本综述整合KRAS驱动胰腺癌发生的生物学基础、突变图谱及其预后意义、KRAS抑制剂类别的结构与机制演变、近期试验的当代与新兴临床数据、毒性特征及其管理,以及耐药机制。该领域正处于转折点:daraxonrasib重新定义了PDAC二线治疗,而daraxonrasib联合化疗的一线方案在早期单臂数据中产生58%的ORR,该结果正在随机RASolute 303试验中接受检验。未来的挑战在于通过合理的联合治疗将这些结果转化为持久缓解,并克服获得性耐药。
Journal of advanced research IF 17.1 2026-10-30 PMID: 42962916
Esophageal cancer (EC) remains a significant public health burden in China. Current diagnostics modalities such as endoscopy and imaging are invasive, poorly accessible, or insensitive for early-stage cases. DNA methylation alterations in circulating free DNA (cfDNA) are promising for non-invasive cancer detection. We aimed to develop and validate a methylation PCR-based assay for EC detection using EC-specific DNA methylation targets. Here, we report myESCAP, a PCR-based assay that amplifies and quantifies levels of EC-specific methylation in cfDNA METHODS: We conducted a multi-center, retrospective case-control study with 489 EC cases and 555 non-malignant controls (benign esophageal/gastric diseases or asymptomatic) to develop myESCAP, a methylation-specific PCR assay containing 11 EC-specific methylation markers from our previous genome-wide methylation screening, selected for strong discriminative performance and PCR compatibility. cfDNA was collected, bisulfite-converted, and tested by myESCAP, and results were analyzed by six modeling strategies (generalized linear model, k-nearest neighbors, C5.0 decision tree, gradient boosting machine, random forest, support vector machine) to train EC-prediction models using 347 EC cases and 349 non-malignant controls, and validated in 142 EC cases and 206 controls. All myESCAP markers demonstrated significant differential methylation between ECs and non-malignant controls, with adjusted p values between 5.8×10⁻3 and 3.1×10⁻88. The six models showed robust performance in the training cohort (average AUC = 0.835, average sensitivity = 76.13%, average specificity = 90.88%). They maintained performance in the validation cohort (average AUC = 0.823, average sensitivity = 75.59%, average specificity = 89%). Specifically, for stage I cases, myESCAP had an average sensitivity of 47.2%, highlighting the challenge of early detection with limited circulating tumor DNA and the need for further optimization. myESCAP accurately differentiated EC from non-malignant controls. The six models collectively confirm myESCAP's robustness and clinical potential as a cost-effective, non-invasive diagnostic tool for EC.
中文摘要:食管癌在中国仍造成显著公共卫生负担。内镜和影像等现有诊断方式具有侵入性、可及性不足或对早期病例不敏感。循环游离DNA(cfDNA)中的DNA甲基化改变为无创肿瘤检测提供了有前景的方向。研究旨在利用食管癌特异性DNA甲基化靶点,开发并验证一种基于甲基化PCR的食管癌检测方法。myESCAP是一种扩增并定量cfDNA中食管癌特异性甲基化水平的PCR检测方法。方法:开展多中心回顾性病例对照研究,纳入489例食管癌病例和555例非恶性对照(良性食管/胃疾病或无症状者),用于开发myESCAP。该甲基化特异性PCR检测包含11个食管癌特异性甲基化标志物,来自既往全基因组甲基化筛查,按较强判别性能和PCR兼容性筛选。收集cfDNA,经亚硫酸氢盐转化后使用myESCAP检测,并用6种建模策略(广义线性模型、k近邻、C5.0决策树、梯度提升机、随机森林、支持向量机)分析结果。以347例食管癌病例和349例非恶性对照训练食管癌预测模型,并在142例食管癌病例和206例对照中验证。所有myESCAP标志物在食管癌与非恶性对照间均显示显著差异甲基化,校正p值介于5.8×10⁻³至3.1×10⁻⁸⁸。6种模型在训练队列中表现稳健(平均AUC=0.835,平均灵敏度=76.13%,平均特异度=90.88%),在验证队列中保持性能(平均AUC=0.823,平均灵敏度=75.59%,平均特异度=89%)。对于I期病例,myESCAP平均灵敏度为47.2%,反映循环肿瘤DNA有限时早期检测的困难以及进一步优化的需要。myESCAP能够准确区分食管癌与非恶性对照。6种模型共同支持myESCAP作为食管癌经济、无创诊断工具的稳健性和临床潜力。
Neuro-oncology IF 13.1 2026-10-30 PMID: 42960872
Postoperative stereotactic radiotherapy (SRT) is the standard adjuvant treatment after resection of brain metastases. It nevertheless requires delineation of a dynamic postsurgical cavity, delays local treatment by 3 to 6 weeks (and thus resumption of systemic therapy) and carries substantial risks of radiation necrosis and leptomeningeal disease. Preoperative SRT targets an intact lesion and may address some of these limitations. In this open-label, single-arm, multicenter phase 2 trial, eligible adults had a Karnofsky performance status ≥70 and up to four brain metastases, including one resectable lesion ≤5 cm, from breast, non-small cell lung, kidney, or digestive cancer or melanoma. Patients received preoperative SRT (three fractions of 7.7 Gy prescribed to the encompassing 70% isodose line, equivalent to 11Gy per fraction at the isocenter) followed by surgical resection within 3 days of the last fraction. The primary outcome was 6-month local control on centrally reviewed MRI. Secondary outcomes included index-lesion radiation necrosis, leptomeningeal disease, distant intracranial control, overall survival, toxicity, cognition, and quality of life. Of 73 patients assessed, 67 were eligible and 63 received both SRT and surgery. Median age was 62 years. At a median follow-up of 12.7 months, the 6-month local control rate was 100% (95% CI, 95%-100%), meeting the primary endpoint; the 12-month rate was 96.4% (95% CI, 87%-99%). No leptomeningeal disease occurred. The 1-year cumulative incidence of index-lesion radiation necrosis was 7% (95% CI, 2%-16%), meeting the key secondary endpoint. Distant intracranial failure occurred in 22 patients (35%); 12-month overall survival was 81.2% (95% CI, 70%-89%). Postoperative complications occurred in 4 patients (6.3%); cognition and quality of life remained stable over the 12 months of protocol follow-up. Three-fraction preoperative SRT followed by resection was associated with high local control, low radiation necrosis, and no leptomeningeal disease, supporting evaluation in ongoing randomized trials.
中文摘要:术后立体定向放疗(SRT)是脑转移瘤切除后的标准辅助治疗。但该方案需要勾画动态变化的术后瘤腔,使局部治疗延迟3至6周(并因此延迟全身治疗恢复),且放射性坏死和软脑膜病变风险较高。术前SRT针对完整病灶,可能解决其中部分局限。在这项开放标签、单臂、多中心2期试验中,符合条件的成人Karnofsky体能状态评分≥70,最多有4个脑转移灶,其中1个为可切除且≤5 cm的病灶,原发肿瘤为乳腺癌、非小细胞肺癌、肾癌、消化道癌或黑色素瘤。患者接受术前SRT(3次,每次7.7 Gy,处方至覆盖70%等剂量线,相当于等中心每次11 Gy),并在末次照射后3天内行手术切除。主要结局为中心复核MRI上的6个月局部控制。次要结局包括指标病灶放射性坏死、软脑膜病变、颅内远处控制、总生存、毒性、认知和生活质量。评估73例患者,67例符合条件,63例同时接受SRT和手术。中位年龄62岁。中位随访12.7个月时,6个月局部控制率为100%(95% CI,95%-100%),达到主要终点;12个月控制率为96.4%(95% CI,87%-99%)。未发生软脑膜病变。指标病灶放射性坏死的1年累积发生率为7%(95% CI,2%-16%),达到关键次要终点。22例(35%)出现颅内远处失败;12个月总生存率为81.2%(95% CI,70%-89%)。4例(6.3%)发生术后并发症;在方案随访12个月内,认知和生活质量保持稳定。三分数术前SRT后行切除术与高局部控制、低放射性坏死和无软脑膜病变相关,支持在正在进行的随机试验中进一步评估。
Trends in cancer IF 21.6 2026-10-29 PMID: 42957523
More than a century after observations linking muscular activity to reduced cancer risk, exercise oncology has progressed from epidemiological association to interventional evidence. Large cohort studies associate physical activity with reduced cancer incidence and mortality, and a Phase 3 randomized trial now demonstrates cancer-specific survival benefits of structured exercise. In parallel, preclinical and emerging human studies provide mechanistic insight into how exercise may modulate tumor biology, including effects on immune surveillance, vascular function, metabolism, and systemic signaling. Despite these advances, gaps remain-notably, the limited integration of exercise variables into oncology trials and sparse mechanistic data from patients, particularly in pediatric cancers. This opinion article synthesizes recent clinical and mechanistic advances and outlines priorities for biologically informed integration of exercise into cancer research and the standard of care.
中文摘要:在观察到肌肉活动与癌症风险降低相关的一个多世纪之后,运动肿瘤学已从流行病学关联推进到干预证据。大型队列研究将身体活动与癌症发病率和死亡率降低联系起来,一项3期随机试验现已证明结构化运动可带来癌症特异性生存获益。临床前研究和新兴人体研究从机制上揭示运动可能如何调节肿瘤生物学,包括对免疫监视、血管功能、代谢和全身信号的影响。尽管取得这些进展,空白仍然存在,尤其是运动变量纳入肿瘤试验有限,来自患者的机制数据稀少,儿童癌症中尤为明显。这篇观点文章综合近期临床与机制进展,并概述以生物学证据为基础将运动纳入癌症研究和标准治疗的优先事项。
JAMA oncology IF 23.9 2026-10-29 PMID: 42955027
Primary bone cancers include multiple histologic types, with survival differing by age and location. Results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 were analyzed to support policies and initiatives worldwide. To estimate the global burden of bone cancer from 1990 to 2023 and forecast future trends to 2050. This systematic analysis estimated bone cancer incidence, mortality, and disability-adjusted life-years (DALYs) in 204 countries and territories grouped by GBD super-regions and World Bank income groups from 1990 to 2023, with forecasts through 2050. Individuals of all ages with bone cancers included in the GBD 2023 study were included in analyses. Data were analyzed from June 2023 to July 2025. The GBD 2023 study used standardized estimation methods to describe bone cancer incidence, mortality, and DALYs in 2023, as well as trends over the past 3 decades and forecasts through 2050. All estimates are presented with 95% uncertainty intervals (UIs), and age-standardized rates (ASRs) were calculated using GBD-specific age weights. In 2023, there were 111 000 (95% UI, 81 300-164 000) malignant bone cancer cases, 76 600 (95% UI, 60 700-96 300) deaths, and 3.02 million (95% UI, 2.29 million-3.96 million) DALYs globally. A bimodal age distribution was noted in both incidence (peaking at ages 10 to 14 years and 65 to 69 years) and mortality (peaking at ages 15 to 19 years and 65 to 69 years). The highest ASRs for incidence were in Southeast Asia, East Asia, and Oceania (1.6 per 100 000; 95% UI, 1.1-2.4), while Sub-Saharan Africa had the highest ASRs for DALYs (51.0 per 100 000; 95% UI, 27.7-79.7). By World Bank income group, upper-middle-income countries had the highest ASRs for incidence, whereas low-income countries exhibited the highest ASRs for both mortality and DALYs. Globally, incident cases, deaths, and DALYs increased from 1990 to 2023, while global mortality and DALY ASRs were relatively stable; high-income countries experienced a decline in mortality and DALY ASRs. Forecasts suggest a potential increase in global cases and deaths by 2050. In this systematic analysis, the burden of bone cancer varied by age, geography, and time, underscoring global disparities. These findings provide valuable insights to inform health system planning and resource allocation tailored to different settings.
中文摘要:原发性骨癌包含多种组织学类型,生存率随年龄和地区不同。对全球疾病负担研究(GBD)2023的结果进行分析,为全球政策和行动提供支持。研究估计1990年至2023年全球骨癌负担,并预测至2050年的趋势。这项系统分析估计了1990年至2023年204个国家和地区骨癌的发病率、死亡率和伤残调整生命年(DALYs),按GBD超级区域和世界银行收入组分组,并预测至2050年。分析纳入GBD 2023研究中所有年龄的骨癌患者。数据分析时间为2023年6月至2025年7月。GBD 2023研究采用标准化估计方法描述2023年骨癌的发病率、死亡率和DALYs,以及过去30年的趋势和至2050年的预测。所有估计值均给出95%不确定性区间(UI),年龄标化率(ASRs)采用GBD特定年龄权重计算。2023年全球有111 000例(95% UI,81 300–164 000)恶性骨癌病例,76 600例(95% UI,60 700–96 300)死亡,302万(95% UI,229万–396万)DALYs。发病率和死亡率均呈双峰年龄分布,发病率峰值在10至14岁和65至69岁,死亡率峰值在15至19岁和65至69岁。发病率年龄标化率最高的是东南亚、东亚和大洋洲(每10万1.6例;95% UI,1.1–2.4),撒哈拉以南非洲的DALY年龄标化率最高(每10万51.0;95% UI,27.7–79.7)。按世界银行收入组,中高收入国家的发病率年龄标化率最高,低收入国家的死亡率和DALY年龄标化率均最高。1990年至2023年,全球发病例数、死亡和DALYs增加,全球死亡率和DALY年龄标化率相对稳定;高收入国家的死亡率和DALY年龄标化率下降。预测显示至2050年全球病例和死亡可能增加。在这项系统分析中,骨癌负担随年龄、地区和时期变化,凸显全球差异。这些发现可为不同环境的卫生系统规划和资源分配提供参考。
ESMO open IF 10.6 2026-10-28 PMID: 42950585
The role of a comprehensive genomic profile (CGP) and molecular residual disease (MRD) in circulating tumor DNA (ctDNA) for risk stratification of resectable colorectal oligometastases (CRMs) remains unclear. This study aimed to investigate the feasibility of ctDNA analysis in patients with CRM and to conduct an exploratory assessment of its recurrence risk. This study assessed ctDNA in patients with previously untreated resectable CRM scheduled for curative resection, before starting treatment and 4 weeks postoperatively. Pretreatment samples were prospectively tested for genomic alteration using a 74-gene CGP assay (Guardant360). The pathogenic mutations in BRAF, KRAS, PIK3CA, SMAD4, or TP53 were defined as poor genomic profiles. Postoperative samples were retrospectively analyzed for MRD using a methylation-based MRD assay (Guardant Reveal). Among 118 eligible patients, pretreatment ctDNA was detected in 114 (96.6%) patients, 75 (63.6%) of whom had poor profiles. MRD was detected in 34 (31.2%) patients out of 109 evaluable patients who underwent surgery. Using multivariable analysis, pretreatment poor profiles and post-operative MRD were significantly associated with shorter recurrence-free survival (RFS) [hazard ratio (HR) 3.28, 95% confidence interval (CI) 1.72-6.25; HR 4.07, 95% CI 2.40-6.90, respectively] and time to surgical failure (TSF) (HR 2.76, 95% CI 1.35-5.64; HR 3.05, 95% CI 1.70-5.45, respectively). Patients with both poor pretreatment profiles and post-operative MRD demonstrated the worst prognosis in RFS (HR 13.28, 95% CI 5.86-30.10), TSF (HR 8.98, 95% CI 3.77-21.40), and overall survival (HR 9.21, 95% CI 2.06-41.18). Combining pretreatment CGP and post-operative MRD in ctDNA showed potential for improved prognostic stratification after CRM resection.
中文摘要:可切除结直肠寡转移(CRM)患者中,循环肿瘤DNA(ctDNA)综合基因组图谱(CGP)与分子残留病灶(MRD)在风险分层中的作用尚不明确。本研究旨在探讨CRM患者ctDNA分析的可行性,并对其复发风险做探索性评估。研究纳入既往未经治疗、计划行根治性切除的可切除CRM患者,在开始治疗前及术后4周检测ctDNA。治疗前样本以前瞻性方式用74基因CGP检测(Guardant360)分析基因组变异,BRAF、KRAS、PIK3CA、SMAD4或TP53的致病性突变定义为不良基因组图谱。术后样本以回顾性方式用基于甲基化的MRD检测(Guardant Reveal)分析MRD。118例符合条件患者中,114例(96.6%)治疗前检出ctDNA,其中75例(63.6%)为不良图谱。109例可评估的手术患者中34例(31.2%)检出MRD。多因素分析显示,治疗前不良图谱和术后MRD均与更短的无复发生存期(RFS)显著相关(风险比3.28,95%置信区间1.72-6.25;风险比4.07,95%置信区间2.40-6.90),也与更短的手术失败时间(TSF)相关(风险比2.76,95%置信区间1.35-5.64;风险比3.05,95%置信区间1.70-5.45)。同时具有治疗前不良图谱和术后MRD的患者预后最差,RFS(风险比13.28,95%置信区间5.86-30.10)、TSF(风险比8.98,95%置信区间3.77-21.40)及总生存(风险比9.21,95%置信区间2.06-41.18)均如此。联合治疗前CGP与术后MRD的ctDNA检测在CRM切除后改善预后分层方面显示出潜力。
Science translational medicine IF 15.6 2026-10-28 PMID: 42950020
B cells are a critical arm of the adaptive immune system. However, the impact of B cells and antibody responses on overall cancer survival remains understudied. Here, we report results from a prospective randomized phase 2 trial of 106 patients treated with immune checkpoint inhibitors (ICIs) and identify that B cell antibody responses are associated with exceptional complete responses to ICI in certain cancer types. To further dissect the impact of B cell subtypes, we generated a comprehensive single-cell RNA sequencing database of intratumoral B cells in 12 tumor types from 152 patients. We found a context-dependent role for B cells, in which they are beneficial in certain cancer types and potentially unfavorable in others, with germinal center and memory B cells enriched in favorable prognosis cohorts and immunoglobulin A-positive plasma cells enriched in unfavorable prognosis cohorts. Depletion of B cells using rituximab in patients before surgery affected intratumoral T cell frequency and diversity. Furthermore, we show that B cells improve long-term overall survival even when T cell infiltrates are already high, indicating that a coordinated dual-arm T cell and B cell adaptive immune response is key to long-term tumor control. Overall, these results demonstrate that B cells and antibody responses in the proper context play an important role in durable complete responses in multiple tumor types.
中文摘要:B细胞是适应性免疫系统的重要分支。B细胞及抗体反应对癌症总生存的影响仍研究不足。我们报告一项前瞻性随机2期试验结果,106例接受免疫检查点抑制剂(ICI)治疗的患者中,B细胞抗体反应与某些癌种对ICI的异常完全缓解相关。为解析B细胞亚型的作用,我们构建了涵盖12种肿瘤类型、152例患者瘤内B细胞的综合单细胞RNA测序数据库。发现B细胞作用具有情境依赖性:在某些癌种中有益,在另一些癌种中可能不利;生发中心B细胞和记忆B细胞在预后良好队列中富集,免疫球蛋白A阳性浆细胞在预后不良队列中富集。术前使用利妥昔单抗清除B细胞影响瘤内T细胞频率和多样性。B细胞在T细胞浸润已较高时仍改善长期总生存,提示协调的双臂T细胞与B细胞适应性免疫反应是长期肿瘤控制的关键。总体,这些结果表明,适当情境下的B细胞和抗体反应在多种肿瘤类型的持久完全缓解中起重要作用。
JAMA surgery IF 15.6 2026-10-28 PMID: 42949735
The extent of negative margin necessary to achieve a high rate of local tumor control in children and young adult patients with nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) is unknown. To evaluate the impact of negative margin extent on local tumor control in children and young adult patients with NRSTS undergoing R0 resection as part of risk-adapted multimodality treatment. This multicenter prospective clinical trial was conducted at Children's Oncology Group (COG) member sites from February 2007 through February 2012. Analysis was performed on the final dataset June 30, 2018, with a median follow-up of 6.2 years. Reviewers of margin status/extent were blinded to local control outcomes. Patients included 266 eligible/evaluable individuals younger than 30 years with nonmetastatic NRSTS who were enrolled in the COG ARST0332 trial and underwent upfront or delayed R0 resection as part of treatment. Patients who underwent an amputation or did not receive protocol-specified radiotherapy were excluded. These data were analyzed from January 2023 through July 2026. Risk-adapted treatment included 3 patient groups with upfront or delayed surgery with or without radiation therapy with or without ifosfamide/doxorubicin chemotherapy, based on the extent of initial resection, surgical margin status, tumor size, and histologic grade. Cumulative incidence of local recurrence based on treatment approach and surgical margin extent and outcomes after local recurrence. Of 266 patients (median age 13.7 [range, 2.1-27.6] years; 138 female [52%] and 128 male [48%]) who underwent upfront (n = 207) or delayed (n = 59) R0 resection, 132 had measured surgical margins: 1 mm (n = 56), 2 to 5 mm (n = 50), or 6-mm or larger (n = 26). The 5-year cumulative incidence of local recurrence overall was 4.4%. Local recurrence occurred in 10 of 178 patients treated with surgery alone (5.6%) and 2 of 88 patients treated with surgery and chemoradiotherapy (2.3%). Among the 132 patients with measured surgical margins, the 5-year cumulative incidence of local recurrence was 4.9% for 1-mm margins, 2.0% for 2- to 5-mm margins, and 0% for 6-mm or larger margins. Local recurrence occurred in 10 of 178 (5.6%) patients with tumors smaller than 5 cm treated with margin-negative surgery alone, 1 of 29 (3.4%) patients with tumors larger than 5 cm treated with margin-negative surgery followed by chemoradiotherapy, and 1 of 59 (1.7%) patients with initially unresectable disease treated with neoadjuvant chemoradiotherapy. Five of 12 patients with local recurrence were alive without further disease progression. In this study, the local recurrence rate after R0 resection among children and young adult patients treated with risk-based therapy for nonmetastatic NRSTS was low, and some patients underwent successful salvage therapy with durable long-term disease control. Wider (>1 mm) negative margins further decrease local recurrence risk. Close surgical margins may be adequate in some clinical settings, particularly in the context of chemoradiotherapy, according to a risk-adapted approach. ClinicalTrials.gov Identifier: NCT00346164.
中文摘要:儿童和年轻成人非横纹肌肉瘤软组织肉瘤(NRSTS)患者达到高局部控制率所需的阴性切缘范围尚不清楚。研究评估在接受风险适应多模式治疗并完成R0切除的儿童和年轻成人NRSTS患者中,阴性切缘范围对局部肿瘤控制的影响。这项多中心前瞻性临床试验于2007年2月至2012年2月在儿童肿瘤协作组(COG)成员机构开展。最终数据集分析于2018年6月30日进行,中位随访6.2年。切缘状态及范围的审阅者对局部控制结局设盲。纳入266例年龄小于30岁、非转移性NRSTS、入组COG ARST0332试验并作为治疗一部分接受初始或延迟R0切除的可评估患者。接受截肢或未接受方案规定放疗者被排除。这些数据于2023年1月至2026年7月分析。风险适应治疗根据初始切除范围、手术切缘状态、肿瘤大小和组织学分级,将患者分为3组,接受初始或延迟手术,联合或不联合放疗,联合或不联合异环磷酰胺/多柔比星化疗。结局包括按治疗方式和手术切缘范围计算的局部复发累积发生率,以及局部复发后的结局。266例患者(中位年龄13.7岁[范围2.1-27.6岁];女性138例[52%],男性128例[48%])接受初始(n=207)或延迟(n=59)R0切除,其中132例有可测量的手术切缘:1 mm(n=56)、2至5 mm(n=50)或6 mm及以上(n=26)。总体5年局部复发累积发生率为4.4%。单纯手术治疗的178例患者中10例(5.6%)发生局部复发,手术联合放化疗的88例患者中2例(2.3%)发生局部复发。在132例有可测量手术切缘的患者中,5年局部复发累积发生率在1 mm切缘者为4.9%,2至5 mm切缘者为2.0%,6 mm及以上切缘者为0%。肿瘤小于5 cm、接受切缘阴性单纯手术治疗的178例患者中10例(5.6%)发生局部复发;肿瘤大于5 cm、接受切缘阴性手术后续放化疗的29例患者中1例(3.4%)发生局部复发;初始不可切除疾病接受新辅助放化疗的59例患者中1例(1.7%)发生局部复发。12例局部复发患者中5例存活且无进一步疾病进展。在这项研究中,接受基于风险治疗的非转移性NRSTS儿童和年轻成人患者R0切除后的局部复发率较低,部分患者通过挽救治疗获得长期疾病控制。更宽(>1 mm)的阴性切缘进一步降低局部复发风险。根据风险适应策略,在某些临床情形下,尤其是联合放化疗时,较近的手术切缘可能足够。ClinicalTrials.gov注册号:NCT00346164。
Cell death & disease IF 12.2 2026-10-27 PMID: 42957626
The biological and clinical significance of the intratumoral microbiota in pancreatic ductal adenocarcinoma (PDAC) remains poorly defined. Using oncogenic Kras-driven mouse models of pancreatic tumorigenesis and human pancreatic tissue from patients with non-metastatic PDAC treated with neoadjuvant (n = 62) or adjuvant therapy (n = 101), along with samples from intraductal papillary mucinous neoplasms (IPMN, n = 24), chronic pancreatitis (CP, n = 33), and healthy donors (n = 9), we determined tissue lipopolysaccharide (LPS), 16S rRNA sequencing, high-resolution quantitative multiplex immunofluorescence of autophagy markers (LAMP2, LC3B) and LPS, 16S rRNA fluorescence in situ hybridization (FISH) staining, and TLR4 signaling. In KrasCre mice, we identified significant bacterial accumulation in the pancreas, indicated by elevated LPS, increased FISH signals, enhanced TLR4 signaling, and activation of autophagy. Administration of exogenous LPS further amplified autophagy and TLR4 signaling, supporting a mechanistic link between microbial sensing and autophagy. In human tissue, both adjuvant and neoadjuvant PDAC samples showed significantly increased bacterial alpha- and beta diversity compared with controls, while CP showed a similar enrichment pattern that IPMN lacks; the underlying microbial diversity differs fundamentally across these conditions. Increased LPS levels, along with elevated autophagy markers and abundant FISH-positive bacteria, support the presence of intratumoral bacteria. Across four independent transcriptomic datasets, PDAC samples showed elevated expression of bacteria-associated pathways (including TLR4) and autophagy-related genes. Clinically, higher autophagy-associated LAMP2-LC3B colocalization and increased densities of FISH-positive cells were independently associated with prolonged survival in both adjuvant and neoadjuvant or combined PDAC patients. Collectively, these findings link intratumoral microbial enrichment to increased autophagy-associated signaling and improved patient outcomes, suggesting that microbial signals within the tumor microenvironment were associated with favorable survival.
中文摘要:胰腺导管腺癌(PDAC)瘤内微生物群的生物学与临床意义仍不明确。我们利用致癌Kras驱动的胰腺肿瘤发生小鼠模型,以及来自接受新辅助治疗(n=62)或辅助治疗(n=101)的非转移性PDAC患者的人胰腺组织,连同导管内乳头状黏液性肿瘤(IPMN,n=24)、慢性胰腺炎(CP,n=33)和健康供者(n=9)的样本,检测了组织脂多糖(LPS)、16S rRNA测序、自噬标志物(LAMP2、LC3B)与LPS的高分辨率定量多重免疫荧光、16S rRNA荧光原位杂交(FISH)染色及TLR4信号。在KrasCre小鼠中,我们观察到胰腺内明显的细菌积聚,表现为LPS升高、FISH信号增加、TLR4信号增强以及自噬激活。给予外源性LPS进一步放大了自噬和TLR4信号,支持微生物感知与自噬之间存在机制联系。在人组织中,辅助治疗和新辅助治疗的PDAC样本均显示细菌α多样性和β多样性较对照显著增加,而CP呈现类似富集模式,IPMN则缺乏这种模式;这些疾病状态下的微生物多样性存在根本差异。LPS水平升高,同时自噬标志物升高和FISH阳性细菌丰富,支持瘤内细菌的存在。在四个独立转录组数据集中,PDAC样本显示细菌相关通路(包括TLR4)和自噬相关基因表达升高。在临床上,较高的自噬相关LAMP2-LC3B共定位和FISH阳性细胞密度增加与辅助治疗、新辅助治疗或两者合并的PDAC患者生存期延长独立相关。这些发现将瘤内微生物富集与自噬相关信号增强及患者结局改善联系起来,提示肿瘤微环境中的微生物信号与有利生存相关。
Cancer cell IF 56.1 2026-10-27 PMID: 42945961
CPS + EG and Neo-Bioscore are prognostic scores estimating the risk of recurrence after neoadjuvant chemotherapy for early breast cancer, but can they predict the long-term outcomes in a clinical trial? In this study, we assessed their surrogacy values at patient level and trial level for long-term outcomes, using data from 8,359 patients across nine neoadjuvant randomized trials conducted by the German Breast Group (GBG) and AGO-B study group. We found that at the patient level, both scores were significantly associated with outcomes, but at the trial level, the associations with distant disease-free survival (DDFS), invasive disease-free survival (iDFS), and overall survival (OS) were weak for both scores (R2 range = 0.03 to 0.24, with wide confidence intervals). Thus, our findings suggest that CPS + EG and Neo-Bioscore are not reliable surrogate endpoints for predicting long-term treatment benefit in neoadjuvant trials but remain valuable for estimating individual patients' residual risk after neoadjuvant treatments and guiding subsequent treatment decisions for early breast cancer patients.
中文摘要:CPS+EG和Neo-Bioscore是预后评分,用于估计早期乳腺癌新辅助化疗后的复发风险,但它们能否预测临床试验中的长期结局?本研究利用德国乳腺癌研究组(GBG)和AGO-B研究组开展的九项新辅助随机试验中8359例患者的数据,评估这两个评分在患者水平和试验水平对长期结局的替代价值。在患者水平,两个评分均与结局显著相关;在试验水平,两个评分与远处无病生存(DDFS)、浸润性无病生存(iDFS)和总生存(OS)的关联均较弱(R2范围=0.03至0.24,置信区间较宽)。研究结果提示,CPS+EG和Neo-Bioscore不是预测新辅助试验中长期治疗获益的可靠替代终点,但仍可用于估计早期乳腺癌患者新辅助治疗后的个体残留风险,并指导后续治疗决策。
Annals of internal medicine IF 17.2 2026-10-27 PMID: 42932883
Obesity and early-onset cancer are both increasing among young adults, yet evidence remains limited. To assess associations between obesity and early-onset cancer risk in young adults. Nationwide population-based cohort study. Korean National Health Insurance Service database, 2009 to 2021. 6 313 338 adults aged 20 to 39 years without prior cancer, from a national health screening program. Body mass index (BMI) was categorized into 5 groups (underweight to class II obesity) according to Asian-specific criteria. The outcome was incident cancer. During a mean follow-up of 11.2 years, 151 893 cancer cases occurred. Ten-year cumulative incidence ranged from 1.84% (95% CI, 1.83% to 1.86%) in the normal-weight group to 2.24% (CI, 2.22% to 2.27%) in class I obesity and 2.62% (CI, 2.56% to 2.68%) in class II obesity, with absolute risk differences of 0.40% (CI, 0.39% to 0.41%) and 0.78% (CI, 0.73% to 0.82%). The relative association was more pronounced in men, and absolute risk differences were greater in women. In combined BMI-waist circumference analyses, people with class I obesity based on BMI and with abdominal obesity had higher 10-year cumulative incidence (2.45% [CI, 2.41% to 2.50%]) than those without abdominal obesity (2.13% [CI, 2.10% to 2.16%]), exceeding that of those with class II obesity without abdominal obesity (2.20% [CI, 2.03% to 2.36%]). The highest cumulative incidence was observed for thyroid, endometrial, and ovarian cancer. Obesity was not associated with higher risk for breast cancer diagnosed by age 50 years. Observational design; nonrepresentative sample limited to screening participants; and unmeasured confounding, including smoking burden. Obesity in young Korean adults, measured by BMI and waist circumference, is associated with higher early-onset cancer risk persisting into midlife, with patterns varying by cancer type. Early weight management may be important for prevention. None.
中文摘要:肥胖与早发癌症在年轻成人中均呈上升趋势,但证据仍有限。研究评估年轻成人肥胖与早发癌症风险的关联。采用全国性人群队列研究,数据来自韩国国民健康保险服务数据库,2009年至2021年,纳入全国健康筛查项目中6313338名20至39岁且既往无癌症的成人。体质指数按亚洲特异性标准分为5组,从体重不足至II度肥胖。结局为新发癌症。平均随访11.2年,发生151893例癌症。10年累积发病率从正常体重组的1.84%(95%CI,1.83%至1.86%)升至I度肥胖组的2.24%(95%CI,2.22%至2.27%)和II度肥胖组的2.62%(95%CI,2.56%至2.68%),绝对风险差分别为0.40%(95%CI,0.39%至0.41%)和0.78%(95%CI,0.73%至0.82%)。相对关联在男性中更明显,绝对风险差在女性中更大。在体质指数与腰围联合分析中,按体质指数为I度肥胖且伴腹型肥胖者的10年累积发病率为2.45%(95%CI,2.41%至2.50%),高于无腹型肥胖者的2.13%(95%CI,2.10%至2.16%),并超过无腹型肥胖的II度肥胖者的2.20%(95%CI,2.03%至2.36%)。累积发病率最高的是甲状腺癌、子宫内膜癌和卵巢癌。肥胖与50岁前诊断的乳腺癌风险升高无关。研究局限包括观察性设计、样本限于筛查参与者而不具代表性、以及未测量混杂因素如吸烟负荷。在韩国年轻成人中,以体质指数和腰围衡量的肥胖与较高的早发癌症风险相关,该风险持续至中年,且模式因癌症类型而异。早期体重管理可能对预防具有重要意义。无。
European heart journal IF 45.3 2026-10-26 PMID: 42234492
Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for patients with low Lp(a) concentrations. Therapeutics that lower Lp(a) are now in clinical testing. Thus, the association between lower Lp(a) concentration and safety outcomes is of clinical importance. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27 564 patients with stable atherosclerotic cardiovascular disease (ASCVD) to evolocumab versus placebo on a background of statin therapy. The relationship between Lp(a) and the risk of prevalent and incident adverse outcomes of interest was examined, adjusting for relevant predictors. Lp(a) was assessed in 25 090 participants at baseline (median 37 nmol/L, interquartile range 13-165). There was no association between Lp(a) concentration and incident risk of haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including those with Lp(a) levels ≤13 nmol/L. There was an inverse association between lower baseline Lp(a) levels and prevalent DM at baseline (adjusted odds ratio 1.03, 95% confidence interval [CI] 1.02-1.04, P < .001; for every 50 nmol/L lower Lp(a)), as well as the incident risk of developing DM during follow-up (adjusted hazard ratio [HR] 1.05, 95% CI 1.02-1.08, P = .002; for every 50 nmol/L lower Lp(a)), with consistent results by treatment arm. Evolocumab did not increase the risk of DM irrespective of baseline Lp(a), even in participants in the top decile of baseline Lp(a) (adjusted HR .72, 95% CI .38-1.35) in whom evolocumab reduced Lp(a) by a median of 71 nmol/L. In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM.
中文摘要:脂蛋白(a)(Lp(a))被视为动脉粥样硬化形成的因果性危险因素。已有报道显示,Lp(a) 浓度较低的患者某些不良事件(包括糖尿病)的发生率较高。降低 Lp(a) 的治疗药物已进入临床测试,因此较低 Lp(a) 浓度与安全性结局之间的关联具有临床意义。FOURIER 试验将 27 564 例稳定型动脉粥样硬化性心血管疾病(ASCVD)患者随机分配至依洛尤单抗组或安慰剂组,两组均在接受他汀治疗的基础上用药。研究在校正相关预测因素后,分析 Lp(a) 与既存及新发关注不良结局风险之间的关系。基线时共 25 090 名参与者检测了 Lp(a)(中位数 37 nmol/L,四分位距 13–165)。Lp(a) 浓度与新发出血性卒中、严重出血、神经认知事件、恶性肿瘤或心房颤动的风险无关联,Lp(a) 水平 ≤13 nmol/L 者亦然。较低的基线 Lp(a) 水平与基线时既存糖尿病呈负相关(校正比值比 1.03,95% 置信区间 [CI] 1.02–1.04,P < .001;Lp(a) 每降低 50 nmol/L),也与随访期间新发糖尿病的风险呈负相关(校正风险比 [HR] 1.05,95% CI 1.02–1.08,P = .002;Lp(a) 每降低 50 nmol/L),按治疗组分析结果一致。无论基线 Lp(a) 水平如何,依洛尤单抗均未增加糖尿病风险,即使在基线 Lp(a) 最高十分位的参与者中亦然(校正 HR 0.72,95% CI 0.38–1.35),该人群中依洛尤单抗使 Lp(a) 中位数降低 71 nmol/L。在 ASCVD 患者中,低 Lp(a) 浓度与多数不良安全性结局风险升高无关,但较低 Lp(a) 与既存及新发糖尿病风险升高相关。
Nature medicine IF 52.5 2026-10-24 PMID: 42926136
Nivolumab plus relatlimab is approved for advanced melanoma based on the RELATIVITY-047 trial; however, long-term data are needed. Here, we report data from RELATIVITY-047 with the longest follow-up at present. In this phase 2-3, double-blind trial, patients with metastatic/unresectable melanoma were randomized 1:1 to nivolumab 480 mg plus relatlimab 160 mg (n = 355) or nivolumab 480 mg (n = 359) intravenously every 4 weeks. The primary endpoint was progression-free survival (PFS) by blinded independent central review. Secondary endpoints were overall survival (OS), response, and safety. Additional post-hoc analyses such as melanoma-specific survival (MSS), and exploratory biomarker analyses are also reported. This analysis shows clear separation in survival curves with the largest absolute differences to date in PFS, OS, and MSS. In this prespecified 5-year analysis, with a minimum follow-up of 57.3 months, nivolumab plus relatlimab demonstrated continued clinically significant benefit versus nivolumab for PFS (hazard ratio = 0.77; 95% confidence interval: 0.65-0.92), OS (hazard ratio = 0.78; 95% confidence interval: 0.64-0.95), and MSS (hazard ratio = 0.71; 95% confidence interval: 0.57-0.88). The safety profile remained consistent with prior reports. Among biomarker-evaluable patients in the programmed death ligand 1 ≥1% subgroup, analyses revealed an association between worse outcomes with nivolumab and high peripheral or tumor lymphocyte activation gene 3 (LAG-3)+ CD8 cell levels. The addition of relatlimab to nivolumab was associated with a lower prevalence of primary resistance than nivolumab alone. These data support the hypothesis that relatlimab can overcome LAG-3-mediated resistance to nivolumab and provides evidence for differential efficacy patterns observed across biomarker subgroups linked to primary versus acquired resistance states. ClinicalTrials.gov identifier: NCT03470922.
中文摘要:基于RELATIVITY-047试验,纳武利尤单抗联合瑞拉利单抗已获批用于晚期黑色素瘤,但仍需要长期数据。此处报告RELATIVITY-047目前随访时间最长的数据。在这项2/3期双盲试验中,转移性/不可切除黑色素瘤患者按1:1随机接受纳武利尤单抗480 mg联合瑞拉利单抗160 mg(n=355)或纳武利尤单抗480 mg(n=359)静脉给药,每4周一次。主要终点为盲法独立中心评审的无进展生存期(PFS)。次要终点为总生存期(OS)、缓解和安全性。另报告黑色素瘤特异性生存期(MSS)等事后分析和探索性生物标志物分析。本次分析显示生存曲线明显分离,PFS、OS和MSS的绝对差异为迄今最大。在这项预设的5年分析中,最短随访57.3个月,纳武利尤单抗联合瑞拉利单抗相较纳武利尤单抗在PFS(风险比=0.77;95%置信区间:0.65-0.92)、OS(风险比=0.78;95%置信区间:0.64-0.95)和MSS(风险比=0.71;95%置信区间:0.57-0.88)方面持续显示具有临床意义的获益。安全性特征与既往报告一致。在程序性死亡配体1≥1%亚组中可评估生物标志物的患者里,分析显示纳武利尤单抗治疗结局较差与较高的外周或肿瘤淋巴细胞激活基因3(LAG-3)+ CD8细胞水平相关。纳武利尤单抗联合瑞拉利单抗较纳武利尤单抗单药与更低的原发性耐药发生率相关。这些数据支持瑞拉利单抗可克服LAG-3介导的纳武利尤单抗耐药这一假说,并为与原发性耐药和获得性耐药状态相关的生物标志物亚组间疗效差异模式提供证据。ClinicalTrials.gov注册号:NCT03470922。

基础研究 (4篇)

Science bulletin IF 20.7 2026-10-30 PMID: 42731919
Doxorubicin-induced cardiotoxicity remains a critical challenge in cancer chemotherapy, as current strategies rarely balance antitumor efficacy with prevention of systemic side effects. Herein, we develop a chiral amino acid-engineered ruthenium-based nanozyme platform for gut-heart axis-mediated cardioprotection. Systematic screening of 20 amino acids identifies L-Met as the optimal ligand, yielding L-AEN with superior superoxide dismutase- and catalase-like cascade activities and efficient scavenging of ROS and RNS. Chirality engineering further endows L-AEN with markedly enhanced antioxidant performance compared with its D- and DL-counterparts, while maintaining excellent biocompatibility. After enteric encapsulation to form L-AENC, oral administration enables intestinal-targeted release and improves in vivo bioavailability. In a doxorubicin-induced chronic cardiac injury model, L-AENC significantly improves cardiac function, reduces myocardial damage, and suppresses systemic oxidative stress without affecting the antitumor efficacy of doxorubicin. Mechanistically, L-AENC restores gut microbiota homeostasis by enriching beneficial taxa, particularly Muribaculaceae, and reshapes host metabolic profiles, notably involving tryptophan, glutathione, and butyrate metabolism, thereby strengthening gut microbiota-metabolite interactions. Collectively, this work demonstrates that a chirality-engineered nanozyme platform coordinates gut microbiota and host metabolism to protect against chemotherapy-induced cardiotoxicity via the gut-heart axis, highlighting stereochemical engineering as an effective strategy for nanozyme-based therapeutic design.
中文摘要:多柔比星诱导的心脏毒性仍是肿瘤化疗中的关键难题,现有策略很少能兼顾抗肿瘤疗效与全身副作用的预防。该研究构建了手性氨基酸工程化的钌基纳米酶平台,用于经肠-心轴介导的心脏保护。对20种氨基酸的系统筛选确定L-蛋氨酸为最优配体,所得L-AEN具有更强的超氧化物歧化酶和过氧化氢酶级联活性,并能高效清除ROS和RNS。手性工程使L-AEN的抗氧化性能较其D型和DL型 counterparts 明显增强,同时保持良好生物相容性。经肠溶包衣形成L-AENC后,口服给药可实现肠道靶向释放并提高体内生物利用度。在多柔比星诱导的慢性心脏损伤模型中,L-AENC显著改善心功能、减轻心肌损伤并抑制全身氧化应激,且不影响多柔比星的抗肿瘤疗效。机制上,L-AENC通过富集有益菌群尤其是Muribaculaceae恢复肠道菌群稳态,并重塑宿主代谢谱,主要涉及色氨酸、谷胱甘肽和丁酸代谢,从而增强肠道菌群与代谢物之间的相互作用。该工作表明,手性工程化纳米酶平台可通过肠-心轴协调肠道菌群与宿主代谢,抵御化疗诱导的心脏毒性,并提示立体化学工程是纳米酶治疗设计的有效策略。
Seminars in cancer biology IF 20.3 2026-10-29 PMID: 42957075
This review provides an overview of DNA methylation, beginning with its chemical modification and biological role, and progressing to its clinical relevance. It is designed for readers without prior knowledge of the field and is divided into two main sections: Biological Mechanisms and Clinical Applications. The first section explores the molecular and biological mechanisms underlying DNA methylation. It examines the different types of methylation marks and the enzymes responsible for their addition and removal. The process is driven by the recruitment and activation of DNA methylation-modulating enzymes, with the nucleosome barrier playing a significant role. A key aspect discussed is the resetting of DNA methylation patterns during development. This resetting occurs in two distinct waves: the first in germ cells and the second after fertilization, which is associated with cellular differentiation and the establishment of transcriptional programs in various lineages. The typical locations and patterns of DNA methylation in normal somatic cells are described. Additionally, the review explains the diverse molecular functions of DNA methylation. These functions are categorized as immediate effects, such as changes in binding of factors to specific DNA sequences, and remote effects, including transcriptional modulation resulting from these changes. The clinical application section focuses on diseases linked to abnormal DNA methylation. These include developmental syndromes caused by inherited mutations in genes encoding methylation modulators, as well as cancers characterized by somatic mutations (such as TET2 or DNMT3A) and abnormal methylation patterns in various diseases. The review discusses the broad uses of DNA methylation assessment. Applications include its role as an epigenetic clock for estimating biological age, its utility in cancer screening and early detection, subcategorization of cancer types, determination of tumor origin, and diagnosis in cases with unclear histology. Finally, the review concludes with a description of DNA methylation-targeting agents used in hematologic malignancies and their limited effectiveness in solid tumors. It briefly addresses the ongoing development of future drugs designed to modulate DNA methylation.
中文摘要:这篇综述概述DNA甲基化,从其化学修饰和生物学作用开始,进而讨论其临床相关性。内容面向不具备该领域先验知识的读者,分为两个主要部分:生物学机制与临床应用。第一部分探讨DNA甲基化背后的分子与生物学机制,考察不同类型的甲基化标记以及负责添加和去除这些标记的酶。该过程由DNA甲基化调节酶的募集和激活驱动,核小体屏障发挥重要作用。讨论的一个关键方面是发育过程中DNA甲基化模式的重置。这种重置以两个不同波次发生:第一次在生殖细胞中,第二次在受精后,与细胞分化以及不同谱系中转录程序的建立相关。文中描述了正常体细胞中DNA甲基化的典型位置和模式。综述还解释了DNA甲基化的多种分子功能。这些功能被归类为即时效应,例如因子与特定DNA序列结合的变化,以及远端效应,包括由这些变化引起的转录调控。临床应用部分聚焦于与DNA甲基化异常相关的疾病,包括由编码甲基化调节因子的基因遗传突变引起的发育综合征,以及以体细胞突变(如TET2或DNMT3A)和各种疾病中异常甲基化模式为特征的癌症。综述讨论了DNA甲基化评估的广泛用途,应用包括其作为表观遗传时钟估算生物学年龄的作用,在癌症筛查和早期检测中的效用,癌症类型的亚分类,肿瘤起源的确定,以及组织学不明确病例的诊断。综述以描述用于血液系统恶性肿瘤的DNA甲基化靶向药物及其在实体瘤中有限的效果作结,并简要提及旨在调节DNA甲基化的未来药物的持续开发。
Cell death and differentiation IF 13.6 2026-10-28 PMID: 42957858
Cisplatin-based chemotherapy constitutes the cornerstone of first-line treatment for muscle-invasive and metastatic bladder cancer (BCa); however, the frequent emergence of chemoresistance presents a formidable clinical obstacle. In the present study, by combining a systematic CRISPR-Cas9 E3 ligase library screen with drug sensitivity data from the GDSC database, DCST1 (DC-STAMP Domain Containing 1) was identified as a pivotal driver of cisplatin resistance. DCST1 expression was found to be markedly upregulated in chemoresistant BCa tissues, and its elevated expression served as an independent predictor of poor patient prognosis. Functionally, DCST1 deficiency sensitizes BCa cells to cisplatin in vitro and in vivo by triggering PANoptosis (simultaneous apoptosis, pyroptosis, and necroptosis). Mechanistically, DCST1 functions as an atypical E3 ubiquitin ligase to catalyze the K11/K27-linked polyubiquitination of NFAT5 at residue K450. This non-canonical ubiquitination stabilizes NFAT5 by preventing its lysosomal degradation and promotes its nuclear accumulation. Nuclear NFAT5 then transcriptionally activates SOD2, orchestrating an anti-PANoptotic program that ensures BCa cell survival under chemotherapeutic stress. Furthermore, through molecular docking and CETSA validation, digoxin was identified as a potent pharmacological inhibitor of NFAT5 that overcomes DCST1-mediated chemoresistance and synergistically restores cisplatin sensitivity. Collectively, these findings unveil a previously unrecognized ubiquitination-dependent mechanism of chemoresistance and establish the DCST1-NFAT5 signaling axis as a promising therapeutic target for overcoming drug resistance in BCa.
中文摘要:以顺铂为基础的化疗是肌层浸润性和转移性膀胱癌一线治疗的基石,但耐药频繁出现构成严峻的临床障碍。该研究将系统性CRISPR-Cas9 E3连接酶文库筛选与GDSC数据库的药物敏感性数据相结合,鉴定出DCST1(DC-STAMP结构域包含蛋白1)是顺铂耐药的关键驱动因子。DCST1在耐药膀胱癌组织中表达明显上调,其高表达是患者预后不良的独立预测因素。功能上,DCST1缺失在体外和体内均通过触发PANoptosis(凋亡、焦亡与坏死性凋亡同时发生)使膀胱癌细胞对顺铂敏感。机制上,DCST1作为非典型E3泛素连接酶,催化NFAT5第K450位点的K11/K27连接型多聚泛素化。这种非经典泛素化阻止NFAT5经溶酶体降解而使其稳定,并促进其核内蓄积。核内NFAT5随后转录激活SOD2,启动抗PANoptosis程序,保障膀胱癌细胞在化疗应激下存活。进一步通过分子对接与CETSA验证,鉴定地高辛为NFAT5的有效药理抑制剂,可克服DCST1介导的耐药并协同恢复顺铂敏感性。这些发现揭示了一种此前未被认识的泛素化依赖的耐药机制,并将DCST1-NFAT5信号轴确立为克服膀胱癌耐药的有前景的治疗靶点。
Trends in cancer IF 21.6 2026-10-24 PMID: 42919756
Liu et al. enabled genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening of primary human T cells in vivo and identified P2RY8 and GNAS through complementary functional readouts. We discuss how context shapes perturbation effects, and how readouts guide prioritization, with implications for T cell engineering in solid tumors.
中文摘要:Liu等人实现了对原代人T细胞的体内全基因组CRISPR筛选,并通过互补的功能读出鉴定出P2RY8和GNAS。我们讨论情境如何塑造扰动效应,读出如何指导优先级排序,以及对实体瘤中T细胞工程的意义。

5肿瘤基础/转化 (14篇)

临床研究 (1篇)

EBioMedicine IF 11.2 2026-10-27 PMID: 42945895
CD30+ T cell lymphoproliferative disorders (CD30+ T LPD) with cutaneous involvement comprise a diverse group of neoplasms with variable clinical outcomes. The molecular mechanisms underlying the prognostic differences in these diseases are poorly understood. In this multi-institutional retrospective study, 79 patients with CD30+ T LPD were evaluated. DNA and RNA sequencing were performed on skin biopsy samples to characterise molecular features. Patients were assigned to low- and high-risk groups based on treatment recommendations in clinical records. Pathogenic pathways, immune microenvironments, transcriptomic profiles, driver mutations, and mutation signatures were compared between the risk groups. Across risk groups, there was high mutational recurrence in genes involved in epigenetic regulation and intracellular signalling pathways. Mutational signature analysis revealed a shared prevalence of 5-methylcytosine deamination, UV exposure, defective mismatch repair, and POLE-associated proofreading deficiency. In contrast, gene set enrichment analysis showed that the high-risk group was enriched in pathways governing cell cycle progression, DNA damage response, and immune activation compared to the low-risk group. Furthermore, immune microenvironment deconvolution showed a higher abundance of resting dendritic cells in the low-risk group. Finally, high-risk patients exhibited significant overexpression of clinically relevant proteins, highlighting potential alternative treatment approaches for this population. Mutation analyses suggest diverse pathogenesis in these diseases. The high-risk and low-risk groups diverge in gene expression profiles and immune microenvironment, suggesting that these biological differences hold prognostic significance. Molecularly informed therapeutic strategies should be investigated prospectively through clinical trials. This work was supported by developmental funds of the Duke Cancer Institute as part of the P30 Cancer Center Support Grant. Data generation was supported in an unrestricted fashion by the NIH, Data Driven Bioscience, Amazon and Google. SSD was supported by the Wellcome Trust Foundation and the NIH.
中文摘要:伴皮肤受累的CD30+ T细胞淋巴增殖性疾病(CD30+ T LPD)包括一组异质性肿瘤,临床结局差异较大。这些疾病预后差异的分子机制仍不清楚。这项多机构回顾性研究评估了79例CD30+ T LPD患者,对皮肤活检样本进行DNA和RNA测序以刻画分子特征。根据临床记录中的治疗建议将患者分为低危组和高危组,比较两组的致病通路、免疫微环境、转录组谱、驱动突变和突变特征。两组均可见表观遗传调控和细胞内信号通路相关基因的高频复发性突变。突变特征分析显示,5-甲基胞嘧啶脱氨、紫外线暴露、错配修复缺陷和POLE相关校对缺陷在两组中均常见。基因集富集分析显示,与低危组相比,高危组在细胞周期进展、DNA损伤应答和免疫激活相关通路上富集。免疫微环境解卷积显示低危组静息树突状细胞丰度更高。高危患者表现出若干临床相关蛋白的显著过表达,提示该人群可能采用替代治疗策略。突变分析提示这些疾病存在多样的发病机制。高危组与低危组在基因表达谱和免疫微环境上存在差异,提示这些生物学差异具有预后意义。应在临床试验中前瞻性研究基于分子信息的治疗策略。本工作由杜克癌症研究所发展基金支持,该基金属于P30癌症中心支持资助的一部分。数据生成得到NIH、Data Driven Bioscience、Amazon和Google的无限制支持。SSD得到Wellcome Trust基金会和NIH支持。

基础研究 (13篇)

Experimental hematology & oncology IF 17.5 2026-10-30 PMID: 42963551
LUAD exhibits diversity in the mechanisms of angiogenesis and the tumor environment's responses to anti-VEGF therapy, while the tumor-cell-intrinsic mechanisms that prevent vascularization are not well understood. SCGB3A2 (secretoglobin 3A2; HIN-2/UGRP1) is a club/secretory marker of pulmonary adenocarcinoma without established angiogenic function. By using an unsupervised integration approach of two public LUAD single-cell RNA-seq cohorts, we described a SCGB3A2-high malignant epithelial state characterized by an angiogenesis-low phenotype as indicated by the low presence of VEGFA, hypoxic conditions, and a low epithelial-mesenchymal transition (EMT), along with a secretory/anti-inflammatory program, which was confirmed in independent bulk cohorts (TCGA-LUAD, GSE72094) showing that SCGB3A2-high tumors experienced lower instances of angiogenesis, hypoxia, and scores related to EMT/invasion. Using spatial transcriptomics, we positioned SCGB3A2-high tumor cells next to endothelial cells and identified a spatially inferred VEGFA/B-FLT1 interaction pattern. In A549 and NCI-H1975 cells, conditioned medium from SCGB3A2-overexpressing cells contained higher levels of extracellular PGK2-immunoreactive signal and angiostatin and was associated with reduced HUVEC tube formation and VEGFR2 phosphorylation. Thus, SCGB3A2 is a marker for LUAD tumors characterized by low levels of angiogenesis, which is associated with an extracellular PGK2/angiostatin signal.
中文摘要:肺腺癌(LUAD)在血管生成机制及肿瘤环境对抗VEGF治疗的反应上存在差异,而阻止血管化的肿瘤细胞内在机制尚不清楚。SCGB3A2(secretoglobin 3A2;HIN-2/UGRP1)是肺腺癌的棒状/分泌细胞标志物,其血管生成功能尚未确立。通过对两个公开LUAD单细胞RNA测序队列进行无监督整合分析,我们描述了一种SCGB3A2高表达的恶性上皮状态,其特征为血管生成水平低的表型,表现为VEGFA存在少、缺氧程度低、上皮-间质转化(EMT)水平低,并伴分泌性/抗炎程序;该结果在独立的bulk队列(TCGA-LUAD、GSE72094)中得到验证,SCGB3A2高表达肿瘤的血管生成、缺氧及EMT/侵袭相关评分均较低。借助空间转录组,我们将SCGB3A2高表达肿瘤细胞定位在内皮细胞邻近区域,并识别出空间推断的VEGFA/B-FLT1相互作用模式。在A549与NCI-H1975细胞中,SCGB3A2过表达细胞的条件培养基含更高水平的细胞外PGK2免疫反应信号与angiostatin,并与HUVEC成管减少及VEGFR2磷酸化降低相关。因此,SCGB3A2是血管生成水平低的LUAD肿瘤的标志物,这一特征与细胞外PGK2/angiostatin信号相关。
Cell death and differentiation IF 13.6 2026-10-30 PMID: 42963414
Chronic stress is associated with increased risk of breast cancer metastasis and poor clinical outcomes; however, the underlying mechanisms remain incompletely understood. Here, we demonstrated that chronic stress elevates lactate levels in the tumor microenvironment, thereby promoting lactylation of metastasis associated 1 family member 2 (MTA2) at lysine 460. Mechanistically, chronic stress not only enhances lactate metabolism within the tumor microenvironment, providing sufficient substrate for lactylation, but also activates the β2-adrenergic receptor (β2-AR)/PKA signaling axis, leading to P300 phosphorylation and cooperatively facilitating MTA2 lactylation. This modification weakens the interaction between MTA2 and RBBP7, resulting in destabilization of the nucleosome remodelling and histone deacetylase (NuRD) complex and impaired transcriptional repression. This is accompanied by increased H3K9 acetylation and upregulation of genes associated with both tumor progression and metastasis, including MMP16, NRP1, and VCAM1. Importantly, a cell-penetrating peptide specifically targeting MTA2 lactylation effectively inhibits breast tumor growth and reduces lung metastatic burden in chronic stress models. Together, our findings identify protein lactylation, especially that of MTA2, as a key regulatory event in chronic stress-induced tumor progression, providing new insights into the link between tumor epigenetics and chronic stress, and suggesting a potential biomarker and therapeutic target for prognostic assessment and clinical intervention in breast cancer patients under chronic stress.
中文摘要:慢性应激与乳腺癌转移风险升高及临床预后不良相关,但其机制尚未完全阐明。研究显示,慢性应激提高肿瘤微环境中的乳酸水平,促进转移相关1家族成员2(MTA2)在赖氨酸460位点发生乳酸化。机制上,慢性应激既增强肿瘤微环境内的乳酸代谢,为乳酸化提供充足底物,又激活β2肾上腺素能受体(β2-AR)/PKA信号轴,引起P300磷酸化,协同促进MTA2乳酸化。该修饰削弱MTA2与RBBP7的相互作用,导致核小体重塑和组蛋白去乙酰化酶(NuRD)复合物不稳定,转录抑制作用受损。这一过程伴随H3K9乙酰化升高以及MMP16、NRP1和VCAM1等肿瘤进展和转移相关基因上调。靶向MTA2乳酸化的细胞穿透肽在慢性应激模型中可有效抑制乳腺肿瘤生长并减轻肺转移负荷。这些结果将蛋白乳酸化,尤其是MTA2乳酸化,确定为慢性应激诱导肿瘤进展中的关键调控事件,为肿瘤表观遗传与慢性应激之间的联系提供了新认识,并提示其可作为慢性应激下乳腺癌患者预后评估和临床干预的潜在生物标志物与治疗靶点。
Nucleic acids research IF 15.0 2026-10-30 PMID: 42958965
Dictyostelium discoideum is a model organism used to investigate a wide array of biological processes including chemotaxis, cell motility, phagocytosis, multicellular development, and autophagy. Many of its genes have human orthologs implicated in disease, making it a useful model organism for studying conditions ranging from cancer to neurodegeneration. dictyBase has served this community for two decades as a home for genomic data, protocols, a stock center, and community news. Here we describe a complete reimplementation of dictyBase as a self-contained service that uses static data files rather than a database server. Each gene record gathers curated function, human-disease context, developmental expression, and protein structure in a single webpage. The site also provides tools for sequence search, genome browsing, enrichment analysis, and experimental design. The complete Dicty Stock Center catalog of 7055 strains and 1265 plasmids is included, and both can be ordered from the site. New literature is curated by an author-in-the-loop pipeline. A language model drafts the annotations, the authors of the paper correct them, and a curator approves them. Analyses can be run on curator-approved annotations alone or extended to include those still awaiting review. dictyBase is freely available at https://dicty.org.
中文摘要:盘基网柄菌(Dictyostelium discoideum)是一种模式生物,用于研究趋化、细胞运动、吞噬、多细胞发育和自噬等广泛的生物学过程。其许多基因具有与疾病相关的人类直系同源基因,因而成为研究从癌症到神经退行性病变等病症的有用模式生物。dictyBase 二十年来作为该群体的资源平台,汇集基因组数据、实验方案、品系保藏中心与社区资讯。dictyBase 的完全重构版本以自包含服务的形式实现,使用静态数据文件而非数据库服务器。每条基因记录在单一网页中汇集经审编的功能、人类疾病背景、发育期表达与蛋白质结构信息。站点还提供序列检索、基因组浏览、富集分析和实验设计工具。Dicty Stock Center 全部 7055 个菌株与 1265 个质粒的目录已收录,两者均可从站点订购。新文献由作者参与式流程审编:语言模型起草注释,论文作者订正,再由审编人员核准。分析既可仅基于审编核准的注释运行,也可扩展至包含尚待审核的注释。dictyBase 可在 https://dicty.org 免费访问。
Autophagy IF 18.6 2026-10-28 PMID: 42922083
The network of transcription factors (TFs) is an integral component of executing macroautophagy/autophagy-lysosome gene expression to maintain cellular homeostasis. Across metazoans, conserved TFs, particularly the helix-loop-helix factor TFEB, convert upstream signals into specific genetic programs through mechanisms ranging from DNA recognition and chromatin remodeling to biomolecular condensates. The dysregulation of TF-governed gene programming disrupts the progression of metabolic disease and cancer, highlighting that dissection of transcriptional regulation makes it a promising therapeutic target. Consequently, instead of indirectly modulating the pathways in which they are involved, targeting these essential TFs directly is becoming a new trend for pharmaceutical development. In this review, we systematically elucidate current mechanisms of the TF-driven autophagic transcriptome, and summarize current small molecules targeting these TFs in various disease.Abbreviations: AD: Alzheimer disease; AFF4: ALF transcription elongation factor 4; AKT: AKT serine/threonine kinase; AMPK: AMP-activated protein kinase; AR: androgen receptor; ATF4: activating transcription factor 4; ATG: autophagy related; BECN1: beclin 1; BNIP3: BCL2 interacting protein 3; BRD4: bromodomain containing 4; CRC: colorectal cancer; CREBBP/CBP: CREB binding lysine acetyltransferase; CTNNB1/β-catenin: catenin beta 1; DBD: DNA-binding domain; DDIT3: DNA damage inducible transcript 3; DRAM1: DNA damage regulated autophagy modulator 1; E2F1: E2F transcription factor 1; EHMT2/G9a: euchromatic histone lysine methyltransferase 2; EO: eltrombopag; EP300/p300: EP300 lysine acetyltransferase; ERBB2: erb-b2 receptor tyrosine kinase 2; FOXO3: forkhead box O3; GSH: glutathione; GSK3B/GSK3β: glycogen synthase kinase 3 beta; HD: Huntington disease; KAT2B/GCN5: lysine acetyltransferase 2B; HMGB1: high mobility group box 1; KDACs: lysine deacetylases; KEAP1: kelch like ECH associated protein 1; KLF4: KLF transcription factor 4; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPK: mitogen-activated protein kinase; MITF: melanocyte inducing transcription factor; MTORC1: mechanistic target of rapamycin kinase complex 1; MiT/TFE: microphthalmia-transcription factor E; MYC: proto-oncogene, bHLH transcription factor; NDs: neurodegenerative disorders; NFE2L2/NRF2: NFE2 like bZIP transcription factor 2; P-TEFb: positive transcription elongation factor b; PARP1: poly(ADP-ribose) polymerase 1; PD: Parkinson disease; PIC: pre-initiation complex; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PTMs: post-translational modifications; POLR2: RNA polymerase II; SIRT1: sirtuin 1; SNAI2: snail family transcriptional repressor 2; STAT3: signal transducer and activator of transcription 3; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: transcription factor EB; TFs: transcription factors; TNKS: tankyrase; TP53: tumor protein p53; ULK1: unc-51 like autophagy activating kinase 1; YWHA/14-3-3: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; YY1: YY1 transcription factor; ZKSCAN3: zinc finger with KRAB and SCAN domains 3.
中文摘要:转录因子网络是执行巨自噬/自噬-溶酶体基因表达以维持细胞稳态的组成部分。在后生动物中,保守转录因子尤其是螺旋-环-螺旋转录因子TFEB,通过DNA识别、染色质重塑到生物分子凝聚体等机制,将上游信号转化为特定基因程序。TF调控基因编程失调会扰乱代谢疾病和癌症进展,解析转录调控使其成为有前景的治疗靶点。因此,直接靶向这些关键TF而非间接调控其参与的通路,正成为药物开发的新趋势。文章系统阐述TF驱动自噬转录组的现有机制,并总结各类疾病中靶向这些TF的小分子。
Cancer letters IF 11.8 2026-10-28 PMID: 42641865
Lineage plasticity has emerged as a central mechanism through which cancer cells adapt to therapeutic pressure, evade immune surveillance, and acquire aggressive phenotypes. Although recognized across tumor types, the regulatory principles governing how cancer cells reprogram cellular identity remain incompletely understood. In this review, we propose that lineage plasticity in cancer reflects the redeployment of regulatory frameworks established during normal development. Rather than representing a stochastic byproduct of genomic instability, cancer plasticity frequently unfolds within gene regulatory architectures that also govern cell fate specification, lineage commitment, and controlled state transitions during embryogenesis and tissue homeostasis. Developmental transcription factors, including members of the SOX family, FOXA1, ASCL1, NKX2-1, and epithelial-mesenchymal transition regulators, function as lineage gatekeepers during development but are repurposed in cancer to destabilize lineage commitment and enable phenotypic switching. Similarly, epigenetic regulators that guide developmental trajectories, including chromatin remodeling complexes, Polycomb group proteins, and DNA methylation machinery, are frequently dysregulated or redistributed in tumors, altering the repression of lineage-stabilizing and alternative lineage programs and thereby weakening epigenetic barriers to lineage transitions. Together, these observations support a model in which development and cancer operate as mirror regulatory systems: one establishing and stabilizing cellular identity, the other exploiting the same regulatory architecture to permit adaptive reprogramming under selective pressure. We further discuss how emerging single-cell and spatial multi-omics technologies, integrated with artificial intelligence-based modeling, enable mapping of cell state landscapes and transitional trajectories, transforming lineage plasticity from a descriptive phenomenon into a measurable and predictable property of tumor evolution.
中文摘要:谱系可塑性已成为癌细胞适应治疗压力、逃避免疫监视并获得侵袭性表型的核心机制。尽管在多种肿瘤类型中已被认识,调控癌细胞如何重编程细胞身份的调控原则仍未被充分理解。在这篇综述中,我们提出,癌症中的谱系可塑性反映了正常发育过程中建立的调控框架的重新部署。癌症可塑性并非基因组不稳定的随机副产物,而常常在同样调控胚胎发生和组织稳态中的细胞命运特化、谱系定向及受控状态转换的基因调控架构内展开。发育转录因子,包括SOX家族成员、FOXA1、ASCL1、NKX2-1及上皮-间质转化调控因子,在发育中作为谱系守门人,但在癌症中被重新利用以削弱谱系定向并促成表型转换。类似地,引导发育轨迹的表观遗传调控因子,包括染色质重塑复合物、Polycomb群蛋白和DNA甲基化机器,在肿瘤中经常失调或重新分布,改变对谱系稳定程序和替代谱系程序的抑制,从而削弱谱系转换的表观遗传屏障。这些观察共同支持一个模型:发育与癌症作为镜像调控系统运行,一个建立并稳定细胞身份,另一个利用相同调控架构在选择压力下允许适应性重编程。我们进一步讨论新兴的单细胞和空间多组学技术如何与基于人工智能的建模整合,从而能够绘制细胞状态景观和转换轨迹,将谱系可塑性从描述性现象转变为肿瘤演化中可测量且可预测的属性。
Cancer letters IF 11.8 2026-10-28 PMID: 42632513
PBRM1 is an important subunit of the SWI/SNF complex, which broadly regulates gene transcription by chromatin remodeling. Genomic alterations of PBRM1 have been found in patients with pancreatic ductal adenocarcinoma (PDAC), but its molecular functions remain unclear. Clinical relevance of PBRM1 was analyzed by using human PDAC samples and public genomic datasets. Mice with concomitant pancreas-specific Pbrm1 deletion in Kras-driven genetic PDAC models were generated. Single-cell transcriptomics were performed to determine tumor phenotype and microenvironment reprogramming. Reduction of PBRM1 expression was observed in human PDAC tissues and correlated with poor prognosis and metastasis. Pbrm1 loss promoted ductal metaplasia and delayed epithelial recovery in mice with caerulein-induced pancreatic injury. In PDAC model with either mutant Kras alone or in combination with Trp53 mutation, lack of Pbrm1 markedly accelerated tumor development and progression. Bulk transcriptomics and scRNA-seq identified reprogramming of both tumor compartment with mesenchymal phenotype acquisition and stroma compartment with inflammatory cancer-associated fibroblasts (iCAFs) transformation. Mechanistically, Pbrm1 deletion induced Zeb1 upregulation through epigenetic chromatin remodeling, thereby enhancing epithelial-mesenchymal and basal-like subtype transition. These findings indicated a tumor-suppressing role of PBRM1 in PDAC. PBRM1-deficient PDAC constitutes a specific subgroup of patients with aggressive phenotype and prognostic significance.
中文摘要:PBRM1是SWI/SNF复合物的重要亚基,通过染色质重塑广泛调控基因转录。在胰腺导管腺癌(PDAC)患者中已发现PBRM1基因组改变,但其分子功能仍不清楚。利用人PDAC样本和公共基因组数据集分析PBRM1的临床相关性。在Kras驱动的遗传性PDAC模型中构建胰腺特异性Pbrm1缺失小鼠。进行单细胞转录组学以确定肿瘤表型和微环境重编程。在人PDAC组织中观察到PBRM1表达降低,并与不良预后和转移相关。Pbrm1缺失促进雨蛙素诱导胰腺损伤小鼠的导管化生并延迟上皮恢复。在仅携带突变Kras或联合Trp53突变的PDAC模型中,Pbrm1缺失显著加速肿瘤发生和进展。批量转录组学和单细胞RNA测序发现肿瘤区域获得间充质表型,间质区域发生炎症性癌症相关成纤维细胞(iCAFs)转化。机制上,Pbrm1缺失通过表观遗传染色质重塑诱导Zeb1上调,从而增强上皮-间充质转化和基底样亚型转变。这些发现表明PBRM1在PDAC中具有抑癌作用。PBRM1缺陷型PDAC构成具有侵袭性表型和预后意义的一个特定患者亚组。
Cancer letters IF 11.8 2026-10-28 PMID: 42607859
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, characterized by persistently poor survival rates and limited effective therapeutic options. Ferroptosis, an iron-dependent form of regulated cell death driven by uncontrolled lipid peroxidation, has recently emerged as a potentially targetable vulnerability in PDAC. In this Review, we synthesize current understanding of the core molecular mechanisms governing ferroptosis, including dysregulated iron metabolism, lipid peroxidation pathways, and failure of antioxidant defense systems. We further discuss the complex regulatory networks that shape ferroptosis sensitivity in PDAC, highlighting the contributions of endoplasmic reticulum stress, mitochondrial dysfunction, autophagy, and DNA damage-associated signaling pathways. Within the broader landscape of PDAC biology, ferroptosis exerts context-dependent and sometimes opposing effects, influencing both tumor initiation and the development of therapeutic resistance. Accordingly, PDAC cells engage diverse epigenetic, metabolic, and microenvironmental adaptations to evade ferroptotic cell death, thereby sustaining resistance to therapy. Finally, we review the rapidly expanding spectrum of ferroptosis-based therapeutic strategies, encompassing small-molecule inducers, natural products, and, in particular, advanced nanomedicine platforms designed to enhance intratumoral drug delivery, overcome stromal barriers, and enable coordinated induction of ferroptosis while remodeling the tumor microenvironment.
中文摘要:胰腺导管腺癌(PDAC)仍是致死率最高的人类恶性肿瘤之一,生存率长期偏低,有效治疗选择有限。铁死亡是一种由脂质过氧化失控驱动的铁依赖性调节性细胞死亡,近年来被视为PDAC中可能可靶向的脆弱点。文章整合了铁死亡核心分子机制的当前认识,包括铁代谢失调、脂质过氧化通路以及抗氧化防御系统失效。文章进一步讨论塑造PDAC铁死亡敏感性的复杂调控网络,强调内质网应激、线粒体功能障碍、自噬和DNA损伤相关信号通路的贡献。在PDAC生物学的整体图景中,铁死亡呈现情境依赖且有时相反的作用,既影响肿瘤起始,也影响治疗耐药的形成。相应地,PDAC细胞通过表观遗传、代谢与微环境适应等多种方式逃避铁死亡,从而维持治疗耐药。文章还回顾了快速扩展的基于铁死亡的治疗策略,涵盖小分子诱导剂、天然产物,尤其是旨在增强瘤内药物递送、克服基质屏障并在重塑肿瘤微环境的同时实现铁死亡协同诱导的先进纳米医学平台。
Cancer letters IF 11.8 2026-10-28 PMID: 42595075
Enhanced glycolysis leads to pathological lactate accumulation and promotes malignant tumor progression through protein lactylation. However, the mechanisms by which lactylation enhances RNA processing to drive prostate cancer metastasis remain unclear. Specifically, we found that pathologically accumulated lactate induces the synthesis of a novel circRNA, circPTK2 (hsa_circ_0135904), which is highly expressed in PCa and predicts poor patient prognosis. Functionally, lactylated EIF4A3-induced circPTK2 promotes PCa metastasis in vitro and in vivo. Mechanistically, we revealed that lactylated EIF4A3 interacts with the flanking introns of exons 16-20 on PTK2 pre-mRNA to trigger sustained circPTK2 biogenesis. Subsequently, circPTK2 upregulates the expression of SLC4A4 by directly sponging miR-582-5p, which in turn activates the PI3K/AKT signaling pathway to drive the epithelial-mesenchymal transition (EMT) and metastasis of PCa. Crucially, SLC4A4-mediated intracellular pH (pHi) homeostasis promotes intracellular lactate accumulation, thereby enhancing EIF4A3 lactylation and establishing a positive regulatory axis. Importantly, circPTK2 overexpression significantly accelerated subcutaneous tumor growth and facilitated lung metastasis in PCa mouse models. Our findings identify a novel mechanism by which lactate metabolism drives circRNA biogenesis, where the lactylation of EIF4A3 promotes the aberrant synthesis of circPTK2. Furthermore, we characterized a unique mechanism involving a lactylation-driven EIF4A3/circPTK2/SLC4A4 positive regulatory axis that promotes distant metastasis in PCa. Targeting this lactylation-mediated axis represents a promising therapeutic strategy for metastatic disease.
中文摘要:糖酵解增强导致病理性乳酸蓄积,并通过蛋白乳酰化促进恶性肿瘤进展。乳酰化如何增强RNA加工并驱动前列腺癌转移,其机制仍不清楚。我们发现,病理性蓄积的乳酸诱导一种新的circRNA circPTK2(hsa_circ_0135904)合成,该circRNA在前列腺癌中高表达并预示患者预后不良。功能上,乳酰化EIF4A3诱导的circPTK2在体外和体内促进前列腺癌转移。机制上,乳酰化EIF4A3与PTK2前体mRNA第16-20外显子侧翼内含子相互作用,触发circPTK2持续生成。随后,circPTK2通过直接海绵吸附miR-582-5p上调SLC4A4表达,进而激活PI3K/AKT信号通路,驱动前列腺癌上皮-间质转化(EMT)和转移。关键的是,SLC4A4介导的细胞内pH(pHi)稳态促进细胞内乳酸蓄积,从而增强EIF4A3乳酰化,形成正调控轴。circPTK2过表达显著加速前列腺癌小鼠模型皮下肿瘤生长并促进肺转移。我们的发现揭示了乳酸代谢驱动circRNA生成的新机制,其中EIF4A3乳酰化促进circPTK2异常合成。我们还阐明了一种独特机制,即乳酰化驱动的EIF4A3/circPTK2/SLC4A4正调控轴促进前列腺癌远处转移。靶向这一乳酰化介导的轴是转移性疾病有前景的治疗策略。
ACS nano IF 17.3 2026-10-27 PMID: 42937568
Bone metastasis remains a major clinical challenge in advanced breast cancer because therapeutic efficacy is limited by poor lesion targeting and systemic toxicity. Moreover, the hypoxic bone microenvironment induces protective autophagy in tumor cells, which maintains metabolic homeostasis and limits therapeutic efficacy. Herein, we develop a bone metastasis-targeted micellar system (AD/R) to overcome this protective autophagy "shield". Based on the low crystallinity of pathological hydroxyapatite (HAP) and the hypoxic bone microenvironment, a pathological HAP-targeting polymer (DSPE-PEG-ALN, DPA) and a hypoxia-responsive polymer (DSPE-AZO-PEG, DAP) are coassembled into micelles encapsulating the oxidative phosphorylation inhibitor resveratrol (RES). Following selective accumulation in bone-metastatic lesions, AD/R undergoes hypoxia-triggered disassembly. The released DPA induces calcium-mediated membrane mineralization to restrict oxygen and nutrient supply, whereas RES suppresses oxidative phosphorylation and ATP production. This "external blockade" and "internal disruption" synergistically aggravate metabolic stress, activate AMPK-dependent autophagy, and impair lysosomal degradation through lysosomal membrane permeabilization, ultimately inducing autophagy dysfunction and autophagy-associated tumor cell death. In murine breast cancer bone metastasis models, AD/R effectively suppresses bone and secondary lung metastases and restores bone homeostasis. This work establishes a "turn shield into sword" paradigm by converting protective autophagy into metabolic stress-induced autophagy dysfunction for the treatment of bone metastasis.
中文摘要:骨转移是晚期乳腺癌面临的主要临床难题,病灶靶向性差和全身毒性限制了治疗效果。缺氧的骨微环境会诱导肿瘤细胞产生保护性自噬,维持代谢稳态并削弱疗效。本研究构建了骨转移靶向胶束系统AD/R,用于破除这种保护性自噬的「盾牌」。基于病理性羟基磷灰石(HAP)的低结晶性以及缺氧骨微环境,将病理性HAP靶向聚合物DSPE-PEG-ALN(DPA)与缺氧响应聚合物DSPE-AZO-PEG(DAP)共组装成胶束,并包载氧化磷酸化抑制剂白藜芦醇(RES)。AD/R在骨转移病灶选择性蓄积后发生缺氧触发的解组装。释放的DPA诱导钙介导的膜矿化,限制氧气和营养供应;RES抑制氧化磷酸化与ATP生成。这种「外部阻断」与「内部破坏」协同加重代谢应激,激活AMPK依赖性自噬,并通过溶酶体膜通透化损害溶酶体降解,最终诱导自噬功能障碍和自噬相关肿瘤细胞死亡。在小鼠乳腺癌骨转移模型中,AD/R有效抑制骨转移和继发性肺转移,并恢复骨稳态。该工作建立了「化盾为剑」的策略,将保护性自噬转化为代谢应激诱导的自噬功能障碍,用于骨转移治疗。
ACS nano IF 17.3 2026-10-27 PMID: 42937553
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) poses a major clinical challenge for EGFR-mutant non-small-cell lung cancer patients with brain metastasis. A key unresolved question is whether the adaptive mechanisms driving TKI resistance also confer new therapeutic vulnerabilities. Here, we reveal that TKI-resistant lung cancer brain metastatic cells develop a redox perturbation state, characterized by elevated oxidative stress and diminished antioxidant capacity, which confers a latent sensitivity to ferroptosis induction. To exploit this vulnerability, we developed MIL-S@M, a brain-targeted nanoplatform capable of efficient blood-brain barrier penetration and glutathione-responsive drug release. MIL-S@M potently induces ferroptosis through the synergistic effects of iron overload, glutathione depletion, and glutathione peroxidase 4 inactivation. In mouse models of osimertinib-resistant brain metastasis, MIL-S@M significantly suppressed tumor growth and extended survival, both as a monotherapy and in combination with osimertinib, without inducing systemic or neurotoxic effects. This work unveils a targetable adaptation in TKI-resistant brain metastasis and presents a translatable nanotherapeutic strategy.
中文摘要:EGFR酪氨酸激酶抑制剂(TKI)获得性耐药是EGFR突变非小细胞肺癌脑转移患者面临的主要临床难题。一个尚未解决的关键问题是,驱动TKI耐药的适应性机制是否同时带来新的治疗脆弱性。研究发现,TKI耐药肺癌脑转移细胞形成氧化还原扰动状态,表现为氧化应激升高和抗氧化能力下降,从而对铁死亡诱导具有潜在敏感性。为利用这一脆弱性,我们构建了MIL-S@M,一种能够高效穿透血脑屏障并实现谷胱甘肽响应性释药的脑靶向纳米平台。MIL-S@M通过铁过载、谷胱甘肽耗竭和谷胱甘肽过氧化物酶4失活的协同作用强烈诱导铁死亡。在奥希替尼耐药脑转移小鼠模型中,MIL-S@M单药及联合奥希替尼均显著抑制肿瘤生长并延长生存期,且未引起全身毒性或神经毒性。该工作揭示了TKI耐药脑转移中可靶向的适应性改变,并提供了一种可转化的纳米治疗策略。
Cancer biology & medicine IF 12.4 2026-10-26 PMID: 42947464
The aims of the study were to elucidate the regulatory role of rhomboid family protein 2 (RHBDF2) in breast cancer chemoresistance and the underlying molecular mechanisms to provide a theoretical basis and research direction to facilitate the development of potential therapeutic interventions. Chemoresistance and apoptosis assays, and mouse tumor-bearing models were used to evaluate the correlation between RHBDF2 expression and breast cancer chemoresistance. Doxorubicin accumulation, rhodamine efflux, immunohistochemical staining, Western blot, and quantitative polymerase chain reaction were used to validate the regulatory relationships in protein expression and function for RHBDF2, MDR1 (ABCB1), and SEC62 (a critical component of the endoplasmic reticulum membrane insertion machinery). Immunofluorescence staining and immunoprecipitation assays were employed to determine the molecular mechanisms underlying RHBDF2-SEC62-MDR1 axis-mediated regulation of breast cancer chemoresistance. The RHBDF2-SEC62-MDR1 axis constitutes the core regulatory pathway in breast cancer chemoresistance. When RHBDF2 is highly expressed, it binds to heat shock cognate protein 70 (HSC70), a central chaperone-mediated autophagy receptor, thereby blocking the HSC70-mediated degradation of SEC62, maintaining SEC62 protein levels, and promoting membrane integration of MDR1 to enhance drug resistance. Under downregulated RHBDF2 expression, the HSC70-mediated degradation of SEC62 increases, leading to impaired MDR1 function and substantially reduced cellular drug resistance. The RHBDF2-SEC62-MDR1 axis is the core signaling pathway that governs chemoresistance in breast cancer. Targeted interventions against key molecules or related signaling nodes in this axis can provide a theoretical basis for developing novel therapeutic strategies to reverse chemoresistance, with great clinical translational value.
中文摘要:研究旨在阐明菱形家族蛋白2(RHBDF2)在乳腺癌化疗耐药中的调控作用及分子机制,为潜在治疗干预的开发提供理论依据与方向。采用化疗耐药与凋亡实验以及小鼠荷瘤模型评估RHBDF2表达与乳腺癌化疗耐药的相关性。通过多柔比星蓄积、罗丹明外排、免疫组化染色、Western blot和定量聚合酶链反应验证RHBDF2、MDR1(ABCB1)与SEC62(内质网膜插入机器的关键组分)在蛋白表达与功能上的调控关系。以免疫荧光染色和免疫沉淀实验确定RHBDF2-SEC62-MDR1轴介导乳腺癌化疗耐药调控的分子机制。RHBDF2-SEC62-MDR1轴是乳腺癌化疗耐药的核心调控通路。RHBDF2高表达时与热休克同源蛋白70(HSC70,分子伴侣介导自噬的中心受体)结合,阻断HSC70介导的SEC62降解,维持SEC62蛋白水平,促进MDR1的膜整合,从而增强耐药。RHBDF2表达下调时,HSC70介导的SEC62降解增加,MDR1功能受损,细胞耐药性明显降低。RHBDF2-SEC62-MDR1轴是控制乳腺癌化疗耐药的核心信号通路。针对该轴关键分子或相关信号节点的靶向干预可为开发逆转化疗耐药的新策略提供理论依据,具有较大的临床转化价值。
Molecular cell IF 16.0 2026-10-26 PMID: 42933402
Single-stranded DNA (ssDNA) gaps are a hallmark of BRCA-deficient cells, yet the mechanisms that safeguard these lesions remain unclear. Using a genome-wide CRISPR screen in isogenic BRCA2-proficient and -deficient cancer cells, we identified the RAD9A-HUS1-RAD1 (9-1-1) complex as essential for BRCA2-deficient cell survival through an ATR-independent mechanism. In this context, loss of 9-1-1 leads to accumulation of PRIMPOL-dependent gaps that fail to undergo post-replicative repair, resulting in pathological expansion and increased DNA damage. Excessive EXO1-mediated degradation drives this genomic instability, as EXO1 depletion rescues the phenotype. We further demonstrate that the 9-1-1 complex contributes to POLζ-dependent gap filling. We propose a model in which ssDNA gaps, when extended beyond a critical length, become inaccessible to translesion synthesis (TLS)-mediated repair and rely entirely on homologous recombination. These findings establish the 9-1-1 complex as a key regulator of ssDNA gap stability and as a promising therapeutic target in BRCA2-deficient cancers.
中文摘要:单链DNA(ssDNA)缺口是BRCA缺陷细胞的特征,但保护这些损伤的机制仍不清楚。我们在同基因的BRCA2功能正常和缺陷癌细胞中进行全基因组CRISPR筛选,鉴定出RAD9A-HUS1-RAD1(9-1-1)复合物通过不依赖ATR的机制对BRCA2缺陷细胞的存活至关重要。在此背景下,9-1-1缺失导致依赖PRIMPOL的缺口积累,这些缺口无法进行复制后修复,造成病理性扩展和DNA损伤增加。过度的EXO1介导降解驱动这种基因组不稳定,因为敲低EXO1可挽救该表型。我们进一步证明9-1-1复合物参与依赖POLζ的缺口填补。我们提出一个模型:当ssDNA缺口延伸到超过临界长度时,便无法被跨损伤合成(TLS)介导的修复所处理,而完全依赖同源重组。这些发现确立9-1-1复合物是ssDNA缺口稳定性的关键调控因子,并作为BRCA2缺陷癌症中有前景的治疗靶点。
Autophagy IF 18.6 2026-10-26 PMID: 42921971
Macroautophagy (hereafter referred to as autophagy) is generally regarded as a cytoprotective process that maintains cellular homeostasis through intracellular recycling and metabolic adaptation. However, under certain conditions, autophagic machinery can contribute directly to cell death. Defining when autophagy functions as a cause rather than a consequence of cellular demise remains a major challenge and complicates the concept of autophagy-dependent cell death (ADCD). Experimental studies indicate that ADCD can occur through multiple mechanisms, including excessive self-digestion, autophagy-dependent lysosomal injury, selective autophagy-mediated degradation of critical cellular components, and specialized death programs such as autosis. These processes intersect extensively with apoptosis, necroptosis, ferroptosis, and pyroptosis, placing ADCD within a broader network of regulated cell death pathways. Evidence from cancer, neurodegenerative, cardiovascular, and inflammatory diseases further suggests that ADCD contributes to pathogenesis and may provide therapeutic opportunities. In this review, we discuss the criteria for defining ADCD, the molecular mechanisms underlying its execution, its interactions with other cell death pathways, and its relevance to human disease. Together, we propose a practical framework for distinguishing bona fide ADCD from cell death merely accompanied by autophagy and provide guidance for establishing autophagy as a causal component of the death process.Abbreviations: AACD: autophagy-associated cell death; ADCD: autophagy-dependent cell death; ADF: autophagy-dependent ferroptosis; ATP: adenosine triphosphate; ATPase: adenosine triphosphatase; AUTACs: autophagy-targeting chimeras; BH3: BCL2 homology 3; CAR-T: chimeric antigen receptor T; cGMP: cyclic guanosine monophosphate; CMA: chaperone-mediated autophagy; DAMPs: damage-associated molecular patterns; DHA: dihydroartemisinin; ER: endoplasmic reticulum; ER-phagy: endoplasmic reticulum-selective autophagy; H2O2: hydrogen peroxide; HIV-1: human immunodeficiency virus type 1; I/R: ischemia-reperfusion; LMP: lysosomal membrane permeabilization; MTOR: mechanistic target of rapamycin kinase; PUFAs: polyunsaturated fatty acids; RHIM: receptor-interacting protein homotypic interaction motif; ROS: reactive oxygen species; sGC: soluble guanylate cyclase; SGLT2: sodium-glucose cotransporter 2; TCR-T: T-cell receptor-engineered T; UPR: unfolded protein response.
中文摘要:巨自噬(以下称自噬)通常被视为细胞保护过程,通过胞内回收和代谢适应维持细胞稳态。然而在某些条件下,自噬机器可直接促成细胞死亡。界定自噬何时作为细胞死亡的原因而非结果仍是重大挑战,也使自噬依赖性细胞死亡(ADCD)的概念复杂化。实验研究表明ADCD可通过多种机制发生,包括过度自我消化、自噬依赖性溶酶体损伤、选择性自噬介导的关键细胞成分降解,以及autosis等特殊死亡程序。这些过程与凋亡、坏死性凋亡、铁死亡和焦亡广泛交叉,使ADCD处于调控性细胞死亡通路的更广泛网络中。来自癌症、神经退行性疾病、心血管疾病和炎症性疾病的证据进一步提示ADCD参与发病机制,并可能提供治疗机会。本综述讨论界定ADCD的标准、其执行的分子机制、与其他细胞死亡通路的相互作用及其与人类疾病的相关性。我们据此提出一个实用框架,用于区分真正的ADCD与仅伴随自噬的细胞死亡,并为确立自噬作为死亡过程的因果组分提供指导。缩写:AACD:自噬相关细胞死亡;ADCD:自噬依赖性细胞死亡;ADF:自噬依赖性铁死亡;ATP:三磷酸腺苷;ATPase:三磷酸腺苷酶;AUTACs:自噬靶向嵌合体;BH3:BCL2同源3;CAR-T:嵌合抗原受体T细胞;cGMP:环鸟苷单磷酸;CMA:分子伴侣介导的自噬;DAMPs:损伤相关分子模式;DHA:双氢青蒿素;ER:内质网;ER-phagy:内质网选择性自噬;H2O2:过氧化氢;HIV-1:1型人类免疫缺陷病毒;I/R:缺血再灌注;LMP:溶酶体膜通透化;MTOR:雷帕霉素激酶机制性靶点;PUFAs:多不饱和脂肪酸;RHIM:受体相互作用蛋白同型相互作用基序;ROS:活性氧;sGC:可溶性鸟苷酸环化酶;SGLT2:钠-葡萄糖协同转运蛋白2;TCR-T:T细胞受体工程T细胞;UPR:未折叠蛋白反应。

6肺癌 (11篇)

临床研究 (5篇)

JAMA oncology IF 23.9 2026-10-29 PMID: 42955021
Consolidation immunotherapy improves outcomes after chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Disease progression remains common, and more effective consolidation strategies are needed. To evaluate the efficacy and safety of benmelstobart with or without anlotinib as consolidation therapy after chemoradiotherapy for unresectable stage III NSCLC. This multicenter double-blind phase 3 randomized clinical trial took place at 42 centers in China from 2020 to 2023 among patients with unresectable stage III NSCLC without progression after concurrent or sequential chemoradiotherapy. In stage 1, patients were randomized 1:1:1 to 2 active regimens or placebo; in stage 2, additional patients were randomized 1:1 between the active regimens to power their direct comparison. Data cutoffs were November 30, 2023, for stage 1 and July 8, 2024, for the pooled analysis. Data analysis was performed from January 17 to March 23, 2025. Patients were randomized to receive benmelstobart plus anlotinib, benmelstobart plus anlotinib placebo, or their matching placebos. Primary end point was independent review committee (IRC)-assessed progression-free survival (PFS). Of 553 participants (median [IQR] age, 62 [56-67] years; 495 male individuals [89.5%]), 390 were randomized in stage 1 and 163 in stage 2. In stage 1, median PFS was 15.1 months (95% CI, 9.4-21.7) with benmelstobart plus anlotinib, 9.7 months (95% CI, 6.0-34.4) with benmelstobart alone, and 4.2 months (95% CI, 3.2-6.8) with placebo. The hazard ratios (HRs) were 0.49 (95% CI, 0.36-0.66; P < .001) for benmelstobart plus anlotinib vs placebo and 0.53 (95% CI, 0.39-0.72; P < .001) for benmelstobart vs placebo. In the pooled stage 1 and 2 analysis, median PFS was 17.4 (95% CI, 12.5-24.8) months with benmelstobart plus anlotinib and 11.2 (95% CI, 7.0-20.7) months with benmelstobart alone (HR, 0.82; 95% CI, 0.63-1.08; P = .12). Grade 3 to 5 treatment-related adverse events occurred in 48.8%, 29.4%, and 19.7% in the benmelstobart plus anlotinib, benmelstobart alone, and placebo groups, respectively; grade 5 events occurred in 7.2%, 1.4%, and 1.5%, respectively. This randomized clinical trial found that benmelstobart with or without anlotinib significantly improved PFS compared with placebo. Adding anlotinib did not significantly improve PFS compared with benmelstobart alone and increased severe and fatal treatment-related adverse events. ClinicalTrials.gov Identifier: NCT04325763.
中文摘要:同步或序贯放化疗后不可切除III期NSCLC患者接受巩固免疫治疗可改善结局,但疾病进展仍常见,需要更有效的巩固策略。评估benmelstobart联合或不联合安罗替尼作为放化疗后巩固治疗用于不可切除III期NSCLC的疗效与安全性。这项多中心、双盲、3期随机临床试验于2020至2023年在中国42个中心开展,纳入同步或序贯放化疗后未进展的不可切除III期NSCLC患者。第1阶段按1:1:1随机分配至2种活性方案或安慰剂;第2阶段额外患者按1:1在活性方案间随机,以增强其直接比较的统计效能。第1阶段数据截止2023年11月30日,汇总分析数据截止2024年7月8日。数据分析于2025年1月17日至3月23日进行。患者随机接受benmelstobart联合安罗替尼、benmelstobart联合安罗替尼安慰剂,或相应匹配安慰剂。主要终点为独立评审委员会评估的无进展生存期。553例参与者(中位[IQR]年龄62[56-67]岁;495例男性[89.5%])中,390例在第1阶段随机,163例在第2阶段随机。第1阶段,benmelstobart联合安罗替尼组中位PFS为15.1个月(95%CI 9.4-21.7),benmelstobart单药组9.7个月(95%CI 6.0-34.4),安慰剂组4.2个月(95%CI 3.2-6.8)。风险比为benmelstobart联合安罗替尼对安慰剂0.49(95%CI 0.36-0.66;P<.001),benmelstobart对安慰剂0.53(95%CI 0.39-0.72;P<.001)。第1和第2阶段汇总分析中,benmelstobart联合安罗替尼组中位PFS为17.4个月(95%CI 12.5-24.8),benmelstobart单药组11.2个月(95%CI 7.0-20.7)(HR 0.82;95%CI 0.63-1.08;P=.12)。3至5级治疗相关不良事件发生率在联合组、单药组和安慰剂组分别为48.8%、29.4%和19.7%;5级事件分别为7.2%、1.4%和1.5%。该随机临床试验发现,与安慰剂相比,benmelstobart联合或不联合安罗替尼均显著改善PFS。与benmelstobart单药相比,加用安罗替尼未显著改善PFS,并增加严重和致死性治疗相关不良事件。ClinicalTrials.gov注册号:NCT04325763。
Cancer treatment reviews IF 10.6 2026-10-29 PMID: 42951714
Small cell lung cancer (SCLC) remains one of the most lethal thoracic malignancies, characterized by rapid progression, early metastasis, and limited durable responses to conventional therapy. Delta-like ligand 3 (DLL3), a Notch pathway inhibitory ligand aberrantly overexpressed on the surface of approximately 70-85% of SCLC tumor cells but largely absent from normal adult tissue, has emerged as a compelling and therapeutically actionable target. Early efforts to exploit DLL3 through the antibody-drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) yielded important mechanistic insights despite failing to demonstrate survival benefit in phase III trials and have since catalyzed a new generation of more refined DLL3-directed strategies. This review critically examines the evolving portfolio of DLL3-targeted therapies across three principal modalities: T-cell engagers, ADCs, and chimeric antigen receptor T-cell (CAR-T) therapies. In parallel, we examine emerging non-DLL3 therapeutic strategies reshaping the broader SCLC landscape. We additionally discuss the translational science underpinning DLL3 as a biomarker, including the emerging roles of circulating tumor cell-based liquid biopsy and DLL3-directed immunoPET-CT imaging in patient selection and treatment monitoring.
中文摘要:小细胞肺癌(SCLC)仍是最致命的胸部恶性肿瘤之一,进展迅速、早期转移,对常规治疗难以获得持久缓解。Delta样配体3(DLL3)是一种Notch通路抑制性配体,在约70-85%的SCLC肿瘤细胞表面异常高表达,而在正常成人组织中基本不表达,已成为极具吸引力且可治疗干预的靶点。早期以抗体偶联药物(ADC)rovalpituzumab tesirine(Rova-T)靶向DLL3的尝试,虽在III期试验中未显示生存获益,却带来重要的机制层面认识,并推动了新一代更精细的DLL3靶向策略。该综述按三类主要模式检视不断演变的DLL3靶向治疗格局:T细胞衔接器、ADC与嵌合抗原受体T细胞(CAR-T)疗法。同时考察正在重塑SCLC整体治疗格局的非DLL3策略,并讨论支撑DLL3作为生物标志物的转化研究,包括循环肿瘤细胞液体活检与DLL3靶向免疫PET-CT显像在患者筛选和治疗监测中的新兴作用。
Cancer discovery IF 29.5 2026-10-27 PMID: 42945155
Patients with previously treated KRAS G12C-mutated non-small cell lung cancer who received the KRASG12C inhibitor divarasib were 42% less likely to experience disease recurrence or die than those who received the standard first-generation drugs sotorasib or adagrasib, an international phase III trial concluded. After a median follow-up of 14.3 months, the median progression-free survival was 9.8 months and 5.7 months, respectively.
中文摘要:一项国际III期试验得出结论:既往接受过治疗的KRAS G12C突变非小细胞肺癌患者中,接受KRAS G12C抑制剂divarasib治疗者发生疾病复发或死亡的可能性,比接受标准第一代药物sotorasib或adagrasib治疗者低42%。中位随访14.3个月后,两组的中位无进展生存期分别为9.8个月和5.7个月。
Cancer discovery IF 29.5 2026-10-27 PMID: 42937295
Mitigating on-target off-tumor toxicity remains a central challenge for chimeric antigen receptor (CAR) T-cell therapy for solid tumors. We developed a hypoxia-inducible CAR-T-cell product targeting carcinoembryonic antigen (CEA) that restricts CAR activation to hypoxic tumor niches via oxygen-dependent expression control. In this first-in-human, phase I trial enrolling heavily pretreated patients with relapsed stage IV non-small cell lung cancer (NSCLC), a single infusion of the investigational product achieved an objective response rate of 47% and a disease control rate of 87%, with a manageable safety profile. Exploratory analyses showed that clinical outcomes were associated with baseline factors. Deep single-cell profiling indicated that the clinical response was associated with the expansion of hypoxia-adapted, tumor-reactive-like CD8+ T cells alongside coordinated functional maturation of natural killer (NK) cells. Collectively, these data provide clinical proof-of-concept for hypoxia-inducible CAR design and inform the rational development of strategies leveraging tumor microenvironmental features in solid tumor cellular immunotherapy.
中文摘要:降低靶向非肿瘤毒性仍是实体瘤嵌合抗原受体(CAR)T细胞治疗的核心难题。研究团队开发了靶向癌胚抗原(CEA)的低氧诱导型CAR-T细胞产品,通过氧依赖性表达调控使CAR激活局限于低氧肿瘤微环境。在一项首次人体I期试验中,纳入既往接受过多线治疗的复发性IV期非小细胞肺癌(NSCLC)患者,单次输注该研究性产品获得47%的客观缓解率和87%的疾病控制率,安全性可控。探索性分析显示,临床结局与基线因素相关。深度单细胞分析表明,临床缓解与低氧适应、肿瘤反应样CD8+ T细胞扩增以及自然杀伤(NK)细胞协调性功能成熟相关。这些数据为低氧诱导型CAR设计提供了临床概念验证,也为利用肿瘤微环境特征合理开发实体瘤细胞免疫治疗策略提供了依据。
Nature IF 56.1 2026-10-25 PMID: 42927884
Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment1-3. NeoCOAST-2 (NCT05061550), a phase 2, randomised platform trial, tested novel perioperative treatments in patients with stage IIA-IIIB NSCLC. At primary analysis, combining standard chemotherapy plus durvalumab (anti-PD-L1 antibody) with oleclumab (Arm 1, n = 76), monalizumab (Arm 2, n = 72) or datopotamab deruxtecan (Dato-DXd; Arm 4, n = 54) resulted in pathological complete response (pCR) rates of 20.3%, 25.7%, and 35.2%, respectively4. Here, we present the first report of prespecified secondary endpoints of event-free survival (EFS) and circulating tumour DNA (ctDNA) clearance, and exploratory analyses of associations between ctDNA dynamics and clinical outcomes. The 24-month EFS rates were 70.5%, 75.7% and 77.9% in Arms 1, 2 and 4, respectively. Using a tumour-agnostic assay, ctDNA clearance at neoadjuvant Cycle 3 Day 1 was highest in Arm 4 (50.9%, 54.5%, and 72.5% in each arm, respectively). ctDNA clearance correlated with prolonged EFS versus non-clearance (pooled hazard ratio (HR) 0.22; 95% CI = 0.11-0.45, P = 0.0000443). Patients with both ctDNA clearance and pCR had favourable EFS outcomes versus those with neither (EFS HR 0.10, 95% CI = 0.02-0.42, P = 0.002). These findings suggest combined assessment of ctDNA clearance and pCR may improve risk stratification, and that the numerically highest pCR4 and EFS rates with the Dato-DXd combination warrant further evaluation.
中文摘要:可切除非小细胞肺癌(NSCLC)患者即使接受围手术期治疗,仍存在较高复发风险。NeoCOAST-2(NCT05061550)是一项2期随机平台试验,在IIA-IIIB期NSCLC患者中评估新型围手术期治疗。主要分析显示,标准化疗联合度伐利尤单抗(抗PD-L1抗体)并分别联合oleclumab(第1臂,n=76)、monalizumab(第2臂,n=72)或datopotamab deruxtecan(Dato-DXd;第4臂,n=54)时,病理完全缓解(pCR)率分别为20.3%、25.7%和35.2%。本文首次报告预设次要终点无事件生存期(EFS)和循环肿瘤DNA(ctDNA)清除情况,并探索性分析ctDNA动态与临床结局的关联。第1、2、4臂的24个月EFS率分别为70.5%、75.7%和77.9%。采用肿瘤不可知检测,新辅助第3周期第1天的ctDNA清除率在第4臂最高,三臂分别为50.9%、54.5%和72.5%。ctDNA清除与EFS延长相关,相较于未清除者合并风险比(HR)为0.22;95% CI=0.11-0.45,P=0.0000443。同时达到ctDNA清除和pCR的患者较两者均未达到者EFS结局更有利(EFS HR 0.10,95% CI=0.02-0.42,P=0.002)。这些结果提示,联合评估ctDNA清除与pCR可能改善风险分层,Dato-DXd联合方案在数值上最高的pCR率和EFS率值得进一步评估。

基础研究 (6篇)

ACS sensors IF 10.9 2026-10-30 PMID: 42962161
High-performance room-temperature CO2 sensors are essential for noninvasive clinical diagnostics, yet achieving high sensitivity in metal-organic frameworks (MOFs) remains challenging due to restricted ionic conduction. Building upon our previous expertise in guest-ion-source assembly, a strategy is proposed to enhance ionic conductivity by constructing long-range order and stable hydrogen-bonding (H-bonding) networks via chiral molecular incorporation. D-Tryptophan (D-Trp) and L-tryptophan (L-Trp) were encapsulated within γ-CD-MOF cavities to serve as chiral ion sources, facilitating the creation of bioinspired anion channels. The results reveal that the superior sensing performance of γ-CD-MOF@D-Trp is attributed to host-guest chiral preference. D‑Trp achieves ordered molecular arrangement via steric hindrance regulation, constructing long‑range order H‑bonding networks to optimize ion hopping pathways and stable sensing channels. The resulting sensor achieves a high response (2.10 toward 1000 ppm CO2), a low practical limit of detection (pLOD) of 10 ppm, and good selectivity. In particular, this work presents superior stability among MOF‑based room-temperature chemiresistive CO2 sensors reported so far, still retaining approximately 90% of its initial value after 35 days. Crucially, the fabricated γ-CD-MOFs@D-Trp-based sensor is preliminarily capable of distinguishing the differences in exhaled CO2 concentration between healthy individuals and lung cancer patients.
中文摘要:高性能室温CO2传感器对无创临床诊断十分重要,但金属有机框架(MOFs)受限于离子传导不足,实现高灵敏度仍具挑战。基于此前在客体离子源组装方面的经验,提出通过引入手性分子构建长程有序且稳定的氢键网络,以提升离子电导率的策略。将D-色氨酸(D-Trp)与L-色氨酸(L-Trp)封装于γ-CD-MOF空腔内作为手性离子源,促进仿生阴离子通道的形成。结果显示,γ-CD-MOF@D-Trp的优异传感性能源于主客体手性偏好。D-Trp通过位阻调控实现有序分子排列,构建长程有序氢键网络,从而优化离子跳跃路径并形成稳定传感通道。所得传感器对1000 ppm CO2具有较高响应(2.10),实际检测限(pLOD)低至10 ppm,并具备良好选择性。该工作在目前已报道的MOF基室温化学电阻型CO2传感器中表现出更优稳定性,35天后仍保持约90%的初始值。所制备的γ-CD-MOFs@D-Trp基传感器初步能够区分健康个体与肺癌患者呼出CO2浓度的差异。
Acta pharmacologica Sinica IF 10.4 2026-10-30 PMID: 42957750
Non-small cell lung cancer (NSCLC) represents the most prevalent form of malignant tumor and constitutes a principal cause of cancer-related mortality globally. Conventional therapeutic approaches predominantly induce apoptosis; however, their efficacy is often compromised by the development of drug resistance. Methuosis, a form of regulated cell death distinct from apoptosis, is characterized by aberrant macropinocytosis and the formation of cytoplasmic vacuoles. Aloperine (ALO), a naturally occurring antitumor alkaloid, has been observed to induce methuosis in cancer cells, although its precise molecular targets and mechanisms remain to be elucidated. This study investigated the anti-NSCLC effects of ALO using cell lines, patient-derived organoids, and mouse xenograft models. Through various assays, it was demonstrated that ALO directly interacts with VPS34 at the I760 residue and promotes TIP60-mediated lactylation of VPS34 at K356 and K781. This interaction inhibits VPS34 kinase activity and reduces intracellular PI(3)P production. The subsequent decrease in PI(3)P levels impedes Armus endosomal recruitment, disrupts Rab7 cycling, leads to the accumulation of macropinosomes, and impairs endolysosomal fusion, ultimately inducing methuosis. ALO exhibits significant antitumor efficacy and acts synergistically with cisplatin to co-activate methuosis and apoptosis, all while avoiding noticeable systemic toxicity. Collectively, ALO targets VPS34 lactylation and disrupts Armus/Rab7 signaling. When used in conjunction with cisplatin, it constitutes a safe and effective therapeutic strategy for NSCLC.
中文摘要:非小细胞肺癌(NSCLC)是最常见的恶性肿瘤类型,也是全球癌症相关死亡的主要原因。传统治疗主要诱导凋亡,但其疗效常因耐药而受限。Methuosis是一种不同于凋亡的调节性细胞死亡,特征为异常巨胞饮和细胞质空泡形成。天然抗肿瘤生物碱Aloperine(ALO)已在癌细胞中观察到可诱导Methuosis,但其确切分子靶点和机制尚待阐明。本研究利用细胞系、患者来源类器官和小鼠异种移植模型考察ALO的抗NSCLC作用。通过多种实验证明,ALO在I760残基直接与VPS34相互作用,并促进TIP60介导的VPS34在K356和K781位点的乳酰化。该相互作用抑制VPS34激酶活性,减少细胞内PI(3)P生成。PI(3)P水平下降随后阻碍Armus在内体上的募集,破坏Rab7循环,导致巨胞饮体积累并损害内溶酶体融合,最终诱导Methuosis。ALO具有显著抗肿瘤效力,并与顺铂协同共同激活Methuosis和凋亡,同时未出现明显全身毒性。ALO靶向VPS34乳酰化并破坏Armus/Rab7信号;与顺铂联用时,它构成安全有效的NSCLC治疗策略。
Nature IF 56.1 2026-10-28 PMID: 42951963
The N7-methylguanosine (m7G) modification is one of the most prevalent tRNA modifications, mainly catalysed by the METTL1-WDR4 protein complex1-4. The m7G methyltransferase METTL1 has been linked to oncogenic transformation and the maintenance of several aggressive malignancies; however, the clinical implications of therapeutically targeting a tRNA-modifying enzyme have not been established. Here we present the development and characterization of STM9005, a highly selective and potent first-in-class tRNA methyltransferase inhibitor of METTL1. Treatment of numerous cancer cell models (including leukaemia, melanoma, pancreatic carcinoma, oesophageal cancer and small cell lung carcinoma) with STM9005 blocks cell growth, causes differentiation changes and dysregulates cell cycle progression. These cellular effects were accompanied by a selective decrease in m7G on a subset of tRNAs and a reduction in their expression levels, which impacted the translation of oncogenic mRNAs. We show that pharmacological inhibition of METTL1 in vivo impairs tumour growth and significantly prolongs survival in multiple mouse cancer models of different tissue origin. Collectively, our results provide a strong proof of concept that targeting of tRNA methylation is a promising avenue of anti-cancer therapy and illustrate that catalytic inhibition of METTL1 represents a therapeutic strategy against a number of aggressive malignancies.
中文摘要:N7-甲基鸟苷(m7G)修饰是最常见的tRNA修饰之一,主要由METTL1-WDR4蛋白复合物催化。m7G甲基转移酶METTL1与致癌转化及多种侵袭性恶性肿瘤的维持相关;但将tRNA修饰酶作为治疗靶点的临床意义尚未确立。STM9005是首创的高选择性、强效METTL1 tRNA甲基转移酶抑制剂,研究对其进行了开发与表征。用STM9005处理多种癌细胞模型(包括白血病、黑色素瘤、胰腺癌、食管癌和小细胞肺癌)可抑制细胞生长,引起分化改变并扰乱细胞周期进程。这些细胞效应伴随部分tRNA上m7G的选择性降低及其表达水平下降,并影响致癌mRNA的翻译。在体内,药理抑制METTL1可削弱肿瘤生长,并在多种不同组织来源的小鼠癌症模型中显著延长生存期。这些结果提供了有力概念验证:靶向tRNA甲基化是颇有前景的抗癌治疗途径,METTL1的催化抑制可作为针对多种侵袭性恶性肿瘤的治疗策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42628869
Mitochondria, central hubs of cellular metabolism, play a pivotal role in tumorigenesis and the regulation of cellular metabolic processes. Cancer cells frequently undergo metabolic reprogramming, characterized by enhanced glycolysis, dysregulated oxidative phosphorylation (OXPHOS), and rewired mitochondrial biogenesis to meet the high bioenergetic and biosynthetic demands of proliferation. In non-small cell lung cancer (NSCLC), these metabolic alterations are hallmark features, yet the upstream regulatory mechanisms governing mitochondrial function remain poorly defined. In this study, we report the novel finding that ubiquitin-specific protease 22 (USP22), a key regulator of protein ubiquitination and transcriptional activity, regulates mitochondrial protein expression and OXPHOS. We further demonstrate that USP22 directly binds to MYB-binding protein 1A (MYBBP1A), thereby modulating the expression of nuclear- and mitochondrial-encoded OXPHOS-related proteins, ultimately promoting mitochondrial biogenesis in cancer cells. To our knowledge, this work provides the first evidence linking USP22 to mitochondrial biogenesis in NSCLC. These findings offer valuable insights into the regulatory network governing mitochondrial metabolism in NSCLC and suggest new avenues for targeting metabolic vulnerabilities in molecular diagnosis and targeted therapies.
中文摘要:线粒体是细胞代谢的中心枢纽,在肿瘤发生和细胞代谢过程调控中起关键作用。癌细胞常发生代谢重编程,表现为糖酵解增强、氧化磷酸化(OXPHOS)失调以及线粒体生物合成重塑,以满足增殖所需的高生物能量和生物合成需求。在非小细胞肺癌(NSCLC)中,这些代谢改变是标志性特征,但调控线粒体功能的上游机制仍不清楚。本研究报告新发现:泛素特异性蛋白酶22(USP22)作为蛋白质泛素化和转录活性的关键调控因子,可调控线粒体蛋白表达和OXPHOS。进一步证明USP22直接结合MYB结合蛋白1A(MYBBP1A),从而调节细胞核和线粒体编码的OXPHOS相关蛋白表达,最终促进癌细胞线粒体生物合成。据我们所知,该工作首次提供USP22与非小细胞肺癌线粒体生物合成相关的证据。这些发现为NSCLC线粒体代谢调控网络提供了有价值见解,并为分子诊断和靶向治疗中靶向代谢脆弱性提示新途径。
Cancer letters IF 11.8 2026-10-27 PMID: 42946197
Neoadjuvant immunotherapy has improved clinical outcomes in resectable non-small cell lung cancer (NSCLC); however, a substantial proportion of patients fail to achieve durable responses, and the mechanisms underlying therapeutic resistance remain incompletely understood. Here, we identified protein phosphatase 1 regulatory inhibitor subunit 1B (PPP1R1B) as a metabolic driver of immunotherapy resistance in NSCLC through RNA sequencing of tumors with differential responses to neoadjuvant anti-PD-1 therapy. PPP1R1B was significantly upregulated in non-responders and correlated with poor prognosis in NSCLC patients. Mechanistically, PPP1R1B directly interacted with IRF3 through the Arg29 residue and promoted dephosphorylation of IRF3 at Ser396, thereby suppressing IRF3 activation and downstream interferon-β (IFN-β) signaling. PPP1R1B-mediated inhibition of IFN-β signaling reduced CD8+ T-cell infiltration and impaired antitumor immunity, ultimately conferring resistance to anti-PD-1 therapy in vivo. Blockade of IFN-β signaling abrogated the antitumor effects induced by PPP1R1B depletion, supporting an immune-dependent mechanism. Notably, tumors resistant to neoadjuvant immunotherapy exhibited impaired oxidative phosphorylation and excessive lactate accumulation. Lactate induced PPP1R1B expression through NF-κB-dependent transcriptional activation, linking metabolic reprogramming to innate immune suppression. Collectively, our findings identify a lactate/NF-κB/PPP1R1B/IRF3 signaling axis that drives immune evasion and resistance to neoadjuvant immunotherapy in NSCLC, and nominate PPP1R1B as a potential biomarker and therapeutic target for overcoming anti-PD-1 resistance.
中文摘要:新辅助免疫治疗改善了可切除非小细胞肺癌(NSCLC)的临床结局,但相当一部分患者未能获得持久缓解,治疗耐药机制仍未完全阐明。通过对新辅助抗PD-1治疗应答差异的肿瘤进行RNA测序,发现蛋白磷酸酶1调节抑制亚基1B(PPP1R1B)是NSCLC免疫治疗耐药的代谢驱动因子。PPP1R1B在无应答者中显著上调,并与NSCLC患者预后不良相关。机制上,PPP1R1B通过Arg29残基与IRF3直接相互作用,促进IRF3在Ser396位点去磷酸化,从而抑制IRF3活化及下游干扰素-β(IFN-β)信号。PPP1R1B介导的IFN-β信号抑制减少CD8+ T细胞浸润并削弱抗肿瘤免疫,最终在体内导致抗PD-1治疗耐药。阻断IFN-β信号可消除PPP1R1B缺失所诱导的抗肿瘤效应,支持其免疫依赖机制。耐药肿瘤还表现为氧化磷酸化受损和乳酸过度蓄积。乳酸通过NF-κB依赖的转录激活诱导PPP1R1B表达,将代谢重编程与先天免疫抑制联系起来。这些发现识别出乳酸/NF-κB/PPP1R1B/IRF3信号轴驱动NSCLC免疫逃逸和新辅助免疫治疗耐药,并提示PPP1R1B可作为克服抗PD-1耐药的潜在生物标志物和治疗靶点。
ACS sensors IF 10.9 2026-10-24 PMID: 42921660
Circulating tumor cells (CTCs) are rare cancer-derived cells in peripheral blood, carrying vital information about tumor heterogeneity and progression. Their reliable detection remains challenging due to extreme rarity and high background interference. Herein, we report an electrochemical biosensor that integrates a DNA-based AND logic gate with cascaded signal amplification for the specific and sensitive determination of CTCs. The system requires the co-recognition of EpCAM and MUC1 on the cell surface via corresponding aptamers, which initiates an amplification cascade comprising hybridization chain reaction, DNAzyme-mediated cleavage, and entropy-driven assembly. This cascade ultimately results in the in situ formation of a DNA network on the electrode, enabling the capture of platinum-coated gold nanoparticles (Au@PtNPs) via biotin-streptavidin interaction, thereby significantly enhancing the electrocatalytic signal. The biosensor exhibits a linear response from 50 to 2.5 × 105 cells mL-1 with a detection limit down to 14 cells mL-1. It also exhibits high selectivity against nontarget cells, isolated proteins, and cellular debris, and displays excellent stability in serum and whole blood. Thus, this work may provide a reliable and clinically translatable strategy for CTC-based liquid biopsy, highlighting its potential for personalized lung cancer management.
中文摘要:循环肿瘤细胞(CTCs)是外周血中罕见的肿瘤来源细胞,携带肿瘤异质性与进展的重要信息。其极度稀少和背景干扰高使可靠检测仍具挑战。基于此,构建了一种电化学生物传感器,将DNA AND逻辑门与级联信号放大结合,用于CTCs的特异、灵敏测定。该系统通过相应适配体共识别细胞表面的EpCAM与MUC1,启动由杂交链式反应、DNA酶介导切割和熵驱动组装组成的扩增级联。该级联最终在电极上原位形成DNA网络,借助生物素-链霉亲和素作用捕获铂包覆金纳米颗粒(Au@PtNPs),显著增强电催化信号。该生物传感器在50至2.5×10^5个细胞 mL-1范围内呈线性响应,检测限低至14个细胞 mL-1。其对非靶细胞、分离蛋白和细胞碎片具有高选择性,并在血清和全血中表现良好稳定性。该工作或可为基于CTCs的液体活检提供可靠且具临床转化潜力的策略,显示其在肺癌个体化管理中的应用前景。

7乳腺癌 (7篇)

临床研究 (2篇)

Nature medicine IF 52.5 2026-10-29 PMID: 42957778
PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I-IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B). In group B, treatment was adapted according to 18F-FDG-PET response after two cycles and pCR, with chemotherapy administered to nonresponders or patients without pCR. We previously reported that this de-escalation approach revealed a 3-year invasive disease-free survival (iDFS) of 94.3% (95% confidence interval (CI): 90.9 to 96.8) in group B. Here we report the prespecified secondary endpoint, 5-year iDFS and exploratory circulating tumor DNA (ctDNA) findings. After a median follow-up of 5.6 years, the 5-year iDFS was 89.5% (95% CI: 85.7 to 93.4) in group B (n = 267) and 92.4% (95% CI: 86.7 to 98.5) among 18F-FDG-PET responders achieving pCR without chemotherapy (n = 86), with one distant recurrence. The latter estimate describes a long-term outcome in a post-randomization subgroup defined by 18F-FDG-PET response and pCR and should be interpreted as descriptive rather than as causal effects of omitting chemotherapy. Detectable ctDNA at baseline or during treatment was associated with inferior iDFS, whereas ctDNA clearance correlated with higher pCR rates and improved long-term outcomes. These findings continue to support the clinical validity of an 18F-FDG-PET-guided, pCR-adapted approach and suggest a potential role for ctDNA in refining treatment individualization. ClinicalTrials.gov identifier: NCT03161353 .
中文摘要:PHERGain是一项随机、非比较性2期试验,评估以18F-氟脱氧葡萄糖-正电子发射断层扫描(18F-FDG-PET)为指导、依据病理完全缓解(pCR)调整策略,在HER2阳性早期乳腺癌中省略化疗。HER2阳性、I-IIIA期可手术乳腺癌女性患者(肿瘤大小≥1.5 cm)被随机分配接受化疗联合曲妥珠单抗和帕妥珠单抗(HP;A组)或HP±内分泌治疗(B组)。B组根据两周期后18F-FDG-PET反应及pCR调整治疗,对无反应者或未达到pCR者给予化疗。此前报告该降阶策略在B组的3年侵袭性疾病无生存(iDFS)为94.3%(95%置信区间(CI):90.9至96.8)。现报告预设次要终点,即5年iDFS和探索性循环肿瘤DNA(ctDNA)结果。中位随访5.6年后,B组(n=267)5年iDFS为89.5%(95% CI:85.7至93.4),在18F-FDG-PET有反应且达到pCR并省略化疗者(n=86)中为92.4%(95% CI:86.7至98.5),其中1例远处复发。后一估计描述的是由18F-FDG-PET反应和pCR定义的随机化后亚组的长期结局,应解释为描述性结果,而非省略化疗的因果效应。基线或治疗期间可检测到ctDNA与较差的iDFS相关,而ctDNA清除与更高的pCR率和改善的长期结局相关。这些发现继续支持18F-FDG-PET指导、pCR调整策略的临床有效性,并提示ctDNA在细化治疗个体化方面可能的作用。ClinicalTrials.gov注册号:NCT03161353。
JAMA ophthalmology IF 10.5 2026-10-29 PMID: 42955022
Tamoxifen can cause retinal toxicity and vision loss, yet no formal screening guideline exists in the US. To characterize ophthalmic use after tamoxifen initiation, identify predictors, and compare 12-month use between those with breast cancer taking tamoxifen and those taking aromatase inhibitors. This was a retrospective cohort study conducted May to June 2026 using All of Us data with 365-day minimum follow-up. The setting was a US multisite research program. Participants included adults with a first tamoxifen prescription recorded in All of Us, excluding those taking hydroxychloroquine. The comparator included those with breast cancer taking aromatase inhibitors. Tamoxifen or aromatase inhibitor initiation. The primary outcome was any ophthalmic encounter within 12 months, identified from eye examination, retinal procedure, and eye visit codes. Retinal optical coherence tomography (OCT) or fundus photography was secondary. Logistic regression assessed predictors and compared treatment groups after adjustment for demographics, preexisting conditions, preindex health care use, region, and initiation year. Among 2327 individuals taking tamoxifen (mean [SD] age, 53.8 [10.6] years; 2232 [95.9%] female), 162 (7.0%) had an ophthalmic encounter within 12 months, and 39 (1.7%) underwent retinal OCT or fundus photography. Among participants with preexisting glaucoma or diabetic retinopathy, 22 of 88 (25.0%) had an encounter vs 140 of 2239 (6.3%) without either condition (difference, 18.7 percentage points; 95% CI, 10.8-28.8 percentage points; P < .001). Preexisting glaucoma (adjusted odds ratio [aOR], 3.87; 95% CI, 2.12-7.06; P < .001), greater preindex health care use (aOR, 1.43; 95% CI, 1.24-1.63; P < .001), and older age (aOR per 10-year increase, 1.21; 95% CI, 1.04-1.42; P = .02) were associated with greater use. Among participants with breast cancer, 126 of 1886 individuals taking tamoxifen (6.7%) had an encounter vs 240 of 2809 individuals taking aromatase inhibitors (8.5%; difference, -1.9 percentage points; 95% CI, -3.4 to -0.3 percentage points; P = .02). After adjustment, tamoxifen use was not associated with greater ophthalmic use (aOR, 1.10; 95% CI, 0.85-1.42; P = .46). Results of this cohort study suggest that ophthalmic use after tamoxifen initiation was uncommon, and retinal-specific testing was rare. Tamoxifen use was not associated with greater adjusted 12-month use than aromatase inhibitor use. Additional evidence on retinopathy incidence, natural history, screening strategies, and clinical benefit is needed to inform guidance.
中文摘要:他莫昔芬可导致视网膜毒性和视力丧失,但美国尚无正式筛查指南。为描述他莫昔芬起始后的眼科服务使用情况、识别预测因素,并比较乳腺癌患者中使用他莫昔芬与使用芳香化酶抑制剂者12个月内的眼科服务使用,该回顾性队列研究于2026年5月至6月开展,使用All of Us数据,最短随访365天,研究场景为美国多中心研究项目。参与者为All of Us中记录到首次他莫昔芬处方的成人,排除使用羟氯喹者;对照为使用芳香化酶抑制剂的乳腺癌患者。暴露为他莫昔芬或芳香化酶抑制剂起始。主要结局为12个月内任何眼科就诊,通过眼科检查、视网膜操作和眼科就诊代码识别;视网膜光学相干断层扫描(OCT)或眼底照相为次要结局。Logistic回归评估预测因素,并在校正人口学特征、既往疾病、索引前医疗服务使用、地区和起始年份后比较治疗组。2327例使用他莫昔芬者(平均(标准差)年龄53.8(10.6)岁;2232例(95.9%)为女性)中,162例(7.0%)在12个月内发生眼科就诊,39例(1.7%)接受视网膜OCT或眼底照相。在既往有青光眼或糖尿病视网膜病变的参与者中,88例中有22例(25.0%)发生眼科就诊,而无这两种情况者2239例中有140例(6.3%)发生眼科就诊(差值18.7个百分点;95%CI 10.8-28.8个百分点;P < .001)。既往青光眼(校正比值比(aOR)3.87;95%CI 2.12-7.06;P < .001)、索引前医疗服务使用较多(aOR 1.43;95%CI 1.24-1.63;P < .001)和年龄较大(每增加10岁的aOR为1.21;95%CI 1.04-1.42;P = .02)与更高的使用相关。在乳腺癌参与者中,1886例使用他莫昔芬者中有126例(6.7%)发生眼科就诊,2809例使用芳香化酶抑制剂者中有240例(8.5%)发生眼科就诊(差值-1.9个百分点;95%CI -3.4至-0.3个百分点;P = .02)。校正后,他莫昔芬使用与更高的眼科服务使用无关(aOR 1.10;95%CI 0.85-1.42;P = .46)。该队列研究结果提示,他莫昔芬起始后的眼科服务使用不常见,视网膜特异性检查少见。他莫昔芬使用与芳香化酶抑制剂使用相比,校正后12个月眼科服务使用并未更高。仍需关于视网膜病变发生率、自然史、筛查策略和临床获益的更多证据,以指导指南制定。

基础研究 (5篇)

Cancer discovery IF 29.5 2026-10-28 PMID: 42949420
Neuroendocrine differentiation (NED) promotes lineage plasticity and therapy resistance in prostate and lung cancers. Here we identify NED as a route of treatment escape in breast cancer: neuroendocrine features emerged or increased in 22% of progressive cases, predominantly, but not exclusively, in HER2-positive subtype. Using patient-derived, epithelial/neuroendocrine organoid and xenograft models, we map the epigenetic and transcriptional divergence between epithelial and neuroendocrine states arising from a shared mutational background and define a breast cancer neuroendocrine signature. NED involves epigenetic silencing of EpCAM and amplified HER2, while NEUROD1 functions as a master transcriptional regulator of the neuroendocrine fate. NCAM-positive putative circulating tumor cells were detected in patients in whom EpCAM-based detection had failed. Neuroendocrine tumor cells exhibit an FGFR1 dependency associated with NCAM-FGFR1 interaction and mesenchymal FGFR1 splicing. Together, these findings establish NED as a mechanism of escape from HER2-targeted therapy in breast cancer, with implications for disease monitoring and intervention.
中文摘要:神经内分泌分化(NED)促进前列腺癌和肺癌中的谱系可塑性和治疗耐药。我们发现NED是乳腺癌治疗逃逸的一条途径:22%的进展病例出现或增加神经内分泌特征,主要但不限于HER2阳性亚型。利用患者来源的上皮/神经内分泌类器官和异种移植模型,我们绘制了由共同突变背景产生的上皮与神经内分泌状态之间的表观遗传和转录差异,并定义了乳腺癌神经内分泌特征。NED涉及EpCAM的表观遗传沉默和HER2扩增,NEUROD1作为神经内分泌命运的主转录调控因子发挥作用。在基于EpCAM的检测失败的患者中检测到NCAM阳性的疑似循环肿瘤细胞。神经内分泌肿瘤细胞表现出FGFR1依赖性,与NCAM-FGFR1相互作用和间质型FGFR1剪接相关。这些发现确立NED是乳腺癌逃避HER2靶向治疗的一种机制,对疾病监测和干预具有意义。
Cancer letters IF 11.8 2026-10-28 PMID: 42601012
Lactylation, a lactate-dependent posttranslational modification, is involved in cancer development. Here, we showed that GCN5L2 physically interacts with nuclear SIX1 and acts as a key regulator of SIX1 lactylation. GCN5L2 depletion promotes APC/Cdh1 binding to SIX1, increases SIX1 ubiquitination, and reduces SIX1 protein stability. Functionally, the GCN5L2-SIX1 axis promotes glucose uptake, glycolysis process, and energy supply in TNBC cells. GCN5L2 knockdown attenuates the growth and migration of TNBC cells, and increases the sensitivity of TNBC cells to paclitaxel. Overexpression of SIX1 reverses the GCN5L2 knockdown-induced glycolysis and growth suppression in TNBC cells. In addition, GCN5L2 expression is enriched and positively correlated with SIX1 in clinical TNBC tissues. More importantly, we demonstrated 9‴-Methyl salvianolate B as a candidate modulator of the GCN5L2-SIX1 complex via an unbiased screening. 9‴-Methyl salvianolate B suppresses the GCN5L2-SIX1 axis and blocks the glycolysis, proliferation, metastasis, and paclitaxel resistance of TNBC cells. Overall, this study highlights the significance of the GCN5L2-SIX1 axis in sustaining glycolysis and TNBC development, and provides experimental evidence of 9‴-Methyl salvianolate B as a candidate modulator of the GCN5L2-SIX1 axis, presenting a promising strategy for TNBC management.
中文摘要:乳酸化是依赖乳酸的翻译后修饰,参与肿瘤发生发展。GCN5L2与核内SIX1发生物理互作,并作为SIX1乳酸化的关键调控因子。敲低GCN5L2促进APC/Cdh1与SIX1结合,增加SIX1泛素化并降低SIX1蛋白稳定性。功能上,GCN5L2-SIX1轴促进TNBC细胞葡萄糖摄取、糖酵解过程及能量供应。敲低GCN5L2减弱TNBC细胞生长和迁移,并提高TNBC细胞对紫杉醇的敏感性。过表达SIX1可逆转GCN5L2敲低引起的TNBC细胞糖酵解和生长抑制。临床TNBC组织中GCN5L2表达富集,并与SIX1呈正相关。通过无偏筛选,研究证明9‴-Methyl salvianolate B是GCN5L2-SIX1复合物的候选调节剂。9‴-Methyl salvianolate B抑制GCN5L2-SIX1轴,阻断TNBC细胞的糖酵解、增殖、转移和紫杉醇耐药。这些结果说明GCN5L2-SIX1轴在维持糖酵解和TNBC进展中的意义,并提供9‴-Methyl salvianolate B作为GCN5L2-SIX1轴候选调节剂的实验证据,为TNBC管理提供有前景的策略。
Nature protocols IF 18.4 2026-10-27 PMID: 42946816
The self-assembly of peptides into well-defined nanostructures represents a versatile strategy for developing biomedical agents. However, cellular internalization of pre-assembled peptide nanostructures is often hampered by insufficient uptake and low selectivity toward target cells, leading to off-target concerns and limited therapeutic efficacy. The past few years have witnessed the development of in situ assembly in living cells as a new endeavor for optimizing the performance of peptide assemblies. In situ assembly of peptides refers to intracellular assembling processes regulated by biocompatible stimuli, thereby enhancing peptide internalization and locally forming assemblies at target sites. Recently, we have developed strategies for establishing in situ assembly of peptides in living cells dictated by stimuli-responsive unnatural amino acids. Here we detail the procedure for developing in situ peptide assembly systems in living cells through incorporating stimuli-responsive unnatural amino acids. We present a thorough workflow encompassing peptide design and synthesis as well as the characterization of peptide responsiveness to glutathione or sulfatase. Self-assembly conditions are described for experiments in solution, in murine macrophage cells, human cervical carcinoma cells and murine breast cancer cells. The applications of in situ-formed peptide assemblies for subcellular targeting and cancer therapy in murine breast tumor-bearing BALB/c mice are also presented. The described methodology provides a robust platform for developing in situ-formed peptide assemblies and advancing the clinical translation of peptide-based supramolecular therapeutics. Performance of this Protocol requires expertise in peptide chemistry, materials engineering and biomedical engineering, taking an expected 92-115 d to complete.
中文摘要:将多肽自组装成结构明确的纳米结构,是开发生物医学制剂的一种通用策略。预组装多肽纳米结构的细胞内化常受摄取不足和对靶细胞选择性低的限制,带来脱靶隐患并限制疗效。过去几年,活细胞内原位组装的发展为优化多肽组装体性能提供了新途径。多肽原位组装是指由生物相容性刺激调控的细胞内组装过程,可增强多肽内化并在靶部位局部形成组装体。最近,我们开发了由刺激响应性非天然氨基酸调控的活细胞多肽原位组装策略。该方案详述通过引入刺激响应性非天然氨基酸来建立活细胞原位多肽组装体系的流程,给出涵盖多肽设计与合成以及多肽对谷胱甘肽或硫酸酯酶响应性表征的完整工作流程。文中描述了在溶液、小鼠巨噬细胞、人宫颈癌细胞和小鼠乳腺癌细胞中开展实验的自组装条件,也介绍了原位形成的多肽组装体在小鼠乳腺肿瘤荷瘤BALB/c小鼠中用于亚细胞靶向和癌症治疗的应用。所述方法为开发原位形成的多肽组装体并推进多肽超分子疗法的临床转化提供了稳健平台。执行本实验方案需要多肽化学、材料工程和生物医学工程方面的专业知识,预计需92-115天完成。
ACS sensors IF 10.9 2026-10-26 PMID: 42932791
Early and sensitive detection of breast cancer biomarkers is essential for improving patient prognosis, yet rapid and amplification-free analysis of low-abundance circulating miRNAs remains challenging. Herein, we report a CRISPR/Cas13a-regulated surface-enhanced Raman scattering (SERS) biosensor, termed the CaRER sensor, for on-site detection of miRNA-511-5p, a clinically relevant breast cancer-associated biomarker. To enhance plasmonic activity and SERS performance, Ag, known for its strong SERS amplification capability, was incorporated into Au-Ni-Au magnetic rods to construct plasmonic-enhanced magnetic rods (PEMRs), which generated markedly stronger Raman signals than conventional Au-Ni-Au rods. Integration of PEMRs with the CRISPR/Cas13a system enabled amplification-free and highly sensitive detection through target-triggered trans-cleavage-induced modulation of the SERS signal after sequence-specific recognition of miRNA-511-5p. The CaRER sensor achieved femtomolar-level detection with high selectivity and reproducibility, and reliably distinguished clinical plasma samples from breast cancer patients and healthy controls. In addition, the magnetic properties of PEMRs enabled efficient separation and robust signal readout, improving assay practicality and operational reliability. The incorporation of Au also enhanced antioxidative stability relative to Ag-dominant plasmonic structures, supporting long-term chemical stability and sensing reliability. Owing to the programmability of crRNA, this platform can be readily adapted to diverse nucleic acid biomarkers through simple sequence redesign, highlighting its potential as a versatile point-of-care testing (POCT) tool for cancer diagnostics and liquid biopsy applications.
中文摘要:乳腺癌生物标志物的早期、灵敏检测对改善患者预后很重要,但低丰度循环miRNA的快速、无扩增分析仍具挑战。我们报道一种受CRISPR/Cas13a调控的表面增强拉曼散射(SERS)生物传感器,称为CaRER传感器,用于现场检测miRNA-511-5p,这是一种与乳腺癌临床相关的生物标志物。为增强等离激元活性和SERS性能,将具有强SERS放大能力的Ag引入Au-Ni-Au磁性棒,构建等离激元增强磁性棒(PEMRs),其产生的拉曼信号明显强于传统Au-Ni-Au棒。PEMRs与CRISPR/Cas13a系统结合后,在序列特异性识别miRNA-511-5p后,通过靶标触发的反式切割诱导SERS信号调制,实现无扩增和高灵敏检测。CaRER传感器达到飞摩尔级检测,具有高选择性和重现性,能可靠区分乳腺癌患者与健康对照的临床血浆样本。PEMRs的磁性有利于高效分离和稳定信号读出,提高检测实用性和操作可靠性。Au的引入还相对以Ag为主的等离激元结构增强了抗氧化稳定性,支持长期化学稳定性和传感可靠性。由于crRNA可编程,该平台可通过简单序列重设计适配多种核酸生物标志物,显示其作为癌症诊断和液体活检应用的多功能即时检测(POCT)工具的潜力。
Cancer research IF 22.6 2026-10-26 PMID: 42929736
Hormone receptor positive (HR+) breast cancer is the most common breast cancer subtype globally and remains a leading cause of cancer-related death in women. Black women diagnosed HR+ breast cancer experience significantly worse outcomes than White women, a disparity that persists even after accounting for factors such as healthcare access and educational attainment. Understanding the biological mechanisms underlying these differences has been limited by the underrepresentation of Black patients in genomic datasets. To address this gap, we generated an HR+ breast cancer transcriptomic dataset enriched for Black patients while controlling for access to healthcare and education level. Tumors from Black women showed enrichment of tumor microenvironment-related signatures, including increased collagen deposition and prognostically unfavorable T-cell landscapes. Data from in vitro and in vivo experimental models showed that race-aligned collagen deposition patterns were driven, at least in part, by tumor cell-intrinsic signaling and promoted metastatic phenotypes associated with poorer outcomes. Further analysis of the patient transcriptomic dataset revealed that unfavorable T-cell signatures previously attributed to race or ancestry were more strongly associated with poverty burden. Across multiple independent datasets, STAT4 emerged as a potential master regulator of this poverty-associated immune phenotype. Collectively, these findings suggest that molecular features of breast tumors are shaped by both biological and structural factors linked to self-identified race and socioeconomic disadvantage. These results demonstrate that integrating social determinants of health with molecular analyses can reveal mechanisms contributing to cancer outcome disparities and provide a foundation for the development of more effective and equitable precision oncology approaches.
中文摘要:激素受体阳性(HR+)乳腺癌是全球最常见的乳腺癌亚型,也是女性癌症相关死亡的主要原因之一。黑人女性确诊HR+乳腺癌后的结局显著差于白人女性,这一差异在考虑医疗可及性和教育程度等因素后仍然存在。基因组数据中黑人患者代表性不足,限制了对这些差异背后生物学机制的理解。为弥补这一空白,我们构建了富集黑人患者的HR+乳腺癌转录组数据集,并对医疗可及性和教育水平进行控制。黑人女性的肿瘤显示肿瘤微环境相关特征富集,包括胶原沉积增加和预后不良的T细胞景观。体外和体内实验模型的数据显示,与种族对应的胶原沉积模式至少部分由肿瘤细胞内在信号驱动,并促进与较差结局相关的转移表型。对患者转录组数据集的进一步分析显示,既往被归因于种族或血统的不良T细胞特征与贫困负担的关联更强。在多个独立数据集中,STAT4成为这一贫困相关免疫表型的潜在主调控因子。这些发现提示,乳腺肿瘤的分子特征受到与自我认同种族和社会经济劣势相关的生物学因素和结构性因素共同塑造。这些结果表明,将健康社会决定因素与分子分析整合,可揭示导致癌症结局差异的机制,并为开发更有效、更公平的精准肿瘤学方法奠定基础。

8神经系统肿瘤 (6篇)

临床研究 (1篇)

Neuro-oncology IF 13.1 2026-10-24 PMID: 42921757
Venous thromboembolism (VTE) occurs in 20-30% and 9.2% of patients with glioblastoma and grade 3 IDH mutant (IDHmut) gliomas respectively, with highest risk during the first months post-surgery. We sought to identify risk factors for early versus late VTE in high-grade gliomas and evaluated the recently proposed 'GliomaPredictVTE' tool. We included 894 patients with newly-diagnosed glioblastoma and grade 3-4 IDHmut gliomas from 2010-2023. Competing-risk analysis estimated VTE cumulative incidence (CumInc), segmented linear regression model identified the change-point between early versus late VTE, and competing-risk regression model identified significant risk factors. GliomaPredictVTE-predicted 6- and 12-month VTE risks were compared to observed CumInc. The estimated 6- and 12-month VTE CumInc was 21.5% and 26.4%, respectively for IDHwt glioblastoma versus 6.3% and 8.3%, respectively for IDHmut gliomas. The VTE CumInc increased rapidly during the first 6 months post-surgery, followed by a more gradual rise thereafter, with a change-point around 6 months. On multivariable analyses, 'Early VTE' (within 6 months post-surgery) was significantly associated with older age, limb weakness, ambulation dependence, and radiotherapy alone; 'Late VTE' (6 months to 5 years) with older age and smoking. GliomaPredictVTE substantially underestimated VTE incidence in our population, with a mean predicted 6- and 12-month risks of 11.0% and 17.4%, versus observed CumInc of 19.9% (p < 0.001) and 23% (p = 0.008), respectively. Distinct risk profiles between early and late VTE support prospective studies of primary prophylaxis in high-risk patients, particularly in the first 6 months post-surgery. GliomaPredictVTE significantly underestimates VTE incidence in this population.
中文摘要:静脉血栓栓塞(VTE)在胶质母细胞瘤患者中发生率为20-30%,在IDH突变型(IDHmut)3级胶质瘤中为9.2%,术后最初数月风险最高。本研究旨在识别高级别胶质瘤早期与晚期VTE的危险因素,并评估新近提出的GliomaPredictVTE工具。纳入2010年至2023年新诊断胶质母细胞瘤及3-4级IDHmut胶质瘤患者894例。采用竞争风险分析估计VTE累积发生率(CumInc),分段线性回归模型确定早期与晚期VTE之间的变化点,竞争风险回归模型识别显著危险因素。将GliomaPredictVTE预测的6个月和12个月VTE风险与观察到的CumInc进行比较。IDH野生型胶质母细胞瘤估计的6个月和12个月VTE CumInc分别为21.5%和26.4%,IDHmut胶质瘤分别为6.3%和8.3%。VTE CumInc在术后前6个月快速上升,之后上升趋缓,变化点约在6个月。多因素分析中,「早期VTE」(术后6个月内)与年龄较大、肢体无力、行走依赖及单纯放疗显著相关;「晚期VTE」(6个月至5年)与年龄较大和吸烟相关。GliomaPredictVTE明显低估了本队列的VTE发生率,预测的6个月和12个月平均风险分别为11.0%和17.4%,而观察到的CumInc分别为19.9%(p<0.001)和23%(p=0.008)。早期与晚期VTE的危险因素谱不同,支持在高危患者中开展一级预防的前瞻性研究,尤其是术后前6个月。GliomaPredictVTE显著低估该人群的VTE发生率。

基础研究 (5篇)

Science translational medicine IF 15.6 2026-10-28 PMID: 42950017
Diffuse midline glioma (DMG) is a lethal pediatric brain tumor with limited therapeutic options and a poor prognosis. The success of chimeric antigen receptor (CAR) T cell therapy requires both improving T cell tumor infiltration and persistence and reducing the risk of on-target/off-tumor toxicity. Here, we adapted and advanced a brain-restricted CAR T cell platform previously validated in glioblastoma to address the anatomical and biological challenges of DMG. We engineered a T cell circuit in which a brain-specific synthetic Notch (synNotch) receptor recognizing brevican (BCAN) induced CAR expression against EphA2 or IL-13Rα2 ("B-SYNC"), thereby restricting CAR expression to the central nervous system (CNS). In immunodeficient DMG models, a single infusion of intravenous (iv) or intracerebroventricular (icv) B-SYNC circuit T cells led to tumor infiltration, sustained persistence, antitumor activity, and extended survival. An alternative BCAN-primed CAR targeting B7-H3 or IL-13Rα2 ("B-SYNC-B/I") similarly improved therapeutic efficacy when delivered intravenously. However, icv administration triggered fatal neurotoxicity because of low-level B7-H3 expression in nontumor CNS regions, indicating that rapid CNS exposure via icv delivery can amplify off-tumor toxicity. In contrast, in an immunocompetent syngeneic DMG model, both iv and icv delivery of a murinized BCAN-gated B7-H3 CAR (mB-SYNC-B7-H3) achieved durable tumor clearance and resistance to rechallenge without any detectable neurotoxicity. Mechanistically, synNotch-primed CAR T cells exhibited reduced exhaustion, enhanced activation, and enrichment of naïve and stem cell memory-like subsets. These findings demonstrate that brain-sensing synNotch CAR T circuits represent a generalizable and translatable strategy for targeting multiple CNS malignancies, including DMG.
中文摘要:弥漫性中线胶质瘤(DMG)是一种致死性儿童脑肿瘤,治疗选择有限,预后差。嵌合抗原受体(CAR)T细胞治疗的成功需要同时提高T细胞对肿瘤的浸润和持久性,并降低靶向非肿瘤组织毒性风险。研究将此前在胶质母细胞瘤中验证的脑限制性CAR-T平台加以改造和推进,以应对DMG的解剖与生物学挑战。工程化T细胞回路中,识别短蛋白聚糖(BCAN)的脑特异性合成Notch(synNotch)受体诱导针对EphA2或IL-13Rα2的CAR表达(B-SYNC),使CAR表达限制于中枢神经系统(CNS)。在免疫缺陷DMG模型中,单次静脉(iv)或脑室内(icv)输注B-SYNC回路T细胞可导致肿瘤浸润、持续存留、抗肿瘤活性并延长生存。另一种以BCAN启动、靶向B7-H3或IL-13Rα2的CAR(B-SYNC-B/I)经静脉递送时同样提高疗效。但icv给药因非肿瘤CNS区域低水平B7-H3表达而引发致命性神经毒性,提示经icv快速暴露于CNS可放大肿瘤外毒性。相反,在免疫健全同源DMG模型中,小鼠化BCAN门控B7-H3 CAR(mB-SYNC-B7-H3)经iv和icv递送均实现持久肿瘤清除和对再攻击的抵抗,未检测到神经毒性。机制上,synNotch启动的CAR-T细胞耗竭减少、活化增强,初始样和干细胞记忆样亚群富集。这些结果说明,脑感知synNotch CAR-T回路是靶向包括DMG在内的多种CNS恶性肿瘤的可推广、可转化策略。
Cancer letters IF 11.8 2026-10-28 PMID: 42532370
Diffuse intrinsic pontine glioma (DIPG) is a highly lethal and therapeutically refractory pediatric brain tumor, and the effects of distinct disease backgrounds on treatment response and residual cell-state plasticity remain poorly understood. We evaluated abemaciclib, an FDA-approved CDK4/6 inhibitor, combined with temozolomide (TMZ) and radiation (XRT) in two patient-derived orthotopic xenograft (PDOX) models established from a treatment-naïve biopsy (IBs-9119DIPG) and a previously treated autopsy tumor (IBs-A0317DIPG). Treatment activity was assessed in PDOX-derived 3D tumor organoids and in randomized DIPG PDOX studies, followed by survival analysis, immunohistochemistry, and endpoint single-cell RNA sequencing (scRNA-seq). The triple therapy generated synergistic antitumor effects in PDOX-derived organoids and significantly prolonged survival in both PDOX models (P < 0.05) despite their distinct baseline molecular and cell-state differences. Endpoint scRNA-seq revealed reduced oligodendrocyte-progenitor-like (OPC-like) cells in both models and decreased astrocyte-like cells in the IBs-A0317DIPG model as cell-state changes associated with treatment response. In contrast, neural progenitor-like (NPC-like) cells expanded in IBs-A0317DIPG, whereas mesenchymal-like and Mitotic populations persisted in IBs-9119DIPG as candidate therapy-tolerant states. Pseudotime trajectory analysis uncovered a resistance-associated trajectory characterized by an exit from stemness toward differentiation in OPC-like cells in treatment-naïve IBs-9119DIPG, in contrast to the enrichment of stem-like OPC-like and NPC-like cells in therapy-resistant IBs-A0317DIPG. A transcriptionally defined radiation-resistance-associated subpopulation with candidate radiosensitization target genes (NPAS3, TBC1D15, and INPP4B) was also identified. Overall, the triple therapy improved survival in clinically distinct DIPG PDOX models and revealed therapy-associated residual cell-state changes that may inform future strategies to improve durable DIPG tumor control.
中文摘要:弥漫性内生型脑桥胶质瘤(DIPG)是一种高度致死且治疗抵抗的儿童脑肿瘤,不同疾病背景对治疗反应及残留细胞状态可塑性的影响仍知之甚少。我们在两个患者来源原位异种移植(PDOX)模型中评估了FDA批准的CDK4/6抑制剂阿贝西利联合替莫唑胺(TMZ)和放疗(XRT)的作用,这两个模型分别来自初治活检(IBs-9119DIPG)和既往治疗后的尸检肿瘤(IBs-A0317DIPG)。在PDOX来源的三维肿瘤类器官及随机化DIPG PDOX研究中评估治疗活性,随后进行生存分析、免疫组化及终点单细胞RNA测序(scRNA-seq)。三联治疗在PDOX来源类器官中产生协同抗肿瘤效应,并在两个PDOX模型中显著延长生存期(P < 0.05),尽管二者基线分子和细胞状态存在差异。终点scRNA-seq显示,两个模型中少突胶质前体细胞样(OPC样)细胞减少,IBs-A0317DIPG模型中星形胶质细胞样细胞减少,这些细胞状态变化与治疗反应相关。相反,IBs-A0317DIPG中神经前体细胞样(NPC样)细胞扩增,而IBs-9119DIPG中间质样和有丝分裂群体持续存在,为候选治疗耐受状态。拟时序轨迹分析发现,初治IBs-9119DIPG的OPC样细胞中存在一条与耐药相关的轨迹,特征为离开干性向分化转变;治疗抵抗的IBs-A0317DIPG则富集干样OPC样和NPC样细胞。还鉴定出一个转录定义的放射抵抗相关亚群,其候选放射增敏靶基因包括NPAS3、TBC1D15和INPP4B。三联治疗改善了临床背景不同的DIPG PDOX模型的生存,并揭示了治疗相关的残留细胞状态变化,可能为改善DIPG持久肿瘤控制的未来策略提供信息。
Cancer cell IF 56.1 2026-10-27 PMID: 42945959
Glioblastoma (GBM) is characterized by diffuse infiltration into the surrounding brain, limiting complete surgical resection, the strongest determinant of patient survival. The mechanisms driving this invasive growth remain incompletely understood. Here, we identify a lipid-mediated paracrine signaling axis through which tumor-associated microglia/macrophages promote glioma invasion. Integrating single-cell transcriptomics, spatial lipidomics, and functional perturbation across mouse models and human GBM samples, we show that invading tumor cells engage and reprogram myeloid cells via colony-stimulating factor-1 receptor (CSF1R)-PI3K signaling. This induces lipid metabolic reprogramming and secretion of bioactive lipids, including lysophosphatidylcholines (LPCs) and lysophosphatidic acids (LPAs), which promote GBM invasion through distinct downstream pathways. Disruption of this myeloid-GBM axis reduces lipid secretion and suppresses invasion. Targeting downstream LPA-LPA receptor (LPAR) or YAP/TAZ signaling further constrains invasion in a context-dependent manner. Together, these findings define a lipid-driven circuit linking the tumor microenvironment to glioma invasion and identify strategies to reduce infiltration and improve surgical resection.
中文摘要:胶质母细胞瘤(GBM)以弥漫性浸润周围脑组织为特征,这限制了完整手术切除,而完整切除是患者生存的最强决定因素。驱动这种侵袭性生长的机制仍未完全明确。本研究识别出一条脂质介导的旁分泌信号轴,肿瘤相关小胶质细胞/巨噬细胞通过该信号轴促进胶质瘤侵袭。整合小鼠模型和人类GBM样本的单细胞转录组学、空间脂质组学及功能扰动实验,研究显示侵袭中的肿瘤细胞通过集落刺激因子1受体(CSF1R)-PI3K信号招募并重编程髓系细胞。该过程诱导脂质代谢重编程并分泌生物活性脂质,包括溶血磷脂酰胆碱(LPC)和溶血磷脂酸(LPA),这些脂质通过不同的下游通路促进GBM侵袭。阻断这一髓系-GBM轴可减少脂质分泌并抑制侵袭。靶向下游LPA-LPA受体(LPAR)或YAP/TAZ信号可在情境依赖的方式下进一步限制侵袭。这些发现界定了一个由脂质驱动的回路,将肿瘤微环境与胶质瘤侵袭联系起来,并提出了减少浸润、改善手术切除的策略。
Cancer cell IF 56.1 2026-10-26 PMID: 42933392
In this issue of Cancer Cell, Patel et al. integrate bulk and single-cell/single-nucleus RNA sequencing with spatial transcriptomics and spatial proteomics across neuroblastoma patient-derived xenografts and annotated tumors to reveal adrenergic and mesenchymal signatures, identify distinct tumor cell populations in vivo, and demonstrate associations with patient outcomes.
中文摘要:在本期 Cancer Cell 中,Patel 等人将批量与单细胞/单核 RNA 测序同空间转录组学和空间蛋白质组学相结合,在神经母细胞瘤患者来源异种移植瘤和已注释肿瘤中揭示肾上腺素能与间充质特征,识别体内不同的肿瘤细胞群体,并展示其与患者结局的关联。
Neuro-oncology IF 13.1 2026-10-24 PMID: 42921754
Glioblastoma is the most common primary brain cancer in adults, with a poor prognosis and median survival of 15 months after treatment. Few in vivo transgenic models exist for testing new therapeutics. A novel mouse model for the classical subtype of human glioblastoma (GBM) has been bred using Cre-mediated EGFRvIII overexpression and homozygous p19-ARF deletion, the mouse homolog of human p14ARF/CDKN2A, in GFAP-expressing cells. Transgenic mice developed intraparenchymal and/or leptomeningeal brain lesions as early as 1 month old and 95% of mice succumb to endpoint symptoms of hydrocephalus and/or paralysis by 6 months. Immunohistochemical analysis confirms EGFRvIII overexpression and p19-ARF loss in Cre-expressing cells, along with patchy positive GFAP and high proliferation by Ki67 as well as loss of H3K27me3. Bulk and single cell RNA sequencing revealed tumors cluster closely with classical GBM and have significant upregulation of downstream markers in the JAK/STAT and P13K/AKT pathways as well as intratumoral heterogeneity. Dissociated tumors generated xenograft tumors by 3 weeks post intracranial injections into NOD-SCID mice and were characteristic of the primary lesion. We developed a spontaneous, immune-competent murine glioma model that enables characterization of tumor development within an intact immune microenvironment and provides a resource for future mechanistic studies.
中文摘要:胶质母细胞瘤是成人最常见的原发性脑癌,预后差,治疗后中位生存期为15个月。可用于测试新疗法的体内转基因模型很少。利用Cre介导的EGFRvIII过表达以及在GFAP表达细胞中纯合缺失p19-ARF(人p14ARF/CDKN2A的小鼠同源物),培育出了一种针对人胶质母细胞瘤(GBM)经典型亚型的新型小鼠模型。转基因小鼠最早在1月龄出现脑实质内和/或软脑膜病变,95%的小鼠在6月龄前因脑积水和/或瘫痪的终点症状死亡。免疫组化分析证实Cre表达细胞中EGFRvIII过表达和p19-ARF缺失,并可见斑片状GFAP阳性、Ki67提示高增殖以及H3K27me3缺失。批量和单细胞RNA测序显示,肿瘤与经典型GBM聚类紧密,JAK/STAT和P13K/AKT通路下游标志物显著上调,并存在瘤内异质性。将解离的肿瘤细胞颅内注射到NOD-SCID小鼠后3周内形成异种移植瘤,其特征与原发灶一致。我们建立了一个自发性、免疫健全的小鼠胶质瘤模型,可在完整免疫微环境中表征肿瘤发展,并为未来机制研究提供资源。

9其他实体瘤 (5篇)

临床研究 (3篇)

Acta neuropathologica IF 10.3 2026-10-26 PMID: 42931941
Pineal region tumors are rare neoplasms that occur in all ages and account for less than 1% of all central nervous system (CNS) tumors in adults but are more frequent in children. Here, we describe a previously unrecognized tumor type of pineal origin characterized by a unique and consistent DNA methylation profile that does not match any known CNS tumor class and is distinct from all currently recognized pineal tumor entities. The presented cohort (n = 27) displayed a balanced sex distribution with a mean patient age of 35 years (range 7-75 years). The histopathological analyses demonstrated a highly cellular tumor showing various degrees of necrosis, mitotic activity, papillary structures, rosettes, epithelioid cytology, or signet-ring cells. The tumors consistently expressed cytokeratin 18, synaptophysin, chromogranin A, and OTX2, whereas CRX expression was absent. Four out of 16 tumors (25%) showed ATRX mutations and/or loss of protein expression as revealed by immunohistochemistry. Single-nucleus RNA sequencing confirmed molecular distinctiveness from other pineal neoplasms but revealed the closest similarities to papillary tumors of the pineal region (PTPR). Projection of the transcriptome data onto the cellular trajectory of the developing murine pineal gland suggests that pinealocyte progenitors are the cellular origins. Taken together, our findings define a novel type of pineal region tumor that we provisionally named 'Pineal Neoplasm with Neuroendocrine and Epithelial Differentiation' (PINNED). Recognition of this tumor type appears to be important for the accurate diagnosis of pineal region tumors and may have implications for future tumor classification and treatment strategies.
中文摘要:松果体区肿瘤是罕见肿瘤,可发生于任何年龄,在成人中占所有中枢神经系统(CNS)肿瘤不足1%,但在儿童中更常见。我们描述一种此前未被认识的松果体来源肿瘤类型,其具有独特且一致的DNA甲基化谱,与任何已知CNS肿瘤类别均不匹配,并不同于目前所有已识别的松果体肿瘤实体。所呈现队列(n=27)性别分布均衡,患者平均年龄35岁(范围7-75岁)。组织病理学分析显示肿瘤细胞密度高,可见不同程度坏死、核分裂活性、乳头状结构、菊形团、上皮样细胞形态或印戒样细胞。肿瘤一致表达细胞角蛋白18、突触素、嗜铬粒蛋白A和OTX2,而CRX表达缺失。16例肿瘤中有4例(25%)显示ATRX突变和/或免疫组化显示蛋白表达缺失。单核RNA测序证实其与其他松果体肿瘤在分子上不同,但显示与松果体区乳头状肿瘤(PTPR)最相似。将转录组数据投射到发育中小鼠松果体的细胞轨迹上,提示松果体细胞祖细胞为其细胞来源。这些发现定义了一种新的松果体区肿瘤类型,我们暂将其命名为「伴神经内分泌和上皮分化的松果体肿瘤」(PINNED)。识别该肿瘤类型似乎对松果体区肿瘤的准确诊断很重要,并可能影响未来肿瘤分类和治疗策略。
Endocrine reviews IF 23.9 2026-10-26 PMID: 42931764
Paraneoplastic syndromes (PNS) represent uncommon but clinically significant manifestations of neuroendocrine neoplasms (NENs) arising from ectopic hormone secretion, aberrant peptide processing, cytokine-mediated effects, or immune-mediated mechanisms. Although NENs are intrinsically capable of producing bioactive substances leading to PNS, the true prevalence of PNS in NENs remains uncertain and is likely underestimated. Paraneoplastic manifestations may precede tumor diagnosis, represent the first indication of an otherwise occult neoplasm, or emerge during disease progression, thereby providing valuable diagnostic, prognostic, and therapeutic information. Endocrine PNS, including ectopic adrenocorticotrophic hormone secretion, carcinoid syndrome, paraneoplastic hypercalcemia, syndrome of inappropriate antidiuretic hormone secretion, hypoglycemia and ectopic acromegaly, account for the majority of cases, whereas neurological PNS are rarer and predominantly associated with high-grade neuroendocrine carcinomas (NECs). Recent advances in molecular biology have revealed the importance of neuroendocrine lineage plasticity, transcriptional dysregulation, epigenetic reprogramming, and abnormal prohormone processing in the pathogenesis of these syndromes. Concurrently, improvements in biochemical testing, functional imaging, liquid biopsy technologies, and molecular profiling have enhanced diagnostic accuracy and disease monitoring. Management requires a multidisciplinary approach combining syndrome-directed therapies with tumor-targeted interventions, including surgery, somatostatin analogs, peptide receptor radionuclide therapy, targeted agents, specific chemotherapy regimens and emerging immunotherapeutic strategies. Despite substantial progress, significant gaps remain regarding epidemiology, accurate biomarkers, prognostic significance, and optimal management. This review summarizes current knowledge on pathophysiology, clinical spectrum, diagnosis, prognostic implications, and treatment of PNS associated with gastroenteropancreatic and lung NENs, while highlighting future research priorities and unmet clinical needs.
中文摘要:副肿瘤综合征(PNS)是神经内分泌肿瘤(NENs)少见但具有临床意义的临床表现,来源于异位激素分泌、肽类加工异常、细胞因子介导效应或免疫介导机制。NENs本身能够产生生物活性物质并导致PNS,但PNS在NENs中的真实患病率仍不确定,且很可能被低估。副肿瘤表现可早于肿瘤诊断出现,成为隐匿性肿瘤的首个提示,也可在疾病进展过程中出现,从而提供有价值的诊断、预后和治疗信息。内分泌性PNS包括异位促肾上腺皮质激素分泌、类癌综合征、副肿瘤性高钙血症、抗利尿激素不适当分泌综合征、低血糖和异位肢端肥大症,占多数病例;神经性PNS较少见,主要与高级别神经内分泌癌(NECs)相关。分子生物学进展显示,神经内分泌谱系可塑性、转录失调、表观遗传重编程和激素原加工异常在这些综合征的发病机制中具有重要性。与此同时,生化检测、功能成像、液体活检技术和分子分型的改进提高了诊断准确性和疾病监测能力。管理需要多学科方法,将针对综合征的治疗与针对肿瘤的干预相结合,包括手术、生长抑素类似物、肽受体放射性核素治疗、靶向药物、特定化疗方案和新兴免疫治疗策略。尽管取得明显进展,流行病学、准确生物标志物、预后意义和最佳管理方面仍存在显著空白。本综述总结与胃肠胰和肺NENs相关PNS的病理生理、临床谱、诊断、预后影响和治疗方面的现有知识,并强调未来研究重点和未满足的临床需求。
Drugs IF 14.7 2026-10-24 PMID: 42925389
Vusolimogene oderparepvec (TUDRIQEV™; vusolimogene oderparepvec-wtpg) is a genetically modified oncolytic viral therapy that targets cancer cells. It is being developed by Replimune for the treatment of skin malignancies and received its first approval for combination treatment with nivolumab on 6 August 2026 in the USA. The combination of vusolimogene oderparepvec and nivolumab resulted in objective responses in patients with unresectable advanced melanoma after progression with an anti-PD-1 regimen during the IGNYTE phase I/II trial. This article summarises the milestones in the development of vusolimogene oderparepvec leading to this first approval in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1-blocking antibody-based regimen.
中文摘要:Vusolimogene oderparepvec(TUDRIQEV™;vusolimogene oderparepvec-wtpg)是一种靶向癌细胞的基因修饰溶瘤病毒疗法。该药由Replimune开发,用于治疗皮肤恶性肿瘤,并于2026年8月6日在美国首次获批与纳武利尤单抗联合治疗。在IGNYTE I/II期试验中,vusolimogene oderparepvec与纳武利尤单抗联合,使抗PD-1方案治疗后进展的不可切除晚期黑色素瘤患者出现客观缓解。本文总结vusolimogene oderparepvec研发过程中的里程碑,这些里程碑促成其首次获批与纳武利尤单抗联合,用于治疗接受PD-1阻断抗体方案后疾病进展的成人不可切除晚期皮肤黑色素瘤患者。

基础研究 (2篇)

Science immunology IF 16.4 2026-10-30 PMID: 42962052
Trained immunity is tightly regulated by metabolic and epigenetic reprogramming, yet how these changes are orchestrated at the chromatin level to establish long-term innate immune memory is not fully understood. Here, we show that induction of trained immunity elevates nuclear levels of nicotinamide adenine dinucleotide (NAD+), which directly binds to KDM5A demethylase and inhibits its activity, thereby sustaining H3K4me3 (histone H3 lysine 4 trimethylation) levels and chromatin accessibility at inflammatory gene promoters to enhance "memory" responsiveness upon restimulation. Genetic deletion or pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme for NAD+ synthesis, impaired trained immunity and associated antitumor activity. Nicotinamide mononucleotide (NMN) supplementation rescued defective trained immunity-mediated antitumor activity in NAMPT-deficient and aged mice. In human cancer, NAMPT expression in myeloid cells correlated with an inflammatory tumor microenvironment. Our findings identify KDM5A as a nuclear NAD+ sensor that orchestrates histone methylation and chromatin accessibility required for trained immunity.
中文摘要:训练免疫受到代谢与表观遗传重编程的严格调控,但这些变化如何在染色质层面被组织起来以建立长期固有免疫记忆,仍未完全清楚。本研究报告,训练免疫的诱导会提高核内烟酰胺腺嘌呤二核苷酸(NAD+)水平,NAD+直接结合KDM5A去甲基化酶并抑制其活性,从而维持炎症基因启动子处的H3K4me3(组蛋白H3第4位赖氨酸三甲基化)水平与染色质可及性,增强再次刺激时的「记忆」应答。基因敲除或药物抑制烟酰胺磷酸核糖转移酶(NAMPT,NAD+合成的限速酶)会削弱训练免疫及其相关的抗肿瘤活性。补充烟酰胺单核苷酸(NMN)可恢复NAMPT缺陷小鼠与老年小鼠中受损的训练免疫介导抗肿瘤活性。在人类癌症中,髓系细胞的NAMPT表达与炎症性肿瘤微环境相关。这些结果确定KDM5A是核内NAD+感受器,负责协调训练免疫所需的组蛋白甲基化与染色质可及性。
Science advances IF 13.9 2026-10-30 PMID: 42962001
Chimeric RNAs are a class of molecules defined as RNA transcripts containing genetic information for multiple genes. While their expression patterns across tissue types and disease states have been well documented, the biological function of these transcripts remains poorly understood. In this study, we developed an integrative prediction pipeline to establish an atlas of 569,640 chimeric RNAs across 1019 cancer cell lines. Leveraging this resource, we performed a systematic functional dependency screen by integrating our predictions with perturbation datasets from The Cancer Dependency Map project. This approach moves beyond prediction to identifying high-confidence functional chimeric RNAs essential for cellular processes, including a subset of recurrent chimeric transcripts generated by cis-splicing of adjacent genes. We demonstrate that depletion of selected candidate chimeras disrupts cell cycle progression and cellular fitness and that these transcripts are frequently dysregulated in primary breast tumors. Together, these results demonstrate that chimeric RNAs constitute a previously underappreciated layer of gene expression, expanding the functional genome beyond conventional genetics.
中文摘要:嵌合RNA是一类由包含多个基因遗传信息的RNA转录本构成的分子。其在不同组织类型和疾病状态中的表达模式已有较充分记录,但这些转录本的生物学功能仍不清楚。该研究建立了一个整合预测流程,在1019个癌细胞系中构建了涵盖569,640个嵌合RNA的图谱。利用这一资源,将预测结果与癌症依赖图谱项目的扰动数据集整合,开展了系统性功能依赖筛选。该策略超越预测层面,识别出对细胞过程必需的高置信功能嵌合RNA,其中包括由相邻基因顺式剪接产生的一组复发性嵌合转录本。研究显示,敲低选定的候选嵌合RNA会干扰细胞周期进程和细胞适应性,这些转录本在原发乳腺癌中频繁失调。这些结果说明,嵌合RNA构成了一层此前未被充分认识的基因表达,将功能基因组拓展到传统遗传学之外。

10泌尿生殖肿瘤 (3篇)

基础研究 (3篇)

Science advances IF 13.9 2026-10-30 PMID: 42962020
Hypoxia-inducible factors (HIFs) are constitutively active in clear cell renal cell carcinoma (ccRCC) cells. Here, we investigated whether these cells could still respond to hypoxia independently of canonical HIF activation. We found that hypoxia provokes a NADH reductive stress that attenuates lactate release when the supply of extracellular pyruvate becomes limited, a response that was restored by the ectopic expression of the cytosolic and mitochondria-targeted NADH oxidase (LbNOX). Suppression of the mitochondrial electron transport chain (mtETC) alone is sufficient to attenuate glycolytic flux when extracellular pyruvate is limited, a situation consistent with metabolomic data from human ccRCCs. Furthermore, this response can be mimicked by pharmacological or genetic inhibition of mitochondrial complex IV (CIV) activity and restored by the mitochondrial-targeted alternative oxidase (AOX). Therefore, our data suggest that cells can respond to low oxygen tension through a mitochondrial-dependent elevation of NADH/NAD+, resulting in the suppression of glycolysis when pyruvate availability is compromised.
中文摘要:缺氧诱导因子(HIFs)在透明细胞肾细胞癌(ccRCC)细胞中呈组成性激活。我们研究了这些细胞是否仍能不依赖经典HIF激活而对缺氧作出反应。我们发现,当细胞外丙酮酸供应受限时,缺氧会引发NADH还原应激,从而减弱乳酸释放;通过异位表达胞质和线粒体靶向的NADH氧化酶(LbNOX)可恢复该反应。仅抑制线粒体电子传递链(mtETC)就足以在细胞外丙酮酸受限时减弱糖酵解通量,这一情况与人类ccRCC的代谢组学数据一致。药理学或遗传学抑制线粒体复合物IV(CIV)活性可模拟该反应,而线粒体靶向的交替氧化酶(AOX)可恢复该反应。数据提示,细胞可通过线粒体依赖性的NADH/NAD+升高对低氧张力作出反应,并在丙酮酸可用性受损时抑制糖酵解。
ACS nano IF 17.3 2026-10-27 PMID: 42937593
Intravesical chemotherapy is a standard adjuvant treatment for nonmuscle-invasive bladder cancer after transurethral resection, but its efficacy is limited by drug exposure resulting from urinary dilution and physiological voiding. Most current delivery strategies aim to prolong the intravesical residence through mucoadhesion, depot formation, or sustained release. Although these approaches increase local drug availability, they do not directly address insufficient intracellular drug accumulation during the short instillation window. Here, we report a poly-l-glutamic acid-modified gold nanourchin platform, PGU3@DOX, designed to enhance intravesical chemotherapy by accelerating drug internalization by bladder cancer cells. By optimizing the nanoparticle morphology, we identified long-spiked gold nanourchins as the most effective architecture for rapid cellular uptake. The PLG coating enabled doxorubicin loading and supported pH-facilitated DOX release, while the internalized nanourchins induced lysosomal swelling and lysosomal membrane permeabilization in bladder cancer cells. Under a 1 h pulse exposure that mimics the short intravesical dwell-time window, PGU3@DOX showed greater cytotoxicity against bladder cancer cells after extracellular drug removal while showing lower toxicity toward normal urothelial cells. Furthermore, PGU3@DOX achieved a broader distribution and stronger damage in tumor spheroids than free DOX. In an orthotopic bladder cancer model, a single short-duration intravesical administration of PGU3@DOX significantly suppressed tumor progression without detectable acute hematological, hepatic, renal, or cardiac toxicity under the tested conditions. These findings support rapid cellular internalization as a complementary strategy to improve intravesical chemotherapy and provide a morphology-guided nanocarrier platform for enhancing drug delivery within short therapeutic exposure windows.
中文摘要:膀胱内化疗是非肌层浸润性膀胱癌经尿道切除术后的标准辅助治疗,但其疗效受尿液稀释和生理性排尿造成的药物暴露不足限制。现有递送策略多通过黏膜黏附、储库形成或缓释来延长膀胱内滞留时间。这些方法虽提高局部药物可利用度,却未直接解决短灌注窗口内细胞内药物蓄积不足的问题。本研究报告一种聚L-谷氨酸修饰的金纳米海胆平台PGU3@DOX,通过加速膀胱癌细胞对药物的内吞来增强膀胱内化疗。通过优化纳米颗粒形貌,发现长刺金纳米海胆是实现快速细胞摄取的最有效结构。PLG包覆可负载多柔比星并支持pH促进的DOX释放,内吞后的纳米海胆在膀胱癌细胞中诱导溶酶体肿胀和溶酶体膜通透化。在模拟短膀胱内滞留窗口的1小时脉冲暴露下,去除细胞外药物后PGU3@DOX对膀胱癌细胞表现出更强细胞毒性,同时对正常尿路上皮细胞毒性较低。PGU3@DOX在肿瘤球中较游离DOX分布更广、损伤更强。在原位膀胱癌模型中,单次短时膀胱内给予PGU3@DOX显著抑制肿瘤进展,在所测试条件下未检测到急性血液学、肝脏、肾脏或心脏毒性。这些结果支持快速细胞内吞作为改善膀胱内化疗的补充策略,并提供了一种形貌导向的纳米载体平台,用于在短治疗暴露窗口内增强药物递送。
Molecular biomedicine IF 13.0 2026-10-24 PMID: 42920026
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death that is driven by lipid peroxidation. In the past decade, it has emerged as a core pathogenic mechanism in a wide range of human diseases, such as neurodegenerative disorders, cardiovascular disease, cancer, and notably, reproductive dysfunction. This review provides a comprehensive overview of the molecular mechanisms underlying ferroptosis with a specific focus on the System Xc⁻-GSH-GPX4 axis, iron metabolism, lipid peroxidation, and the regulatory roles of key modulators such as Nrf2, ACSL4, and CISD2. This review also explores the physiological roles of ferroptosis in development, tissue homeostasis, and immune regulation, as well as its pathological contributions to obesity, diabetes mellitus, atherosclerosis, neurodegeneration, stroke, cancer, infectious diseases, and reproductive disorders. A substantial part of this review discusses the role of ferroptosis in the pathogenesis of reproductive disorders, such as male reproductive pathologies, including varicocele, testicular ischemia-reperfusion, cryptorchidism, oligospermia, erectile dysfunction, and testicular cancer, and female pathologies like primary ovarian insufficiency, polycystic ovary syndrome, endometriosis, ovarian cancer, and pre-eclampsia. Moreover, the interplay between ferroptosis and immune dysfunction in reproductive tract infections was highlighted. Furthermore, we evaluated current biomarkers, emerging therapeutic strategies, and key translational challenges, highlighting the promise of ferroptosis-modulating agents for novel diagnostic and therapeutic interventions in reproductive medicine and beyond.
中文摘要:铁死亡是一种依赖铁、非凋亡性的调节性细胞死亡形式,由脂质过氧化驱动。过去十年中,它已成为多种人类疾病的核心致病机制,涉及神经退行性疾病、心血管疾病、癌症,尤其是生殖功能障碍。该综述概述铁死亡的分子机制,重点讨论System Xc⁻-GSH-GPX4轴、铁代谢、脂质过氧化,以及Nrf2、ACSL4和CISD2等关键调控因子的调节作用。综述还讨论铁死亡在发育、组织稳态和免疫调节中的生理作用,及其在肥胖、糖尿病、动脉粥样硬化、神经退行性疾病、卒中、癌症、感染性疾病和生殖障碍中的病理贡献。较大篇幅讨论铁死亡在生殖障碍发病中的作用,包括男性生殖病理如精索静脉曲张、睾丸缺血再灌注、隐睾、少精症、勃起功能障碍和睾丸癌,以及女性病理如原发性卵巢功能不全、多囊卵巢综合征、子宫内膜异位症、卵巢癌和子痫前期。同时强调铁死亡与生殖道感染中免疫功能障碍之间的相互作用。综述评估现有生物标志物、新兴治疗策略和关键转化挑战,指出铁死亡调节剂在生殖医学及其他领域的新型诊断和治疗干预中的前景。

11其他 (4篇)

基础研究 (4篇)

Cancer cell IF 56.1 2026-10-29 PMID: 42956741
In this issue of Cancer Cell, Zhang et al. perform multi-omics profiling on a large collection of patient-derived pancreatic ductal adenocarcinoma organoids to elucidate the mechanisms underlying intrinsic resistance to KRAS inhibition. This work identifies suppression of innate immune signaling through sustained MYC activity as the principal driver of intrinsic resistance.
中文摘要:本期《Cancer Cell》中,Zhang 等对大量患者来源的胰腺导管腺癌类器官进行多组学分析,以阐明 KRAS 抑制内在耐药的机制。该工作发现,持续的 MYC 活性导致先天免疫信号受抑,是内在耐药的主要驱动因素。
Nature cell biology IF 22.7 2026-10-28 PMID: 42951907
Migrating cancer cells release diverse extracellular vesicles (EVs) that carry cargo capable of influencing tumour progression and intercellular communication. However, the mechanisms by which intracellular components are incorporated into EVs remain poorly understood. Here we identify and characterize a previously undescribed population of large EVs (2-5 μm), termed motile vesicles (MoVes), that are generated during active cancer cell migration and associated with epithelial-mesenchymal transition. Comparative analyses across EV populations show that MoVes display distinct ultrastructural features, molecular composition and sedimentation behaviour. Live-cell imaging and scanning electron microscopy reveal that MoVes arise from trailing-edge retraction during mesenchymal migration and are actively shed by cancer cells but rarely by non-transformed cells. MoVes contain genomic DNA spanning the genome of the parent cell, recapitulating its mutational landscape, as well as organelles and proteins associated with epithelial-mesenchymal transition. Moreover, MoVes-associated mitochondrial cargo can enhance oxidative phosphorylation in recipient cells. Together, these findings identify MoVes as a cancer cell migration-associated EV population capable of disseminating genomic DNA and organelles.
中文摘要:迁移中的癌细胞会释放多种细胞外囊泡(EVs),其携带的货物能够影响肿瘤进展和细胞间通讯。细胞内组分如何被纳入EVs的机制仍不清楚。该工作鉴定并表征了一类此前未被描述的大型EV群体(2-5 μm),称为运动囊泡(motile vesicles,MoVes),它们在活跃的癌细胞迁移过程中产生,并与上皮-间质转化相关。跨EV群体的比较分析显示,MoVes具有不同的超微结构特征、分子组成和沉降行为。活细胞成像和扫描电子显微镜显示,MoVes起源于间质迁移过程中的尾缘回缩,由癌细胞主动释放,非转化细胞很少释放。MoVes含有覆盖亲本细胞基因组的基因组DNA,重现其突变图谱,并携带与上皮-间质转化相关的细胞器和蛋白质。MoVes相关线粒体货物可增强受体细胞的氧化磷酸化。这些发现将MoVes鉴定为一类与癌细胞迁移相关、能够播散基因组DNA和细胞器的EV群体。
Nature protocols IF 18.4 2026-10-26 PMID: 42934361
Genomic duplication is a common type of structural variation that has important roles in gene dosage regulation and contributes to the development of various human diseases including cancer and inherited disorders. However, current genome-editing technologies are limited in their ability to introduce precise and efficient DNA duplications. Amplification editing (AE) is a genome-editing strategy that enables efficient and precise duplication of genomic sequences ranging from tens of base pairs to chromosomal scales. AE offers high precision and efficiency and the ability to duplicate endogenous sequences across multiple targeting sites and in diverse cell types. Here, we describe detailed procedures for the design, execution and analysis of AE-based genomic duplication. These include protocols for duplicating endogenous loci across a range of fragment sizes, as well as workflows to quantify editing efficiency and validate duplication outcomes. In addition, we provide guidance for optimizing AE performance and extending its applicability across diverse genomic targets and experimental contexts. Most AE experiments can be completed within 2 weeks, supporting efficient implementation of targeted genomic duplication in mammalian cells.
中文摘要:基因组重复是常见的结构变异类型,在基因剂量调控中具有重要作用,并参与包括癌症和遗传性疾病在内的多种人类疾病发生。现有基因组编辑技术在引入精确、高效的DNA重复方面仍有局限。扩增编辑(AE)是一种基因组编辑策略,可对从数十个碱基对到染色体尺度的基因组序列进行高效、精确的重复。AE具有高精度和高效率,并能在多种靶向位点和多种细胞类型中重复内源序列。本文介绍基于AE的基因组重复的设计、执行和分析的详细流程,包括在不同片段长度范围内重复内源位点的方案,以及量化编辑效率和验证重复结果的工作流程。文中还给出优化AE性能、将其适用性拓展到不同基因组靶点和实验场景的指导。多数AE实验可在2周内完成,有助于在哺乳动物细胞中高效实现靶向基因组重复。
Trends in molecular medicine IF 18.1 2026-10-26 PMID: 42934058
Microphthalmia/transcription factor E (MiT/TFE) transcription factors are central regulators of lysosomal function, mechanistic target of rapamycin complex 1 (mTORC1) signaling, and cellular metabolism, and their dysregulation is increasingly recognized as a key driver of kidney cancer. This forum provides an overview of the molecular mechanisms underlying MiT/TFE-associated renal tumorigenesis and discusses their implications for cancer biology and therapy.
中文摘要:小眼畸形相关转录因子/转录因子E(MiT/TFE)是溶酶体功能、雷帕霉素机制靶点复合物1(mTORC1)信号和细胞代谢的核心调控因子,其失调日益被视为肾癌的关键驱动因素。本论坛概述MiT/TFE相关肾肿瘤发生的分子机制,并讨论其对肿瘤生物学和治疗的意义。